ARCHIVE
Some links to outside sources
may be discontinued by the provider
over time
|
Tuesday, February 11
Select "lymphomation" items posted by Anjou, Carol, and Karl for Patients Against Lymphoma - sometimes with comment.
Please feel free to share items of interest -- or your questions -- by sending an email to .
* JCO, 2010:
Second Malignant Neoplasms in Survivors of Pediatric Hodgkin's Lymphoma Treated With Low-Dose Radiation and Chemotherapy http://bit.ly/1m33v6f
Cumulative incidence of first second malignant neoplasms (SMN) was 17% (95% CI, 10.5 to 26.7) at 20 years after HL diagnosis. The standard incidence ratio (SIR*) for any second malignancy was 22.9 (95% CI, 14.2 to 35) with an absolute excess risk of 93.7 cases per 10,000 person-years.
Standard Incidence ratio (SIR): "The expected number is calculated by multiplying each age-specific cancer incidence rate of the reference population by each age-specific population of the community in question and then adding up the results. If the observed number of cancer cases equals the expected number, the SIR is 1. If more cases are observed than expected, the SIR is greater than 1. If fewer cases are observed than expected, the SIR is less than 1. www.state.nj.us
Monday, February 10
*Lymphoma Hub 2014: for oncologists mainly
Prognostic tool outperforms standard IPI in DLBCL http://bit.ly/1oaEBjz
The authors recommend that patients in the low-risk group should be treated with conservative chemotherapy, while those in the high-risk group should be given intensive treatment with stem-cell transplant and/or novel targeted agents.
* Fox Chase 2014: frequently asked question
Can a Patient Be Too Old for Stem Cell Transplant? http://bit.ly/1bEKk92
Recent studies have clearly demonstrated that older patients reported similar benefits from transplant when compared with younger patients. There is no clear way to define “young” or “old” when it comes to patients. ....
*NY Times 2014: communications
Lost in Clinical Translation http://nyti.ms/1fWALXH
A classic “Far Side” cartoon shows a man talking forcefully to his dog. The man says: “Okay, Ginger! I’ve had it! You stay out of the garbage!” But the dog hears only: “Blah blah Ginger blah blah blah blah blah blah blah blah Ginger …”
* Science Based Medicine 2014:
The return of the revenge of high dose vitamin C for cancer http://bit.ly/1oaFUPG
Sunday, February 9
Select "lymphomation" items posted by Anjou, Carol, and Karl for Patients Against Lymphoma - sometimes with comment:
* ASCO Post: “Major Cancer Advances in 2013 Highlight Importance of Federal Funding” http://bit.ly/1dzCa1p
The resulting databases are available to researchers worldwide and can facilitate the search for new targeted therapies. While developing targeted treatments is generally the province of drug and biotech companies, discovery of the target has often been in federal laboratories or with federal dollars, Dr. Schilsky noted.
The report also recommends more support for clinical trials in general and the NCI-sponsored cooperative groups, now consolidated into the National Clinical Trials Network, in particular. It notes that long-planned trials have not been able to open for patient enrollment and that as a result, the number of patients taking part in clinical trials has dropped from a high of more than 29,000 a year in 2009 to 20,000 in 2013.
* The ASCO Post Lenalidomide/Rituximab Doublet a Potential Front-Line Treatment in Some Lymphomas http://bit.ly/1dZk9cT
* The ASCO Post ‘R-Squared’ Lymphoma Treatment: Possible Markers of Response Identified http://bit.ly/1inMYow
* PAL query: Lenalidomide (immune modulation) with Rituxan Find trials
Saturday, February 8
Select "lymphomation" items posted by Anjou, Carol, and Karl for Patients Against Lymphoma - sometimes with comment:
* Fred Hutchinson CRC 2014:
New drug shows promise in treating indolent non-Hodgkin lymphomas http://bit.ly/1dwtmcv
See also Idelalisib / GS-1101 (formerly CAL101) Find trials
relapsed CLL, MCL, WM, and lymphoma, single agent or with Rituxan
* Brian Koffman's Blog 2014:
ASH 2013: Dr. Jennifer Brown Discusses the New Data on Obinutuzumab (GA-101 or Gazyva) http://bit.ly/1ip5KMf
See also GA-101 (Obinutuzumab), next generation cd20 antibody Find trials
* Clinical Oncology News 2014:
CAR T-Cell Therapies: Positive Early Results http://bit.ly/1nhfJU7
See also Cd19 CAR T-cell therapy Find trials
chemotherapy-refractory CLL / Lymphoma
*In the Pipeline 2014:
The Evidence Piles Up: Antioxidant Supplements Are Bad For You http://bit.ly/1iDMWsf
*J Clin Onc 2014:
Role of Radiotherapy to Bulky Disease in Elderly Patients With Aggressive B-Cell Lymphoma. http://1.usa.gov/1iyFkaY
*Am J Hem 2014:
Role of routine imaging in detecting recurrent lymphoma; a review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma. http://1.usa.gov/1f2C6bp
* Clinical Oncology News 2014:
ASH 2013: Study Suggests Wider Use of Half-Match Transplant-Immediate implications for transplantation referral http://bit.ly/NgLzpw
* NYT 2014
Living With Cancer: An Artist’s View http://nyti.ms/Mzjysp
* Int J Cancer 2014:
Cytokines in serum in relation to future non-Hodgkin lymphoma risk: Evidence for associations by histologic subtype. http://1.usa.gov/1jl5AIW
* J NCI 2014:
Crizotinib in advanced, chemo-resistant anaplastic lymphoma kinase-positive lymphoma patients. http://1.usa.gov/1ezA6g2
* Brian Koffman Blog 2014:
ASH 2013: Giora Sharf and Jan Geissler Discuss Mediation Adherence or “Drugs don’t work in patients who don’t take them.” – C. Everett Koop http://bit.ly/1iDK4LS
*Diagn Interv Radiol 2014:
Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma. http://1.usa.gov/LY93io
* MNT 2014:
Caregiving and psychological stress http://bit.ly/1aYUg2s
* Lymphoma Hub 2014:
Obese patients with DLBCL have “improved OS” http://bit.ly/1lxQ2mF
* BBC 2014:
Cancer 'tidal wave' on horizon, warns WHO http://bbc.in/MWxnly
* Science Daily 2014:
Why cancer incidence increases with age http://bit.ly/LNWPZv
* Posted to PAL cost page:
News Article : More Assistance Programs to Accept Medicare Beneficiaries http://bit.ly/1cfCwL0
Dated but relevant to current concerns about high out of pocket costs for on-patent cancer drugs:
BETHESDA, MD, 12 May 2006—A growing number of drug manufacturers are rethinking their decisions to bar Medicare beneficiaries from patient assistance programs (PAPs).
The AstraZeneca Foundation announced Wednesday that its assistance programs are now open to all Medicare beneficiaries who meet financial and eligibility criteria. The programs had previously been closed to Medicare beneficiaries who had enrolled in a Part D prescription drug plan.
Also this month, two companies—GlaxoSmithKline and ELi Lilly— announced that qualified Medicare beneficiaries who do not sign up for a Part D drug plan can enroll in the companies' assistance programs. Both companies had previously stated that all Medicare beneficiaries would be ineligible for the programs.
Friday, February 7
Select "lymphomation" items posted by Anjou, Carol, and Karl for Patients Against Lymphoma - sometimes with comment:
* Ther Adv Hematol v.4(3); Jun 2013
Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma http://1.usa.gov/1cc7vr2
* Study completed - will evaluate role of MRD in assessment:
Zevalin® First Line in Follicular Lymphoma - Full Text View - ClinicalTrials.gov http://1.usa.gov/1o2eg7x
ASCO Answers: |
Managing the Cost of Cancer Care http://ow.ly/tjnGz
Includes Financial resources.
5 years ago today, we released the first edition of our booklet for patients and caregivers on managing the cost of care. And, it’s gone through several updates since then, including for 2014! Get our new update of “Managing the Cost of Cancer Care” (PDF).
* Test overuse: Why does it happen and what can we do about it? http://bit.ly/1eFVluY
* Study of interest:
Testing GDC-0199 (ABT-199) with CHOP-R for non-Hodgkin's lymphoma ClinicalTrials.gov http://1.usa.gov/1isYhvH
Not yet recruiting
There is considerable interest in ABT-199, an agent that targets the inhibitors of apoptosis -- based on significant single-agent activity in early studies. This study will evaluate different doses of the study drug with standard R-CHOP and also a new version of the Rituxan antibody called Obinutuzumab.
See also Targeting Apoptosis http://lymphomation.org/apoptosis.htm for background on ABT199
==
* BMT 2014: “Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?” http://bit.ly/1eyiWiF
Speaks to an urgent unmet need and novel approaches. Encouraging that pd-1 antibody was noted as a possible advance - as I wasn't sure if I was overestimating the significance of the recent report by Leo Gordon's group on pd1 consolidation after transplant. No mention of CART 19 ... which is another very promising approach for patients with lymphoma refractory to chemo. (Karl)
* Multi Media Presentations on Radiation Protection &
Radiation Safety Training
Excellent explanation of dosing, effective dose, etc., with animations. Added to radiotherapy and CT safety topics.
* Am Soc Clin Oncol Educ Book 2014:
Targeting CD30 in Hodgkin Lymphoma: Antibody-Drug Conjugates Make a Difference. http://1.usa.gov/1mQ94mm
* NEJM:
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma http://bit.ly/1jJAyrl
* KevinMD 2014:
After a medical mistake: Honesty is the best policy http://bit.ly/M1wV4U
* NYT 2014
Living With Cancer: Life of the Party http://nyti.ms/1hQlkQI
Tuesday, February 4
Select "lymphomation" items posted by Anjou, Carol, and Karl for Patients Against Lymphoma - sometimes with comment:
*MNT 2014:
Caregiving and psychological stress http://bit.ly/1aYUg2s
* Lymphoma Hub 2014:
Obese patients with DLBCL have “improved OS” http://bit.ly/1lxQ2mF
* Brian Koffman's Blog 2014:
ASH 2013: Dr. Jennifer Brown Discusses the New Data on Obinutuzumab (GA-101 or Gazyva) http://bit.ly/1ip5KMf
* BBC 2014:
Cancer 'tidal wave' on horizon, warns WHO http://bbc.in/MWxnly
Monday, February 3
Select "lymphomation" items posted by Anjou, Carol, and Karl for Patients Against Lymphoma - sometimes with comment:
* Walter and Eliza Hall Inst 2014:
Red alert: Body kills 'spontaneous' blood cancers on a daily basis http://bit.ly/1fmBkY9
* Leuk Lymph 2014:
Phase III Safety Study of Rituximab Administered as a 90-minute Infusion in Patients With Previously Untreated Diffuse Large B-Cell and Follicular Lymphoma. http://1.usa.gov/1afEcbW
* Thinking outloud a cancer blog 2014:
1 Year Post-Chemo: 10 More Things I've Learned From Cancer http://bit.ly/1i5Gnyh
* What Next 2014:
Be Prepared: 22 Things to Bring to Chemo http://bit.ly/1kvFd0B
* MSKCC 2014:
What You Need to Know about Non-Hodgkin Lymphoma http://bit.ly/1j0GleJ
* Cancer 2014:
Insurance status is related to diffuse large B-cell lymphoma survival. http://1.usa.gov/1fmx4b6
** Items of interest for those who are developing study concepts for lymphoma:
** Lymphoma hub 2014:
Use hematopoietic cell transplantation “early” in chemotherapy-sensitive mantle cell lymphoma http://bit.ly/1eIcPTH
** Blood 2014:
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. http://1.usa.gov/1fmwRol
** Proc Natl Acad Sci U S A. 2014:
High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. http://1.usa.gov/1eiyeIg
Friday, January 31
We feel that the opportunity for patients to benefit by participation in clinical trials has never been higher – however patients and treating physicians cannot consider trials unless informed about the new agents, the outcomes reported so far, and which study protocols are best matched with the patients clinical circumstances and needs.
See PAL resources to foster participation in trials PAL
Select "lymphomation" items posted by Anjou, Carol, and Karl for Patients Against Lymphoma - sometimes with comment:
* PAL topic: update and resource added
Off-label use of cancer drug PAL
* Huff Post 2014: important to note!
Your Cancer Is Not My Cancer: The Danger of Comparison http://huff.to/1i9r6gF
* Science Daily 2014:
Concerned about the health risk of soda? http://bit.ly/1ecctd7
Well written review of study has been in the news recently
* Oncology Times 2014: Important debate!
Hodgkin Lymphoma: Brentuximab Active in Relapsed Disease, but Use as Maintenance Debated http://bit.ly/1ifxing
Younes said he does send some of his patients in this setting to allogeneic transplant, but he does not consider it the standard of care. His algorithm for patients with less than a complete remission or a relapse after autologous transplant is treatment with brentuximab. Those achieving a CR in his practice continue on observation, he said. “I don't rush them to transplant because if they relapse I can use brentuximab vedotin again, with allogeneic transplant always an option.”
* Oncology Times 2014:
For CLL and Myeloma Patients, MRD Remains Uncertain Goal http://bit.ly/1aLFPic
Kay, MD: “Right now, we conventionally use clinical trial data for progression-free survival and overall survival estimates, but you'd have to be immortal to use those in routine trials. But if you could substitute MRD as a surrogate for progression-free or overall survival you could shorten clinical trials, test the promising new drugs more quickly, and then if they are effective, bring them to the patient in a reasonable time frame.”
Furman, MD: The new tyrosine kinase inhibitors cause preferential lymphocytosis by interfering with adhesion molecules that hold the cells in the lymph nodes and in the different niches, ... “So I believe that MRD status will have lost its predictability and its importance when we deal with these tyrosine kinase inhibitors.”
* The Oncology Nurse Community 2014:
Cancer of the Hangnail http://bit.ly/1ehAXjD
* Nature 2014:
Antioxidants speed cancer in mice: Study suggests supplements such as vitamin E promote tumour growth. http://bit.ly/1bzHQIJ
* MNT 2014:
Vitamin D supplements: are they really good for our health? http://bit.ly/1a5l1S5
* The ASCO Post:
Science Magazine Names Cancer Immunotherapy as Scientific Breakthrough of the Year http://bit.ly/LstHXyc
* Related trial of interest:
Safety Study of Anti-Programmed Death-1 in Hematologic Malignancy http://1.usa.gov/Q9kY96
for non-Hodgkin's lymphoma or Hodgkin lymphoma must have at least one measureable lesion > 1.5 cm
Wednesday, January 29
* PAL topic: update and resource added
Off-label use of cancer drug PAL
|
NCI: Off-Label Drug Use in Cancer Treatment - About Off-Label Drugs
|
* the Onc 2014:
What Not to Say http://bit.ly/1egxYIf
* Huff Post 2014;
Your Cancer Is Not My Cancer: The Danger of Comparison http://huff.to/1i9r6gF
* Lymphoma Hub 2014:
Idelalisib–rituximab combination superior to rituximab alone in relapsed CLL http://bit.ly/1dMFypt
* Oncology Times 2014:
ONLINE FIRST: Improved Access to Stem Cell Transplants for Elderly, Ethnic Patients http://bit.ly/1dMGWbD
* J Clin Onc 2014:
Treatment of Hodgkin Lymphoma: A 50-Year Perspective http://bit.ly/1cQCRD0 (link to full article)
* KevinMD 2014:
The truth about juicing http://bit.ly/1gnnoCp
* MNT 2014:
Many internists don't feel equipped to manage care of adults who had cancer as children http://bit.ly/19ZqVUP
Monday, January 27
Select "lymphomation" items posted by Anjou, Carol, and Karl for Patients Against Lymphoma - sometimes with comment:
* Weill Cornell 2014:
Two Modes of DLBCL Relapse http://bit.ly/19XkYrp
* MNT 2014:
Leukemia pill 'can melt away' cancer cells http://bit.ly/1jXbWvn
* Medscape 2014:
Subcutaneous Rituximab Recommended in the EU http://bit.ly/1aCCu4O
* NYTimes 2014:
How Long Have I Got Left? http://nyti.ms/M2oPsa
* evertday Health 2014;
It’s Not a War. It’s Not a Football Game. It’s Cancer, and It’s Scary, Okay? http://bit.ly/1iBNqlM
(Ethan Zohn, hodgkin's survivor)
* Respectful Insolence 2014:
Cancer quack Robert O. Young is arrested and arraigned, but will he be convicted? http://bit.ly/19XkmSG
* Time out!
Andy Griffith on football (1953) YouTube http://bit.ly/1cltYWv
Sunday, January 26
Select "lymphomation" items posted by Anjou, Carol, and Karl for Patients Against Lymphoma - sometimes with comment:
* Positive developments last week for Idelalisib reported in the NEJM for CLL and for NHL
* PAL background on Idelalisib
* NEJM: Idelalisib in Patients with Relapsed Indolent Lymphoma http://bit.ly/1jJAyrl
* NEJM: Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia — http://bit.ly/1aV2iXv
PAL Query: Idelalisib / GS-1101 (formerly CAL101) Find trials
* The ASCO Post Mounting Success in Trials of Genetically Engineered T Cells to Treat Leukemias and Lymphomas http://bit.ly/KXVaPV
SNIP: ‘Smart Bomb’ Approach: The promise of the “smart bomb” approach with this immunologic therapy has attracted industry to partner with some investigators and their institutions. For example, CAR-T cells developed at the National Cancer Institute have been licensed to Kite Pharmaceuticals, and CAR-T cells developed at the University of Pennsylvania have been licensed to Novartis. In fact, Novartis is building a manufacturing facility to produce these cells near the University of Pennsylvania campus. Most recently, Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center, and Seattle Children’s Research Institute have joined forces to launch Juno Therapeutics, a new biotechnology company that will develop CAR-T cells.
PAL query: Cd19 CAR T-cell therapy: Find trials
chemotherapy-refractory CLL / Lymphoma
* KevinMD 2014:
When undergoing chemotherapy, savor the small victories http://bit.ly/1aTXC14
* Br J Hem. 2014:
Autologous stem cell transplantation for follicular lymphoma is of most benefit early in the disease course and can result
in durable remissions, irrespective of prior rituximab exposure.
http://1.usa.gov/1dXOC0N
* Chemotherapy 2014:
Bendamustine as Monotherapy and in Combination Regimens for the Treatment of Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma: A Retrospective Analysis. http://1.usa.gov/1laelXP
* PAL: update
Maintenance Rituxan after initial therapy - tradeoffs PAL
* NEJM:
Idelalisib in Patients with Relapsed Indolent Lymphoma http://bit.ly/1jJAyrl
PAL Query: Idelalisib / GS-1101 (formerly CAL101) Find trials
Thursday, January 23
Select "lymphomation" items posted by Anjou, Carol, and Karl for Patients Against Lymphoma - sometimes with comment:
* NYTimes.com
New Truths That Only One Can See - http://nyti.ms/1g4qdZb (Thanks, Paul)
It has been jarring to learn in recent years that a reproducible result may actually be the rarest of birds. Replication, the ability of another lab to reproduce a finding, is the gold standard of science, reassurance that you have discovered something true.
* BIG news! - Dr Sharman 2014:
Idelalisib prolongs survival in CLL http://bit.ly/1jEi6QV
* Weill Cornell 2014:
A pill 'melts away' common form of leukemia: Results on test of Idelalisib suggest CLL may be treated without toxic chemotherapy http://bit.ly/1eguuBT
* Medscape 2014:
Idelalisib Shows Efficacy in Relapsed CLL and Lymphoma http://bit.ly/1eTtHIy
* Brian Koffman's Blog 2014:
Dosing of Ibrutinib and Other Oral Agents http://bit.ly/1jBWN2z
* Cancer Research Inst 2014:
You Wanted to Know "What the Hell is Immunotherapy." We Answered. http://bit.ly/1jwOuVB
* KevinMD.com 2014;
Twitter and cancer patients: What to make of the outrage? http://bit.ly/KAm5Sh
* Medscape 2014:
FDA Drug Approvals: Quality of Evidence Varies Widely http://bit.ly/1aM72vA
* Deutsches Aerzteblatt International 2014:
Breast cancer in young women after treatment for Hodgkin's disease http://bit.ly/KI6cJD
Tuesday, January 21
Select "lymphomation" items posted by Anjou, Carol, and Karl for Patients Against Lymphoma - sometimes with comment:
* Increasing number of trials for Pd1/L antibodies for lymphoma http://bit.ly/QlPona
See also background on immune checkpoint blockade with links to trials.
* J Clin Onc2014:
Treatment of Hodgkin Lymphoma: A 50-Year Perspective http://bit.ly/1cQCRD0
* Science Based Medicine 2014:
Stanislaw Burzynski: Using 1990s techniques to battle the FDA today http://bit.ly/1eMRcD4
* Brian Koffman's blog 2014:
iwCLL 2013: Dr. Byrd Discusses If and When to Stop and the Long Term Use of Ibrutinib http://bit.ly/1hDVXS9
Important questions raised here - that will be challenging to answer. (Karl)
* MSKCC 2014:
How do I know if a dietary supplement contains what the label says it contains? http://bit.ly/1mhYIsk
*KevinMD.com 2014:
Beyond Dr. Google: How new technologies will affect patient-provider relationship http://bit.ly/1bbFOhA
* Lymphoma Hub 2014:
Rituximab maintenance cost-effective in real-world patients with relapsed FL http://bit.ly/1mn09FZ
Comment: This report is specific to the relapsed setting. In the PRIMA study testing the first line use of maintenance both arms of this large study had equivalent (excellent) overall survival at 6 years. (Karl)
* Bone Marrow Transplant 2014:
Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!
http://1.usa.gov/1mAJpOu
Sunday, January 19
Select "lymphomation" items posted by Anjou, Carol, and Karl for Patients Against Lymphoma - sometimes with comment:
* Lorig, RN: Speaking on behalf of patients is not the same as speaking as a patient http://bit.ly/1aBPpS5
* Hutchings, Medscape: Expert review
PET Imaging in Lymphoma http://bit.ly/19F57NU
* Leuk Lymph 2014:
Symptom-oriented clinical detection versus routine imaging as a monitoring policy of relapse in patients with diffuse large B-cell lymphoma. http://1.usa.gov/19CxZ9K
* Leuk Lymph 2014:
Is there a role for therapy response assessment with FDG-PET/CT in Mantle cell Lymphoma? http://1.usa.gov/1kJKjtF
* Br J Hem 2014:
Incidence of marginal zone lymphoma in the United States, 2001-2009 with a focus on primary anatomic site http://1.usa.gov/1eIGrBI
* Br J Hem 2014:
Improved population level survival in younger Hodgkin lymphoma patients in Germany in the early 21st century. http://1.usa.gov/1dEHvKx
* Br J Cancer 2014:
Chronic fatigue in Hodgkin lymphoma survivors and associations with anxiety, depression and comorbidity. http://1.usa.gov/1h0B9U3
* Maclean's 2014:
When science isn’t science-based: In class with Dr. John Ioannidis http://bit.ly/1gY60Ra
* Ottowa Citizen 2014:
Reluctant panhandler Scott Murray ‘flabbergasted’ by strangers’ kindness http://bit.ly/1eSv64c
* Sunrise Rounds 2014:
Doctors often don’t have the time to address social slander http://bit.ly/1eStace
* Cancer Research Institute 2014:
Cancer Immunotherapy: The Next Decade? http://bit.ly/1dwr5RQ
Nice review of recent advances (Karl)
* LeuK Lymph 2014:
High dose chemotherapy with autologous stem cell transplantation for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era. http://1.usa.gov/KqjPwl
Friday, January 17
Select "lymphomation" items posted by Anjou and Karl for Patients Against Lymphoma - sometimes with comment:
* Dr Sharman 2014;
Talking to friends and loved ones http://bit.ly/1kH3iVy
* KevinMD.com 2014:
Thoughts after being diagnosed with cancer http://bit.ly/1dCrx1Y
* kevinmd.com 2014:
Prevention, detection, and treatment of cancer has become more nuanced http://bit.ly/1avYVmL
* Cancer Network 2014:
What Did We Learn in 2013? http://bit.ly/1ePdlCQ (registration required)
* What Next 2014:
20 Things We Want Strangers to Know About Having Cancer http://bit.ly/19ydg6L
* News Medical 2014:
US underestimated its progress in war on cancer, say Dartmouth researchers http://bit.ly/1fBRP7E
* Unsustainable prices of cancer drugs: from the perspective of a large group of CML experts - bloodjournal.hematologylibrary.org: Rising Costs and Access to Quality Cancer Care
The doctrine of justum pretium, or just price, refers to the “fair value” of commodities. In deciding the relationship between price and worth (or value), it advocates that, by moral necessity, price must reflect worth. This doctrine may be different from the doctrine of free market economies where prices reflect “what the market bears,” or what one is willing to pay for a product.
Which doctrine is better? One could argue that when a commodity affects the lives or health of individuals, just price should prevail because of the moral implications. Examples include the price of bread during famines, polio vaccine, ivermectin for river blindness (provided for free by Merck and estimated to have saved the vision of 30 million individuals), and treatments of chronic medical conditions (cardiovascular, hypertension, diabetes, tuberculosis, multiple sclerosis, etc). When commodities are not essential to life or suffering, what the market will bear is appropriate (competition will take care of price) because it is not restrained by ethical considerations. Examples include the price of a Picasso painting, a luxury cruise, a 2-week vacation in New York (or 4 weeks in Houston), a Bentley car, a Brioni suit, etc.
Thursday, January 16
Select "lymphomation" items posted by Anjou and Karl for Patients Against Lymphoma - sometimes with comment:
* Oncology Times 2014;
Burkitt Lymphoma: Low-Intensity Therapy Shown as Highly Effective http://bit.ly/1m64DRl
* Oncology Times 2014:
CLL: Can IMiDs & TKIs Replace Chemotherapy? http://bit.ly/1clEHM3
* Medscape 2014:
Rituximab, Abatacept May Interfere With Influenza Vaccine http://bit.ly/1m7TLT1
""If it is practically possible, patients planning to start rituximab should get immunized against influenza before treatment initiation. In patients who have been taking rituximab, the probability of initiating a protective immune response is best if H1N1 vaccination is performed a few weeks before the next rituximab course," Dr. Kapetanovic explained."
* Upworthy 2014:
Everything you Wanted to Know About Cancer But Your Doctor Was Too Busy To Tell You
Good intro into the basics about cancer and how standard therapies work.
* Digital Journal 2014:
Narrow Networks and High Cost-Sharing Among Concerns Raised by New Report on Affordable Care Act from The Leukemia & Lymphoma Society http://bit.ly/1apFcov
Comment: It's important to choose wisely on the exchange - if feasible: to choose plans that have lower out of pocket cost sharing.
* Support Care Cancer 2014:
Role of oncologists and primary care physicians in providing follow-up care to non-Hodgkin lymphoma survivors within 5 years of diagnosis: a population-based study. http://1.usa.gov/1aHsRj6
* MNT 2014:
Growing artificial bone marrow http://bit.ly/KjQtjl
* NYtimes 2014:
After Cancer ‘Disruption,’ a Determined Comeback http://nyti.ms/1a81zEH
* Science Daily 2014:
Research Shows Early Promise of New Drug for Cancers Caused by Viruses http://bit.ly/1kB1BZX
After documenting the role of an enzyme called sphingosine kinase (SK), in the generation of biologically active sphingolipids in PEL tumors that keep the tumor cells alive, the researchers tested a novel clinical-grade small molecule that selectively targets SK.
Clinical trials: clinicaltrials.gov/ for sphingosine kinase (none yet for lymphoma)
* CBC New 2014:
Dr. C: We've all got stories to tell, about cancer and more: Dr. Nikhil Joshi has found sharing his story healing http://bit.ly/1j5nWNC
* You Tube 2014:
Risk Factors for Lymphoma http://bit.ly/1ktmsvI
* AACR journal: Catch-22 for Cancer Tests http://bit.ly/1aBUKZQ
It seems that a similar "catch" prevents researchers from moving forward with biomarkers: it won't be used as an integral part of the study (to select patients) unless previously validated, and can't be validated unless previously tested in a prospective study. (Karl)
NEJM, 2014: Global Trends in Biomedical R&D Expenditures — http://bit.ly/1alcRmo
For skeptics of government-funded research: In 2012, NIH funding accounted for $30.9 billion of the R&D investment in the United States. U.S. government funding contributed to the development of 48% of all drugs approved by the Food and Drug Administration (FDA) and 65% of drugs that have received priority review between 1988 and 2005.1
* PAL trial of interest:
T Cells Engineered to Contain Anti-CD19 ... in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas
PAL - Clinical Trials of Interest
Updated background on CARs by PAL
Tuesday, January 14
Select "lymphomation" items posted by Anjou and Karl for Patients Against Lymphoma - sometimes with comments:
* AACR journal: Catch-22 for Cancer Tests http://bit.ly/1aBUKZQ
It seems that a similar "catch" prevents researchers from moving forward with biomarkers: it won't be used as an integral part of the study (to select patients) unless previously validated, and can't be validated unless previously tested in a prospective study. (Karl)
NEJM, 2014: Global Trends in Biomedical R&D Expenditures — http://bit.ly/1alcRmo
The National Institutes of Health (NIH) has been a key enabler of the global dominance of the United States in biomedical research and development (R&D). In 2012, NIH funding accounted for $30.9 billion of the R&D investment in the United States. U.S. government funding contributed to the development of 48% of all drugs approved by the Food and Drug Administration (FDA) and 65% of drugs that have received priority review between 1988 and 2005.1
* PAL trial of interest:
T Cells Engineered to Contain Anti-CD19 ... in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas
PAL - Clinical Trials of Interest
Updated background by PAL
* infoEXCHANGE
Suicide Threats on Social Network Sites http://www.sprc.org/sites/sprc.org/files/library/Suicide_threats_on_social_network_sites.pdf
* Lifescience online 2o13:
Studies Evaluating REVLIMID® (Lenalidomide) in Lymphoma Presented at ASH
Posted to PAL- Lenalidomide mechanisms of action
* Yottafire 2014:
NEJM study evaluates early stem cell transplants for non-Hodgkin’s lymphoma http://bit.ly/1a1oQrR
* Helio 2014:
Lymphoma expert elected ASCO president for 2015-2016 term http://bit.ly/1af5OIJ
* Brian Kauffman's Blog 2014:
The News about Ibrutinib from My Infusion Chair, The Resonate Trial, and Lancet Oncology http://bit.ly/1cXi00C
* Br J Haematol. 2014:
The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. http://1.usa.gov/1eMlqGK
* PAL update:
Guidance on how to report symptoms - and why it's important that we do so! PAL: reporting symptoms
* NPR - off topic (sort of) history of science-based protection of public health:
The Poisoner's Handbook - American Experience - PBS (must see - but long)
Saturday, January 11
Select "lymphomation" items compiled by Anjou and Karl for Patients Against Lymphoma - sometimes with comments:
* Dr Sharman's Blog 2014: highly recommended read
Relapsed Diffuse Large B Cell Lymphoma http://bit.ly/1ewMVUn
* Common Misconceptions in the Management of H-Pylori-associated Gastric MALT-lymphoma
That ... Antibiotic Treatment Has No Role in the Management of H. pylori-negative MALT Lymphoma" http://bit.ly/1iqPvxS
* Helio 2014:
Lymphoma expert elected ASCO president for 2015-2016 term http://bit.ly/1af5OIJ
* OncLive 2014:
Brentuximab Vedotin Should Not Be Combined With Bleomycin in First-Line Treatment of Hodgkin Lymphoma http://bit.ly/1a3m8iT
* Medscape 2014:
CLL Trial Stopped as Ibrutinib Shows Significant Benefits http://bit.ly/1evkDte
SNIP: All patients were at least 65 years of age, and most patients (74%) were at least 70 years old. They all received oral ibrutinib once daily at a dose of 420 mg (some initially received the higher dose of 840 mg, but this was discontinued after comparable activity of the 2 doses was shown).
After a median follow-up of 22.1 months, a complete response was reported in 4 patients (13%), a partial response in 17 (55%), and a nodular partial response in 1 (3%). The overall objective response rate was 71% (22 of 31 patients).
* MNT 2014
Potential new target for many cancers http://bit.ly/1iWyuyz
* USA Today 2014:
Texas charges controversial doctor with false ads http://usat.ly/1aIWLjp
* Respectful Insolence 2014:
It’s 2014, and Stanislaw Burzynski has begun his counteroffensive http://bit.ly/1eus2sN
* PAL - new and recently updated topics:
How to Help Please give what you can to support our mission.
Giving Thanks! ... which are due for most recent and generous donations by Bill (today), Scott (recent) Jeffrey (recent), Iva (recent), Rebecca (recent), Scott, Mark Phyllis, Teresa, Mina, Doug/Barb David, Mary, Mark, Jama, Daniel , Judith, Bill, Phillip, Elizabeth , Toby, Patricia, Gail, Tina Paul, Erin, Steve, Betty, Leonard, Carol, Naomi , Marshall, Nancy, Dennis, David, Cheryl, Susan, and Jane ...
Thursday, January 9
Select "lymphomation" items compiled by Anjou and Karl for Patients Against Lymphoma - sometimes with comments:
* Common Misconceptions in the Management of H-Pylori-associated Gastric MALT-lymphoma
Management of H. Pylori-associated Gastric MALT-lymphoma: Antibiotic Treatment Has No Role in the Management of H. pylori-negative MALT Lymphoma http://bit.ly/1iqPvxS
* Herald Sun News 2014: Early but interesting
Melbourne scientists' discovery gives hope of new fight against cancer http://bit.ly/1iV6MC8
* American Psychological Association Monitor 2014:
Facing Cancer Together http://bit.ly/1czTvdf
* TedTalks 2014:
Roger Stein: A bold new way to fund drug research http://bit.ly/1lOdW8c
* News Medical 2014:
Cancer cells less likely to develop resistance when multiple drugs delivered simultaneously http://bit.ly/19PT54P
* Scientific American Blogs 2014:
Why drug discovery is hard – Part 2: Easter Island, Pit Vipers; Where do drugs come from? http://bit.ly/1dNM2bJ
* Medscape 2014:
US Cancer Death Rates Continue to Drop, Says ACS http://bit.ly/1idu6bz
* Innovations Report 2014:
Out-of-pocket costs play major role in treatment adherence for cancer patients http://bit.ly/1gBYhZv
"Your money or your life!" Already, we have heard from investigators that patients have declined ibrutinib because of the “financial toxicity.” Karl
* 2014 Physician's Desktop Reference (PDR) eBook |
available for download or use on the web (Carol) http://bit.ly/1a3TH4y
* PAL: Coming soon:
Pathways to Progress - highlights of 2013: numerous pportunities and key challenges
Our notions about the most promising developments in the fight against lymphoma in year 2013 – and there were many!
* PAL - new and recently updated topics:
How to Help Please give what you can to support our mission.
Giving Thanks! ... which are due for most recent and generous donations by Bill (today), Scott (recent) Jeffrey (recent), Iva (recent), Rebecca (recent), Scott, Mark Phyllis, Teresa, Mina, Doug/Barb David, Mary, Mark, Jama, Daniel , Judith, Bill, Phillip, Elizabeth , Toby, Patricia, Gail, Tina Paul, Erin, Steve, Betty, Leonard, Carol, Naomi , Marshall, Nancy, Dennis, David, Cheryl, Susan, and Jane ...
Tuesday, January 7
* Dana Farber 2013:
Excellent Web Conversation on lymphoma with Dr. Ann LaCasce
Posted to Talks by Experts on Lymphoma
How to Help Please give what you can to support our mission.
Giving Thanks! ... which are due for recent generous donations by Jeffrey (today), Iva (today), Rebecca (today), Scott (today), Mark Phyllis, Teresa, Mina, Doug/Barb David, Mary, Mark, Jama, Daniel , Judith, Bill, Phillip, Elizabeth , Toby, Patricia, Gail, Tina Paul, Erin, Steve, Betty, Leonard, Carol, Naomi , Marshall, Nancy, Dennis, David, Cheryl, Susan, and Jane ...
Monday, January 6
How to Help Please give what you can to support our mission.
Giving Thanks! ... which are due for recent donations by Rebecca (today), Scott (today), Mark (today) Phyllis, Teresa, Mina, Doug/Barb David, Mary, Mark, Jama, Daniel , Judith, Bill, Phillip, Elizabeth , Toby, Patricia, Gail, Tina Paul, Erin, Steve, Betty, Leonard, Carol, Naomi , Marshall, Nancy, Dennis, David, Cheryl, Susan, and Jane ...
* PAL: Draft of new topic page
Minimal Residual Disease (MRD) testing - Minimal Residual Disease status
an investigational test using PCR amplification ... having the potential to predict the quality and duration of response to therapy.
* PAL: Quality of Life
Capturing and Evaluating Patient Reported Outcomes (PROs) PAL
* PPM: Placebos in Pain Management http://bit.ly/1aysa80
A reason that studies recording patient reported outcomes (PPO) for new agents may need to have a placebo control
Sunday, January 5
* PPM: Placebos in Pain Management http://bit.ly/1aysa80
A reason that studies recording patient reported outcomes (PPO) for new agents may need to have a placebo control
* PAL Query:
Find Trials that apply MRD (minimal residual disease) testing with PCR
added to PAL's Biomarkers topic page
* PAL topic: Epigenetic therapies PAL
background including videos ... and links to trials for this novel class of investigational therapy
*Huff Post 2014:
Love Is... (Holy S@#$$, I Have Cancer) http://huff.to/1bIAfqm
* The Economist 2014:
Getting close and personal http://econ.st/Kr8ugs
* Brian Kauffman's Blog 2014: iwCLL 2013:
Dr. Michael Hallek Discusses Clinical Trials in Germany versus the USA and BR versus FCR http://bit.ly/1gsbJPn
* NYT 2014:
Missing a Cancer Diagnosis http://nyti.ms/1a3OutL
* Consumer Repts 2013:
Don't mix your meds with these foods:
Some fruits, vegetables, and even some drinks can cause dangerous interactions http://bit.ly/19MDjFo
* Respectful Insolence 2014:
A fungus among us in oncology? (2014 edition) http://bit.ly/1evw2d1
* Cancer Treatment.met 2014:
Asparagus and Cancer Treatment http://bit.ly/JOCbHa
* edge 2014
Cancer’s Early Warning Signs http://bit.ly/JAwxbY
* KevinMD 2014:
Doctors cannot predict when the end of life truly comes http://bit.ly/1cRunzA
Saturday, January 4
* PAL - Find by agent:
XmAb5574 / MOR00208 (optimized cd19 Mab) for CLL or Lymphoma
Posted to PAL - Find Trials by Agent Type
MOR00208 is a novel humanized IgG1 CD19 monoclonal ab with an engineered Fc region to enhance ...
* PAL new study of interest:
Urelumab and Rituximab for B-cell Non-Hodgkins Lymphoma or CLL - ClinicalTrials.gov
Posted to Find Trials by Agent Type
* PAL topic: Targeting Apoptosis ...
or more precisely: Agents that inhibit the inhibitors of apoptosis PAL
background and links to trials for this class of investigational agents
includes a VERY interesting and encouraging video interview: Dr. John Seymour
on the Efficacy of ABT-199 in High-Risk CLL
NEJM
Engineered in India — Patent Law 2.0 — full text http://bit.ly/1iCyO5d
A patent law that treats incremental innovation and significant innovation in the same way encourages companies to prioritize less important research over more important research. Provisions like Section 3(d) can help reverse this effect and encourage companies to undertake the riskier and more expensive research that is required to generate breakthrough drugs. Amen! (Karl)
* PAL updated content:
Find trials by agent - In the News with focus on agents with encouraging recent reports
PAL find trials by type of AGENT
How to Help Please give what you can to support our mission.
Giving Thanks! ... which are due for recent donations by Rebecca (today), Scott (today), Mark (today) Phyllis, Teresa, Mina, Doug/Barb David, Mary, Mark, Jama, Daniel , Judith, Bill, Phillip, Elizabeth , Toby, Patricia, Gail, Tina Paul, Erin, Steve, Betty, Leonard, Carol, Naomi , Marshall, Nancy, Dennis, David, Cheryl, Susan, and Jane ...
Thursday, January 2
* PAL topic: Targeting Apoptosis ... or more precisely:
Agents that inhibit the inhibitors of apoptosis PAL
background and links to trials for this class of investigational agents
Including Video interview: Dr. John Seymour on the Efficacy of ABT-199 in High-Risk CLL
* The Nocebo effect - this Video Will Hurt http://bit.ly/1iwpCiR
Studies show how belief in harm can cause symptoms - can spread even from mind to mind.
A reason, perhaps, to avoid reading the list of possible side effects for that new drug you're about to take?
*The Atlantic 2014:
When Will Genomics Cure Cancer? A conversation with the biogeneticist Eric S. Lander about how genetic advances are transforming medical treatment http://bit.ly/19J7QUJ
*Imedex 2014:
Autoimmunity in CLL CLL & SLL in the News
*Leuk Lymph 2013:
Impact of 18F-FDG PET/CT Staging in Newly Diagnosed Classical Hodgkin Lymphoma:
Less Cases with Stage I Disease and More with Skeletal Involvement. http://1.usa.gov/1hTyWdP
*Blood 2013:
Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma. http://1.usa.gov/KiijNG
*MSKCC 2013:
Treatment Approaches for Localized and Systemic Lymphoma http://bit.ly/KhjInH
*Blood 2013:
Monoclonal B-cell lymphocytosis in healthy blood donors: an unexpectedly common finding http://bit.ly/Khjo8v
*Johns Hopkins:
Cancer Update Email -- It's a Hoax! http://bit.ly/JrIHnr
Tuesday, Dec 31
* PsychCentral 2013:
A New Type of New Year’s Resolution http://bit.ly/1cQaUkl
* Science-based Medicine 2013:
Doctors Are Not “Only Out to Make Money” http://bit.ly/JrFAfq
* NYTimes 2013:
Medical Billing Nears a New Era of Ultra-Specific Codes http://nyti.ms/1bwCHjK
* Flu shot recommended by expert:
Cancer Patients Vulnerable to Complications From Flu http://bit.ly/19x0nud
* Sunrise Rounds 2013:
Is giving false hope malpractice? http://bit.ly/1gdLgVH
* UMass 2013: Early
Activating aging in tumor cells may be effective against lymphoma http://bit.ly/1fVRtVv
SNIP: The study, published in Nature Communications, details a novel, tumor-suppressive role for the Smurf2 protein—which typically plays an “enforcer” role in cellular aging, also called senescence —in a subset of DLBCL. Identification of this novel function for Smurf2 provides a new therapeutic target for treating this cancer.
* Youtube 2013:
Aggressive Non Hodgkin's Lymphoma: Michael Wang http://bit.ly/1cf4FE4
Focus on investigational protocols for Mantle Cell
* Targeted OncologyYoutube 2013
Updates from ASH 2013:
Dr. Amengual discusses dual targeting with an HDAC 6 Inhibitor and Bortezomib in lymphoma http://bit.ly/1jXyJup
Early: New direction for epigenetic treatment - inhibiting HDAC 6 with ACY-215
* PAL updated today:
Biomarkers for lymphoma - about biomarkers, trials, perspectives, and resources PAL
* PAL updated content:
Find trials by agent - In the News with focus on agents with encouraging recent reports PAL find trials by type of AGENT
How to Help Please give what you can to support our mission.
Giving Thanks! ... which are due for recent donations by Phyllis, Teresa, Mina (today) , Doug/Barb David, Mary, Mark, Jama, Daniel , Judith, Bill, Phillip, Elizabeth , Toby, Patricia, Gail, Tina Paul, Erin, Steve, Betty, Leonard, Carol, Naomi , Marshall, Nancy, Dennis, David, Cheryl, Susan, and Jane ...
Sunday, Dec 29
* PAL updated today:
Biomarkers for lymphoma - about biomarkers, trials, perspectives, and resources PAL
* PAL updated content:
Find trials by agent - In the News with focus on agents with encouraging recent reports PAL find trials by type of AGENT
This NEW section helps to find trials for agents that have encouraging recent reports.
*Medscape 2013:
Top Clinical Cancer Advances: ASCO 2013 Report http://bit.ly/1hJJKLy
*ASCO 2013:
Talking With Someone Who Has Cancer, with Dr. Lidia Schapira http://bit.ly/1hGRMou
*MSKCC 2013:
Lymphoma Q&A http://bit.ly/K7B4U7
*Patient Power 2013:
Promising Advances in Treating Mantle Cell Lymphoma http://bit.ly/1ij2ZOG
*MNT 2013: discusses secondary targets as well
Study confirms target of potent chronic leukemia drug http://bit.ly/18OBcTf
How to Help Please give what you can to support our mission.
Giving Thanks! ... which are due for recent donations by Doug/Barb (today) David, Mary, Mark, Jama, Daniel , Judith, Bill, Phillip, Elizabeth , Toby, Patricia, Gail, Tina Paul , Erin, Steve, Betty, Leonard, Carol, Naomi , Marshall, Nancy, Dennis, David, Cheryl, Susan, and Jane ...
Just a few days remaining to make a tax-deductible contribution for 2013 to show your support for PAL's mission.
Friday, Dec 27
* PAL: Message to supporters and advisors from the president: Thankful, encouraged, enthused, and determined PDF
How to Help Please give what you can to support our mission.
Giving Thanks! ... which are due for recent donations by Mary (today), Mark (today), Jama (today), Daniel , Judith, Bill, Phillip, Elizabeth , Toby, Patricia, Gail, Tina Paul , Erin, Steve, Betty, Leonard, Carol, Naomi , Marshall, Nancy, Dennis, David, Cheryl, Susan, and Jane ...
Just a few days remaining to make a tax-deductible contribution for 2013 to show your support for PAL's mission.
* NEJM: Perspective, full text:
First FDA Authorization for Next-Generation Sequencer Francis S. Collins, M.D., Ph.D., Margaret A. Hamburg, M.D. http://bit.ly/1dAzWQQ
*ASCO Post 2013:
“The Quest to Optimize Personalized Therapies for Cancer -- A Conversation With Brian J. Druker, MD” http://bit.ly/1a85k73
* ASCO post 2013:
“Sustained Complete Responses With Novel Immunotherapy in Lymphoma” http://bit.ly/1dCMEyI
*ASCO post:
“Oncology Drug Dosing: Can an Optimal Dose Be Fine-Tuned for Each Patient?” http://bit.ly/1gWKkbb
This is an important item to read for research advocates I feel. (Karl)
* MDA 2013:
Ibrutinib keeps CLL in check http://bit.ly/1cQvQlY
* The Atlantic 2013:
When Will Genomics Cure Cancer? A conversation with the biogeneticist Eric S. Lander about how genetic advances are transforming medical treatment http://bit.ly/19J7QUJ
*Cancer Research UK 2013:
Genetic profiling tracks progression from manageable blood cancer into deadly disease http://bit.ly/Joci0D
* Cancer Network 2013:
Regimen Shows Promise for Lymphoma Patients With Cardiac Conditions http://bit.ly/1cx1cDn
* J Nuc Med 2013:
Early Determination of Prognosis by Interim 3'-Deoxy-3'-18F-Fluorothymidine PET in Patients with Non-Hodgkin Lymphoma. http://1.usa.gov/1dD7HBb
* Medscape: Do Antihistamines Relieve Neupogen-Induced Bone Pain? http://bit.ly/1dbkCvX
* A trial to help find out:
Evaluation of Loratadine for Prevention of Pegfilgrastim-Induced Pain - Full Text View - ClinicalTrials.gov http://1.usa.gov/1c9nvc9
Monday, Dec 23
* “First FDA Authorization for Next-Generation Sequencer Francis S. Collins, M.D., Ph.D., Margaret A. Hamburg, M.D. http://bit.ly/1dAzWQQ
* NYT 2013:
Life, Interrupted: By a Dog http://nyti.ms/1cNbwlr
* News Medical 2013:
Engineered immune cells show antitumor activity in two patients with advanced cancers http://bit.ly/1icV2KT
* Brian Koffman's blog 2013:
ASH 2013: Dr. Wiestner Discusses Why Therapy in CLL Needs to be Individualized http://bit.ly/19leNxp
* MSKCC 2013:
Understanding Lymphoma http://bit.ly/1eyBOPb
* Video - imedex 2013: Dr. Myron Czuczman
ASH 2013: Lymphoma - Ibrutinib & Idelalisib - posted to Experts on Lymphoma
Sunday, Dec 22
* Study of interest:
Lenalidomide + Vaccine for Early-Stage Asymptomatic CLL/SLL - ClinicalTrials.gov http://1.usa.gov/1bYB4ew
Lenalidomide modulates the immune system so this seems a rationale combination with relatively low risk. Look for similar studies combining immune-checkpoint antibodies with vaccine, such as anti-pd1/L in future.
See also for Len: http://lymphomation.org/lenalidomide-mechanism.htm
* Ann S. LaCasce, MD - excellent video presentation
Lymphoma at ASH 2013 BMT Grand Rounds
Excellent summary of highlights for indolent lymphoma
* Imedex 2013: Video
ASH 2013: CLL - Best of the day - video interview with Dr. Brown on outcomes in relapsed disease
Impressive insights provided by Dr. Jennifer Brown. Discussion and questions raised here on immune and targeted therapies. A caution about use of fish oil with some targeted agents, such as ibrutinib.
* MSKCC 2013: Video
Risk Factors for Lymphoma and how it's diagnosed Posted to Risk factors
* Leuk Lymph 2013:
Body mass index, height and risk of lymphoid neoplasms in a large United States cohort. Posted to PAL - Risk factors
* Br J Haematol 2013:
Safety and efficacy of Zevalin for untreated follicular lymphoma patients. An Italian cooperative study.
Posted to PAL - Zevalin In the News
Single arm study: 50 patients with stage II "bulky", III or IV FL received a single treatment course with (90 Y)-Ibritumomab-Tiuxetan as initial therapy. The median age was 60 years. Bone marrow involvement (<25%) was observed in 24 patients (48%) and 7 (14%) had an elevated LDH level. The overall response (ORR) and CR rates were 94% and 86%, respectively with a median follow-up of 38·8 months. The median progression-free survival (PFS) was not reached, whereas the 3-year estimated PFS and overall survival (OS) rate was 63·4% and 90%, respectively.
* Br J Haematol 2013:
A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas. http://1.usa.gov/1dvY1sd
Whereas efficacy of this combination was low in heavily pre-treated DLBCL, there was a signal of activity in relapsed/refractory PTCL utilizing the modified schedule.
* University of Iowa 2013:
Staph stoppers: New vaccine from University of Iowa protects against lethal pneumonia caused by staph bacteria http://bit.ly/JMPmsq
Saturday, Dec 21
Featuring today recent updates and new topic pages by PAL
* PAL: Holiday card best wishes from Image file
* PAL: New topic
Off-label use of treatments for lymphoma
A new topic page to keep track of possible changes in how the off-label use of treatments may evolve in the wake of the approval of expensive targeted oral drugs for narrow indications (such as ibrutinib for Mantle Cell lymphoma).
* PAL: Message to supporters and advisors from the president: Thankful, encouraged, enthused, and determined PDF
How to Help Please give what you can to support our mission.
Giving Thanks! ... which are due for recent donations by Judith (today), Bill (today), Phillip (today), Elizabeth , Toby, Patricia, Gail, Tina Paul , Erin, Steve, Betty, Leonard, Carol, Naomi , Marshall, Nancy, Dennis, David, Cheryl, Susan, and Jane ...
* PAL - Perspective on endpoints for first line treatment of indolent lymphoma
How might we better measure success ? PAL
* PAL - Perspective on Rising Healthcare Costs ...
Threatening Access to Quality Cancer Care PAL
Friday, Dec 20
* Holiday card best wishes from PAL
* Blood 2013:
How I treat nodular lymphocyte predominant Hodgkin lymphoma http://bit.ly/1jq4Keu
* Ann Onc 2013:
Systematic review and meta-analysis on the diagnostic performance of FDG-PET/CT in detecting bone marrow involvement in newly diagnosed Hodgkin lymphoma: is bone marrow biopsy still necessary? http://1.usa.gov/1fLYOHL
* Clinical Oncology 2013:
Bruce Cheson, MD: How I Treat Follicular Lymphoma—Part II http://bit.ly/1kqnmJn
* Medscape 2013:
Is Obinutuzumab the Drug to Watch in CLL? video http://bit.ly/19Bi4qm
* Dana Farber 2013:
Live Webchat: Current and Future Treatments for Lymphoma http://bit.ly/1jlULXt
* Patient Power 2013:
Treating CLL: More Options Than Ever Before http://bit.ly/1cRraQg
* MSKCC 2013:
Will I become addicted to the pain medications I may need during my cancer treatment? http://bit.ly/1i22yIv
*Med Onc 2014;
Hodgkin lymphoma transformation of chronic lymphocytic leukemia: cases report and discussion http://1.usa.gov/1kkl26E
* Sunrise Rounds
The 46-Gallon Gift http://bit.ly/1eqUccZ
As lymphoma patients, we can't donate blood, but we are thankful for those who can and do.
* Medpage today 2013:
Tumors May Give Rise to Autoimmunity http://bit.ly/19BitZM
* Boing Boing 2013:
At 'The Houston Cancer Quack,' Skeptics call on Congress to investigate Stanislaw Burzynski http://bit.ly/1jpAvEo
See the web site and write your representatives here http://thehoustoncancerquack.com/
Wednesday, Dec 18
How to Help Please give what you can to support our mission.
Giving Thanks! ... which are due for recent donations by Elizabeth (today), Toby, Patricia, Gail, Tina Paul , Erin, Steve, Betty, Leonard, Carol, Naomi , Marshall, Nancy, Dennis, David, Cheryl, Susan, and Jane ...
"Faith. Gut feeling. Call it what you will. Science and reason could not produce one best option. Only because they couldn't, I trusted a feeling to make the final call." Great advice here from a physician and patient on the "distressing decisions" that are so common for lymphoma - because we have so many effective (standard) and promising (investigational) therapies to chose from. (Karl)
* Oncology Times 2013:
HIV-Associated NHL: Pooled Analysis Reinforces Several Standard Treatment Practices http://bit.ly/JFDJE1
* Weill Cornell 2013
EZH2 Represents a New Target for Treatment of B-cell Lymphomas http://bit.ly/1kfD9um
* Oncology Times 2013:
Novel Agents Rapidly Emerging for CLL http://bit.ly/19wQrPd
* Plain Dealer 2013:
Hodgkin's lymphoma patients who freeze sperm before treatment have better chance of becoming dads after, study shows http://bit.ly/1kVprdB
* MNT 2013:
Improving the prognosis of patients with chemo-resistant lymphoma http://bit.ly/1dOf3lP
* Medscape 2013:
Tailoring CLL Treatment to a TTT http://bit.ly/1gCvpTf
Karl: Reposting this item with excellent vision here I feel – how to evaluate and make use of these new active agents.
Tuesday, Dec 17
* PAL:
Helping to overcome barriers to participation in trials through education, outcome reporting, and trial location tools.
How to Help Please give what you can to help us ...
Giving Thanks! ... which are due for recent donations by Toby (today), Patricia, Gail, Tina Paul , Erin, Steve, Betty, Leonard, Carol, Naomi , Marshall, Nancy, Dennis, David, Cheryl, Susan, and Jane ...
* Medscape 2013:
Idelalisib Raises Eyebrows in Lymphoma -- Posted to PAL PI-3-kinase inhibitors
* Patient Power 2013:
CLL Research: How Far Have We Come? Where Are We Headed? - http://bit.ly/IQpnQL
* Helio 2013L
Brentuximab vedotin induced long-term remissions in Hodgkin’s lymphoma http://bit.ly/1bLjSZG
* Oncology Times 2013:
ONLINE FIRST: Genetically Modified T Cells Now Shown to Produce Long-Term Responses in Leukemia Patients http://bit.ly/18Mx7cQ
* Baylor College of Medicine 2013:
Activated “killer” T-cells effective against resistant lymphoma http://bit.ly/1bLXOSa
* Patient Power 2013:
Optimism and Changes Ahead for Blood Cancer Patients http://bit.ly/1heU7Xp
* Medscape 2013:
Tailoring CLL Treatment to a TTT http://bit.ly/1gCvpTf
Karl: Excellent vision here I feel – how to evaluate and make use of these new active agents.
SNIP: (Applies to lymphoma too) “We are thinking about using a sequential TTT treatment (triple T), combining the best agents in a sequence that tailors the treatment according to the initial tumor load and the response to therapy (ie, complete response vs partial response), minimal residual disease [MRD]-positive vs MRD-negative). This treatment approach will utilize all currently available options in a nonaggressive, nontoxic way and will aim to eliminate or control the malignant clone.”
* Neurologica Blog 2013:
Strike Three for Multivitamin Use http://bit.ly/19PH75c
Monday, Dec 16
* Study of interest: not yet recruiting
ABT-199 + Rituxan Versus Bendamustine + Rituxan for Relapsed or Resistant CLL http://1.usa.gov/J0zsdl
seems like everyone is taking aim at CLL as the path to take towards initial approval. Here we see ABT199 (a targeted agent) combined with Rituxan ... going up against Bendamustine + Rituxan.
* Reposting this VERY encouraging report for DLBCL - MNT 2013:
Patients with non-Hodgkin lymphomas resistant to treatment benefit from drug-antibody pair http://bit.ly/18IETHK
"To date, the trial has enrolled 62 patients with B-cell lymphomas, including 44 diagnosed with DLBCL. Most the patients were no longer responding to previous therapy, and 23 percent had never responded to any treatment.
* ASH Education Program 2013:
Novel therapy for Hodgkin lymphoma http://bit.ly/19LtK69
* MSKCC 2013:
New Diagnostic Test for Blood Cancers Will Help Doctors Tailor Treatments http://bit.ly/1b5oDxs
* MNT 2013
Improved cooling cap for chemotherapy hair loss 'more effective' http://bit.ly/18LORZ3
* Targeted Oncology:
Promising Ibrutinib Responses Demonstrated in Waldenström’s Macroglobulinemia http://bit.ly/1b6yeE2
* Br J Haematology 2013:
Hodgkin lymphoma patients in first remission: routine positron emission tomography/computerized tomography imaging is not superior to clinical follow-up for patients with no residual mass. http://1.usa.gov/1kMBsSJ
* KevinMD.com 2013:
Herbal supplements may be natural, but that doesn’t mean they’re safe http://bit.ly/IPHDJR
* NYtimes 2013:
Skip the Supplements http://nyti.ms/1bKFdpz
Sunday, Dec 15
* Onclive 2013:
Dr. Goy on CAR-Modified T Cells in Lymphoma http://bit.ly/1bNnG0V
* MNT 2013:
Patients with non-Hodgkin lymphomas resistant to treatment benefit from drug-antibody pair http://bit.ly/18IETHK
"To date, the trial has enrolled 62 patients with B-cell lymphomas, including 44 diagnosed with DLBCL. Most the patients were no longer responding to previous therapy, and 23 percent had never responded to any treatment.
Forty percent of the 43 evaluable DLBCL patients had an objective response to the drug with a median duration of 36 weeks, including some of more than eight months. Seven had complete remissions and 10 had partial remissions. In the other B-cell lymphoma patients, 22 had an objective response.
This and other reports on this story Posted to PAL - antibody-drug conjugates
* MSKCC 2013: When the Holiday Cheer Gets You Down:
Eight Tips for Coping with Difficult Emotions http://bit.ly/1dbH6ei
* New Statesman 2013:
Why it's time to ditch the word "cancer": A former president of the Association of Surgeons of Great Britain and Ireland argues that the word “cancer” is unhelpful in efforts to lead patients away from quacks. http://bit.ly/1fq12wi
* PAL resources:
2 news items on activity of Immune Checkpoint Blocker Combo Posted to PAL - Immune Therapy
* ASCO Connection 2013:
Parenthood and Cancer http://bit.ly/1kEriU3
* Cure 2013:
Why Observing Treatment Milestones is an Individual Decision http://bit.ly/1dv07ZE
* MSKCC 2013
Lymphoma Clinical Update http://bit.ly/1kEr3Iy
* Science-based Medicine 2013:
5 out of 4 Americans Do Not Understand Statistics http://bit.ly/1dblyON
Fri, Dec 13
* Lympho Bob:
Rituxan + Pidilizumab for Follicular Lymphoma http://bit.ly/1bCkJfk
* PAL:
How to Help Please give what you can to help us ... to help accelerate progress against lymphoma!
Giving Thanks ... which are due for recent donations by Tina (today) Paul (today), Erin (today), Steve, Betty, Leonard, Carol, Naomi , Marshall, Nancy, Dennis, David, Cheryl, Susan, and Jane!
* Study approach of interest:
Romidepsin + Oral 5-Azacitidine in Relapsed/Refractory Lymphoid (b and t-cell) Malignancies - ClinicalTrials.gov http://1.usa.gov/1frcpUP Location: NY City
Thu, Dec 12
* BMNT 2013:
Growing umbilical cord blood stem cells in lab before transplant boosts leukemia, lymphoma survival http://bit.ly/18E8U8k
* News Medical 2013:
Combination therapy safe and active in follicular lymphoma http://bit.ly/1hOICbQ
* MNT 2013:
Discovery of CXCR4 mutations in Waldenstrom's Macroglobulinemia helps identify which patients are more likely to benefit from ibrutinib http://bit.ly/18CHVNR
* MNT 2013:
Scientists shed new light on the fight against cancer - They have discovered how the anti-tumor activity of immune cells can be restored http://bit.ly/Ja9ap9 (not lymphoma specific but interesting)
* NY Times 2013:
Limits of Vitamin D Supplements http://nyti.ms/1flbMMp
* Med xpress 2013
Targeted antibody, immune checkpoint blocker rein in follicular lymphoma (pidilizumab and Rituxan) http://bit.ly/JfFTKz
One drug attacks tumor cells directly, the other treats the immune system by taking the brakes off T cell response. Together, they put half of the patients with relapsed follicular lymphoma into complete remission in a phase II clinical trial at The University of Texas MD Anderson Cancer Center.
* News Medical 2013:
Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting http://bit.ly/1gZAsKM
* Brian Kauffman's Blog 2013:
ASH 2013: A Quick Perspective http://bit.ly/1jNsaZ0
* MNt 2013:
Discovery of CXCR4 mutations in Waldenstrom's Macroglobulinemia helps identify which patients are more likely to benefit from ibrutinib http://bit.ly/18CHVNR
* Medscape 2013:
Idelalisib With Rituximab Boosts Survival in Relapsed CLL http://bit.ly/1cBVK05
* Brian Kauffman's blog 2013:
iwCLL 2013: Dr. Tom Kipps Discusses the Changing Role of Chemo-immunotherapy in CLL and the New Role of BCL-2 Blockers http://bit.ly/1cqbfot
Wed, Dec 11
* Business Wire 2013:
Studies Evaluating REVLIMID® (Lenalidomide) in Lymphoma Presented at ASH Posted to PAL - Lenalidomide
* ASCO 2013: Overview
Clinical Cancer Advances 2013: Blood and Lymphatic Cancers http://bit.ly/1bBNJIx
* FHCRC 2013:
Study finds link between allergies and increased risk of blood cancers in women: Gender may play a role in the association of chronic immune stimulation and development of hematologic cancers Posted to PAL - Risk factors
* Medical Xpress 2013:
Drug-antibody pair has promising activity in non-Hodgkin lymphoma Posted to PAL - antibody-drug conjugates
* Helio 2013:
Reduced-intensity HSCT recipients spared from post-HSCT cognitive impairment http://bit.ly/1gnsWfj
* Onc Live 2013:
Dr. van den Brink on Adding Ibrutinib to R-CHOP in NHL http://bit.ly/18AjnF4
* Dr Sharman 2013:
Ibrutinib in front line elderly (CLL) http://bit.ly/1d7nZSr
* Onc Live 2013
Dr. Furman on Avoiding Chemotherapy With Idelalisib (CLL) http://bit.ly/1fhcVoe
* Onc Live 2013:
Dr. Flinn Discusses the Efficacy of IPI-145 in CLL http://bit.ly/1kwujG0
* Targeted Oncology 2013;
Novel PI3K Inhibitor IPI-145 Shows Promise in CLL http://bit.ly/IO2flc
* Medscape 2013:
Novel Targeted Therapies in CLL Might Expand Treatment Option http://bit.ly/1kwELgM
* Onc Live 2013:
Dr. Seymour on the Efficacy of ABT-199 in High-Risk CLL http://bit.ly/1d6ZOnf
Tues, Dec 10
* Dana Farber 2013:
Drug-antibody pair has promising activity in non-Hodgkin lymphoma http://bit.ly/18RLL8n
* Dr Sharman's Blog 2013:
IWCLL videos - thanks Brian http://bit.ly/INz41G
* MEdscape 2013:
Cognitive Impairment After HSCT Varies With Intensity of Regimen http://bit.ly/1cllF8X
* Medscape: 2013:
Excitement Over CAR-Engineered T-cells in Leukemia and Lymphoma http://bit.ly/1bQRLOL
* NYTimes 2013:
On Health Exchanges, Premiums May Be Low, but Other Costs Can Be High http://nyti.ms/18whwBe
* MNT 2013:
Penn study results for first 59 leukemia patients who received cell therapy http://bit.ly/18k9wVV
* OncLive 2013:
Dr. Brown on Idelalisib Plus Rituximab in CLL http://bit.ly/1bqXg0p
* News Medical 2013:
Bortezomib reduces GVHD, boosts survival for patients receiving stem-cell transplants http://bit.ly/18wy4WC
* Pharmagossip 2013:
FDA official: “clinical trial system is broken” - BMJ http://bit.ly/1iQVVdt
Monday, Dec 9 - late edition
* Publicly Funded Clinical Trials and Cancer Care -
by Richard L. Schilsky, MD - YouTube http://bit.ly/J7W8sZ
Long ... but very important information regarding the unique role of publicly-funded clinical research
-- that ask important questions that would not be asked in industry-funded trials.
* Broad Potential of IPI-145 in Blood Cancers http://bit.ly/18ua86e
NYT 2013:
Cancer Survivors Celebrate Their Cancerversary http://nyti.ms/1ckI7Pn
* Loyola 2013:
Breakthrough in treating leukemia, lymphoma with umbilical cord blood stem cells: Study finds that growing stem cells in lab before transplant boosts survival http://bit.ly/1e0NY3k
* J Clin Onc 2013:
Fractionated 90Y-Ibritumomab Tiuxetan Radioimmunotherapy As an Initial Therapy of Follicular Lymphoma: An International Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria. http://1.usa.gov/1f05uRI
* Dana Farber 2013
Gene 'driver' of Waldenstrom's Macroglobulinemia in up to one-third of patients identified: Drug that targets the driver mutation proves effective in animal studies http://bit.ly/1hI8FRW
* PAL - Compiled articles on CAR-Engineered T-cells
Chimeric antigen receptor t-cells - CART 19) - brief overview: where they harvest your killer t-cells ... then program the antigen receptor on these cells to bind to cd19 on the tumor cells - then give the cells back to you. The key is that the cells can persist and expand in the body - having the potential to eradicate all b-cells with cd19 - normal and malignant. Karl
* Medscape 2013:
New Drug Combo Potentially 'Practice Changing' in CLL http://bit.ly/1hH4s0Y
* ASH 2013:
Innovative Compounds, Combination Therapies Improve Care of Patients with Wide Range of Blood Disorders http://bit.ly/1bpVOz5
* Leuk Lymphoma. 2013:
Use of Positron Emission Tomography-Computerized Tomography (PET-CT) in the Management of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL). http://1.usa.gov/1cuAauw
Monday, Dec 9, 2013
* Publicly Funded Clinical Trials and Cancer Care -
by Richard L. Schilsky, MD - YouTube http://bit.ly/J7W8sZ
Long ... but very important information regarding the unique role of Publicly funded clinical research
-- that ask important questions that would not be asked in industry-funded trials.
* Brian Kauffman's Blog 2013:
iwCLL 2013: Dr. Byrd Discusses 17 p deletion with Ibutinib http://bit.ly/1bt9Occ
* Nature 2013:
Policy: Twenty tips for interpreting scientific claims http://bit.ly/197FZgT
* Lymphobob 2013:
ASH Day! Zevalin and Follicular Lymphoma http://bit.ly/J0bSOM
Some ASH press releases:
* Dana Farber 2013:
Novel drug regimen can improve stem cell transplantation outcomes: Bortezomib (Velcade) reduces GVHD, boosts survival http://bit.ly/1bpTyHZ
* Oncology Report 2013:
Treated T-cells induce remissions in chemo-refractory B-cell lymphomas http://bit.ly/1dYIqWU
* ASH :2013
High-tech gene-therapy advances offer hope for patients with hard-to-treat blood disorders http://bit.ly/1btaXjO
* For Traders 2013:
Sequenta's ClonoSIGHT MRD Test Can Detect Relapse of Diffuse Large B-Cell Lymphoma More Than Seven Months Before CT Scan Posted to PAL - Programmed T-cells - Licensed to Kill (CAR T-cells)
See also compiled MRD abstracts by PAL
* CHOP 2013:
T cell immunotherapy: Promising results in children and adults with leukemia: Researchers from The Children's Hospital of Philadelphia and University of Pennsylvania harness engineered T cells to eliminate tumors in blood http://bit.ly/1bnIuYr
Saturday, Dec 7, 2013
* PAL - Draft Perspective on endpoints for first line treatment of indolent lymphoma
How might we better measure success ? PAL
* PAL - Draft Perspective on Rising Healthcare Costs ...
Threatening Access to Quality Cancer Care PAL
*Medpage today 2013
Major Studies, Novel Talks Highlight ASH http://bit.ly/IIuxgV
* Social Reader 2013:
Watch How These Cancer Patients Reacted To Getting Hilariously Awful Makeovers http://bit.ly/19nlCbM
* The Atlantic 2013:
How to Read About Science http://bit.ly/IIggRi
* Patient Power 2013:
Why MRD (Minimal Residual Disease) Matters for CLL http://bit.ly/18dPegI
Friday, Dec 6, 2013
* Draft Perspective on endpoints for first line treatment of indolent lymphoma
How might we better measure success ? PAL
* MNT 2013
Doubts cast over benefits of vitamin D supplements http://bit.ly/18do9dG
"What this discrepancy suggests is that decreases in vitamin D levels are a marker of deteriorating health."
* Dr Sharman's Blog 2013;
Diffuse Large B Cell Lymphoma (knowing your ABC's and GCB's) http://bit.ly/1f1lALn
"This should be in their interest anyway because the FDA loves "companion diagnostics" for selecting individuals for therapy. I predict that in the future, DLBCL management will go like ..."
* Cancer Research Inst 2013:
Emily's Story: A Young Girl Beats Cancer with Immunotherapy http://bit.ly/18mlyfp
* Medpage Today 2013:
Should Bone Marrow Donors Be Paid? http://bit.ly/1kgyWnt
* Brian Kaufman's blog 2013:
iwCLL 2013: Dr. John Byrd Discusses the Role of Novel Therapies versus Standard Chemo-Immunotherapy http://bit.ly/1iEd1uV
News Medical 2013:
Cancer triggers scleroderma, shows evidence http://bit.ly/18pZWf1
Anjou: not directly related to NHL, but I find this interesting given the association btw NHL and autoimmune diseases.
* We morn the loss of fellow advocate: Lori Monroe
See tribute to Lori: Lung Cancer Foundation of America http://bit.ly/18dMaRT
* PAL - lymphomation.org ... We can report many thousands of query clicks on our Locate Trials tools
See How to Help Please give what you can to help us ... to help accelerate progress against lymphoma!
Giving Thanks ... which are due for recent donations by Steve (today), Betty, Leonard, Carol, Naomi , Marshall, Nancy, Dennis, David, Cheryl, Susan, and Jane!
Thursday, Dec 5, 2013
* Stanford Social Innovation Review
The Elusive Craft of Evaluating Advocacy (politically charged reform) http://bit.ly/ILfyD5
Yet grantmakers have often hesitated to plunge in. Sometimes they worry about appearing too political or partisan. But more often they hesitate because effective advocacy is difficult, and evaluating whether various approaches are working is even harder.
* OncLive 2013:
ASH 2013 Preview: CAR Modified T Cells, Novel Assays, and Ibrutinib http://bit.ly/IPFLRN
* Medscape 2013:
ASH: 5 Hematology Procedures That Should Stop or Be Limited http://bit.ly/1iB8p8I
key points discussed page 2:
1) "limit the use of CT scans in asymptomatic patients following curative-intent treatment for aggressive lymphoma."
2) "diagnosis of lymphoma should be based on excisional biopsies, and clinicians should not initiate treatment of lymphoma based of tissue obtained exclusively from fine-needle aspirations."
* Stanford 2013:
An in-depth look at fertility and cancer survivorship http://stanford.io/1aBk1ic
* In the Pipeline 2013:
Cancer Cell Line Assays: You Won't Like Hearing This http://bit.ly/1bi7h4n
* Science Daily 2013:
New Insights Into Cancer Evolution Help Define Screening Window of Opportunity http://bit.ly/1cYRwxQ
* Medscape 2013:
'Tragedy' of Millions of Cancer Patients Not Getting Opioids http://bit.ly/1gFRrBN
* The ASCO Post:
Discussion of Protective Effect of Marriage' Found in 10 Most Clinically Significant Cancers http://bit.ly/IAvBUf
“Being married may contribute to improved outcomes because spouses may encourage their counterparts to seek medical attention for worrisome symptoms and to undergo definitive treatments. “There are many explanations for the vital question of why marriage is associated with improved cancer-specific survival after adjustment for demographics, stage, and treatment, but the most likely reason is that married patients have better adherence with prescribed treatments than unmarried patients,” the researchers reported.”
Comment: Research advocates might recommend that marriage status be included in the risk factors that will be accounted for in clinical trials. Patient-reported outcomes might do well to account for marriage status (and response to treatment) in the analysis.
Tuesday, Dec 3, 2013
* ASH Papers, 2013: MANY on Minimal Residual Disease (MRD) testing - ASH papers compiled by PAL
* Brian Kauffman's Blog 2013:
iwCLL 2013: Dr. Jeff Sharman Discusses Richter's Transformation in CLL http://bit.ly/18eeXU1
* KevinMD 2013:
The importance of sex in the midst of a cancer diagnosis http://bit.ly/18z5I3J
* Lympho Bob 2013:
ASH: Follicular Lymphoma and Lifestyle Factors http://bit.ly/1cO8ZsU
* NYT 2013:
Palliative Care, the Treatment That Respects Pain http://nyti.ms/1aoEWoJ
* News Medical 2013:
Tips to protect yourself from getting sick during cold and flu season http://bit.ly/1eLfGNy
* Brian Kauffman's Blog 2013:
We are all Fragile http://bit.ly/1cIxJ5H
* Brian Kauffman's Blog 2013:
iwCLL 2013: Dr. Jeff Sharman Discusses Two Issues: 17p deletion and Residual Disease in CLL http://bit.ly/1cgFjGz
*MNT 2013:
New genetic links found to most common type of leukaemia (CLL) http://bit.ly/1beZgsN
* The ASCO Post:
Discussion of Protective Effect of Marriage' Found in 10 Most Clinically Significant Cancers http://bit.ly/IAvBUf
Call 800-813-HOPE (4673) and speak with a CancerCare® social worker
The ASCO Post 2013:
FDA Announces Strategic Plan to Prevent Drug Shortages Posted to PAL - Shortages of Vital Blood Cancer Drugs!
snip:
The strategic plan, which was required by FDASIA and has been sent to Congress, describes actions the FDA will undertake to improve its current efforts to respond to early notifications of a potential shortage. These include improving the FDA’s communications about shortages, clarifying manufacturers’ roles and responsibilities by encouraging them to engage in certain practices that will reduce the likelihood of a shortage, updating the FDA’s internal procedures for responding to early notifications of potential shortages.
The plan also describes efforts the FDA is considering to address the manufacturing and quality issues that are most often the root cause of drug shortages. These include broader use of manufacturing metrics to assist in the evaluation of manufacturing quality, as well as incentives for high-quality manufacturing; internal organization improvements to focus on quality; and risk-based approaches to identify early warning signals for manufacturing and quality problems.
Saturday, Nov 30, 2013
* Financial, Assistance, Help, Cancer, Patients | CancerCare http://bit.ly/IoA5O9
Call 800-813-HOPE (4673) and speak with a CancerCare® social worker
* Am J Hematology 2013:
Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management. Posted to PAL - Mantle Cell Lymphoma
For selected indolent, low MIPI MCL patients, initial observation may be appropriate therapy. For younger patients with intermediate or high risk MIPI MCL, aggressive therapy with a cytarabine containing regimen ± autologous stem cell transplantation should be considered. For older MCL patients with intermediate or high risk MIPI, combination chemotherapy with R-CHOP, R-Bendamustine, or a clinical trial should be considered. At the time of relapse ...
* Brian Koffman's Blog 2013
iwCLL 2013: Dr. Jeff Sharman Outlines Options if You Need Treatment NOW http://bit.ly/1cSspMS
* Sunrise Rounds 2013:
Playing doctor http://bit.ly/ItOEQb
* Brian Kauffman's Blog 2013:
More on to Tell or Not to Tell http://bit.ly/1eGgCUi
* Medscape 2013:
Advances in Follicular Lymphoma http://bit.ly/1iWXvId
"This activity is intended for hematologists and oncologists. The goal of this activity is to educate clinicians on key prognostic and clinical factors to be considered when selecting treatment for patients with follicular lymphoma, as well as the benefits and risks of current and emerging evidence-based treatment strategies in the first-line, consolidation/maintenance, and relapsed/refractory settings."
HODGKINS REPORTS
* Hematol Oncol Clin North Am. 2013
Relapsed/Refractory Hodgkin Lymphoma: What Is the Best Salvage Therapy and Do We Need RIC-Allo SCT?
Posted to PAL - Hodgkins Disease
* Hematol Oncol Clin North Am. 2013
Early Intensification Treatment Approach in Advanced-stage Hodgkin Lymphoma. http://1.usa.gov/1eJqoVz
* Hematol Oncol Clin North Am. 2013
Induction Therapy for Advanced-stage Hodgkin Lymphoma: Late Intensification (ABVD Chemotherapy Followed by High-dose Chemotherapy and Autologous Stem Cell Transplant Only for Those Who Relapse). http://1.usa.gov/Iu0aLd
TIPS for Using ACA Insurance Exchange:
There is no need to shop for insurance on the exchange if you have Medicare.
If you already have private insurance it’s wise to apply on the Exchange anyway so you can take advantage of providers competing with price when selling ACA compliant plans. If you received cancelation notices from your private insurance … there is no need to panic as you should shop on the exchange anyway.
Prudent - first step: SECURITY
Any online system (banking, etc) provides security risks - one such risk is when your local computer is infected with a program that can capture sensitive private information.
MalewareBytes is a free cleaning program that's highly rated.
You might run it prior to using ANY online system that involves private information:
http://www.malwarebytes.org/ (3 steps: download, install, run)
ACCOUNT (step 1):
Go to http://1.usa.gov/GzzB6L the Exchange and create an account
To create an online account requires a working email account and verification by email
After entering a username, desired password and email account, you will have to respond to the email sent to that account to create the Insurance Exchange online account.
APPLICATION (step 2):
I think there is only one application you can maker per account.
If you filed a joint tax return ... you probably want to apply for insurance as a family.
FINANCIAL INFO:
To create an application you will need last year's financial tax information. Have ready your 1040 and other income statements.
These are unofficial tips and tricks (not guarantees) ... that we hope will help you and others in the application process.
Friday, Nov 29, 2013
HOLIDAY ITEMS:
* NYT 2013:
Living With Cancer: Giving Thanks and Latkes http://nyti.ms/IhD0b8
* Dana Farber 2013:
Managing the Holidays When You Have Cancer http://bit.ly/1bXikNb
* News Medical 2013
Ten tips for safe Thanksgiving meals http://bit.ly/1ibWzlv
* NYT 2013:
Bad Thanksgiving http://nyti.ms/1bWNpAn
“So you think you have time for a cup of coffee?” Sybil asks finally. “If I make it instant?”... I am laughing. I am doubled over, laughing. Here is my big insight: You can have a Stage 3 cancer but when a friend cracks you up, you are as alive as anyone else. So here we are 18 years later.
PERSPECTIVES:
* Brian Kaufman's blog 2013:
iwCLL 2013: Dr. Jeff Sharman Discusses Why We Feels so Lousy with Cancer http://bit.ly/1b4wWsS
* Dr Sharman's Blog 2013:
Off label drug use http://bit.ly/187feFg
SURVIVORSHIP
* Study of interest:
Testing Ibrutinib for Relapsed/Refractory Marginal Zone Lymphoma - ClinicalTrials.gov http://1.usa.gov/1863kvn
Key eligibility: Previously received one or more lines of therapy including one CD20-directed chemoimmunotherapy regimen with documented failure to achieve at least PR or documented PD after, the most recent systemic treatment regimen
* Science Daily 2013:
Cancer Patients at Increased Risk for Severe Flu Complications Posted to PAL - Immunization Guide
* Science Daily 2013:
Supporting Others Brings Healing to Cancer Survivors http://bit.ly/1ep92wn
Wednesday, Nov 27, 2013
* ASH Paper:
Outcomes In Splenic Marginal Zone Lymphoma: Analysis Of 108 Patients Treated In British Columbia http://bit.ly/1h7ozoK
* Study of interest:
Testing Ibrutinib for Relapsed/Refractory Marginal Zone Lymphoma - ClinicalTrials.gov http://1.usa.gov/1863kvn
Key eligibility: Previously received one or more lines of therapy including one CD20-directed chemoimmunotherapy regimen with documented failure to achieve at least PR or documented PD after, the most recent systemic treatment regimen
If effective (given the eligibility requirement above) would show that Ibrutinib addresses an unmet need.
* NCI: Cancer Health Disparities: http://1.usa.gov/1jKkMe7
* The ASCO Post:
IOM report on looming crisis in cancer care http://bit.ly/1hfYiEV and proposed solutions.
* Medscape 2013:
Dr. Cheson on ASH 2013: Big Year for CLL, Lymphoma http://bit.ly/1b0SQNA
* ASH Paper:
Rituximab Maintenance For a Max Of 5 Years In Follicular Lymphoma: Randomized Phase III Trial SAKK 35/03
Posted to PAL: Maintenance Rituxan - Comments on News
Monday, Nov 25, 2013
* Medscape 2013:
ASH 2013: Big Year for CLL, Lymphoma http://bit.ly/1b0SQNA
* Nami.org:
Fact sheet on patient protections under Affordable Care Act (ACA) http://bit.ly/18wZor7
* American Journal of Gastroenterology:
Efficacy of an Encapsulated Probiotic Bifidobacterium infantis 35624 in Women with Irritable Bowel Syndrome http://bit.ly/18hIiQ5
* J Clin Oncol. 2013
False-Positive PET in allo but not auto SCT treatment for #lymphoma - Posted to PAL: PET imaging
* NPR 2013:
Remember 'French Fries Cause Cancer'? Here's The Acrylamide Update http://n.pr/1izHg3J
* U Nebraska MC 2013:
UNMC researchers work to improve outcomes of lymphoma patients http://bit.ly/17S8Bqb
* PAL - lymphomation.org
Day and night we provide evidence-based support for patients and caregivers.
Today we need your support in order to continue our services.
See How to Help Please give what you can.
Giving Thanks ... which are due for recent donations by Michelle (today),
Naomi , Marshall, Nancy, Dennis, David, Cheryl, Susan, and Jane!
Friday, Nov 22, 2013
* Dr Harpham 2013:
The Dangers of Pseudoscience --II http://bit.ly/1c857CA
* Oncology Times 2013: ONLINE FIRST:
HIV-Associated NHL: Pooled Analysis Reinforces Value of Several Standard Treatment Practices http://bit.ly/1jqRwJ3
* Medscape 2013:
Burkitt's Yields to Longer-Duration, Lower-Dose Chemo Posted to PAL: Burkitt's lymphomas
Nature 2013: timely with ASH
Policy: Twenty tips for interpreting scientific claims http://bit.ly/1jqIsnH
* ASH Paper:
Outcomes In Splenic Marginal Zone Lymphoma: Analysis Of 108 Patients Treated In British Columbia http://bit.ly/1h7ozoK
The BC finding is that splenectomy remains a reasonable treatment option for patients with SMZL.
* ASH Paper:
Prognostic Impact Of Somatic NOTCH2 Mutation In Splenic Marginal Zone Lymphoma http://bit.ly/I8buNl
A technical item that could guide research (such as selecting patients with a need for novel or more aggressive therapies). We assume that the test needs to be validated and is not yet available to guide clinical practice. (Karl)
ASH Paper:
Effective Treatment Of Chemo-Refractory DLBC Lymphoma With Anti-CD19 CAR T-cells http://bit.ly/1h7HnUX
* ASH Paper:
The Role Of PET/CT For Staging /Response To Chemo In Marginal Zone #Lymphoma (retrospective) http://bit.ly/1caC4i3
* Ottawa Edu:
Personal Decision Guide for helping to make tough health or social decisions http://bit.ly/I9pQ04
* NEJM:
Making Medical Decisions for Patients without Surrogates http://bit.ly/1bcxIdn
* NEJM:
Association of Nut Consumption with Total and Cause-Specific Mortality http://bit.ly/1cIfc9q
Good news for us "squirrels." (Karl)
Thursday, Nov 21, 2013
* ASH Paper:
Myeloablative cd-45 Radioimmunotherapy then Auto transplant for High-Risk T/B-cell and Hodgkin lymphoma http://bit.ly/1jprN3H
Early but very encouraging and interesting approach with goal of addressing urgent unmet need - relapse in high risk lymphomas.
* Brian Kauffman's Blog 2013:
iwCLL 2013: Dr. Jeff Sharman Gets Down to Discussing How He Treats Patients with High Risk Disease http://bit.ly/1fm72sw
Excellent discussion on when to treat ... in light of new insights about cytogenetic risk factors, such as p17 deletion. (KarlS)
* LymphoBob 2013:
ASH: Why Revlimid (Lenalidomide) + Rituxan Works (Maybe) http://bit.ly/18p5DgC
Nice discussion here on this important combination study and the clues or reactions in the body that are associated with best response. We would add that there's a need to validate the importance of cereblon (a molecule that Lenalidomide binds to) as a potential predictive marker for response to this agent. (KarlS)
See for example on Cereblon expression: Lenalidomide efficacy in activated B-cell-like... [Br J Haematol. 2013] - PubMed - NCBI http://1.usa.gov/1e3wb7x
* NYT 2013:
How Doctors Die http://nyti.ms/1bD59kd
"Of the 765 doctors studied, 64 percent had advanced directives, compared with about 47 percent for American adults over 40."
See also
CARING CONNECTIONS - NHPCO
Download Your State's Advance Directives - (scroll down to states) http://bit.ly/1a50vdr
* Today Health 2013:
Dishing up comfort: Program aims to boost cancer patients' appetites http://on.today.com/18mAlHk
See also Cancer Nutrition Consortium | Nutritional Guidance & Support Posted to PAL: Diet & Exercise
Tuesday, Nov 19, 2013
* PAL update:
Statistics versus Prognosis - a frequently asked question PAL on Statistics
* Oncology Times 2013:
Large Study Shows: For Pregnant Women with Lymphoma, Standard Chemotherapy Causes Few Complications http://bit.ly/18iSCVS
*Medscape 2013:
Replacing Doxorubicin in DLBCL Patients With Cardiac Problems http://bit.ly/1dbpDqQ
* Medscape 2013:
Burkitt's Yields to Longer-Duration, Lower-Dose Chemo http://bit.ly/Id5xxU
* Lympho Bob 2013:
ASH: Rituxan vs. Watching and Waiting (in terms of cost) http://bit.ly/1jha6mN
I'm a fan of Lympho Bob and he does a very nice job here with the outline of the analysis. I wonder if Rituxan monotherapy was included in the simulation as a possible initial first therapy for the watch and wait group and if that would have changed the findings in respect to cost? KarlS
* Onclive 2013:
Dr. DeVita on Chemotherapy in Hodgkin's Lymphoma http://bit.ly/1az5OFF
* Lymphoma Hub 2013:
Study evaluates early stem cell transplants for non-Hodgkin’s lymphoma http://bit.ly/181teWH
* Selected papers from ASH:
Oral drug Idelalisib In Patients With Double Refractory Indolent B-Cell Lymphoma http://bit.ly/1bKKzSB
PET Compared With CT After Rituximab Induction Therapy In Follicular Lymphoma: National Lymphocare Study http://bit.ly/1f9TRuv
We've heard expert comment that if you are PET negative after R-chemo following first treatment of FL that you probably don't need Rituxan maintenance - will do as well without it. We don't know if this is a consensus opinion though.
Follicular Lymphoma Grade 3 Treated With R-CHOP - long term outcomes (retrospective, single center) http://bit.ly/18jaQGI
Follicular #lymphoma in young adults: clinical characteristics and early treatment outcomes http://bit.ly/I1MW96
Selinexor (KPT-330) Phase I First-In-Class Oral Inhibitor Of SINE in Non Hodgkin’s #Lymphoma & CLL http://bit.ly/IdlxzY
No lymphoma trials listed on clinicaltrials.gov so far for this agent. Always good to see a new class of drug showing activity this early in testing
CEOP Alternating With Pralatrexate Front Line for Peripheral T-Cell Lymphoma (PTCL): Preliminary results http://bit.ly/1bGrJMf
* PAL - lymphomation.org
Day and night we provide evidence-based support for patients and caregivers.
Today we need your support in order to continue our services.
See How to Help Please give what you can.
Thanks are due for recent donations by Michelle (today), Naomi , Marshall, Nancy, Dennis, David, Cheryl, Susan, and Jane!
Monday, Nov 18, 2013
* * * 6 Year Follow-Up Of The PRIMA Study of Rituximab Maintenance In previously untreated Follicular Lymphoma Pts following Frontline r-chemo http://bit.ly/1j082j2
UPDATE: One perspective I've heard from experts .. on the six year follow up of the PRIMA study .. is that it has failed to demonstrate that delaying relapse with regularly scheduled Rituxan provides clinical benefit (improved survival). Another perspective is that that being free of disease improves one's quality of life because you have less stress and anxiety when there's no evidence of the disease. So it seems that patient and physician preference will continue to determine the use of maintenance Rituxan. ~ KarlS
* Brian Kauffman's blog 2013:
iwCLL 2013: Pharmacogenetics and Dr. Jeff Sharman Discusses New Prognostic Factors (CLL ) http://bit.ly/HTnJwU
* YouTube 2013:
Developing New Treatments for T Cell Lymphoma http://bit.ly/I9LQXR
* Blood 2013:
In the spotlight: a novel CD37 antibody-drug conjugate http://bit.ly/I9LBfi
* Newsweek 2013:
So Many Supplements, So Little Regulation http://bit.ly/1ilHI5r
* MNT 2013:
Personalized therapy using antitumor T cells from a patient's own cancer http://bit.ly/1cxvAcW
* * ASH Paper, 2013:
Bcl-2 Inhibitor ABT-199 Shows Anti-Tumor Activity Including CRs In High-Risk Relapsed/Refractory CLL http://bit.ly/18BOCwa
Find trials for ABT199 for CLL and Lymphoma http://1.usa.gov/SRZotl
* ASH Paper: ABT-199 in Relapsed/Refractory lymphoma: Responses Observed In All Mantle Cell Lymphoma (MCL) http://bit.ly/1b1rOM4
* Donations to PAL have increased of late but we are still well behind our goal and need -- of meeting expenses.
See How to Help Please give what you can.
Thanks are due for recent donations by Marshall (today) Nancy, Dennis, David, Cheryl, Susan, and Jane!
* * ASH Paper:
Prolonged Survival Of Poor Risk Follicular Lymphoma after primary R-CHOP Or HDS Auto SCT http://bit.ly/1eeifIp
A randomized multicenter study of 134 Follicular Lymphoma (FL) patients, selected for age less than 60 yrs. and poor prognostic features according to age-adjusted IPI (2-3) and IIL-score (3 or greater).
This study found an improved survival at 10 years for either approach (70%). The study shows the importance of achieving a complete response (CR) and molecular remission (MR) with primary therapy.
Friday, Nov 15, 2013
* PAL - carrying out our mission depends on public support - entirely: See How to Help Please give what you can.
Thanks are due for recent donations by Nancy (today), Dennis, David, Cheryl, Susan, and Jane!
such as by fostering the informed and routine consideration of clinical trials
* * * Ibrutinib in the News!
approved by FDA under accelerated pathway for MCL (a Btk-inhibitor) PAL
Studies recruiting patients PAL query - Find trials
* Dr Sharman 2013:
ASH 2013 - my abstracts http://bit.ly/1bySDWe
* ** ASH Paper: Minimal Residual Disease (MRD) Predicts PFS In Mantle Cell #Lymphoma: CALGB 50403 (Alliance) http://bit.ly/18Bzj6q
Comment: I'm very encouraged about this finding ... as the MRD test can substantially accelerate progress against lymphoma if it can be used reliably (instead of PFS) as a surrogate for clinical benefit. ~ Karl
* NYT 2013:
When the Doctor Disappears http://nyti.ms/HPHZiV
* Nat Rev Clin Oncol 2013:
Diffuse large B-cell lymphoma-treatment approaches in the molecular era. http://1.usa.gov/HWAUh0
* Dr Harpham 2013:
The Dangers of Pseudoscience http://bit.ly/1brUhpg
* Mayo Clinic Youtube 2013:
Celiac Disease and Risk of Lymphoma - Celiac Disease in the News http://bit.ly/17uAeFC
* USA Today:
Doctor accused of selling false hope to families http://usat.ly/18AzgYP
* Science-Based Medicine
USA Today versus Stanislaw Burzynski http://bit.ly/1aIgmif
Thursday, Nov 14, 2013
* PAL - carrying out our mission depends on public support - entirely: See How to Help Please give what you can.
Thanks are due for recent donations by Dennis, David, Cheryl, Susan, and Jane!
such as by fostering the informed and routine consideration of clinical trials
* * * Ibrutinib in the News!
approved by FDA under accelerated pathway for MCL (a Btk-inhibitor) PAL
To locate trials for Ibrutinib see PAL: Find Trials by Agent
* Blood 2013:
How I treat nodular lymphocyte predominant Hodgkin lymphoma. http://1.usa.gov/HRYBqQ
* Clinical Oncology 2013
Hodgkin Lymphoma Treatment Increases Stomach Cancer Risk http://bit.ly/HUb5OL
* ASH 2013:
6 Year Follow-Up Of The PRIMA Study of Rituximab Maintenance Posted to PAL with commentary
* Medical Xpress 2013:
Low-intensity therapy for Burkitt lymphoma is highly effective, study finds http://bit.ly/HUtsTE
* Br J Haemato
Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody Lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma. http://1.usa.gov/HSIQQ1
= SURVIVORSHIP
* KevinMD 2013:
The one little question that could save your life http://bit.ly/1hFFTmb
* CBS 2013:
Advocates push for straight talk about sex for cancer patients Posted to PAL: Sex & Fertility
= LEVELS of EVIDENCE - can we have confidence in scientific findings?
* Nature 2013
Weak statistical standards implicated in scientific irreproducibility http://bit.ly/HSZ8Jb
* E cancer news 2013"
World’s largest disease database will use artificial intelligence to find new cancer treatments http://bit.ly/1bCarOp
* Ars Technica
Is it time to up the statistical standard for scientific results?
A statistician says science's test for significance falls short http://bit.ly/HZ6UjH
= FINANCIAL SIDE EFFECTS OF TREATMENT
* Medscape 2013:
Frustration in Australia Over Slow Access to New Cancer Drugs http://bit.ly/1aEXvEQ
* ASH
American Society of Hematology as Part of “NDD United” Releases “Faces Of Austerity” Report http://bit.ly/1cpBpJi
= OTHER
* NY times 2013:
New Cholesterol Advice Startles Even Some Doctors http://nyti.ms/174CaYh
* Science Daily 2013:
Working Towards Personalized Cancer Treatment http://bit.ly/183IOyW
* NBCnews 2013
Vitamins don’t prevent heart disease or cancer, experts find http://nbcnews.to/17k5Spn
* Onclive 2013:
Another Immune Checkpoint Emerges as Anticancer Target http://bit.ly/1bp9smp
* Science Daily:
Finding Antitumor T Cells in a Patient's Own Cancer http://bit.ly/1bqCcI1
* John's Hopkins 2013:
Mystery explained: How a common chemo drug thwarts graft rejection in bone marrow transplants http://bit.ly/1apUc7U
Tuesday, Nov 12, 2013
* PAL: While improving of late ...
we are still very much behind and cannot sustain operations at current levels of donations
Our services depends on public support - entirely:
See How to Help
Please give what you can. Thank you.
* Blood 2013:
How I treat nodular lymphocyte predominant Hodgkin lymphoma. http://1.usa.gov/HRYBqQ
* NBCnews 2013
Vitamins don’t prevent heart disease or cancer, experts find http://nbcnews.to/17k5Spn
* Front Oncology 2012:
Therapy of newly diagnosed follicular lymphoma http://1.usa.gov/1dZEIJi
* Onclive 2013:
Another Immune Checkpoint Emerges as Anticancer Target http://bit.ly/1bp9smp
* Archives of Medical Research 2013:
Peri-Infusional Adverse Reactions to Rituximab in Patients with Non-Hodgkin's Lymphoma http://bit.ly/1i19VhI
*Brian Koffman's Blog 2013:
wCLL 2013: Part 2: Dr. George Calin Explains more about the Critical Role of micro-RNA in CLL http://bit.ly/19UfcEw
* Science-Based Medicine 2013:
Revealed by the FDA: The result http://bit.ly/1fwdUk7
* Forbes 2013
FDA Documents Paint Disturbing Picture Of Burzynski Cancer Clinic http://onforb.es/1bzIiYk
ASH
* * 6 Year Follow-Up Of The PRIMA Study of Rituximab Maintenance In previously untreated Follicular Lymphoma Pts following Frontline r-chemo http://bit.ly/1j082j2
* ASH 2013: Zevalin Vs. Maintenance With R In Patients With Newly Diagnosed Follicular Lymphoma after response to R-chemo http://bit.ly/17jNgpg
PAL and comments from others pending on these two important abstracts.
Sunday, Nov 10, 2013
* PAL depends on and appreciates your support: See How to Help
Thanks are due for recent donations by Jill, B&B , and Molly!
* Dartmouth 2006
Important study facts often missing in media reports about medical research http://bit.ly/17xcqVx
Anjou: posting this again before big meetings like ASCO and ASH
* Leuk Lymphoma 2013:
Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma. http://1.usa.gov/1da8vOn
*J Natl Cancer Inst 2013:
Independent validation of a model using cell line chemo-sensitivity to predict response to therapy. http://1.usa.gov/1exkYiZ
* Blood 2013:
Eradication of non-Hodgkin lymphoma through the induction of tumor-specific T cell immunity by CD20-Flex BiFP. http://1.usa.gov/17UMin9
Early but interesting: "We found that the BiFP exhibited stabilities that were comparable to the parental antibody rituximab, and were able to bind to both targets with unaltered binding affinity. Notably, our data indicated that CD20-Flex BiFP could not only eliminate lymphoma temporarily, but also potentiate tumor-specific T cell immunity, which affords a long-lasting protection from tumor recurrence."
* Kevin MD 2013:
A not-to-do list for those with chronic pain or illness http://bit.ly/HiIKBb
* Youtube 2013:
What is lymphoma http://bit.ly/1aLitI3
* Youtube 2013:
Cutaneous Lymphomas: Diagnosis and Staging Posted to PAL: T-cell subtype - cutaneous
Karl: Very nice, clear presentation
* Science-Based Medicine 2013
New concerns about the safety and quality of herbal supplements http://bit.ly/1eoYC39
* J Clin Onc 2013:
Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome http://bit.ly/1atL3aT
* Healthline 2013:
Hodgkin's Lymphoma and MS: A Genetic Connection http://bit.ly/1fkSAy7
Saturday, Nov 9, 2013
* Clinical Oncology News 2013:
Bruce D. Cheson, MD: How I Manage Follicular Lymphoma: Part I http://bit.ly/1iNRISj
*Sunrise Rounds 2013:
Should I say “Goodbye?” http://bit.ly/1cKrZwH
Anjou: Very interesting article on doctor-patient relationship
* Immunotherapy - not lymphoma-specifi:
Engineering hematopoietic stem cells to create melanoma specific CTL http://1.usa.gov/1bn64qu
ASH items:
* 3028 Long-Term Remissions Of Patients With Follicular Lymphoma Grade 3 Treated With Rituximab, Cyclophospamide, Doxorubicine, Vincristine and Prednisone (R-CHOP) https://ash.confex.com/ash/2013/webprogram/Paper64525.html
Anjou Comment: interesting abstract on grade 3 altho I am guessing it has a typo and they meant 1993 instead of 1973 given that tx includes rituxan-- shows good LT responses for grade 3....
4401 Patterns Of Care and Outcomes Of Anthracyclines In Grade 3 Follicular Lymphoma (FL) https://ash.confex.com/ash/2013/webprogram/Paper62376.html
Anjou comment: suggests that w grade 3, CHOP-R best initial tx altho retrospective large sample
4321 Proliferative Activity Of Neoplastic B Cells - Impact On The Prognosis Of Follicular Lymphoma https://ash.confex.com/ash/2013/webprogram/Paper62455.html
Wednesday, Nov 6, 2013
* PAL needs your support: See How to Help
Thanks are due for recent donations by Linda, Joseph, Elizabeth, and Deborah!
* Good Science and Good Medicine
Proposing the Patient-selected Control Trial (PCT) PCT-Published-to-Lymphomation.pdf
* Brian Kaufman's CLL blog 2013:
iwCLL 2013: Dr. George Calin on Micro-RNA http://bit.ly/HGq8LY
* Oncolink 2013:
The Affordable Care Act: The Basics Cancer Patients Need to Know http://bit.ly/1b3I9xR
* Dr Sharman's Blog 2013:
11q deletion CLL http://bit.ly/1gq1jlw
* YouTube 2013:
Lymphoma Explained Clearly! 1 of 2 http://bit.ly/YpModN
* YouTube 2013:
Lymphoma Explained Clearly! 2 of 2 http://bit.ly/VbCmwj
* Science Daily 2013:
Do You Want the Good News or the Bad News First? http://bit.ly/177nGZU
Tuesday, Nov 5, 2013
* YouTube 2013:
Dr. Goy on Lenalidomide for Mantle Cell Lymphoma http://bit.ly/HE5jRc
*Targeted Oncology 2013:
Brentuximab Vedotin as Frontline Therapy in Diffuse Large B-Cell Lymphoma http://bit.ly/1cJJMjB
*Oncology Times
Found: Inherited Cause of Predisposition to DLBCL http://bit.ly/1a3i9lc
*MNT 2013:
Liver tropism is key for B cell deletion immunotherapy http://bit.ly/HE75Sp
*MNT 2013
Study evaluates early stem cell transplants for non-Hodgkin's lymphoma http://bit.ly/1feNWl5
Lat Times: Science has lost its way, at a big cost to humanity - latimes.com#%21#%21 http://lat.ms/178gyMS
But concern about what is emerging as a crisis in science extends beyond the open-access movement. It's reached the National Institutes of Health, which last week launched a project to remake its researchers' approach to publication. Its new PubMed Commons system allows qualified scientists to post ongoing comments about published papers. The goal is to wean scientists from the idea that a cursory, one-time peer review is enough to validate a research study, and substitute a process of continuing scrutiny, so that poor research can be identified quickly and good research can be picked out of the crowd and find a wider audience.
NYT: Insurance Policies Not Worth Keeping - NYTimes.com http://nyti.ms/HEks58
* PAL: (subscription required)
Discussion and new articles on cd20 antibody approved for CLL http://lymphomation.forumchitchat.com/
Monday, Nov 4, 2013
* NYT 2013:
Doctor, First Tell Me What It Costs http://nyti.ms/1b799Jv
*NYT 2013:
Hopeful Glimmers in Long War on Cancer http://nyti.ms/17C378C
* NYTimes 2013:
Herbal Supplements Are Often Not What They Seem http://nyti.ms/1fdwHk9
* Targeted Oncology 2013:
Frontline Obinutuzumab (Gazyva) Approved for CLL http://bit.ly/1avCBxL
* Science Based Medicine 2013:
The sad saga of an Amish girl with a curable cancer whose parents are refusing chemotherapy in favor of “natural healing” http://bit.ly/1gn7GWI
* MNT 2013:
Study evaluates early stem cell transplants for non-Hodgkin's lymphoma http://bit.ly/1feNWl5
* PAL:
We're getting close to the end of year and are not close to achieving what is needed to sustain our operations.
How to support this site and the fight against lymphoma
Saturday, Nov 2, 2013
*Dr. Sharman's CLL & Lymphoma Blog
Gazyva (obinutuzumab -new cd20 antibody) approved http://bit.ly/1aQznTN
*Onclive 2013:
FDA Approves Frontline Obinutuzumab for CLL http://bit.ly/1h6BqbE
* Philly.com 2013:
Early Stem Cell Transplant May Benefit Some Non-Hodgkin's Lymphoma Patients http://bit.ly/19mSxQQ
* Medscape 2013:
Your Patient's Brain on Drugs -- Cancer Drugs http://bit.ly/16SQyVC
* Haematologica 2013:
Autologous stem cell transplantation after conditioning with Zevalin plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. http://1.usa.gov/1aigtkq
* Brit J Haematol 2013:
Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated aggressive non-Hodgkin lymphomas. http://1.usa.gov/181hk9b
* Medscape 2013:
Mindfulness Helps Improve Sleep in Cancer Survivors http://bit.ly/1iAxprE
* You tube 2013:
Diffuse large b-cell lymphoma http://bit.ly/1aZyEMS
* You Tube 2013:
Mr T T Cell Lymphoma Survivor http://bit.ly/HjoH59
You Tube 2013:
Medicines in Development - Leukemia & Lymphoma http://bit.ly/1ahTbvd
* Science Daily 2013:
Study Offers New Theory of Cancer Development http://bit.ly/HtgtI8
Friday, Nov 1, 2013
* * FDA Approves Gazyva™ (Obinutuzumab) for People With Previously Untreated Chronic Lymphocytic Leukemia (CLL) | http://bit.ly/1h6sza7
Gazyva AKA obinutuzumab (GA101) was approved for use in combination with chlorambucil for untreated CLL and is the first drug that the FDA has approved under its "Breakthrough Therapy" designation.
Comment: Another drug name I will have trouble pronouncing. You have to hand it to Roche - they know how to pick a protocol to go up against. That Chlorambucil + Gazyva beat Chlorambucil alone does not seem surprising. Why was the comparator not Chlorambucil + Rituxan ... or Chlorambucil + ofatumumab? Having new effective options is good for patients! Hopefully the off-label use of this drug will not inhibit testing of how it actually compares to other cd20 antibodies. ~ KarlS
*You Tube 2013:
Hodgkin's Lymphoma http://bit.ly/1aZvokv
*Columbia University 2013:
Celiac and Lymphoma: What Have We Learned? http://bit.ly/1hzAMRU
* U Mich 2013:
Newly identified proteins make promising targets for blocking graft-vs.-host disease
Finding could help improve outcomes from bone marrow transplants http://bit.ly/1dVVXxA
*NY Times 2013:
The Pills of Last Resort: How Dying Patients Get Access to Experimental Drugs http://nyti.ms/1afTJBB
* NEJM
Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma — http://bit.ly/1aiasUM
*Medpage Today 2013:
Stem-Cell Therapy Misses Mark in Lymphoma Trial http://bit.ly/17yjj8G
*Annals of Oncology 2013:
Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study http://bit.ly/1aHJKHR
*JCO 2013
Patient-Physician Communication About Health-Related Quality-of-Life Problems:
Are Non-Hodgkin Lymphoma Survivors Willing to Talk? http://bit.ly/17uTBnA
*Medscape 2013:
Early Transplant Improves Survival in High-Risk Lymphoma http://bit.ly/16ne4rp
* NIH VideoCasting and Podcasting --
Interesting Upcoming Events: http://1.usa.gov/16Tg2gk
Thursday, October 31, 2013
*Your support is what makes this resource - lymphomation.org possible!
How to support Patients Against Lymphoma -
with the easy-to-use vehicle donation program http://bit.ly/11tqxX8
A shout-out Thanks to John for his generous contribution on Oct 24th via PayPAL!
*Medscape 2013:
PD-1 Blockade Agent Promising for Hematologic Malignancies http://bit.ly/16NeQLl
* PAL query of ClinicalTrials.gov: Lymphoma Trials using PD-1 blockade: http://1.usa.gov/QlPona
*Psych Central 2013:
How Healthy Couples Handle Tough Times http://bit.ly/HuLzhQ
*Medscape 2013:
'Dead Man Walking': A Too Common Cancer Patient in the US http://bit.ly/16Nfb0C
*Science Daily 2013:
Unpublished Trial Data 'Violates an Ethical Obligation' to Study Participants, Say Researchers http://bit.ly/1dNT8yw
* Science Daily 2013:
Quality of Care Improves for Cancer Patients Who Get Palliative Care Consultation http://bit.ly/17xKwZ6
* JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma http://bit.ly/1aIdggu
The finding that SEC31A-JAK2 responds to JAK inhibitors indicates that patients with cHL and JAK2 rearrangements may benefit from targeted therapies.
* Related study: Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and PMLBL -http://1.usa.gov/19YXLEf
Wednesday, October 30, 2013
For patients, caregivers, or oncologists!
* News Medical 2013:
High levels of omega-3 fatty acid consumption may lead to unintended health consequences http://bit.ly/1amAvjT
* New Yorker 2013:
The Cost of Living: New drugs could extend cancer patients’ lives—by days. At a cost of thousands and thousands of dollars.
Prompting some doctors to refuse to use them. http://nym.ag/1dIyEqP
* Respectful Insolence 2013:
So chemotherapy does work, after all (revisited) http://bit.ly/1aoAqMk
Tuesday, October 29, 2013
* Medpage Today 2013:
Statin May Cut GVHD in Stem-Cell Recipients http://bit.ly/1dFEysO
* Blood 2013:
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study http://bit.ly/1aap74v
* KevinMD 2013:
When a patient teaches you to tango http://bit.ly/17TM4Jo
* Digital Journal 2013:
The Non-Hodgkin's Lymphoma Drug Market Will Nearly Double to More Than $10 Billion by 2022 http://bit.ly/HoT62H
* Rheumatology News 2013:
Anti-TNFs Have Not Raised Lymphoma Risk http://bit.ly/1dE61uO
* Psych Congress 2013:
No Link Between Depression and Cancer Risk: Study http://bit.ly/1aBbKyu
* Science-based Medicine 2013:
Chemotherapy doesn’t work? Not so fast… (A lesson from history) http://bit.ly/1aOS0nD
* MSKCC 2013: At Work:
Anas Younes, Chief of the Lymphoma Service http://bit.ly/1ar0VgE
* Oncology Tube 2013:
Subtyping of Non-Hodgkin Lymphoma in Adults, with John Sweetenham, MD http://bit.ly/17pjcMx
* Targeted Oncology 2013:
Addressing Challenges in Indolent Non-Hodgkin Lymphoma and Mantle Cell Lymphoma - http://bit.ly/16eDqI4
* Sunrise Rounds 2013:
What is End-of-Life Quality? http://bit.ly/17VKYg9
* Drugs from the Crucible of Nature |
Guest Blog, Scientific American Blog Network by David Kroll http://bit.ly/16HtsRW
Monday, October 28, 2013
* PAL Update to transformation page:
Clinical trial search tool ... and
Lossos and Gascoyne, 2011:
Transformation of Follicular Lymphoma Posted to About Transformation
* Helio 2013:
Regimen produced durable response in indolent B-cell, mantle cell lymphomas http://bit.ly/Hipxjc
* Therapy for CLL:
Where Are We Today? Where Will We Be Tomorrow? - http://bit.ly/1gQoYNb
* Targeted Oncology 2013:
Emerging Therapies for the Treatment of Mantle Cell Lymphoma http://bit.ly/1anio9z
* KevinMD 2013: A not-to-do list for those with chronic pain or illness http://bit.ly/HiIKBb
* Ann Hematol 2013:
GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma. http://1.usa.gov/HlRTsN
* Science Daily 2013:
Nano-Dwarves Turn Tumor Assassins http://bit.ly/1asg6bg
* Science Daily 2013:
Debunking Myths About How Cancer Spreads http://bit.ly/1chEr72
* Live Science 2013: 11
Surprising Facts About the Immune System http://bit.ly/1hh39nH
* Leuk Lymph 2013:
High-dose therapy and autologous hematopoietic stem cell transplantation in T-cell lymphoma: a single center experience. http://1.usa.gov/H9ek3W
Friday, October 25, 2013
* CDC:
Vaccines: Recs/Vac-Admin/Contraindications to Vaccines Chart for Adults PAL: Immunization Guide
* CDC: Vaccine Information Statement:
Diphtheria, Tetanus, and Pertussis - Vaccines - CDC PAL: Immunization Guide
* Targeted Oncology 2013:
Dr. Zelenetz Discusses Diagnosis and Treatment Issues in Indolent NHL http://bit.ly/17O4Emf
Comment: This could be a tough read for patients in that it discusses survival expectations and the uncertainty about how an indolent lymphoma will behave. Other experts say that even advance indolent lymphoma is cured but at a modest rate - about 20%. KarlS
* Sunrise Rounds 2013:
…so sayeth the proxy http://bit.ly/Hgsu3w
NYtimes 2013:
Living With Cancer: Brains on Chemo http://nyti.ms/1ihhLkz
Comment: It's important to appreciate that the chemo agents and doses used to treat lymphoma are not expected to cause major cognitive problems and that when it happens it is generally reversible with time. KarlS
* Medscape 2013:
Dazed and Confused About Molecular Data? http://bit.ly/H5xg3t
* Study ties bone marrow transplant to negative sexual side effects: Radiation, graft-versus-host disease cited as particularly damaging http://bit.ly/18hv27i
* Live Science 2013:
Suzanne Somers' Health Advice May Be Dangerously Wrong http://bKit.ly/17hWCrl
* CARING CONNECTIONS - NHPCO
Download Your State's Advance Directives - (scroll down to states) Posted to PAL: Palliative Care
Thursday, October 24, 2013
* CARING CONNECTIONS - NHPCO
Download Your State's Advance Directives - (scroll down to states) http://bit.ly/1a50vdr
* Targeted Oncology 2013:
Clinical Advances in Mantle Cell Lymphoma http://bit.ly/1fXycWr
* OncLive 2013:
Novel B-Cell Receptor Signaling Inhibitors Show Promise http://bit.ly/1aHLHSU
* U Penn 2013:
Penn docs find successful strategy to expand patient participation in hard-to-enroll clinical trials http://bit.ly/Hi5KzE
* Helio 2013:
Rituximab prevented corticosteroid-requiring chronic GVHD http://bit.ly/19wD8wx
* Science Daily 2013:
Cancer Wasting Due in Part to Tumor Factors That Block Muscle Repair, Study Shows http://bit.ly/1cfGoRt
* PAL notice: 2 new trials of interest for indolent b-cell lymphoma:
Testing Idelalisib combinations - ClinicalTrials.gov Clinical Trials of Interest
Comment: Idelalisib is an oral drug that targets a kinase in the b-cell receptor pathway, which is overactive in b-cell lymphomas.
Wednesday, October 23, 2013
* Science Daily 2013:
Genome of Aggressive Lymphoma Sequenced (mantle cell) http://bit.ly/1adZvrE
* Helio 2013:
Combination therapy plus WBRT effective in CNS lymphoma http://bit.ly/Hgxfth
* Immunol Lett 2013:
Standard Therapies versus Novel Therapies in Hodgkin Lymphoma. http://1.usa.gov/1aEWVYj
* Oncology Tube 2013:
Owen O'Connor, MD, PhD lymphoma, targeting b-cell receptors, CD 30, Rituxan http://bit.ly/18I1hk9
EJNMMI 2013:
Explorative analyses on the value of interim PET for prediction of response in pediatric and adolescent non-Hodgkin lymphoma patients. http://1.usa.gov/1gDesc6
* New Statesman 2013: article by Jerome Groopman
Inside the quackish cult of alternative medicine http://bit.ly/1bSHZbx
KevinMD 2013:
Admit when you fall short: The power of “I don’t know” http://bit.ly/1adZNyy
* Cancer Research UK 2013:
Genetic risk factor links Hodgkin lymphoma and multiple sclerosis http://bit.ly/1bcRLEo
Tuesday, October 22, 2013
* Kaiser Health News
Thousands Of Consumers Get Insurance Cancellation Notices Due To Health Law Changes - http://bit.ly/H6nQoM
The main reason insurers offer is that the policies fall short of what the Affordable Care Act requires starting Jan. 1.
* Health News Review 2013:
Canadian journalist: every cancer cure claim needs scrutiny http://bit.ly/1h0mzx8 (on DCA)
Comment on conspiracies: The US drug evaluation process truly deserves our respect and admiration. If you have a drug product that you believe can cure, you write up the protocol that pre-specifies what it will achieve, run it and then submit the results. ... It will get approved in a timely fashion if it meets the primary endpoint -- worked out between the sponsor and the regulatory agency. We can also be thankful and reassured that the review of such evidence is done independent of financial conflict of interest. KarlS.
* Onclive 2013:
Evidence-Based Medicine: Examining the Gap Between Rhetoric and Reality - http://bit.ly/1fRABlF
* New York Mag 2013
The Cost of Living: New drugs could extend cancer patients’ lives—by days. At a cost of thousands and thousands of dollars. Prompting some doctors to refuse to use them. http://nym.ag/1fSGtuP
Monday, October 21, 2013
* Respectful Insolence 2013:
No, redefining cancer doesn’t mean death panels http://bit.ly/1azzbou
Esquire 2013:
The End of Cancer In the near future, our immune systems will be genetically supercharged to kill cancer. We will all be like Logan Parker. http://bit.ly/GX90AA
* SafeShare TV 2013:
The Operating Room of the Future http://bit.ly/1a2hVx7
Not lymphoma related but interesting research from Israel.
* Today Health 2013:
After diagnosis, some keep their cancer a secret http://on.today.com/1d8U540
* ASH Paper: A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in
Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL)
Posted to related study in Clinical Trials of Interest - mixed types
* ASH 2012, Paper: A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A
Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL)
Posted to related study in Clinical Trials of Interest - mixed types
* Testing Ibrutinib in Patients With Refractory Follicular Lymphoma - ClinicalTrials.gov Clinical Trials of Interest
* Testing Ibrutinib With Bendamustine and Rituxan for Newly Diagnosed Mantle Cell #Lymphoma -
ClinicalTrials.gov Clinical Trials of Interest
Saturday, October 18, 2013
* PAL: Updated Trials of Interest:
status of trials and click counts updated for all types Clinical Trials of Interest
Satisfying to see that a good number of trials in our list achieved enrollment goals ... and that perhaps we played a part.
* Cleveland Clinic 2013:
6 Scary Myths About Cancer http://bit.ly/16XRAhj
* Clin Lymphoma Myeloma leuk 2013:
Limited Utility of Surveillance Imaging for Detecting Disease Relapse in Patients With Non-Hodgkin Lymphoma in First Complete Remission. http://1.usa.gov/19KMktM
* Dr Len's Cancer Blog 2013:
Personalized Medicine Revolution Will Require Revolutionary Changes In How We Care For Cancer Patients
http://bit.ly/19gaf7u
* NYT 2013:
In Sickness and in Health: A Wedding in the Shadow of Cancer http://nyti.ms/H2wlBb
* Slate 2013:
What’s the Point of Finding Cancer Mutations? http://slate.me/1avYtUD
* Study of interest: Untreated Follicular Lymphoma - ALLIANCE study:
Rituximab, Lenalidomide, and Ibrutinib http://1.usa.gov/1cBniFe
Exploring non-chemo, targeted combination approach
* Br J Haematol. 2013 Transformed non-hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. PubMed - NCBI http://1.usa.gov/1avIWEi
See also PAL: About Transformation
* Medscape:
Old Drugs That Are Still Good Drugs http://bit.ly/H7orXx
(Requires free login)
Friday, October 18, 2013
* Healthleadersmedia.com:
Med Schools Failing on Conflict of Interest Policies http://bit.ly/1cDfZtp
* PAL: Updated Trials of Interest: Lymphoma - mixed type section
status of trials and click counts Clinical Trials of Interest
* PAL: New topic Background on support group policies
PAL support groups options: PAL forum, Lymphomation yahoo group, Facebook, Twitter: Support Groups
Snip from Background: On the Yahoo groups lists we sometimes get emails from subscribers who want information only and resent getting their inbox filled with patient-to-patient correspondence. That said, others appear to like having a feeling of community - where they can talk about anything anytime ... encourage one another, and get reassured (the community approach). So these are two equally valid and understandable desires and expectations ... Background on support group policies
* The ASCO Post
Comparative Effectiveness Research: Its Time Has Arrived
A Conversation With Gary Lyman, MD http://bit.ly/16iAxTm
* Helio 2013:
Alisertib active in relapsed, refractory B-cell, T-cell non-Hodgkin’s lymphomas http://bit.ly/18sChgG
* Telemanagement 2013:
Infection (Chlamydia) linked to eye lymphoma http://bit.ly/1atNpao
* Sunrise Rounds 2013:
Thoughts on suicide http://bit.ly/1gR66el
* Onc Times 2013:
Leukemia & Lymphoma Society Survey Finds 'Alarming' Gap in Public Knowledge about Hematologic Cancers http://bit.ly/1asFdqY
* Medscape 2013:
Discuss Costs of Tests and Therapies With Patients http://bit.ly/16jrly8
* NEJM 2013: Full Disclosure —
Out-of-Pocket Costs as Side Effects http://bit.ly/19VzdtW
* MedPage Today 2013:
Doctors Urged to Talk About Costs of Treatment http://bit.ly/17PoYTj
* Onc Times 2013: MUSINGS OF A CANCER DOCTOR:
How Much Life? http://bit.ly/175I5Pu
Wednesday, October 16, 2013
* Weill Cornell 2013:
Two Newly Opened Clinical Trials Evaluate Idelalisib (targeting a kinase in the B-cell receptor pathway)
in Indolent non-Hodgkin Lymphoma http://bit.ly/1aom8pW
* Cancer Research UK 2013;
A new age of cancer classification and treatment http://bit.ly/1epDA1f
Provides an excellent overview of the complex picture of cancer - "the inadequacy of simple anatomical explanations of the disease."
* Helio 2013:
Rituximab plus epratuzumab effective in follicular lymphoma http://bit.ly/1apxlq5
“The combination therapy was continued as extended induction in weeks 12, 20, 28 and 36.”
“Our study confirms that immunotherapy without cytotoxic therapy can achieve durable remissions in untreated follicular lymphoma,” Cheson and colleagues wrote. “The high response rate and prolonged time to progression observed with this antibody combination ... further support the development of biologic, nonchemotherapeutic approaches for these patients.”
* Respectful Insolence 2013: An article about Gerson Therapy
Sharyn dies tragically because she followed the example of her daughter, The Wellness Warrior http://bit.ly/16dfjvm
BBC 2013:
The problem with taking too many vitamins http://bbc.in/19TxYvg
* From ajcp.ascpjournals.org:
Fine-Needle Aspiration Cytology in the Diagnosis of Lymphoma The Next Step
Linda M. Sandhaus, MD Post to PAL - Diagnostic
Tuesday, October 15, 2013
* Goda - 2010 - Cancer (full text)
Long-term outcome in localized extranodal MALT lymphomas treated with Radiotherapy http://bit.ly/19LlMbW
* Neurologica 2013:
What’s In Your Herbal Supplement? http://bit.ly/19L4Y94
* MNT 2013:
Nearly 60 per cent of herbal products studied omitted ingredients, contained fillers http://bit.ly/1coCAdd
Comment: This is what can happen when you don't regulate an industry - some of the companies will take shortcuts to gain a competitive advantage - putting the public at risk.
* ANN Oncol 2013:
An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma. http://1.usa.gov/19EcXCO
* Leuk Lymphoma 2013: Treatment with cyclophosphamide, vindesine, cytarabine, dexamethasone, and bleomycin in patients with relapsed/refractory diffuse large B cell lymphoma. http://1.usa.gov/1gfMWkG
* Blood 2013:
The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). http://1.usa.gov/17q1GE8
* J Clin Onc 2013:
Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome. http://1.usa.gov/17DZd8i
* NYT 2013:
Breaking Through Cancer’s Shield http://nyti.ms/1alNyNc
* NewsMedical 2013:
Study provides novel link between cellular aging and diffuse large B-cell lymphoma http://bit.ly/19EdVPB
* Science Based Medicine 2013:
Yes, Chris beat cancer, but it wasn’t quackery that cured him http://bit.ly/19L6eJ9
Monday, October 14, 2013
* Eurekalert.org:
protein experiment in mice links exercise to brain health ... http://bit.ly/1brokPU
* Study: Herbal products omit ingredients, contain fillers http://bit.ly/1bRFYAC
* Dr. Sharman's CLL & Lymphoma Blog:
Engineered T Cells for Lymphoma at NIH http://bit.ly/164yAiu
* ClinicalTrials.gov:
Show studies recruiting for CART-19 (Engineered Lymphocyte Therapy) http://1.usa.gov/1cDypNe
* PAL: Advocates needed
Introducing The North American Consortium for
Familial (common to families) Hematologic (blood cell) Malignancies PAL
* * Brian Koffman interviews - iwCLL 2013:
Dr. Jan Burger tells us how the kinase-targeted agents,
specific to the B-cell receptor pathway, are thought to work in CLL PAL: Experts on Lymphoma and CLL
First and Second interview embedded from the source: http://bkoffman.blogspot.com/
Friday, October 11, 2013
* HELP needed!
How to support Patients Against #Lymphoma - with the easy-to-use vehicle donation program http://bit.ly/11tqxX8
* Vitamin D supplements ineffective in preventing osteoporosis, Lancet published study finds http://bit.ly/16B6YzW
Taking vitamin D supplements does not improve bone mineral density at the total hip, spine, forearm, or in the body as a whole, a large meta-analysis involving more than 4000 healthy adults published in The Lancet has found.
* MNT, 2013:
Persistent anti-tumor immune response enabled by novel gene therapy for lymphoma and CLL http://bit.ly/GP4Uuu
* Dr. Sharman's CLL & Lymphoma Blog:
The race [for marketing approval of CLL agents] tightens http://bit.ly/15YLnmK
Thursday, October 10, 2013
* HELP needed!
How to support Patients Against #Lymphoma - with the easy-to-use vehicle donation program http://bit.ly/11tqxX8
* Press release
Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic Leukemia Early Because of Positive Risk-Benefit http://bit.ly/16Thk0k
Study 116 was a randomized, double-blind, placebo-controlled, Phase 3 study evaluating the efficacy and safety of idelalisib in combination with rituximab. The study enrolled 220 adult patients with previously treated recurrent CLL who had measureable lymphadenopathy with disease progression less than 24 months following completion of prior therapy, and who required treatment but were not fit to receive cytotoxic therapy. Eligible patients were randomized to receive eight infusions of rituximab over 24 weeks plus either idelalisib (150 mg) or placebo taken orally twice daily continuously until disease progression or unacceptable toxicity. Patients who progressed on Study 116 were eligible to receive active idelalisib therapy in a double-blind extension study (Study 117).
* From well.blogs.nytimes.com:
exercise-as-preventive-medicine http://nyti.ms/1grxHme
* Kevin, M.D. - Medical Web
How do we empower patients with information while not scaring them? http://bit.ly/1e9GrLT
* Study of interest: Relapsed or Refractory Hodgkin Lymphoma
Ipilimumab and Brentuximab Vedotin in Treating Patients With http://1.usa.gov/16ECdpo
Exploring inhibiting immune checkpoint blockade with a proven targeted therapy.
* Immunol Lett. 2013
Reprogramming cell death: bcl2 family inhibition - PubMed - NCBI http://1.usa.gov/16Sfm0j
* Managing Infections in Patients With Hematologic Malignancies
Medscape 2003 (free login req.) http://bit.ly/axtWSg
Initial Evaluation, Initial Management, Bacterial Infections,
Intravascular Devices, Community Respiratory Viruses, Fungal Infections
* HemOnc Today
Single-agent lenalidomide safe, effective in mantle-cell lymphoma: http://ow.ly/pG7D4
Wednesday, October 9, 2013
* Kevin, M.D. - Medical Weblog
Clinicians do not have the luxury to not care about costs http://bit.ly/1a8Maxg
* Non-Hodgkin Lymphoma Risk and Variants in Genes Controlling Lymphocyte Development.
From ncbi.nlm.nih.gov: http://1.usa.gov/GMoI12
* The ASCO Post, 2013:
Ibrutinib in Mantle Cell Lymphoma Yields 'Unprecedented' Response Rates http://bit.ly/Yu9Ru3
The investigational agent ibrutinib demonstrated “unprecedented” single-agent activity in relapsed or refractory mantle cell lymphoma, according to the lead author of an international phase II study reported at the Annual Meeting of the American
* Ther Adv Hematol. 2013
Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma
From ncbi.nlm.nih.gov: http://1.usa.gov/12H6NDw
Minimal residual disease (MRD) is defined as any approach aimed at detecting and possibly quantifying residual tumor cells beyond the sensitivity level of routine imaging and laboratory techniques.
Tuesday, October 7, 2013
* Brian Koffman interviews:
iwCLL 2013: Dr. Jan Burger Discusses the Role of the Micro-environment in #CLL: Part 1 http://bit.ly/17e2lsk
* PAL trial of interest: Look mom, no R!
Lenalidomide and Ibrutinib for Relapsed B-Cell Non-Hodgkin #Lymphoma - ClinicalTrials.gov http://1.usa.gov/19aHfwU
* The ASCO Post
The Direction of Immunotherapy Over the Next Decade
A Conversation With David L. Porter, MD http://bit.ly/19wbz2W
* Science Blog:
Cancer Treatment Centers of America:
Revisiting the epitome of “integrative” cancer care « Science-Based Medicine http://bit.ly/1e6cBHT
* PAL:
Donate to support our mission and receive a set of 4 postcards
with original line drawings as a thank you.
Monday, October 7, 2013
* The ASCO, 2013:
Under-treatment of Cancer Pain Remains a Persistent Problem in Oncology
A Conversation With Russell K. Portenoy, MD Post Lymphomation - Pain: In the News
* The ASCO Post:
New Research on Combination Chemotherapy, Prognostic Biomarkers, and PET-guided Radiation Therapy in B-cell Malignancies http://bit.ly/1bCF4Yq
* Medical News Today:
Depression affects memory by 'impairing ability to differentiate similarities' http://bit.ly/15RyiM1
* Choosing a Medigap Policy:
A Guide to Health Insurance for People with Medicare (PDF) medicare.gov
* PAL - Advocate perspective on PAL
Phase I studies - when to participate? Should participants receive increasing doses?
TIP: Searching for phase I trials is a good way to keep current with the direction of research as this is where you will find what novel agents are in development. FIND: Phase I studies for Lymphoma OR CLL: ClinicalTrials.gov
Saturday, October 5, 2013
* The Medical News:
Tips to avoid food-borne illness PAL Treatment Support page
* Brian Koffman's Awesome Transplant and CLL Adventure:
Learning from and about Cancer: iwCLL 2013: The Patient's Perspective http://bit.ly/GBzPKi
* NPR:
Some Online Journals Will Publish Fake Science, For A Fee http://n.pr/19pefoO
The importance of being selective about the journals you read and take seriously. A short list for me: Lancet, NEJM, JCO, Blood, ...
TED talks -
Can technology solve our big problems? http://bit.ly/192fHJP
Karl: Maybe a bit off topic as I'm optimistic we can and will solve the lymphoma problem
* NeuroLogica Blog:
CAM Research – Be Careful What You Wish For http://bit.ly/15c2cYI
Edzard Ernst is the first professor of complementary and alternative medicine (CAM). He began 20 years ago as a CAM enthusiast, and a trained homeopath, and genuinely wanted to point the critical eye of science onto CAM. Many CAM proponents claim this, but Ernst was different in a key respect – he wanted to use rigorous scientific research to find out if
Thursday, October 3, 2013
* Healthcare.gov: The ACA insurance exchange is open http://1.usa.gov/GzzB6L
Wait for a login screen to create a secure account - which could take a while today because of VERY high volume
For patients, caregivers, or oncologists!
* MD Anderson Cancer Center
Tips for organizing your medical records - Cancerwise http://bit.ly/GAVRNM
* The ASCO Post, 2013: FDA Approves Mechlorethamine Gel for Cutaneous T-Cell Lymphoma http://bit.ly/18Ultxa
This gel is the first and only FDA-approved topical formulation of mechlorethamine, which is commonly known as nitrogen mustard. The gel is applied topically once a day and dries on the skin.
RISK FACTORS
* Research, 2013:
Children with inherited anti-inflammatory defect may have predisposition to lymphoma http://bit.ly/1f2t2YO
Fits with a known risk factor for lymphoma - chronic inflammation and infection.
* PubMed - NCBI Asian Pac J Cancer Prev. 2013:
Breastfeeding and the Risk of Childhood Hodgkin Lymphoma: A Systematic Review and Meta-analysis. - http://1.usa.gov/GBb4O1
TRIALS
* Constellation Pharmaceuticals
Initiates Clinical Development of CPI-0610, a Novel BET
Protein Bromodomain Inhibitor, in Patients with Lymphoma http://bit.ly/18R2V0T
* Study to consider?
A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma - Full Text View
- ClinicalTrials.gov http://1.usa.gov/15MC83D
This is a safety study ... perhaps reasonable to consider when you are out of other options ... reasonable given
its unique mechanism of action.
TECHNICAL ITEMS:
* Haematologica. 2012: Technical
MicroRNA profiling of follicular lymphoma identifies microRNAs related to cell proliferation and tumor response From ncbi.nlm.nih.gov: http://1.usa.gov/172EDxW
The potential value of prognostic markers being it helps to identify patients who may benefit from novel experimental approaches to treatment.
* PubMed - NCBI, 2013:
Lactate Dehydrogenase 5 Expression in NHL predicts higher risk lymphoma http://1.usa.gov/GAWfvF
* PubMed 2013: Technical
CLL Cells Respond to B-Cell Receptor Stimulation with a MicroRNA/mRNA Signature Associated with MYC Activation and Cell Cycle Progression http://1.usa.gov/1a2u0hT (full text)
BELIEF SYSTEMS
* Medscape Today video:
Do You Believe in Magic? Topol, Offit on Alternative Medicine http://bit.ly/1g767L2
Dr. Offit takes a look at the billion-dollar, unregulated supplement, vitamin, and alternative medicine industries.
* NeuroLogica Blog:
Science Rejection, and Conspiracy Thinking http://bit.ly/GATNFj
This item nicely explains how our view of the world influences what we tend to believe.
Wednesday, October 2, 2013
* Exchange and Government shutdown dominates the news:
* NEJM: Only the Beginning — What's Next at the Health Insurance Exchanges? http://bit.ly/172LOat
Perspective by Henry J. Aaron, Ph.D., and Kevin W. Lucia, J.D., M.H.P.
Excellent overview of the Exchange - challenges and advantages.
* CNN 2013:
Government shutdown forces clinical trial patients to wait http://bit.ly/1c5sSi6
* ASCO 2013: ASCO Update:
Government Shutdown Impact on Cancer Care http://bit.ly/1hlfoNo
* MNT 2013:
Government shutdown delays NIH trials and impairs CDC http://bit.ly/1bvZdfo
* MDA 2013:
Depression in cancer patients: What you should know http://bit.ly/1c5masH
* Scientific American 2013:
Hallmarks of Cancer 3: Evading Apoptosis http://bit.ly/1fJo9oI
* KevinMD.com 2013: Social support matters in cancer survival http://bit.ly/15J0DDZ
* List of Health Apps for Phones http://bit.ly/GzJjX0 (pharma sponsored)
* INSERM 2013:
Depression does not expose someone to a greater risk of cancer http://bit.ly/18r9Tuw
* Sunrise Rounds 2013:
Sex versus Cancer http://bit.ly/152g9bL
* Fierce Drug Delivery 2013:
John Theurer Cancer Center touts two oral lymphoma drug studies http://bit.ly/19m0i57
* Video feature - Dr. James Grime: PAL: expert videos
A simple controlled study showing how our political beliefs affect how we interpret the same numbers - applied to different questions (neutral vs. controversial).
If you don't like what the numbers show - you look deeper. If you like it, you stop.
Dr. Grimes then explains how the peer review system protects against this in science.
* Gottlieb, BMJ. 2000:
Part of the rationale for ACA - to prevent personal bankruptcy from medical bills http://1.usa.gov/19hocVe
The findings illustrate how fragile middle class status is for many American families, Professor Warren said. These families are “just one serious illness away from financial collapse,” she said. “What a scary way to think about America.”
Tuesday, October 1, 2013
* A phase III randomized study comparing CHOP plus rituximab with CHOP plus RIT for front-line treatment of follicular lymphoma: Results of subset analyses and a comparison of prognostic models. http://bit.ly/16ejO7g
Elevated B2M AND LDH (blood test markers) were equivalent to the FLIPI (an large index of risk factors) in predicting high risk follicular lymphoma. Limitation: a retrospective analysis.
* News medical 2013:
Biology of tumour more important than primary site, say researchers http://bit.ly/19c6nqD
* Cancer Research 2013:
Poetically Inspired by the Emperor of all Maladies http://bit.ly/18mrsMb
* ECCO 2013:
The State of Oncology 2013: New report draws attention to urgent need to tackle disparities in cancer care worldwide
http://bit.ly/16a19cG
* Science Daily 2013:
New Approaches to Testing Cancer Drugs Needed http://bit.ly/16bzTKW
* Univ of Michigan 2013:
Liquid biopsy could improve cancer diagnosis and treatment http://bit.ly/16DOn8z
Early research- not lymphoma specific
* Annals of Oncology 2013:
Lymphoma occurring in patients over 90 years of age: characteristics, outcomes, and prognostic factors.
A retrospective analysis of 234 cases from the LYSA PAL - In the News: Lymphoma in elderly patients
Monday, September 30, 2013
* Leuk Lymphoma 2013:
Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned? PAL: Splenic MZL - In the News
* KevinMD 2013:
How to meet your doctor and receive your diagnosis in a better way http://bit.ly/1fQJ5b3
* CNN 2013:
In cancer drug battle, both sides appeal to ethics http://bit.ly/18yrS2I
* Bone Marrow Transplant 2013:
Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma:
A pilot study. http://1.usa.gov/1bk7Tc0
* J Clin Onc 2013:
Patient-Physician Communication About Health-Related Quality-of-Life Problems:
Are Non-Hodgkin Lymphoma Survivors Willing to Talk? http://1.usa.gov/16VJTob
Saturday, September 28, 2013
* NYTimes 2013:
A Guide to the New Exchanges for Health Insurance http://nyti.ms/1haLSK7
* Mitt Romney explains ACA - better than Obama: YouTube http://bit.ly/1fQWTCo
* Helio 2013:
Rituximab maintenance did not significantly extend PFS in follicular lymphoma http://bit.ly/18vB73O
* Columbia Univ- Youtube 2013:
Celiac and Lymphoma: What Have We Learned? http://bit.ly/1awbgYU
* Mindbodygreen 2013:
5 Things You Should NEVER Say To People With Cancer http://bit.ly/198rxjA
* Irish Medical Times 2013:
Tracking the trends in Hodgkin’s lymphoma http://bit.ly/1avopS4
Friday, September 27, 2013
* Medscape 2013:
Making Cancer Survivorship Last: How Docs Can Help http://bit.ly/17jcdQK
* Medscape 2013:
8 ways to keep cancer survivors healthy http://bit.ly/187fINy
* J Clin Onc 2013:
Patient-Physician Communication About Health-Related Quality-of-Life Problems:
re Non-Hodgkin Lymphoma Survivors Willing to Talk? http://1.usa.gov/1bgss9a
* NYTimes:
Living With Cancer: Feeling Older Than My Age http://nyti.ms/196j54d
* Weill Cornell 2013:
Ibrutinib Promotes a High Frequency of Durable Response in Relapsed/Refractory
and Older Treatment Naive CLL Patients http://bit.ly/15Xf1H4
* Medscape 2013: C difficile:
Symptomatic Patients No Longer the Main Source http://bit.ly/15W1VK8
* KevinMD 2013:
Defining the 3 goals of palliative care http://bit.ly/19KQToy
* Science-Based Medicine 2013:
A closer look at Dr. Oz’s 15 Superfoods http://bit.ly/1749tKI
Thursday, September 26, 2013
* LLS 2013:
The Affordable Care Act: What Blood Cancer Patients Need to Know http://bit.ly/1fDRgaz
* Sequester Still Impacting Scientific Research.
The Washington Post (9/25, Cha, 4.28M) reports on George Mason University researcher Yuntao Wu, “one of thousands of scientists who lost his grant in the wake of sequester cuts,” which “took effect March 1 have sent shock waves through the nation’s research labs, delaying research and forcing layoffs.” The National Institutes of Health budget was reduced 5.5 percent, and its impact on the scientific and medical community has been described as “deeply demoralized,” by NIH Director Francis Collins. According to Collins, “the NIH issued 640 fewer grants in the last fiscal year and that if the cuts continue at the same level next year, several hundred more projects will not be funded.” The odds of receiving funding now stand at one in six, compared to the previous one in three chance.
A segment on Kansas Public Radio (9/26) reports on the sequester’s impact on medical research funding. The piece notes that ASCO’s “Chief medical officer Dr. Richard Schilsky says 75 percent of cancer researchers surveyed say the struggle for federal funding is having a direct impact on their work.”
* Statistician Susan Murphy
2013 MacArthur Fellow | MacArthur Foundation - YouTube http://bit.ly/1arV7ni
* Weill Cornell:
An Open-Label Treatment Use Protocol for Ibrutinib (PCI-32765) in Subjects with Relapsed or Refractory Mantle Cell Lymphoma http://bit.ly/16KcxIP
* Medscape 2013:
Boxed Warning on HBV Reactivation for Blood Cancer Drugs http://bit.ly/191AtqW
Product labeling updates for 2 drugs used in the treatment of hematological malignancies, rituximab (Rituxan) and ofatumumab (Arzerra)
* Medpage Today 2013:
Novel Antiviral Blocks CMV After Stem Cell Tx http://bit.ly/1h2L4Xu
* Patient Power 2013:
Why an Expert is Excited About New Pills vs. Chemo for CLL http://bit.ly/172iPqy
Comment: Ibrutinib appears to be a cytostatic agent, thus a key to the successful management of CLL (and other b-cell cancers) will be its safety profile with long term use. Anecdotally the CLL comes back soon after the drug is discontinued.
* We are greenbay.com 2013: HealthWatch: video on Ibrutinib for CLL
Experimental Drug Turns Off Leukemia Cells http://bit.ly/191zHKz
* Sunrise Rounds 2013:
When the mirror cracks http://bit.ly/1fDdSYG
* Scientific American
The Hallmarks of Cancer: 2 – Insensitivity to Antigrowth Signals http://bit.ly/1aotCeo
* Dr Sharman 2013:
Video update from IWCLL http://bit.ly/182um8J
Excellent overview of current treatments-- some are also used for other indolent b cell lymphomas
* PAL update: In the News
Medical xpress 2013: Cancer: Lymphoma-linked risk factor identified Risk factors
Wednesday, September 25, 2013
* Psych Central 2013:
Tips for Coping with Chronic Illness http://bit.ly/14FxBm4
* KevinMD 2013:
The side effects of cancer treatment can become permanent glitches http://bit.ly/18ozMdf
* Dr Sharman 2013:
Summer off http://bit.ly/1bCvG68
* Ny Times 2013: more on:
Married Cancer Patients Live Longer http://nyti.ms/1dHVYlP
Monday, September 23, 2013
* NYTimes 2013:
After Cancer, Fertility Is Often Within Reach http://nyti.ms/16CrgFG
* Science Daily 2013:
Public Says Childhood Cancer Should Be Top Children's Health Research Priority http://bit.ly/1fvmGQg
* Opposing Views 2013:
BP Oil Spill Cleanup Workers Have Elevated Risk of Leukemia, Lymphoma and Liver Damage http://bit.ly/18SEHkB
Reminds that there's a need to speak up regarding the risks to public safety of fracking in public areas
* Dana Farber 2013:
Marriage associated with better cancer outcomes, study finds http://bit.ly/1eCBSw8
Authors state: "We don't just see our study as an affirmation of marriage, but rather it should send a message to anyone who has a friend or a loved one with cancer: by being there for that person and helping them navigate their appointments and make it through all their treatments, you can make a real difference to that person's outcome,"
* Science-Based Medicine 2013:
Obesity, cancer, and chemotherapy http://bit.ly/16m3kvW
* Respectful Insolence 2013:
Cancer quackery promoted on Fox News http://bit.ly/18lmcXS
* MNT 22013:
Tackling drug-resistant cancers using a genome-forward approach http://bit.ly/15mfzTb
* PAL update: final tweaks
The Patient-selected Controlled Trial PAL
Saturday, September 21, 2013
* Patient Advocacy: http://bit.ly/1bzyAsy
a non-partisan tool to help you to write your elected officials regarding your views on the defunding of the Affordable Care Act
* Haematologica 2013:
Actual prognosis during follow-up for B-cell non-Hodgkin lymphoma survivors in the Netherlands. http://1.usa.gov/16gTrzF
Five-year conditional relative survival was computed for every additional year of survival up to 16 years after diagnosis, according to entity, grade, gender, age, and Ann Arbor stage. The prognosis for indolent B-cell non-Hodgkin lymphoma survivors improved slightly with each additional year survived up to 91%. For patients with aggressive non-Hodgkin lymphoma conditional relative survival improved strongly during the first year after diagnosis (from 48% to 68%) and gradually thereafter to 93% after 16 years.
* Psychological Interventions for people with Cancer:
Therapy and Self-Help http://bit.ly/1gLNx8G
Helio 2013:
BEACOPP escalated may be new standard of care for advanced-stage Hodgkin’s lymphoma http://bit.ly/14tvvpi
* Weill Cornell 2013:
Interview with the Dean: Unlocking Cancer’s Code http://bit.ly/1b0hkgv
* Medscape 2013:
Federal Funding Cuts Have Huge Impact on Cancer Research http://bit.ly/16vKw7w
* Br J haemoatol 2013:
A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma.
http://1.usa.gov/14ttF83
J Clin OncL 2013:
Lymphoma Occurring During Pregnancy: Antenatal Therapy, Complications, and Maternal Survival in a Multicenter Analysis
http://1.usa.gov/1bxQyvx
* PAL update: Interesting that there have been more clicks for untreated than relapsed.
Find trials by type of lymphoma and treatment status (2,027 clicks versus 1,295 respectively)
Friday, September 20, 2013
* Haematologica 2013: technical
Origin and migration of follicular lymphoma cells http://bit.ly/15NpIOv
Takeaway: "the bone marrow may harbor a small pool of less-cycling “founder” cells, either fully malignant (FL) or “premalignant” (FLLC), which may be relatively resistant to chemotherapy, explaining the frequent but sometimes very late relapses observed in FL. It would, therefore, be very informative to have a more thorough characterization of the bone marrow resident cells in FL (and possible also other B-cell lymphomas) at the molecular level,"
* USA TODAY 2013:
Obese cancer patients often shorted on chemo doses http://usat.ly/1etycg8
* Forbes 2013:
A Day In The Life Of A Patient: Why Can't We Do Better http://onforb.es/16K7JGo
Thursday, September 19, 2013
* Cure 2013:
Fear Factor Ruminating on possible cancer recurrence can adversely affect quality of life. http://bit.ly/155g897
* Onc Times 2013:
View from the Other Side of the Stethoscope: The First Recurrence http://bit.ly/16op4l3
* Cure 2013:
Worse Off Alone-Emotional isolation during cancer can negatively impact healing. http://bit.ly/15Ekcvx
* KevinMD 2013:
When a physician resorts to jargon, educating patients can fail http://bit.ly/1557iYN
* Onc Times 2013:
How I Talk to Patients about Difficult Issues http://bit.ly/18Atj2w
* Respectful Insolence 2013:
The Institute of Medicine report on cancer care: Is the system “in crisis”? http://bit.ly/18Ca2hc
* Pharmaceutical Processing 2013:
FDA Approves Teva’s TREANDA® Injection, a New Liquid Formulation http://bit.ly/16GsQcL
* Cancer Network 2013:
NDA Filed for Idelalisib for Treating Non-Hodgkin Lymphoma http://bit.ly/1558RGq
* PAL update - Onc Times 2013:
Lymphoma Specialists Lament the Discontinuation of Under-prescribed Bexxar Bexxar information
Wednesday, September 18, 2013
* CancerNetwork 2013:
Peripheral T-Cell Lymphoma: New Therapeutic Strategies http://bit.ly/16jvstM
* Time 2013:
Reality Check on Cancer: Fast Progress But Too Many Preventable Deaths http://ti.me/154IuuU
* Weill Cornell 2013:
Ofatumumab Granted Breakthrough Therapy Designation for Untreated CLL http://bit.ly/18vpWtP
* Reuters 2013:
Looking for lessons in cancer's 'miracle' responders http://reut.rs/19cljQu
* Live Science 2013:
Some Antioxidants Linked with Shorter Life http://bit.ly/1a2p7Gd
* ASCO Post:
Clinical Trials, Crossover, and Clinical Equipoise: patients, company, and FDA perspectives
* A Patient's Perspective By Bob Levis http://bit.ly/1a3WfND
I am writing with regard to two articles on the ethical imperative of clinical equipoise written by Susan O’Brien, MD, and Stephen J. Schuster, MD, and published recently in The ASCO Post.1,2 I was a victim of Pharmacyclics’ policies during one of their randomized ibrutinib trials (PCI-32765) conducted in 2012. I was diagnosed with chronic lymphocytic leukemia (CLL) in 2002. …
* An Advocate's Perspective By Karl Schwartz The ASCO Post http://bit.ly/14iNf6T
* Pharmacyclics' Reply http://bit.ly/15CLpOV
* FDA perspective http://bit.ly/1f6DL2R
Thanks is due to the ASCO post for publishing all sides of this story.
Tuesday, September 17, 2013
* MNT 2013:
Patients warn other patients about the danger of untested cures on the web http://bit.ly/16784W2
* Science Daily 2013:
Immune System Marker Tied to Improved Bone Marrow Transplant Outcomes http://bit.ly/1677qIj
* Ann Onc 2013: Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. http://1.usa.gov/199XAAn
* Sunrise Rounds 2013:
Medical Secret: 1 + 1 = 1 http://bit.ly/18t5SSX
Article explore how an onc looks at the wife's body language to try to determine if the husband is telling the truth when he says he is "fine" etc....
* Ped Blood Cancer 2013:
Ten-year follow-up of pediatric patients with non-hodgkin lymphoma treated with allogeneic or autologous stem cell
transplantation. http://1.usa.gov/1boW0k9
* MNT 2013:
New approach subtypes cancers by shared genetic effects; a step toward personalized medicine http://bit.ly/16bBcoi
* Onclive 2013:
Ofatumumab Receives Breakthrough Therapy Designation for Earlier Use in CLL http://bit.ly/1aOxCZX
* Haematologica 2013:
Actual prognosis during follow-up for B-cell non-Hodgkin lymphoma survivors in the Netherlands. http://1.usa.gov/15AbZIL
* Scripps Research Inst 2013:
Scientists create extremely potent and improved derivatives of successful anticancer drug http://bit.ly/15y6Lgr
Way to make vincristine more potent
* MSNBC 2013:
Looking for lessons in cancer's 'miracle' responders http://nbcnews.to/1aNMXdk
* Medscape 2013:
Trial Participation May Affect Care of Non-enrolled Patients http://bit.ly/187SlSK
Monday, September 16, 2013
* Brian Koffman's Blog 2013:
Interview with Dr. Castro on the Biology of CLL http://bit.ly/18rkwjy
* Science-Based Medicine 2013:
Is U.S. cancer care “in crisis,” as the Institute of Medicine proclaims? http://bit.ly/180lrFp
* Blood 2013:
Staging DLBCL: bone marrow biopsy or PET-CT? http://1.usa.gov/183M6zf
* Blood 2013:
PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. http://1.usa.gov/166J0IV
* MNT 2013:
First randomized trial of targeted cancer medicine in all tumor types http://bit.ly/1aNBZEx
* News Medical 2013:
New approach subtypes cancers by shared genetic effects; a step toward personalized medicine http://bit.ly/150aVtV
Sunday, September 15, 2013
* September 15th is World Lymphoma Awareness Day!
What is Lymphoma? PDF
Please print the tri-fold brochure prepared by PAL and distribute to friends and local businesses
* NEJM Perspective -
e-Referral — A New Model for Integrated Care http://bit.ly/1dg7sg2
"Overall, we believe that the eReferral model has the potential to transform the primary–specialty care interface by enabling a move away from a narrow reliance on visit-based care. It reinforces the patient-centered medical home by supporting PCPs in providing longitudinal care for a broader range of conditions and reducing fragmentation of care without placing PCPs in the difficult position of “gatekeeper.” It has also enhanced teamwork and collegiality between PCPs and specialist reviewers"
KarlS: Makes sense, increasingly. This idea resonates with me ... after having to wait 2 months for a specialist to look at a suspicious lesion. There should be a way to make this system more efficient.
* Radiother Oncol 2013:
Reduction of the treated volume to involved node radiation therapy as part of combined modality treatment for early stage aggressive non-Hodgkin's lymphoma. http://1.usa.gov/191s3QQ
* KevinMD:
Researching your health is about balance http://bit.ly/140WxEo
* Health Canal 2013:
Study explores breakthrough drug for mantle cell lymphoma (Ibrutinib) http://bit.ly/18ZoACw
* Hum Path 2013:
B cells in classical Hodgkin lymphoma are important actors rather than bystanders in the local immune reaction.
http://1.usa.gov/190tmRk
* Medscape 2013:
US Cancer Care in Crisis, Says IOM Report http://bit.ly/1behfoN
* Cancer Research UK 2013 :
Miracle cancer cures? Ask for evidence http://bit.ly/16q3nnz
* Sense about Science 2013:
Ask for evidence http://bit.ly/17w0Ckj
Sound to good to be true? You can ask for evidence here.
Friday, September 13, 2013
* Institute of Medicine:
High-Quality Cancer Care - System In Crisis (Complete Video): http://bit.ly/14RQrDr
* Gilead Submits New Drug Application to U.S. FDA for Idelalisib for the Treatment of Indolent lymphoma http://bit.ly/13Wb8AZ
* NYtimes 2013: Living With Cancer:
A Rainbow Coalition http://nyti.ms/15ojdiI
* Anticancer Res 2013:
Brentuximab Vedotin: First-line Agent for Advanced Hodgkin Lymphoma. http://1.usa.gov/15U2AxL
* Telegram.com 2013:
Six things parents of children with cancer should know http://bit.ly/13QAoIC
Wednesday, September 11, 2013
* CNN 2013:
More than 1,100 have cancer after 9/11 http://bit.ly/15S48Cx
* PAL update:
SEER-based Lymphoma Subtype Statistics Lymphomation.org
* PAL update:
Describing Waldenstrom's Lymphomation.org
* NEJM: Chris Feudtner, M.D., Ph.D. et al
Perspective Risks (and Benefits) in Comparative Effectiveness Research Trials nejm.org
* Blood 2013:
Exposure to ultraviolet radiation and risk of Hodgkin lymphoma: a pooled analysis. http://1.usa.gov/14Fhwil
* Medscape 2013:
Not-so-negative to Super-negative Trials http://bit.ly/14FgAut
* MSNBC 2013:
US cancer care in crisis, experts say http://nbcnews.to/14DE3wd
* NEJM: Perspective: Henry J. Aaron, Ph.D., and Kevin W. Lucia, J.D., M.H.P.
Only the Beginning — What's Next at the Health Insurance Exchanges? http://www.nejm.org/doi/full/10.1056/NEJMp1308032
* NEJM, 2013:
Probability of Cancer in Pulmonary Nodules Detected on First Screening CT http://bit.ly/14FeuuB
the rates of cancer in the two data sets were 5.5% and 3.7%, respectively. Predictors of cancer in the model included older age, female sex, family history of lung cancer, emphysema, larger nodule size, location of the nodule in the upper lobe, part-solid nodule type, lower nodule count, and spiculation (needle-like structure).
* Science-based medicine 2013:
Everything Causes Cancer http://bit.ly/17qcjZM
* News Medical 2013:
New Report Lays Out Guidelines To Improve Cancer Care http://bit.ly/17OWqgc
* KevinMD 2013:
Survivorship care after cancer is a shared effort http://bit.ly/19El3Mb
* KevinMD 2013:
People who participate in clinical trials are trailblazers http://bit.ly/17OUapm
* NYT 2013:
Futile Care at Life’s End http://nyti.ms/16kukcj
Tuesday, September 10, 2013
* IOM, 2013:
Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis http://bit.ly/1anG12E
* J Clin Onc 2013:
Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly
increased use, older recipient age, and use of unrelated donors. http://1.usa.gov/1d0WGdx
* J Clin Onc 2013:
Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to
Bortezomib: Phase II MCL-001 (EMERGE) Study. http://1.usa.gov/15LBDGF
* Haematologica 2013: (TECHNICAL)
Origin and migration of follicular lymphoma cells http://bit.ly/15NpIOv
* Haematologica 2013;
Transplantation in follicular lymphoma: not "yes or no" but "whom and when". http://bit.ly/14ABWch
As lymphoma-treating physicians, we should stress the point that future randomized trials applying new agents in FL should also address the aspect of sequence in that we ask for overall rather than event-free survival. The study groups and working parties should stimulate experimental treatment arms that are randomized against either autologous or allogeneic stem cell transplantation following the current standard of care as defined by the best available evidence, even if this is “only” a consensus of experts. Otherwise, the possible economic impact of new and potentially effective pharmacological agents will direct the attention away from defining a more definite role for ASCT and allo-HSCT in the therapeutic sequence for patients with follicular lymphoma.
* Leuk Lymph 2013:
7-Year Follow-up of Allogeneic Transplantation using BEAM chemotherapy in Hodgkin Lymphoma Patients after Autograft Failure: Importance of Minimal Residual Disease. http://1.usa.gov/19CzYq9
* Cancer 2013:
Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: Results of the National LymphoCare Study. http://1.usa.gov/19CynAE
* Leuk Lymph 2013:
NODAL MARGINAL ZONE LYMPHOMA. http://1.usa.gov/1d0WScA
* Medpage Today 2013:
'Nose Knows' Devices Not Ready for Clinic http://bit.ly/1d0PwpN
* Health News Review 2013:
The NY Times Well blog isn’t always so well http://bit.ly/1ayfhQB
Excellent discussion about some of the problems in scientific journalism in stories with headlines like "Some fruits are better than others" (at reducing risk of type 2 diabetes" Worth a read. --anjou
* Health News Review 2013:
A patient’s perspective on an NIH/NCI news release – a punch in the gut http://bit.ly/14Hb9WC
Excellent commentary and perspective on recent news story about Hodge patients being at risk of developing stomach cancer down the road-- anjou "The following thoughts were sent to me by Carol Countryman, who had chemotherapy and radiation therapy for Hodgkin’s disease in the early ’70s. She’s had two mastectomies and last year was diagnosed with delayed-onset myopathy from the radiation – a new disease and very rare. She says her quality of life “is already a bit grim and now I read about stomach cancer.” Here’s what she wrote: Dear Gary: Today I read a news release headlined “NIH Study Links Hodgkin Lymphoma Treatment to Possible Risk of Stomach Cancer.” After reading the article, I felt like someone punched me in the gut. This sentence was most troubling: “Of 17,477 Hodgkin lymphoma cases examined, the researchers identified 89 survivors who later developed stomach cancer.” Isn’t that an infinitesimal number? That’s only one-half of one percent. But that wasn’t made clear in the article."
* KevinMD 2013:
Don’t confuse death with dignity with suicide http://bit.ly/15RRi6i
Monday, September 9, 2013
* J Natl Cancer Inst. 2013
Ginseng for cancer-related fatigue - randomized trial http://1.usa.gov/1fRx2HP
KarlS: Positive studies for natural products in their native forms are rare. This seems to be an exception.
* Patient Power 2013:
Exercise-and-complementary-medicine#sthash.66rznJzt.dpuf http://bit.ly/19AU18v
* Helio 2013:
Cutaneous T-cell lymphoma incidence stabilized in US http://bit.ly/15QxlwT
* Philly.com 2013:
Cancer pills convenient but costly, confusing http://bit.ly/16f1oTb
* Dr Sharman's blog:
GA-101 (Obinituzumab) Strikes Again http://bit.ly/1eu7eDu
* JCI 2013:
Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells http://bit.ly/1dU3219
Saturday, September 7, 2013
* MNT 2013:
Cancer may get help from immune cell http://bit.ly/15Dw9gY
The Guardian 2013:
Six stubborn myths about cancer: The internet is awash with misinformation about cancer, with potentially tragic consequences for patients http://bit.ly/15EL8gH
* Blood 2013:
Defining characteristics of classical Hodgkin lymphoma microenvironment T helper cells. http://1.usa.gov/19pArf9
* Medscape 2013: Free registration and login required
Cancer Drug Costs: Oncologists Must Be 'Part of the Solution' http://bit.ly/165hUFk
* Sunrise Rounds, 2013:
The Bridge http://bit.ly/18zWmzf
Thoughts from an onc on what it means to be a good doctor "While a good doctor must have a solid foundation of knowledge and the proper skills to perform his or her specialized task, I believe that the “great” doctor is one who recognizes, at least intuitively, the gap between the emotional, irrational state in which we live our lives and the rational- objective structure of the healthcare system. The skilled physician understands that he must bridge the chasm."
* Eur Heart J. 2012: (technical - describes a research method to decrease bias in non-randomized trials.)
Do observational studies using propensity score methods agree with randomized trials?
A systematic comparison of studies on acute coronary syndromes http://1.usa.gov/18Kt7Zo
For this indication, "observational studies using PS methods produce treatment effect estimates that are of more extreme magnitude compared with those from RCTs, although the differences are rarely statistically significant."
* Proposing the Patient-selected Controlled Trial (PCT) - PAL
We are seeking input from statisticians on the PCT (Patient-selected Controlled Trial) - as an additional tool to consider when comparing treatments for cancer - such as (but not limited to) when the compared interventions have very different risks, or when both treatments can be used off-study … study questions that are unlikely to be answered with a RCT design because of low patient acceptance.
Briefly, the PCT lets the patient either (1) choose to be randomized or (2) pick the study arm they want to be in. The arm they select may be based on their own expectations, preference, or their unique clinical risk factors. Such decisions will most often be guided by the patient's physician.
Mary, for example, might prefer the study arm that would not put her fertility at risk. John might prefer the treatment arm that appears to have the greater chance to achieve a cure. Tom, having no opinion or expectation about which is better, might well choose to let a computer decide.
Our thought is that for the PCT to provide reliable answers would require pre-specified rules for adapting the study size and perhaps Propensity Score Methods described above. Not having background in this area we don’t know if it’s feasible to get unbiased answers with the PCT … or put differently, if this method would be better than doing a large single arm study using historical controls?
Friday, September 6, 2013
* Clinical Oncology News 2013:
Minimizing Hodgkin Lymphoma Treatment With PET http://bit.ly/1abgDx1
Requires registration to enter the site
* Bionews 2013:
MD Anderson Researcher Testing New Therapies For Refractory Mantle Cell Lymphoma http://bit.ly/17cdoV8
* Science Daily 2013:
New Research Suggests Cutting Calories May Improve Response to Cancer Treatment http://bit.ly/1dWGopU
based on an animal model - lymphoma cells in mice.
* Patient Power 2013:
Promising Advances in Treating Mantle Cell Lymphoma (talk by Dr Sharman) http://bit.ly/14n6PRr
* Rational Wiki 2013:
Alternative Medicine 2013: http://bit.ly/17S04b2
* KevinMD 2013:
Treating cancer patients puts everything else into perspective http://bit.ly/151KKGG
* Medscape 2013:
New PET/MRI Hybrid May Enhance Cancer Diagnoses http://bit.ly/18FDbD0
Thursday, September 5, 2013
* Psychology Today: Rant: Shared Decision Making in Medicine http://bit.ly/19ioEiN
Several excerpts:
"when a physician resorts to jargon, the effort to educate patients can fail. Imagine yourself sitting half naked on an exam table with the word cancer rattling around your brain. Do you think you'd be able to comprehend such a conversation? Jargon is ubiquitous in physician-patient encounters; doctors frequently use undefined technical terms and patients rarely have the confidence or assertiveness to ask for clarification.
All too often, the result is precious time wasted on ineffective communication despite the many important decisions doctors and patients need to make together"
"To make matters worse, physicians often fail to account for a patient's negative emotional state during medical consultations. In one study of senior oncologists, researchers discovered that when patients expressed negative emotions ("I'm scared" or "I can't sleep because of pain"), the oncologists acknowledged and responded to the emotions only one in five times"
* NYT 2012: Is the Cure for Cancer Inside you? http://nyti.ms/100LMAo
Wednesday, September 4, 2013
* Science Daily 2013:
New Therapeutic Approach to Fight Cancer: Inhibiting Cancer Cells' Energy Metabolism http://bit.ly/17qXYsA
* NYTimes 2013:
Values Conflict at the End of Life http://nyti.ms/175uhAJbbb
* J Clin Onc 2013:
Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma http://bit.ly/17ocMIB
Outcomes of 241 patients (112 anaplastic large-cell lymphoma, 102 peripheral T-cell lymphoma not otherwise specified, 27 angioimmunoblastic T-cell lymphoma) undergoing autologous HCT (autoHCT; n = 115; median age, 43 years)
or allogeneic HCT (alloHCT; n = 126; median age, 38 years) were analyzed.
* Sunrise Rounds 2013:
Cancer Chaos http://bit.ly/1cE3Hkj
* Lymphoma coalition 2013:
Know your nodes http://knowyournodes.org/
* PAL, 2013 - update:
Patient Recommended Oncologists - OH Cleveland Clinic PAL
Monday, September 2, 2013
* PAL, 2013
6 New Lymphoma and CLL studies of interest PAL
* Salon 2013:
Cancer research in crisis: Are the drugs we count on based on bad science? http://bit.ly/1dFQTxN
A paper finding that important preclinical experiments can't always be reproduced suggests that some new drugs could be based on bad science. KarlS: Not publishing (or being able to publish) failed experiments could contribute to this problem.
* Brian Koffman's CLL Blog 2013:
Large Granular Lymphocytic Leukemia:
What We CLL Patients Can Learn from a Novel Therapy for a T Cell Cancer http://bit.ly/19WnVof
* Exchange shopping for health insurance begins soon
This information is provided in the state of PA ... which should be about the same elsewhere.
The Marketplace (overview of the rules) http://bit.ly/15Pymtd
The Federal Marketplace (shop Oct 2013- effective Jan 2014) http://bit.ly/15PyGrK
* PAL, 2013 ... What is Lymphoma? PDF
September 15th is World Lymphoma Awareness Day
Please print the tri-fold brochure about lymphoma prepared by PAL and distribute to local businesses
Friday, August 30, 2013
* Medscape 2013:
Reprogramming Aggressive Lymphoma Into More Benign Disease http://bit.ly/14ImY25
More on low dose azacitidine as a pretreatment for DLBCL ... a promising new approach. Requires login in and one-time registration.
* Patient Power 2013:
Gauging the Success of Relapsed-Refractory Hodgkin Lymphoma Treatment - http://bit.ly/15qsxOB
Use of PET scan to monitor for relapse following transplant.
* Medical Daily 2013:
Court Rules That Sarah Hershberger, Amish Girl Battling Cancer, Should Be Appointed Legal Guardian After Parents Stop Her Chemotherapy http://bit.ly/1cofCCC
When values clash ... is particularly difficult issue to resolve when the decision to forgo lifesaving therapy involves a child
* Science Daily 2013:
New Imaging Technology Promising for Several Types of Cancer (PET/MRI) http://bit.ly/1fn4p51
* NYTimes 2013: Living With Cancer: Is It Back? http://nyti.ms/15krDtR
* The Economist 2013:
Lucrative lifesavers: The hopes and perils of betting on cancer treatments http://econ.st/159rFyD
Thursday, August 29, 2013
* KevinMD 2013:
How long do you continue to fight when death is certain? http://bit.ly/1chxQFS
* Medscape 2013:
Can We Identify Risk for Drug Toxicity? http://bit.ly/1dmKWVk
* KevinMD 2013:
Choosing a doctor is like choosing a spouse http://bit.ly/1dqeAKo
* Science-Based Medicine 2013:
The Science of Clinical Trials http://bit.ly/17gKGVB
* Respectful Insolence 2013:
A cancer quackfest http://bit.ly/1dtZiEl
* PAL, 2013 - Revision 3 - ready for stakeholder input
Proposing the Patient-selected Controlled Trial design PAL
Wednesday, August 27, 2013
* American Psychological Association 2013:
Coping with a diagnosis of chronic illness http://bit.ly/1dnbJBU
* xconomy 2013:
Why Good Drugs Sometimes Fail: The Bexxar Story
And In the Pipeline 2013: Promise that didn't pan out.
Posted to PAL's Bexxar page with commentary
* KevinMD 2013:
After cancer treatment, primary care becomes even more important http://bit.ly/15v9whP
* Violent Metaphors 2013:
How to read and understand a scientific paper: a guide for non-scientists http://bit.ly/12JbHgI
* U S Florida 2013:
New treatments better than standard ones just over half the time: That's evidence the randomized clinical trial system works, University of South Florida researcher reports in Nature http://bit.ly/181NdiB
Article citation: "Medical research: Trial unpredictability yields predictable therapy gains;"
* Sunrise Rounds 2013:
An unneeded apology? http://bit.ly/16JVZzd
* Fox Business 2013:
I've Had Lymphoma. Can I Get Life Insurance? http://fxn.ws/16NOP0r
* Forbes 2013:
Alternative Medicine Providers Show Their Greedy Side http://onforb.es/12HHCON
* MNT 2013:
Discovery of novel way gene controls stem cell self-renewal http://bit.ly/1aLHZg7
* News Medical 2013:
Tips from experts can help cancer survivors continue pre-diagnosis daily routines http://bit.ly/1ccVeUU
Tuesday, August 26, 2013
* NIH 2013:
NIH study links Hodgkin lymphoma treatment to possible risk of stomach cancer http://1.usa.gov/13UGZnN
* KevinMD 2013:
6 tips to prevent being intimidated at the doctor's office http://bit.ly/1c9GhDc
* Slate 2013:
Why Aren’t There More Cancer Vaccines? Blame America’s lousy patent system. http://slate.me/13T3pWn
* MNT 2013:
How our own bodies help turn cancer against us http://bit.ly/17gURpp
Not lymphoma specific but interesting. Talks about how the immune system can be a "double edged sword" when it comes to cancer...
* Forbes 2013:
Death With Dignity Should Not Be Equated With Physician Assisted Suicide http://onforb.es/143aO04
* Cancer Network 2013:
Maintenance Rituximab in Advanced Follicular Lymphoma: Therapy does not significantly improve PFS after chemoimmunotherapy induction and consolidation http://bit.ly/174IBMj
Sunday, August 25, 2013
* Sunrise Rounds, 2013: Once more into the fray http://bit.ly/1ddvlHC
* Fox: Hospital Fights to Treat 10-Year-Old Amish Girl’s Cancer http://bit.ly/1dDuiiNancer/
* Karmanos
App Helping Patients & Caregivers Find Cancer Clinical Trials http://bit.ly/16qD4JO
Iphone app to find clinical trials
* NYT 2013:
Life, Interrupted: A Test of Faith http://nyti.ms/17OMgKw
* News Medical 2013:
Novel Approach Developed On Antitumor Immunotherapy http://bit.ly/1bYNwOg
Preclinical but interesting...
* J Clin Onc 2013:
Rituximab Maintenance Compared With Observation After Brief First-Line R-FND Chemoimmunotherapy With Rituximab Consolidation in Patients Age Older Than 60 Years With Advanced Follicular Lymphoma: A Phase III Randomized Study by the Fondazione Italiana Linfomi. Posted with comment to PAL Maintenance page
Thursday, August 22, 2013
* Medscape 2013: BEACOPP Beats ADVD for Survival in Hodgkin's Lymphoma http://bit.ly/1bTMZwY
This is an important report -- likely to stimulate very active debate among experts -- as it finds in favor of an approach that has lost favor in the US. See also comment on this news item PAL
* ASH 2013:
New research suggests cutting calories may improve response to cancer treatment http://bit.ly/1d5zkGd
A mouse study ... so very preliminary evidence here - an influence that could vary from cancer to cancer and by drug. Off-hand, due to the common influence of treatments on appetite, restricting calories during treatment could already be common practice.
* The New Yorker 2013:
How Should Doctors Share Impossible Decisions with Their Patients? http://nyr.kr/13G3YCJ
* PsychCentral 2013: How to Read a Journal Article http://bit.ly/17KmwyK
* Pesticides: after Parkinson's the Non-Hodgkin's Malignant Lymphoma http://bit.ly/1f2l0L3
Article appears to be about a legal judgment linking a farmer's non-hodgkin's a herbicide
(although the title says pesticides)
Wednesday, August 21, 2013
* U Penn 2013:
Penn Medicine study shows survivorship care plans empower cancer patients: Online tool for planning life after cancer fills knowledge gaps, arms patients with information to take charge of their care http://bit.ly/14UApYm
"Despite the close watch from health care providers cancer patients receive during their treatment, it's often not clear who – an oncologist, a primary care physician, or another type of specialty physician – is responsible for mechanizing the disparate aspects of a survivor's health, from monitoring for and managing late effects of therapy to ordering routine preventive health exams such as bone density tests and colonoscopies. Consequently, important health needs among cancer survivors needs may go unmet, the authors say."
|
Survivorship Care Plan - an Online Tool Powered by Penn Medicine's OncoLink Posted to PAL Support Topics
IOM recommended - this online tool can help to make a "survivorship care plan" that is individualized based on the answers you provide in a brief questionnaire.
|
* KevinMD.com 2013:
How fear affects cancer survivorship http://bit.ly/157z58v
* Sunrise Rounds 2013:
Goodby in the Mist http://bit.ly/16sJbRb
An oncologist talks about his feelings when a long-term patient is dying.
* KevinMD.Com 2013:
The complicated existential dilemma of living with cancer http://bit.ly/16uj8cm
Tuesday, August 20, 2013
* Respectful Insolence 2013:
The key difference between alternative medicine and evidence-based medicine http://bit.ly/155yg05
* Scientific American 2013:
Sex Makes You Rich? Why We Keep Saying “Correlation Is Not Causation” Even Though It’s Annoying http://bit.ly/14gc03G
* Oncology Times 2013:
Survey: Most Oncologists Avoid Using the Word 'Cure' in Discussions with Patients http://bit.ly/19u8L9I
* Oncology Times 2013:
View from the Other Side of the Stethoscope: Patient Handout-Facing Cancer Together http://bit.ly/1d0VSHW
Helpful tips for couples
* Weill Cornell 2013:
Pre-treating DLBCL with Targeted Therapy Improves Patient Outcomes and Chemotherapy Effectiveness http://bit.ly/17ECoCY
SNIP: The implications for this study are far ranging. Dr. Cerchietti explained, ”Oncologists have long believed that using high doses of an anti-cancer drug is the best strategy. Our study shows that is not the case in this kind of lymphoma, and suggests this new approach can potentially be translated to other tumor types.”
Researchers plan on expanding the study to additional DLBCL patients in a multi-center clinical trial, while studying pre-treatment strategy options in other tumor types and lymphomas.
* Also on this: Science Daily 2013: http://bit.ly/18AhdmF
Monday, August 19, 2013
* KevinMD 2013:
Why you should consider a second opinion from a pathologist http://bit.ly/16kUieX
Comment: An important piece - a way for patients to help to optimize their care.
"Expert second opinions are also particularly valuable if the patient’s initial diagnosis is inconclusive or supposedly diagnostic of a rare or unusual tumor. In addition to identifying incorrect diagnoses, in many other cases an expert second opinion can fine-tune a diagnosis in a way that may be significant, such as reclassifying the subtype of a lesion or changing the grade or stage of a tumor. Even when the expert consultation results in no change in the diagnosis, it provides the patient with peace of mind that their diagnosis is correct."
* Fox News 2013:
Indian cancer patients forced to camp in the street http://fxn.ws/14NGbLk
* Blood 2013:
Egress of CD19+CD5+ cells into peripheral blood following treatment with the BTK inhibitor ibrutinib in mantle cell lymphoma patients. http://1.usa.gov/14Vv0nS
* Am J Hem 2013:
The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy. http://1.usa.gov/13tlB8Z
* Haematolgica 2013:
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving
1191 patients, in the pre and post rituximab era. http://1.usa.gov/15Ta6Su Full Text
The 5 years OS was 60% and 72% for LMR ≤2.1 and >2.1, respectively (Figure 1c).
Saturday, August 17, 2013
* Onclive 2013:
Ibrutinib Combo Achieves 100% Response Rate in Patients With NHL - http://bit.ly/16UWta3
"Adding ibrutinib to standard (R)-CHOP chemotherapy for non-Hodgkin lymphoma (NHL) resulted in an objective response rate of 100% In the study, first-line treatment with ibrutinib and chemotherapy led to complete responses in 10 of 15 patients, and the remaining five patients had partial responses."
Comment: It's a small study with no control group. Focus should be on the Complete Response rate for this indication, which is treated with curative intent. Complete response rates are also very good with standard therapy so more study is needed to validate these encouraging results.
* Oncology Report 2013:
Epigenetic approach tames aggressive B-cell lymphoma http://bit.ly/14kVKuH
"Complete responses were achieved in 11 of 12 newly diagnosed patients treated with the novel strategy, with 10 remaining in remission after a median follow-up of 13 months (range 5-28 months).
* Also Science Daily 2013: http://bit.ly/18AhdmF
* Also Medical Xpress 2013: http://bit.ly/18zXnIn
Comment: This is a report on encouraging outcomes but in a very small study - for 12 patients. The novel approach was not compared to regular therapy in a controlled study. Complete response rates are also very good with standard therapy so more study is needed.
* Huff Post 2013:
Surviving Cancer Won't Be My Biggest Accomplishment http://huff.to/17SlZK8
* Cancernetwork 2013:
“I’m the Decider! (Is That OK with You?)” http://bit.ly/14Q59Ao
* xkcd 2013:
Increased risk cartoon http://imgs.xkcd.com/comics/increased_risk.png
* Brian Koffman's CLL blog 2013:
More Comments on to Tell or Not to Tell About Our CLL http://bit.ly/15OmzGU
* KevinMD 2013: How should doctors and patients look critically at medical decisions? http://bit.ly/19n3xfP
* Forbes 2013:
Beware Of Cancer Metastasizing To Your Wallet http://onforb.es/16hebnc
* J Natl Compr Canc Netw 2013:
Targeted therapy in relapsed classical Hodgkin lymphoma. Posted to Hodgkin page - In the News
Comment: This technical article highlights some of the agents either approved or in development for relapsed/refractory Hodgkin lymphoma, such as cd30 antibodies and much more.
Friday, August 16, 2013
* Oncology Times: ONLINE FIRST:
Underprescribed Bexxar Discontinued by GlaxoSmithKline http://bit.ly/18yBbyc
* The Jewish Voice 2013:
Lymphoma Risk Varies for Celiac Disease Patients http://bit.ly/1a9Mn8s
* Cancer Research Inst 2013:
Cancer and the Immune System http://bit.ly/16RVGXo
* Cur Opin Oncol 2013:
Refractory hodgkin lymphoma. http://1.usa.gov/17PJZ0j
* WSJ 2013:
Epratuzumab and Rituximab Produce High Rate and Durable Progression-Free Survival in Previously Untreated Follicular Lymphoma http://on.wsj.com/1cPXep7 (company press release)
* Lymphobob 2013:
Follicular Lymphoma: Epratuzumab http://bit.ly/18xqyLU
* Science Based Medicine 2013:
facts of the alternative medicine industry http://bit.ly/14fWAJ2
* The ASCO Post, 2013:
B-cell Receptor Signaling Inhibitors Moving Forward in Lymphoma http://bit.ly/1eNkArP
Thursday, August 15, 2013
* Medscape 2013:
New Scoring System Evaluates Prognosis in Burkitt Lymphoma http://bit.ly/140xHVo
* Cancer Research UK 2013:
Huge genetic analysis points to cancer-causing culprits http://bit.ly/1cDCTnL
* BBC 2013:
Milestone study probes cancer origin http://bbc.in/1bwX2YE
* My Angry Cancer 2013:
Speak No Evil: Or, "What Not To Say To a Cancer Patient." http://bit.ly/1cBFZbM
* Eurpean J Cancer 2013:
A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide
(Revlimid®) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: The EXPECT trial http://bit.ly/1cNvl0F
* Leukemia Research:
Hepatitis B infection increases the risk of non-Hodgkin lymphoma: A meta-analysis of observational studies
http://bit.ly/16kdQ5J
* In the Pipeline:
Another T-Cell Advance Against Cancer http://bit.ly/1eJx4AV
early, pre-clinical work with engineered t-cells
* Huff Post 2013:
How a Car Accident and Cancer Taught Me Different Things About Mortality http://huff.to/15C5FeM
Wednesday, August 14, 2013
* Weil Cornell 2013:
New Clinical Trials: Innovative Approaches for Follicular Lymphoma http://bit.ly/16862RU
"The Weill Cornell Lymphoma Program has recently opened two clinical trials sponsored by The Alliance for Clinical Trials in Oncology. These trials are notable for their innovative approach. As Lymphoma Program Director and current chair of the committee, Dr. John Leonard explained, “Under the leadership of Bruce Cheson, MD, the lymphoma committee has been focused on ‘biologic doublets’ with targeted agents, a treatment approach that has been quite innovative. Following up on his work we are now moving toward ‘targeted triplet therapy’ which is a first in lymphoma therapeutics.”
See for details study details, eligibility, trial location:
* Rituximab, Lenalidomide, and Ibrutinib in Untreated Follicular Lymphoma -
ClinicalTrials.gov http://1.usa.gov/1cBniFe
The primary objective is to determine the recommended phase II doses of ibrutinib and lenalidomide for combination with rituximab.
* KevinMD 2013:
After a medical mistake, an apology is both simple and difficult http://bit.ly/123uGSS
* J Clin Onc2013:
Follicular Lymphoma Cells Induce Changes in T-Cell Gene Expression and Function:
Potential Impact on Survival and Risk of Transformation http://bit.ly/17If33X
Tuesday, August 13, 2013
* Channel5 2013:
Super Strength Immune Cells Fighting Cancer http://bit.ly/1bq66hZ
Interesting interview about a treatment used for multiple myeloma, another blood cancer
* Brian Koffman CLL blog 2013: ASCO 2013:
Dr. Sharman on The Biology of CLL being Cracked with a Therapeutic Renaissance Underway http://bit.ly/162FykB
* OncLive 2013:
The Antibody Arsenal: More Complex Targeted Agents Primed for Increased Potency http://bit.ly/19cF396
* Onclive 2013: Novel PI3K Inhibitor Active in Non-Hodgkin Lymphoma http://bit.ly/15uTj7Y
* blog 2013
The OTHER Burzynski Patient Group http://bit.ly/14HaSIN
* Science Based Medicine 2013:
When doctors betray their patients and science-based medicine for money http://bit.ly/1eEj3o8
* Consumer Reports
Compare over-the-counter drugs for common ailments http://bit.ly/1cvl7Ca
Nice to have an independent group helping to sort through the gazillion options and ads.
Lancet:
Probiotics for C-diff in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, trial http://bit.ly/17huIq9
Sunday, August 11, 2013
* Dr Harpham 2013:
Naked Statistics http://bit.ly/1630ryF
Recommends a good basic book on statistics
* Health Canal 2013:
Burkitt lymphoma survival improves for some http://bit.ly/17eVlvL
* Brian Koffman's CLL Blog 2013:
CLL: More on to Tell or Not to Tell http://bit.ly/161p8M3
* Cancer: 2013:
Population-based prognostic factors for survival in patients with Burkitt lymphoma: An analysis from the Surveillance, Epidemiology, and End Results database. http://1.usa.gov/11U96jM
* KevinMD 2013;
More health information is not necessarily better http://bit.ly/13rhsNq
* Cancer 2013:
Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab:
A comprehensive analysis from the NCCN lymphoma outcomes project. http://1.usa.gov/1cn5iyn
Patients who underwent autoSCT (N=136) were older compared with patients who underwent alloSCT (N=48) (54 versus 51 years, respectively, P=.01) and more frequently had grade 3 FL (35% versus 8%, respectively, P = .006).
Patients who underwent alloSCT received more prior therapies (4 versus 3, respectively, P < .0001) and more often had resistant disease at SCT (19% versus 6%, respectively, P = .008).
Comment: ... highlighting the challenge of comparing outcomes from different approaches across different studies. KarlS
* * Leuk Lymph 2013:
Loss of utility of bone marrow biopsy as a staging evaluation for Hodgkin lymphoma in the PET imaging era: a West of Scotland study. Posted to Hodgkins - In the News
Sat, August 10, 2013
* Cancer 2013:
Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab:
A comprehensive analysis from the NCCN lymphoma outcomes project. http://1.usa.gov/1cn5iyn
* Cancer 2013:
A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. http://1.usa.gov/14h2atR
* Research to Practice 2013:
Go "Beyond the Guidelines" with the video proceedings from RTP's lymphoma & myeloma symposium
held at ASCO 2013. http://bit.ly/14CVMnH
* Onc Times 2013:
Orphan Drug Status for E7777 for CTCL http://bit.ly/1cQQ6av
* Dr Len's Cancer Blog 2013:
Palliative Care Is About Quality Of Life Throughout The Cancer Journey http://bit.ly/14Ckwwg
* Scripps Research Inst 2013:
Scripps Research Institute study shows microRNAs can trigger lymphomas http://bit.ly/11Q5aR6
* Brown Univ 2013:
Study shows who survives Burkitt lymphoma: Proposed score delineates risk, prognosis http://bit.ly/13RZ9Rg
* Int J Pharm 2013:
Pharmaceutical follow-up for patients on rituximab therapy for NHL: what is the evidence? http://1.usa.gov/1cxnPXD
J Nucl Med 2013:
Interim 18F-FDG PET in Hodgkin Lymphoma: Would PET-Adapted Clinical Trials Lead to a Paradigm Shift? http://1.usa.gov/17zw6n0
====
* MNT 2013:
Biomarker identified to predict immune response risk after stem cell transplants PAL - comments on the news
Thu, August 8, 2013
* Medpage Today 2013:
Marker Warns of GVHD After Stem Cell Transplant http://bit.ly/15NnjSL
* KevinMD 2013:
Do you worry about the diseases you learn in medical school? http://bit.ly/14yKxfV
* LymphoBob 2013:
Cancer Cup Song http://bit.ly/1ccvRpP
Wed, August 7, 2013
* New Medical 2013
Study finds cancer survivors do not always have best access to primary care http://bit.ly/14juDmS
* Dana-Farber 2013
Vaccine stirs immune activity against advanced, hard-to-treat leukemia CLL http://bit.ly/16t2E2T
“scientists at Dana-Farber Cancer Institute report in the Journal of Clinical Investigation that they observed a strong and selective immune response in some patients who received, shortly after the transplant, several doses of a "personalized" tumor vaccine composed of their own inactivated leukemia cells combined with an immune stimulant, GM-CSF.”
KarlS: This setting for vaccine seems more promising … as a way to build on the graft versus lymphoma effect. Perhaps with a donated immune system there is less ability for the lymphoma / CLL cells that survived high dose therapy to turn off the immune response. So activating that response with a vaccine could actually work more reliably.
Consider that for abnormal cells to develop into a lymphoma and grow that they must evolved ways to shut down the immune system – to give the bad cells a free pass. With a new immune system any previous "deals" could well be null and void – (as evidenced by the graft vs. disease effect).
* Cambridge University 2013
Cancer patients want more shared-decision making about their treatment: http://bit.ly/17wf9d1
* Oncology Report 2013
Immune microenvironment linked to prognosis of follicular lymphoma http://bit.ly/1baBNf7
* Reuters 2013
Unhealed intestines in celiac disease tied to lymphoma http://reut.rs/13iFpq0
Tues, August 6, 2013
* Sunrise Rounds, 2013:
What we blame on chemo http://bit.ly/15KwDUZ
* Forbes, 2013:
Can We Build A Kickstarter For Cancer? http://onforb.es/1c5mEiX
* Onc Times, 2013:
Debating the Role of Interim PET Scans in Lymphoma http://bit.ly/11IPfnn
* Columbia Univ, 2013:
Celiac disease patients with ongoing intestine damage at lymphoma risk http://bit.ly/15Iw51S
* MNT, 2013:
Tumor cell vaccination trial to promote anti-leukemia responses http://bit.ly/1c3IYcI
* HEMOnc Today, 2013:
Obinutuzumab active in three types of lymphoma http://bit.ly/13Apg2I
"Obinutuzumab demonstrated encouraging single-agent activity with acceptable toxicity in the treatment of indolent non-Hodgkin’s lymphoma, diffuse large B-cell lymphoma and mantle cell lymphoma, according to results of the phase 2 GAUGUIN study."
KarlS: Activity is good -- but is not necessarily a way to measure benefit.
* Medical News Today, 2013:
Novel drug shuts down master protein key to lymphoma http://bit.ly/1cDiwEy
* UT San Diego, 2013:
Cancer drug resistance mechanism unraveled http://bit.ly/17sOYDZ
* MedLexicon, 2013: Diffuse Lymphoma: PET/CT bests gold standard bone marrow biopsy for diagnosis and prognosis of lymphoma patients http://bit.ly/15HB6rw
Thursday, July 25, 2013
From various news sources: PAL; In the Pipeline, New Yorker
* New Treatments for indolent lymphomas: How do you measure success?
An advocate's perspective on endpoints - old, misleading, new, and investigational
* More Details on T-Cell Therapy for B-cell Leukemia / lymphoma
SNIP: "This all should be seen in a larger context of immunotherapy, too. People have been trying to recruit the immune system for years in the fight against tumor cells, with mixed success. But we may be just on the verge of knowing enough about what we're doing to get more of these to work. At this point, it would not surprise me if immune system approaches become the dominant form of treatment for several types of cancer over the next 25 years. The next few years will tell us."
* When Doctors Tell Patients What They Don’t Want to Hear
Wednesday, July 24, 2013
From various news sources: OncLive, News Medical, Semin Cancer Biology, Med Lexicon, Sunrise Rounds
* Novel therapies for peripheral T-cell lymphomas (full text)
KarlS: Posted to In the News on the PTCL page
* Conclusion: Final Thoughts on Managing Hodgkin Lymphoma
* Female cancer patients unhappy with the way doctors discussed about fertility preservation options
* The microenvironment in classical Hodgkin lymphoma: an actively shaped and essential tumor component
* Time between cancer diagnosis and treatment provides 'window of opportunity' to optimize health
* Wasting a precious gift
Anjou: Deals with end of life issues. An oncologist talks about the sometimes futile, brutal care for terminal patients
Tuesday, July 23, 2013
From various news sources: Detroit News, NYTimes, Kevin MD, Leuk Lymph, Haematologica, Cancer Research, Br J Cancer, Science Daily, Lymphobob, Science Based Medicine, The Health Care Blog
* Big pharma mobilizing patients in battle over drugs trials data
Leaked memo from industry bodies reveals strategy to combat calls by regulators to force companies to publish results
KarlS: This story has angered patient advocates. It reminds that developing new drugs is a business - thankfully a regulated business ... to some degree.
* Omega-3s May Raise Prostate Cancer Risk
* A Guide to giving patients bad news
snip: It is a mistake to simply walk up to a patient and say, “sorry but the cancer has come back, I’ll get back to you.”
* Dissecting the grey zone between follicular lymphoma and marginal zone lymphoma (technical)
* Increased risk of second malignancies in CLL compared with follicular lymphoma: a Canadian population-based study
* Too Many Antioxidants? Resveratrol Blocks Many Cardiovascular Benefits of Exercise
* Stanislaw Burzynski: The Early Years, part 1
* How Doctors Die
SNIP: It’s not a frequent topic of discussion, but doctors die, too. And they don’t die like the rest of us. What’s unusual about them is not how much treatment they get compared to most Americans, but how little. For all the time they spend fending off the deaths of others, they tend to be fairly serene when faced with death themselves. They know exactly what is going to happen, they know the choices, and they generally have access to any sort of medical care they could want. But they go gently.
Sunday, July 21, 2013
From various news sources: KevinMD, The Atlantic, OncLive, OncLive
* News on cancer breakthroughs: Curb your enthusiasm
KarlS: Timely information - resonates in light of recent findings for Lenalidomide in elderly patients with CLL
* The Vitamin Myth: Why We Think We Need Supplements
* On the Frontier of Cancer Care Holland Helped Pioneer Psychosocial Treatment
Anjou: Excellent interview with one of the leaders in the field of psychology and social needs of cancer patients
*** Experts on Novel Treatment Approaches in Hodgkin Lymphoma - with video
KarlS: Direct link to excellent and important interviews video
Friday, July 19, 2013
From various news sources: The ASCO Post, NYT, Counsel and Heal News, Nature, Dr Kauffman, GEN, Bloomberg, KevinMD, DigTriad.com, Med News Today, Cancer Research Inst, Cancer Network
* Idelalisib, Obinutuzumab Show Encouraging Results in CLL Studies
* Walking 800 Miles Away From Cancer
* Nemo, the First Hampshire Pig to be Treated for Lymphoma
* Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737
* Cancer Immunotherapy Goes Viral
*** Celgene Halts a Phase III B-Cell CLL Trial Because of imbalance of Deaths in Lenalidomide arm of study
* Lenalidomide (Revlimid) Associated with Excess Deaths in the Elderly
* Deaths Force End to Celgene Trial to Expand Top Cancer Drug
KarlS: Did the eligibility criteria influence the risk for this drug - 65 years or older?
The finding speaks to the importance of doing randomized trials - not only to compare efficacy but to understand risks.
In this case it’s a sobering reminder that the setting can count – that safety for one indication does not assure safety in another. Lenalidomide has been studied (in randomized trials) for other indications – such as myeloma and MDS. It may be that something in this setting (CLL, older patients) that increases the risk. So the risks may also depend on the class of drug in respect to how unexpected the side effects can be when used in a new setting. How Lenalidomide works (it’s mechanisms of action) is a bit of a mystery.
* What is the biggest mistake patients make?
"No, the biggest mistake patients make is thinking anecdotally rather than statistically"
* Houston Woman Gets Chemo, Later Learns She Doesn't Have Cancer
Anjou: Good discussion about importance of getting second opinions on pathology
* Link Discovered Between Intestinal Bacteria And White Blood Cell Cancer
* Death With Dignity Program Well Accepted at Seattle Cancer Center
Thursday, July 18, 2013
From various news sources: Oncology Times, Blood, Medscape, Medscape, Dr Len's Cancer Blog, NPR, News Medical, The North American Menopause Society (NAMS), The Onc, Science Based Medicine, Respectful Insolence, Koffman blog, News Medical
* FDA Grants Obinutuzumab Priority Review for CLL
The FDA's priority review designation shortens the time to complete a drug's review and aims to deliver a decision on marketing approval
* Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase II trial
We hypothesized that post-transplantation B cell depletion could prevent the occurrence of chronic GVHD.
* Universal HBV Screening Is Cost-Effective in Lymphoma (hepatitis b screening)
There has been some debate about whether all patients with cancer should be screened for HBV before treatment with chemotherapy and immunosuppressive drugs.
* Want To Help Make This Cancer's Last Century? Then Sign Up For Cancer Prevention Study 3
* Mining Cell Data To Answer Cancer's Tough Questions
The group has decided to make all of their data publicly available on the NIH sponsored website Cell Miner, so that it can be widely used for hypothesis-driven pharmaceutical research, and hopefully speed up our understanding and improvement of cancer treatments.
* Cancer patients who receive chest radiation should screen for heart disease every 5-10 years
He added: "Survivors of Hodgkin's lymphoma and breast cancer received high doses of radiation on their chest under the old treatment regimes.
* Cancer survivors have more frequent and severe menopausal hot flashes: But they fare better than other women psychologically and socially
* Sexuality and the Cancer Patient
* Researching SBM Online (science Based Medicine)
* Orac does Stanislaw Burzynski propagandist Eric Merola a favor…
* ASCO 2013: Dr. Wierda on Prognostic Factors in CLL
* Mechanisms of chemotherapy-induced neurological side effects
Wednesday, July 17, 2013
From various news sources: News Medical, News Medical, MNT, Newswise, Cancer Research, Pharmagellan, Oncology Times, Science Daily
* White blood cells and the spread of cancer (not lymphoma specific)
* Study explores mechanisms of chemotherapy-induced #neurological side effects
* Having Type 2 Diabetes Increases Risk For Some Cancers
* Researchers Find Link Between Intestinal Bacteria and #White Blood Cell Cancer
* Intestinal Bacteria Modify #Lymphoma Incidence and Latency by Affecting Systemic Inflammatory State, Oxidative Stress, and Leukocyte Genotoxicity
* How to cure cancer? A review of “The Truth in Small Doses” by Clifton Leaf
* Debating the Role of #Interim PET Scans in Lymphoma
* Strong #Pregnancy Outcomes for Survivors of Childhood Cancer
Tuesday, July 16, 2013
From various news sources: Pharmagellan, Oncology Times, Science Daily
* How to cure cancer? A review of “The Truth in Small Doses” by Clifton Leaf
* FIRST: Debating the Role of Interim PET Scans in Lymphoma
* Strong Pregnancy Outcomes for Survivors of Childhood Cancer
Monday, July 15, 2013
From various news sources: Science Daily, NewsFix, The Onion, NYTimes, NCCAM, Science Daily
* DNA Flaws May Contribute to Cancer Risk in People With Type 2 Diabetes
* Infection may be linked to eye lymphoma
* Deleted - found to be offensive.
* Do Clinical Trials Work?
Snip: Disappointing though its outcome was, the study represented a victory for science over guesswork, of hard data over hunches. As far as clinical trials went, Dr. Gilbert’s study was the gold standard. The earlier studies had each been “single-arm,” in the lingo of clinical trials, meaning there had been no comparison group.
KarlS: So important to realize -- for the benefit of patients.
* How Safe Is This Product or Practice?
* New Theory Uncovers Cancer's Deep Evolutionary Roots
Anjou: Interesting hypothesis
Sunday, July 14, 2013
From various news sources: Psych Central, Boston Globe, Leuk Lymph, J Clin Onc, Br J Hem, Blood, Am J Hematololgy
* What to Do with Worry Thoughts
* Hope for women dealing with infertility after childhood cancer
* Comparison of outcomes among patients aged 80 and over and younger patients with diffuse large B cell lymphoma: a population based study
* Obinutuzumab (GA101) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase II GAUGUIN Study
* Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study
* Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-hodgkin lymphoma who received prior stem cell transplantation
* Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients
* Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study
* Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-hodgkin's lymphoma: Experience on 142 patients
Saturday, July 13, 2013
From various news sources: Sunrise Rounds, Weill-Cornell, NYTimes
* Ibrutinib is Effective Therapy for Relapsed CLL Patients
* Anxiety Lingers Long After Cancer
Discusses anxiety in both the patient and caregivers
Friday, July 12, 2013
From various news sources: OncLive, NY Times, KevinMD, Science-based Medicine
* A Cancer Doctor of One’s Own
* Ask the (Science-Based) Pharmacist: What are the benefits of coffee enemas?
Anjou: Over the years, some lymphoma patients on lymphoma support boards have brought up alternative cancer treatments that involve coffee enemas
* Genomics and personalized medicine: Is it really different this time
* 3 secrets my doctor doesn’t know
* Video: Emerging treatments for CLL Dr. Sharman's CLL & Lymphoma Blog
* First Washington Leukemia Patient to New Therapy ... is Cancer Free
* OT: Link Between High Blood Levels of Omega-3 Fatty Acids and Increased Risk of Aggressive Prostate Cancer Confirmed
Thursday, July 11, 2013
From various news sources: OncLive, AIDs Meds, Medscape, Huffington Post, Cancer Research Institute, Brian Koffman's Blog
* NDA (New Drug Application) Filed for Ibrutinib in CLL and MCL
* Abolishing High Co-pays for Oral Chemotherapy: Is the Third Time the Charm for the Cancer Drug Coverage Parity Act?
* Cancer: Things I wish I were told when diagnosed… Wicked Local Danvers
* Cancer Is Not All I Have
* Cancer and the Immune System
* Single-agent LENALIDOMIDE is active in patients with relapsed or refractory aggressive NHL who received prior stem cell transplantation
a retrospective analysis of two phase II trials (NHL-002 and NHL-003) that studied single-agent lenalidomide in patients with relapsed/refractory aggressive NHL with prior (n = 87) compared with no prior ASCT (n = 179).
* Radioimmunotherapy deemed safe and effective for lymphoma patients: New study evaluates maximum tolerated dose and clinical response (177Lu-DOTA-rituximab)
The prospective study included 31 patients with histologically confirmed relapsed or refractory CD20-positive B-cell lymphoma.
* ASCO 2013: Dr. Wierda Discusses Immune Therapies in CLL
Wednesday, July 10, 2013
From various news sources: Cancer Research UK, AIDs Meds
* HIV Viral Load Associated with Risk of Death After Lymphoma Diagnosis
The risk of death from HIV-related lymphoma is associated with a higher cumulative viral load during the first six months after diagnosis with the cancer, supporting the argument for early antiretroviral (ARV) intervention, aidsmap reports. Publishing their findings in the online edition of the journal AIDS, investigators culled the records of more than 25,000 people receiving care for HIV between 1996 and 2011 and identified 224 who were diagnosed with lymphoma. All members of the group were still living six months after their lymphoma diagnosis and had received at least two viral load screens during that period.
* ‘Chocolate detects cancer’ headlines are misleading
Anjou- very well written article about an MRI imaging technique, in early development, that uses glucose that does not have to be radioactive. Also addresses the oversimplified notion that "sugar feeds cancer," message one finds all over the internet.
* Anaplastic large cell lymphoma, ALK-neg Review - includes promising investigational agents
Tuesday, July 9, 2013
From various news sources: Lymphoma Weill Cornell, Oncology Practice , Medscape, Medpage Today, KevinMD, Medical News Today, Blood, Asian Scientist
* Preliminary Results From a Phase I Trial of Palbociclib (PD 0332991) plus Bortezomib in Patients with Previously Treated Mantle Cell
Palbociclib is an oral drug that specifically inhibits CDK4, enzyme that is central to the proliferation of mantle cell lymphoma cells
* Ibrutinib shows promise for CLL del 17p
KarlS: Interesting how many trials evaluating agents with targeted mechanisms of action are selecting patients with a marker of high risk CLL - in this case a marker that predicts resistance to standard chemotherapy. A form of personalized medicine. This can also be an accelerated path to marketing approval - to address an unmet need.
* Personalized Medicine in Oncology: Where Have We Come From and WHERE Are We Going?
* Researchers Develop MRI Scan To Detect Cancer Using SUGAR
* AFRICAN Americans With Blood Cancer Do Not Live As Long As Caucasians, Despite Equal Care
* Statin On-Board MAY Cut Cancer Risk in HIV Infection
* Genetic Variant That Increases Lymphoma Risk In Chinese Discovered
* PET-CT staging of DLBCL provides new insight into the clinical significance of bone marrow involvement
* It's hard to grasp the experience of being a patient
Monday, July 8, 2013
Also see late Sunday post below
From various news sources: KevinMD, Haematologica, Am J Hematology, Leuk Lymphoma,Br J Cancer, Brit J Cancer,
* When the weight of illness suddenly descends on an individual
* Recognizing nodal marginal zone lymphoma: recent advances and pitfalls. A systematic review
Anjou: The expert pathologist who read my path in 99 had trouble determining if mine was follicular or marginal zone-- wonder if the distinction would have been clearer 14 years later? Sounds like there still is some difficulty with certain presentations.
* Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party
* Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era
* Respect diagnostic radiation, but don’t have an irrational fear of it
* FDG-PET/CT for assessment of response to Brentuximab Vedotin treatment in relapsed and refractory Hodgkins
* Risk and outcome of non-Hodgkin lymphoma among classical Hodgkins
* Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy
* Why docs don’t do death?
PAL's new web-based support message board:
Sunday, July 7, 2013
From various news sources: Live Science, NPR, News Medical, Respectful Insolence, Medical News Todaygov
* Blinatumomab (bITE) induces autologous T cell killing of CLL cells
* Dr. Sharman's CLL & Lymphoma Blog Monoclonal B Cell Lymphocytosis
"Monoclonal" means that there is a single population of cells (a clone) that look identical. In the normal healthy situation B cells should look different from one another. When they all look alike, we get worried that it could be a sign of cancerous growth. "B-Cell lymphocytosis" means that the ratio of lymphocytes are off and there are too many of them.
* Ice Pops May Lead to False Positive Fungal Test (aspergillosis)
* Is Alternative Medicine Really 'Medicine'?
Anjou: Excellent interview with Dr Offit about his recent book
* Oncologist urges drug companies to include key information in cancer drug labels
* When patient expectations battle with reality
Anjou: Deals with end of life issues in oncology. Not lymphoma specific.
* Immunotherapy Is Beginning To Have A MAJOR Impact For Patients With Cancer And Infectious Diseases
Saturday, July 6, 2013
From various news sources: Oncologypractice.com, The ASCO Post, ClinicalTrials.gov
* Study of interest: ABT-199 in Subjects With Relapsed or Refractory CLL with 17p Deletion
* Rituximab plus chlorambucil extend event-free survival in MALT lymphoma
* Primary Mediastinal B-Cell: It's Déjà Vu All Over Again
Joseph M. Connors, MD cites history as reason for caution
"Yogi Berra's pithy remark neatly summarizes my reaction when I read the article, "Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma," by Drs. Dunleavy, Wilson, and colleagues in The New England Journal
of Medicine.1 ... as strong as these circumstantial pieces of evidence may seem, we need to be careful not to allow hope to triumph over evidence.
Thursday, July 5, 2013
From various news sources: Sciencebase, NEJM, NY Times, Medical News Today, The Oncology Report, News Medical, Huff post
* Why your personal CAM story is not evidence
* Toward Patient-Centered Drug Development in Oncology
* Keeping Cancer a Secret
Who do you tell about your cancer? Have you kept quiet about it with certain people?
* What Are Benzodiazepines? What Are The Risks Of Benzodiazepines? - PAL
Anjou: Article discusses benzodiazepines, medications used for anxiety, sleep and some may be used as anticonvulsants
* Ice Pops May Confound Tests After Transplant
* Rituximab plus chlorambucil extend event-free survival in MALT lymphoma
* Antibody-Drug Conjugates and Cancer Treatment: Making “Smart Bombs” Smarter Scientific American
Anjou: Excellent blog post - well written for a lay audience
* Nobody Shaved Their Head for Me
* Second Draft NICE Guidance For Aggressive Non-Hodgkin Lymphoma Treatment, PIXUVRI® (Pixantrone)
Wednesday, July 3, 2013
From various news sources: PAL, PBS, Oncology Times, Salon.com, KevinMD.com, Psychology Today, Clinical Oncology News, J Nuclear medicine
* Medication and Consult Organizer - PDF
Print, then fill in. Provide a copy for each physician to assist in your consults. Includes tips on how to avoid common medical errors
* Nanoparticles Show Big Promise in Fight Against Cancer
* FDA Approvals of Revlimid for MCL
* Two Studies Reveal Important Genetic Insights Into The Development of NHL
* Are Vitamins a scam?
* The tension between oncology and palliative care
* Don’t Be Intimidated in the Doctor’s Office: Six Strategies
* Cytarabine Improves Combination Therapy for Mantle Cell Lymphoma
* Interim PET in Hodgkin Lymphoma: Would PET-Adapted Clinical Trials Lead to a Paradigm Shift?
Anjou: Full article with a good bit of review regarding what is known about the use of PET in Hodgkin Lymphoma
Monday, July 1, 2013
From various news sources: ASCO Post, PAL, NEJM
* Primary Mediastinal B-Cell Lymphoma: It’s Déjà Vu All Over Again By Joseph M. Connors, MD
* Survival Rates for Patients with Burkitt’s Lymphoma Improve, Especially among Young Adults
* GA101 (type II cd20 antibody) OR Rituxan in Untreated Low Tumor Burden Indolent NHL
* Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Sunday, June 30, 2013
From various news sources: NYtimes, KevinMD, CBS, OncLive
* Confronting the reality of uncertainty in medicine
anjou: Interesting article talks about cases that are difficult to diagnose
* Management of Hodgkin Lymphoma
KarlS: comprehensive. Includes expert perspective and insights
* Video: Chemotherapy could soon be obsolete with new treatments
KarlS: Expert describes progress in exploiting differences between cancer and normal cells
* Breaking the Seal on Drug Research
Saturday, June 29, 2013
From various news sources:
* FDG-PET/CT for assessment of response to Brentuximab Vedotin (Adcetris) treatment in relapsed and refractory Hodgkin Lymphoma
* Risk and outcome of non-Hodgkin lymphoma among classical Hodgkin lymphoma survivors
* Limited role for surveillance PET-CT scanning in patients with diffue large B-cell lymphoma in complete metabolic remission following primary therapy
* For follicular patients can calculate their FLIPI score here
* Dr. Sweetenham: How I Manage Primary Mediastinal Large B-Cell Lymphoma
* Aggressive B-cell lymphomas: how many categories do we need? * Book raises alarms about alternative medicine
* 5 benefits of online patient communities
Friday, June 28, 2013
From various news sources:
* Life, Interrupted: Un-kept Resolutions
* Allogeneic Transplantation in Hodgkin Lymphoma
* John Theurer Cancer Center leads multicenter clinical trial for chemotherapy-induced neuropathic pain
KarlS: Important area of clinical study - an effective treatment would help address a common unmet need.
* ADA: Insulin Does Not Hike Cancer Risk
* Studying Tumors Differently, in Hopes of Outsmarting Them
Anjou: Excellent article exploring the issue of how tumors develop resistance, and that using targeted drugs together, rather than sequentially may be more effective.
* PACT Act May Improve Cancer Care for Medicare Patients Medscape
* New cancer treatment beats chemotherapy without the toxic side effects
"If a locked door must be opened, explosives can be used, but normally it is better to use a key."
* Cancer Clinics Closing: Community Oncology 'Near Crisis'
Thursday, June 27, 2013
From various news sources:
|
Dr. Sharman's CLL & Lymphoma Blog: The doctor is out?
|
|
How to Navigate a Cancer Diagnosis
|
|
No more chemo: Docs say it's not so far-fetched
|
|
Climbing Mountains
Essay that explores "one of the toughest questions of life. How long do you continue to fight, when death is certain? When does striving become vain hope which drains quality and creates only suffering? What makes struggle worth the pain; when is it time to yield? You've heard about the "asparagus cure", laetrile..etc now... the Bicarbonate Maple Syrup Cancer Treatment!
|
|
Sweet and alkaline won’t win the war against cancer
|
|
Research IDs Potential Treatment for Deadly, HIV-Related Blood Cancer
"The USC team shows that a class of drugs called BET bromodomain inhibitors effectively targets primary effusion lymphoma (PEL), a type of cancer for which those drugs were not expected to be effective."
|
|
Human and Canine Lymphomas Share Molecular Similarities, First Large-Scale Comparison Shows
|
|
Safety Concern Halts Study of Seattle Genetics' Lymphoma Drug
|
|
Sex and Cancer -- Breaking the Taboo
|
|
Ibrutinib Shows High Response Rate in Mantle-Cell Lymphoma
|
|
Antibiotic therapy in non-gastrointestinal MALT lymphoma: a review of the literature
|
|
A Potential Turning Point in Treatment of CLL
Medscape summary of recent New England Journal of Medicine article on use of Ibrutinib in CLL
|
|
Clinical Oncology News: How I Manage Primary Mediastinal Large B-Cell Lymphoma
|
|
Mitti Mithai Viral Cancer Cure Conspiracies
Wonderful cartoon and essay about bogus cancer cures hyped on the net. The author says copying is cool, so I'll put the essay here, but use the link and check out the cartoon!
|
|
KevinMD: Genomics and personalized medicine: Is it really different this time?
|
|
Pharmatimes: Celgene's Revlimid succeeds in lymphoma in Rituxan combo
|
|
Weill Cornell: ASCO Update: Ibrutinib Combined with R-CHOP Shows Positive Results for in patients with CD20-positive, B-cell non-Hodgkin Lymphoma
|
|
Weill Cornell: ASCO Update: Idelalisib Effective in Combination Therapy for Indolent non-Hodgkin Lymphoma http://bit.ly/15ze6b9
|
|
KevinMD: Help patients find information on the Internet: Tips to surf safely
|
|
KevinMD: The medicine that kept her alive was not in a bottle
(end of life issues)
|
|
The Oncology Report: Idelalisib and rituximab produce responses in 97% with CLL (CAL-101)
|
|
NYTimes: Employers Test Plans That Cap Health Costs
|
|
Pubmed: (Cancer): Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission
|
|
Pubmed (J Clin Onc) Follicular Lymphoma Cells Induce Changes in T-Cell Gene Expression and Function: Potential Impact on Survival and Risk of Transformation
|
|
Pubmed: (Cancer) The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT
Very Good news!!! Lets hope it keeps getting better and better!
|
|
PubMed: Improvements in observed and relative survival in follicular grade 1-2 lymphoma over four decades: the Stanford University experience.
|
|
Mwd News Today: Ibrutinib Shows Surprising Efficacy As Treatment For Chronic Leukemia, Mantle Cell Lymphoma
|
|
MSN Money: Pharmacyclics could get ibrutinib approval this year: The FDA should make a speedy review of the breakthrough cancer drug a top priority
|
|
US News and World Report: How the Sequester Hurts Cancer Patients: Budget cuts are slicing into clinical trials CNN Health: New drug may be best treatment for leukemia yet
Video about Ibrutinib
|
|
Medscape: Ibrutinib: A Step Change in the Treatment of Mantle Cell Lymphoma
|
|
Dr. Sharman's CLL & Lymphoma Blog: Generic Cancer Drugs - aka "Biosimilar"
|
|
Sunrise Rounds: Cancer Office Gossip
|
|
OncLive: Utilization of Brentuximab Vedotin in Hodgkin Lymphoma
|
|
Medscape: Proton Therapy 'Sells Hope': No Clear Benefit for Patients
|
|
Dr. Sharman's CLL & Lymphoma Blog: Ibrutinib for CLL and MCL in New England Journal of Medicine
Thank you Dr Sharman for being part of this important research and for providing a link to the papers and the editorial
|
|
Haematologica. 2013 Jun 10.: High cure rates in Burkitt lymphoma and leukemia: NILG study of the German short intensive rituximab-chemotherapy program. http://1.usa.gov/12AKHRQ
|
|
Oncology TImes: CLL: ‘Potent,‘ Well-Tolerated Activity for Ibrutinib, Irrespective of Deletion 17p http://bit.ly/17kh2hJ
Sunrise Rounds: Why is the doctor ANGRY? http://bit.ly/18GhTqZ
Dr Len's Cancer blog: Genomics And Personalized Medicine: Is It Really Different This Time? http://bit.ly/11vyhEt
Dr. Sharman's CLL & Lymphoma Blog Personalized Medicine - turning drug development upside down! http://bit.ly/18GBcTq
Psychology Today: 12 Tips from 12 Years Sick http://bit.ly/1aKOR8J
The onc: Are Oncology Studies Really Less Robust? http://bit.ly/Zzc3am
NPR: Cherishing The Gift Of Friendship Through A Cancer Bout http://n.pr/11cDvpC
News Medical: Three easy steps for cancer survivorship http://bit.ly/11Hx96w
NYT: Life, Interrupted: Going Public With Cancer http://nyti.ms/140Xmwl
Medpage Today: Combo Boosts PFS as Initial Leukemia (CLL)Therapy http://bit.ly/11q3FUM
Cancer.net: What to Know: ASCO's Guideline on Fertility Preservation http://bit.ly/15aFkak
Sunrise Rounds: Doc, how about some marijuana? http://bit.ly/12OJouy
News Medical; Survival rates increased among patients who received blood stem cell transplants: Study http://bit.ly/1az7qwL
Science-Based Medicine: Patient Participation in Decision-Making http://bit.ly/1599OK6
Respectful Insolence: Cutting, poisoning, and burning naturally http://bit.ly/11p0nBh
OncLive: Primary Management of Advanced Hodgkin Lymphoma http://bit.ly/12ZlCxC
MNT: Intensified, Liposomal Anthracycline-Based Chemo Regimen For Children With Leukemia May Offer High Survival Rates Without Added Heart Toxicity http://bit.ly/1asgweF
NYTimes: Battling Cancer Together http://nyti.ms/11sLPWY
MailOnline: The mother and daughter diagnosed with the SAME cancer (hodgkins) at exactly the SAME age - even though it's not hereditary http://bit.ly/11lGSte
MedicalXpress: Non-Hodgkin lymphoma survival doubles since early 1970s http://bit.ly/14Fh6ov
Science Daily: It's Not Your Imagination: Memory Gets Muddled at Menopause http://bit.ly/ZhsdVL
Some women get thrown in to menopause from treatment....is it chemobrain or menopause, combination?
Medscape: After Cancer: Debate About Terminology Beyond Treatment http://bit.ly/16Y1Nvu
NYT: Mothers With Cancer http://nyti.ms/11epTZI
Huff Post: Medical No Man's Land: A 20-year-old Cancer Patient http://huff.to/16RxgyD
NYT: What's in Your Green Tea? http://nyti.ms/10OaO17
Cancer and careers: Working with Chemo Brain http://bit.ly/10RtUrm
Onclive: ONLINE FIRST: In Phase I Study, CLL Patients Appear to Benefit from Isoform-Specific PI3K Inhibitor http://bit.ly/168zCK9
Dr. Sharman's CLL & Lymphoma Blog: Inotuzumab sinks.... http://bit.ly/10PI108
Reuters: Pfizer halts study of lymphoma drug unlikely to help survival http://reut.rs/13GKNpE
inotuzumab ozogamicin
Comments: A good example of a "failed" controlled study that provides valuable information. Without the randomized design and the comparator ... the results may have seemed "encouraging" or "deserving of further study." IO may still find its place as an effective lymphoma treatment (such as in consolidation or in indolent lymphoma). Relapsed / refractory aggressive lymphoma ineligible for SCT is a challenging setting and it seems that chemo has an edge over antibody therapy in this population (based on RIT for example) - perhaps because chemo is faster acting?
Science Daily: Radioactive Nanoparticles Target Cancer Cells http://bit.ly/16N4LCr
Sunrise Rounds: Don’t play the numbers http://bit.ly/12J3CYi
MNT: Cancer Survivors Suffer Physical & Emotional Impairments Which Often Go Untreated http://bit.ly/1a0imTH
|
|
Dr. Sharman: How expensive are new drugs? http://bit.ly/10zY11Z
|
|
April 2013: Pharmacyclics Completes Enrollment of Phase III Ibrutinib CLL Study and Phase II Ibrutinib MCL Study ascopost.com
|
|
Latif and Morris: Monoclonal Antibody Therapy of T-Cell Leukemia and Lymphoma: http://bit.ly/WimCgm
|
|
Oncology Times: Stage I Follicular Lymphoma: LymphoCare Study Questions Role of Radiation—Many Options, ‘Rigorous’ Staging Key http://bit.ly/O6rWhP
|
|
Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? http://1.usa.gov/S2hWsi
|
|
Parenthood in Survivors of Hodgkin Lymphoma: An EORTC-GELA General Population Case-Control Study. http://1.usa.gov/RkQTWB
|
|
Doctors Lounge: Watch & Wait OK in Low-Tumor Burden Follicular Lymphoma http://bit.ly/Sl49va
|
|
Watchful Waiting in Low-Tumor Burden Follicular Lymphoma in the Rituximab Era: Results of an F2-Study Database. http://1.usa.gov/P9pAdW
|
|
Dr. Cheson on expectant management of follicular lymphoma: Waiting is the Hardest Part http://bit.ly/Sm3plQ
|
|
oNLINE FIRST: Stage I Follicular Lymphoma: LympoCare Study Questions Role of oncology Times: Radiation; Many Options, ‘Rigorous’ Staging Key http://bit.ly/NuPdda
|
|
OncLive: Dr. Furman on Trials Examining Ibrutinib's Safety in CLL http://bit.ly/VPeLF7
|
|
Cancer Connect: Cystitis from treatments http://bit.ly/10ndcRH Tips on how to avoid it etc
|
|
NBC: If you can't pay: How to get insurance to cover specialty drugs http://nbcnews.to/SfsNiu
|
|
Dr. Sharman's CLL & Lymphoma Blog What is R-CHOP?
|
|
Dr. Sharman's CLL & Lymphoma Blog: What is FCR? http://bit.ly/PBQkI6
An excellent explanation. A good read- even if your battle is not with CLL.
|
|
HemOnc Today: Optimized fertility advice needed for Hodgkin's lymphoma survivors http://bit.ly/U2KmjV
|
|
Dr. Sharman's CLL & Lymphoma Blog: Making sense of all the different lymphomas http://bit.ly/OfCYNs
|
|
MNT: Improving Cell-Based Immune Therapies For Cancer http://bit.ly/VaFLxN Exciting concept
|
|
ASH Education, 2012:
The many faces of marginal zone lymphoma
by Dr. Zinzani http://bit.ly/TTcdUk
|
|
ASH Education, 2012:
Is there a role for "watch and wait" in follicular lymphoma in the rituximab era? by Dr. Brad Kahl
http://bit.ly/U40lNi
|
|
Medscape: Is R-Benda a New Standard in Lymphoma? http://bit.ly/X5Azh5
|
|
KevinMD.com: How to get the most out of your oncology appointments http://bit.ly/Wts8Xs
|
|
Dr. Sharman's CLL & Lymphoma Blog:
Richter's Syndrome / Histologic Transformation: Richter's Syndrome / Histologic Transformation http://bit.ly/UQj6al
|
|
Medscape: Fatigue-Busting Programs Work Even in Advanced Cancer http://bit.ly/X6O9gV
|
|
NYT: Living With Cancer: Chemo-Feet (peripheral neuropathies) http://nyti.ms/100QEqw
|
|
Cancer Connect: Prophylactic Vorinostat Cuts Risk of Graft-Versus-Host Disease in Half http://bit.ly/VGbpQJ
ASH abstract: https://ash.confex.com/
|
|
Medscape: A Call to Eliminate 'Chemotherapy Concession' http://bit.ly/RtRuHz
|
|
KevinMD: Are you a thrifty patient? How to get the care you need and save money http://bit.ly/W3P4vu
|
|
KevinMD.Com: How to deliver bad news to patients: 9 tips to do it better http://bit.ly/Uljp9A
|
|
On Healthy Survivorship: Tips for Adult Children of Newly Diagnosed Patients http://bit.ly/X0OJww
|
|
Dr Sharman's CLL and Lymphoma Blog: The Slow (Indolent) Lymphomas http://bit.ly/VqwvmE
Thank you Dr Sharman for this patient friendly explanation!
|
|
Sunrise Rounds: 100% Inconclusive http://bit.ly/XeN9Lu
MSNBC: How to avoid spreading the flu: Stay home for 4 days http://nbcnews.to/WXacGF
|
|
NYT: Juggling Diabetes and Cancer http://nyti.ms/Vfv0YM excellent article
|
|
Health News Reviews:
3rd annual year-ender on health care Public Relations crap we receive http://bit.ly/UEmQfg
|
|
KevinMD.Com: Physicians can be better doctors by being patients http://bit.ly/ZPnuuz
|
|
Forbes: Making a Profit from Offering Ineffective Therapies to Cancer Patients http://onforb.es/XaKKkN
|
|
Dr. Sharman's CLL & Lymphoma Blog :
New CLL Prognostic Groups http://bit.ly/Vo0X3u
|
|
Science Daily: New Technique Catalogs Lymphoma-Linked Genetic Variations http://bit.ly/10kVmOM
|
|
NEJM: The Impact of Drug Shortages on Children with Cancer — The Example of Mechlorethamine http://bit.ly/TyYyEz
|
|
Science Daily: Immune System Changes May Drive Aggressiveness of Recurrent Tumors
http://bit.ly/Vj72OE
|
|
Science Based Medicine: Why Do People turn to Alternative Medicine http://bit.ly/U9vHSn
|
|
Onc Times: View from the Other Side of the Stethoscope: False Hope http://bit.ly/Tp5wsf
|
|
CNN: Why I donated my bone marrow http://bit.ly/U8apo8
Lymphoma patients cannot make donations but can encourage others to do so!
|
|
New Yorker: Cleaning up Science: http://nyr.kr/VZsB30
|
|
ASH 2011 lymphoma and CLL abstracts
|
|
Effectiveness of First-Line Management Strategies for Stage I Follicular Lymphoma: Analysis of the National LymphoCare Study jco.ascopubs.org http://bit.ly/POvLsJ
|
|
Medscape: Early Follicular Lymphoma -- Need to Revisit Guidelines? http://bit.ly/SViGe0
|
|
Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial http://bit.ly/O2E6nq
|
|
Annals of Oncology: Follicular lymphoma, A Review article http://bit.ly/O2FJBz
|
|
News Medical: FDA requests Biovest to conduct second Phase III trial of BV301 for NHL http://bit.ly/NFf7GS
|
|
Medpage Today: Drug (Maraviroc is a CCR5 antagonist) Staves Off Graft-vs-Host Disease http://bit.ly/RQiy3h
|
|
Medical Express: Exercise may improve quality of life during and after cancer http://bit.ly/PoaoL4
In two separate Cochrane systematic reviews, the authors gathered together evidence showing that activities such as walking and cycling can benefit those who are undergoing or have completed treatment for cancer.
|
|
Onc Times: Indolent & Mantle Cell Lymphoma: Bendamustine-Rituximab Superior to R-CHOP, Long-Term Results Confirm http://bit.ly/O3tTMu
|
|
Medscape: Standard of Care for Older Patients With Mantle Cell Lymphoma? http://bit.ly/O5RA3R
|
|
International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: Altered Utility in the Modern Era. [J Clin Oncol. 2012] - PubMed - NCBI http://1.usa.gov/OXVehO
|
|
Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori-positive gastric diffuse large B-cell lymphomas.. [Blood. 2012] - PubMed - NCBI http://1.usa.gov/QX6z4D
|
|
Rituximab Maintenance Effective in Elderly Mantle-Cell Lymphoma Patients - Cancer Network
http://bit.ly/S3EnrM
|
|
Cancer Research UK: Cannabis, cannabinoids and cancer – the evidence so far http://bit.ly/NuPhtL
|
|
Medscape: CT Overused in Monitoring Pediatric Hodgkin's Lymphoma http://www.medscape.com/viewarticle/768239
|
|
Science Codex: Novel drug therapy targets aggressive form of non-Hodgkin's lymphoma http://bit.ly/UtxBf3
Interesting pre-clinical research on new target MALT-1 that is highly active in ABC-DLBCL - from a very well-respected researcher and team.
|
|
Doctors Lounge: Predictors of QoL ID’d for Long-Term Lymphoma Survivors http://bit.ly/Un97X2
|
|
Cancer Research UK: Alternative cancer treatment claims in the media are damaging and misleading http://bit.ly/TOXxnb
|
|
Helicobacter pylori: Epidemiology and Routes of Transmission http://bit.ly/113izUs
|
|
PsychCentral: 12 Depression Busters for Caregivers http://bit.ly/UDSFSR
|
|
Find published articles on
Fertility and Hodgkin lymphoma ncbi.nlm.nih.gov
|
|
Insect bite-like reaction associated with mantle cell lymphoma: a report of two cases and review of the literature. http://www.ncbi.nlm.nih.gov/pubmed/15485536
|
|
Psychcentral: 8 Simple Ideas for Remembering to Take Your Medication http://bit.ly/SFxVqf
|
|
LewisGale Regional Health System:
Evidence based info on herbs and supplements: http://bit.ly/Ui0j9p
Be sure to check out the What is the Scientific Evidence link for each item.
|
|
Memorial Sloan Ketterings mobile app on herbs and supplements http://bit.ly/VA3gzO
|
|
MNT: Improving Stem Cell Transplant Outcomes By Harnessing The Immune System http://bit.ly/VlHaTj
Interesting research with multiple myeloma, another blood cancer-- Hopefully one day, this type of process might help lymphoma patients.
|
|
Science fact or science fiction? Making sense of cancer stories in the media http://bit.ly/OFmzro
|
|
Science Based Medicine: Patients Still Respect Evidence http://bit.ly/PapIQ3
|
|
WSJ: Access to Doctors' Notes Aids Patients' Treatment http://on.wsj.com/T1d5rc
While patients legally have the right to see their entire medical record, including doctor's notes, the notes aren't automatically included in requests for records and doctors don't make it easy for patients to see them
|
|
KevinMD: How well does your doctor play with others? http://bit.ly/SxTltL
|
|
Respectful Insolence: Are mouse “avatars” useful for predicting human response to chemotherapy and targeted agents in cancer? http://bit.ly/R0DeSu
|
|
Sunrise Rounds: CancerLand, the undiscovered country http://bit.ly/Ql2WAk
|
|
TedTalks: Ben Goldacre: What doctors don't know about the drugs they prescribe http://bit.ly/UQduxa
|
|
NYT: A Cancer Patient’s Best Friend http://nyti.ms/STK1ww
In the short time Oscar has been in my life, he’s had an effect on my relationships. Rather than staring at my bald head, passers-by stop to play with Oscar and to tell me how cute he is. The other tenants in my building now say hello to my dog before greeting me.
|
|
NBC: Cancer doctor reveals the 'very dark side' of hospital errors http://nbcnews.to/QhkWvs
|
|
NYT: Needles or Port? A Cancer Patient Decides
“They are tiny and rollers,” the nurse says as his fingertips
trace the veins on my arms. My part in a trial has begun,
but the only “good” vein in the crook of my left arm looks
alarmingly bruised, as do both of my wrists.
|
|
MSN: Why patients don't report medical errors http://nbcnews.to/PoB5j0
|
|
Dr. Sharman's CLL & Lymphoma Blog CLL treatment - avoiding chemotherapy http://bit.ly/QxAwGi
|
|
JCO; Waiting is the hardest part http://bit.ly/UuWvfh
Commentary by Cheson on news story posted earlier about watch and wait for follicular
|
|
Cancer Connect: Advanced Directives http://bit.ly/NPME5s
clear explanations of things like living wills, advanced directives etc.
|
|
Sunrise Rounds: food and cancer http://bit.ly/OnA66N
|
|
News Medical: Cancer-related medical costs to more than double in some states in less than eight years http://bit.ly/UsReF7
|
|
Science Daily: Researchers Solve Puzzle of B-Cell Lymphoma Development http://bit.ly/VvgPQ9
|
|
MDC researchers solve puzzle of B-cell lymphoma development http://bit.ly/Q9Y4RY
|
|
Navigating through Chemobrain http://bit.ly/OLpEGb
|
|
KevinMD: 5 ways to help make a cancer diagnosis more manageable http://bit.ly/Q5Ke2Z
|
|
Dr. Sharman's CLL & Lymphoma Blog: How drugs are created / why does it take so long? http://bit.ly/PZF4p8
|
|
Oncology Report: Is Anyone Listening? http://bit.ly/QFdGu0
Talks about how couples communicate when one has cancer. How has it been for you?
|
|
NYT: Needles or Port? A Cancer Patient Decides http://nyti.ms/RzvXxp
|
|
NYT: Poor Pain Control for cancer patients http://nyti.ms/PsDHxl
|
|
Sunrise Rounds: The aggressive chemo fallacy http://bit.ly/Rz2zY8
|
|
KevinMD: Despite the best evidence, oncologists cannot dictate treatment http://bit.ly/UkjCt0
Allowing myself time to step back, however, made me realize it was not me who was in a position to determine what toxicity is “acceptable.” I am not the one who must live with treatment and its impact on daily life. Indeed, only one person has to look at herself every day, fight cancer, and fight to remain true to who she is despite it. It was my patient in front of me, and she did not want PLD. In essence, she did not want to take the risk that her cancer would mean giving up yet one more passion.
|
|
Oncology Times: POINT-COUNTERPOINT: Mantle Cell Lymphoma: Observation vs. Immediate Treatment for Asymptomatic Patients with Low Tumor Burden http://bit.ly/NB0HMf
|
|
The Daily Star: Orangutan's cancer treatment similar to humans http://bit.ly/UfqQyq (Peanut)
|
|
Scientific American: Killer skills of a neutrophil http://bit.ly/OT8XEv
Nice explanation, helpful in understanding what those blood count labs mean.
|
|
Respectful Insolence: Overselling preclinical results http://bit.ly/NxvDgd
|
|
Mayo: Melanoma Up to 2.5 Times Likelier to Strike Transplant, Lymphoma Patients http://bit.ly/O5CcXH
Highlights the importance of regular checks with the dermatologist
|
|
Business and Health: Quality-of-life Program May Help Cancer Patients http://bit.ly/RSv8PP
|
|
NYT The Trials of Cancer Trials http://nyti.ms/QM8AhF
See also Expanded Access a possible option for patients not eligible for trials: lymphomation.org
|
|
MDA: Shifting opponents: From fighting cancer to fighting sepsis http://bit.ly/O1Css4
|
|
NYT: The Widow’s Doctor Visit http://nyti.ms/O0KdOP
|
|
Shrink Rapt: Saying the Right Thing http://bit.ly/Pym80o
|
|
News Medical: New model reveals how immune system functions under conditions of neutropenia http://bit.ly/OGrnIl
|
|
Science Based Medicine: An Acupuncture Meta-Analysis http://bit.ly/PbhT8Z
|
|
Respectful Insolence: Can we finally just say that acupuncture is nothing more than an elaborate placebo? Can we? (2012 edition) http://bit.ly/Pio61s
|
|
Sci Amer: Scientists play a large role in bad medical reporting http://bit.ly/QDQmyA
|
|
KevinMD: How to tell your friends and family that you have cancer http://bit.ly/OEYfBx
|
|
NYT: Coping With Mild Cognitive Impairment http://nyti.ms/RCmg0F
|
|
MSNBC: Should you fire your doctor? http://nbcnews.to/NjblXI
|
|
Medical NEws Today; Junk DNA Not Junk After All http://bit.ly/Qdaq8T
|
|
Science Based Medicine, Video: Fairy Tale Science and Placebo Medicine http://bit.ly/NU5No2
|
|
KevinMD: Experiencing my first Facebook era death http://bit.ly/UCkTOa
|
|
News Medical: Vitamin D supplements {MAY} have unintended lipid consequences http://bit.ly/NfjwnP
|
|
NYT: Not a Cancer Survivor http://nyti.ms/OepRS5
|
|
Cornell: ASH Patient Advocacy Alert: Help Protect Medical Research Funding http://bit.ly/TZDIsf
|
|
Science Daily: Stem-Cell-Protecting Drug Could Prevent the Harmful Side Effects of Radiation Therapy http://bit.ly/P0ANzy
|
|
Dr Len's Cancer Blog: Expert Opinion: A US Perspective On Beating Cancer http://bit.ly/TZCyND
|
|
Respectful Insolence: The Real Way to Prevent Cancer http://bit.ly/RoS4Ab
|
|
The Oncology Report: Biologic Agents for RA Don't Appear to Raise Malignancy Risk - meta-analysis of 63 randomized clinical trials http://bit.ly/Nbe0me
|
|
Weill Cornell: Research Study: Dietary Cholesterol Associated with Increased Cancer Risk, Including NHL http://bit.ly/RIhIAq
|
|
Moffitt Cancer Center on 'chemo brain': on average the deficits are slight and limited to verbal ability and visuo/spatial skills http://bit.ly/RCP7QY
|
|
FHCC: New genetic clues to why most bone marrow transplant patients develop graft-versus-host disease http://bit.ly/Teev1q
|
|
News Medical: Missing link between bone marrow stem cells and human immune system http://bit.ly/RdfPv3
|
|
KevinMD: My doctor isn’t listening to me! How you can help http://bit.ly/UjJ6J1
|
|
KevinMD: How to plan for a long hospital stay http://bit.ly/NIEIhP
|
|
Dr. Sharman's CLL & Lymphoma Blog What is R-CHOP? http://bit.ly/Q9jgX7
|
|
MSNBC: Reducing infection risk:Bagged lettuce or bulk? Experts offer food safety advice
http://nbcnews.to/Ru72oR
|
|
Science Based Medicine: Questioning Whether Psychotherapy and Support Groups Extend the Lives of Cancer Patients http://bit.ly/N3u1uu
|
|
KevinMD: End of life ethics and the importance of doing the right thing http://bit.ly/N3uooQ
|
|
NYTimes: Life, Interrupted: Five Days of Chemo http://nyti.ms/SVUn2e
|
|
KevinMD: Hospice care and palliative care: What’s the difference? http://bit.ly/Owd08t
|
|
Mayo study: Exercise can help cancer patients, but few oncologists suggest it http://bit.ly/SOszyt
|
|
Treanda (bendamustine) approved in Canada http://reut.rs/OGOELa
|
|
WSJ: To Treat the Cancer, Treat the Distress http://on.wsj.com/PnYEw3
|
|
Science Based Medicine: Andrew Weil’s Seasonal Supplements http://bit.ly/SM8R6c
|
|
Cancer drug helps patient despite faltering in trials http://fxn.ws/PcoPG8
|
|
Sunrise Rounds: Picking your doctor’s team http://bit.ly/Q90DnH
|
|
KevinMD: Test results without physician guidance will cause patient anxiety http://bit.ly/PfCS9y
|
|
ScienceDaily (Aug. 22, 2012) — Particle physicists have developed a new medical technology that combines PET and MRI in one. Benefit: Improved image quality and less radiation. http://bit.ly/Nic392
|
|
NYTimes: Life, Interrupted: Six Ways to Cope With Cancer http://nyti.ms/OxNBxd
"At first, I bristled at the idea of a cancer community. It was enough to have cancer; did I also have to share my experience with a group of strangers? It felt like extra homework"
|
|
DBs Medical Rants: Compassionate paternalism http://bit.ly/PH8tU1
"We have, I believe, overdone the shared decision making concept. Patients cannot really make informed decisions about everything. We have a professional responsibility to provide our opinions and "argue" with patients about their health care decisions."
|
|
KevinMD: Helpful things to say to someone who’s sick http://bit.ly/O67463
“How are you holding up? Do we need to stop visiting so you can rest?"
|
|
Dr. Sharman's CLL & Lymphoma Blog Campath is going away? http://bit.ly/MNyWiV
|
|
Respectful Insolence: Quackademic medicine versus cancer quackery http://bit.ly/NFhwGQ
|
|
The Telegraph: Green tea extract 'eradicates cancer tumours - piggy-backing the extract on proteins that carry iron molecules. http://bit.ly/SnAtyn
|
|
Cancer Quackery: The Persistent Popularity of Useless, Irrational 'Alternative' Treatments http://bit.ly/PviT9Q
Have to register for site to read but a good article
|
|
Modern Medicine: Clinicopathologic diagnosis minimizes misidentification of lymphoma http://bit.ly/PDUKxa
|
|
NYtimes: Gene Tests in Yeast Aid Work on Cancer http://nyti.ms/PQ8aaX
|
|
KevinMD: Don’t accept advice from physicians until they understand your values http://bit.ly/NeOeJ4
|
|
KevinMD.com: Googling cancer information: Tips from a cancer survivor http://bit.ly/Qgb0AH
|
|
USA TOday: My Semicolon Life: Welcome to the cancer club http://usat.ly/MDJTDG
|
|
KevinMD: How I define patient engagement http://bit.ly/NPXNT5
|
|
Hospital discharge planning: Involve the patients http://bit.ly/N7De6i
|
|
Dana Farber: 7 Tips to Remember When Visiting Cancer Patients http://bit.ly/MDJFwq
|
|
KevinMD.com Patient care suffers when nurses are overloaded with work http://bit.ly/NJPkPi
|
|
Medical News Today: Two Approaches To Understanding The Basic Mechanics Of Cancer http://bit.ly/Q7kdLA
|
|
Medscape: Cancer Treatment During Pregnancy Feasible http://bit.ly/Rncz70
|
|
Dr. Sharman's CLL & Lymphoma Blog: Why the B-Cell Receptor Matters / Another possible explanation for Ibrutinib or CAL-101? http://bit.ly/PtvSWS
|
|
KevinMD: Helping cancer survivors fight neuropathy http://bit.ly/RlDyQs
|
|
Science Daily: B Cell Survival Holds Key to Chronic Graft Vs. Host Disease http://bit.ly/NIR89A
|
|
UNC: B cell survival holds key to chronic graft vs. host disease http://bit.ly/N675pR
|
|
The Conversation Project http://bit.ly/NpkZ7M
"We are all mortal, yet as a society we have been painfully slow in recognizing how many of the people we love are not dying in the way they would choose."
|
|
Stanislaw Burzynski versus regulations protecting human research subjects http://bit.ly/RjGvAM
|
|
Life, Interrupted: Putting a Positive Spin on Cancer - NYTimes.com http://nyti.ms/MzEbmo
|
|
Medical News Today: Cause Of Burkitt Lymphoma Discovered http://bit.ly/PpWNmn
|
|
Medical News Today: Scientists Develop Model For New Burkitt Lymphoma Treatments http://bit.ly/OiMVf2
|
|
PsychCentral: Key Questions to Ask When Choosing a Psychotherapist | World of Psychology http://bit.ly/PkPD6z
|
|
"Background and credentials aren’t the only things to consider when hiring a therapist."
|
|
The Globe: Exercise is powerful cancer medicine http://bit.ly/NAtIDc
|
|
Naturopathic cancer treatments versus reality – Respectful Insolence http://bit.ly/P9Tgej
|
|
Science Daily: New Key Element Discovered in Pathogenesis of Burkitt Lymphoma http://bit.ly/NyLvuu
|
|
News Medical: Researchers uncover how pathological cells activate themselves in chronic lymphocytic leukaemia http://bit.ly/MrIBM5 Science Daily: http://bit.ly/MrIro3
|
|
Bone Marrow Transplant.
A cautionary tale for probiotic use in hematopoietic SCT patients-Lactobacillus acidophilus sepsis in a patient with mantle cell lymphoma undergoing hematopoietic SCT. (no abstract)
|
|
|
Cure: Letting Go: Saying Goodbye When a Loved One Says It’s Time http://bit.ly/MZ1h72
|
|
NPR: David Rakoff: 'There Is No Answer As To Why Me' http://n.pr/OaWWe3
|
|
USA Today: My Semicolon Life: What to say to a cancer patient http://usat.ly/MLBQGg
|
|
MSNBC: Cholesterol drugs may lower cancer risk http://nbcnews.to/MISAYH
|
|
What if the Doctor Is Wrong? - WSJ.com http://on.wsj.com/ydUuLG
|
|
Book recommendation from On Healthy Survivorship: Help Me Live http://bit.ly/P8omnu
|
|
NYTimes: Life, Interrupted: Medical Bills, Insurance and Uncertainty http://nyti.ms/MkNPJx
|
|
Dr. Sharman's CLL & Lymphoma Blog: Trisomy 12 in CLL http://bit.ly/MBJ93o
|
|
NEJM: Treatment of Older Patients with Mantle-Cell Lymphoma http://bit.ly/NkrGJ2
|
|
Medical Express: Grapefruit juice lets patients take lower dose of cancer drug http://bit.ly/QLr8kC
Good that they are exploring this, but not something for patients to explore on their own without consulting docs as could be harmful!
|
|
Patients in clinical trials of new targeted cancer therapies appear to have lower risk of side-effects http://bit.ly/QLoD1t
|
|
U Penn: The Daily Pennsylvanian :: Penn partners with Novartis to fight cancer http://bit.ly/PeXUoQ
|
|
Dr. Sharman's CLL & Lymphoma Blog: Genetically Modified T-Cells for CLL (and eventually NHL) http://bit.ly/Nkly1E
|
|
Bloomberg: Novartis Gets Immune-Cell Cancer Therapy in UPenn Pact http://bloom.bg/QFoWLm
|
|
In the Pipeline: Novartis Bankrolls T-Cell Cancer Therapies http://bit.ly/OHk6dG
|
|
KevinMD: Patients who receive test results instantly: Doctors need to be ready http://bit.ly/TbfBs4
|
|
Neurologica blog: Health Information on the Internet http://bit.ly/Q4JgPH
Conclusion: We are still living in the wild west of the internet. The net is becoming a critical resource, and health information is near the top of the list. It is difficult, however, to create and maintain accurate resources of health information. The topics are complex and the information is constantly changing. In my experience the more controversial the topic also the more misinformation there is out there clogging up Google searches.
|
|
USA Today: Column: Lab test access carries unintended consequences http://usat.ly/QvgiwK
|
|
10 surprising dangers of vitamins and supplements Don't assume they're safe because they're 'all natural'
Consumer Reports magazine: September 2012 http://bit.ly/OCRuQ0
|
|
Dr. Sharman's CLL & Lymphoma Blog: How I approach follicular lymphoma (part 1) - patients with low risk disease http://bit.ly/T0OZtV
(part 2) - patients with higher risk disease http://bit.ly/MjgQQW
|
|
Oncology Times: View from the Other Side of the Stethoscope: Patient Handout—Managing Primary Care Needs http://bit.ly/NS3GAg
|
|
LIKE: Accuracy of Medical Information on the Internet | Guest Blog, Scientific American Blog Network http://bit.ly/MC1Y1z
Comment: Excellent conclusions.
Regarding "Always seek out the counter opinion for anything that seems controversial" I learned this lesson the hard way. It took a few mistakes for it to sink in!
|
|
Cancer Connect: Antidepressant Cymbalta Might Tame Post-Chemotherapy Pain Http://bit.ly/NWTBPV
|
|
Lifescript: 8 Ways to Fight the Fatigue of Chemotherapy Treatment http://bit.ly/PoEWtP
|
|
Medical xpress: Mayo Clinic completes first genome-wide analysis of peripheral T-cell lymphomas http://bit.ly/NlY5w7
Researchers at Mayo Clinic have completed the world's first genome-wide sequencing analysis of peripheral T-cell lymphomas, unlocking the genetic secrets of this poorly understood and highly aggressive cancer of the immune system. We need better treatments for this type of lymphoma-- hopefully this will help lead to them!
|
|
‘Chemo brain’ frustrating for cancer patients http://bit.ly/MRzNjD
|
|
Dr. Sharman's CLL & Lymphoma Blog: What is BCL-2 and why should we inhibit it? http://bit.ly/R05pj6
|
|
Kevin MD: 5 questions every patient needs to ask http://bit.ly/O7bE4i
|
|
Dr Sharman's CLL and Lymphoma Blog: CLL: Going nowhere fast or going fast to nowhere? How Growth Kinetics Apply to Clinical Picture http://bit.ly/Ot702S
|
|
Dr. Sharman's CLL & Lymphoma Blog: PCI-32765 (ibrutinib), CAL-101 (GS-1101) Changing the future of CLL http://bit.ly/QqXStq
|
|
NYTimes: When Dr's words aren't Soothing http://nyti.ms/SXM19q
|
|
UC San Diego: CLL Tumor cells' inner workings predict cancer progression Molecular markers help reveal nature of chronic lymphocytic leukemia -- slow or fast http://bit.ly/PSdiu5
|
|
Opposing views: Dating With Cancer: Not an Easy Prospect http://bit.ly/PS6i0a
|
|
Dating after cancer http://bit.ly/Qn7o6A
|
|
When Should You Tell Your New Love Interest That You Have Cancer http://bit.ly/O2XCTY
|
|
Livestrong: DATING AND NEW RELATIONSHIPS http://bit.ly/N1O9ca
|
|
Pubmed: Atypical burkitt's lymphoma transforming from follicular lymphoma http://1.usa.gov/N1NkQx
|
|
News Medical: Lymphoma drug dislodges hidden virus in HIV patients http://bit.ly/OT6Z4V
|
|
Respectful Insolence: New cancer drugs: Fitter, happier, more productive? Or not? http://bit.ly/PRikHa
|
|
NBC news: Life-threatening illness: To tell or not to tell? Nora Ephron kept quiet on her leukemia; others share to build emotional support http://bit.ly/MIKhjk What would you do?
|
|
Wendy Harpham, MD blog: What Not to Say to a Cancer Patient http://bit.ly/OnzVDJ
|
|
Better Health: In Defense Of Doctors: Why We Act Like Jerks, And How To Handle Us When We Do http://bit.ly/NXdmoL
|
|
NYTimes: When Health's at Stake, Waiting Is Hardest Part - http://nyti.ms/O4eP0u scanxiety, scanic attack...you name it...
|
|
Family Life | Cancer.Net http://bit.ly/MRc4dd
|
|
MSN: Consulting Dr. Google is rarely a good idea. Here's why http://bit.ly/PolH4M
|
|
Medical News Today: Google Is Not A Doctor http://bit.ly/LyeXjc
|
|
U Colorado, Denver: Meta-analysis: Depression -
Interventions improve depression in cancer patients Especially cognitive behavioral therapy and pharmacologic interventions decrease depressive symptoms in cancer patients http://bit.ly/MN0TmD
|
|
Psychology Today: Does Your Oncologist Care About Your Quality of Life? Preference for Quantity over Quality in a National Survey http://bit.ly/Ly7uR6
In cancer treatment, patients and doctors are often faced with the difficult job of balancing the desire for quantity versus quality of life.
|
|
Science Daily: Potential Key to New Treatment for Mantle Cell Lymphoma (MCL) http://bit.ly/NKIWJX
|
|
|
Cell. 2011 Hallmarks of cancer: the next generation
|
|
DLBCL - ASCO 2012: High-dose chemotherapy followed by allogeneic stem cell transplantation in high-risk relapsed and refractory aggressive non-Hodgkin lymphoma: Results of a prospective study of the German high-grade non-Hodgkin lymphoma study group.
|
|
B-R vs. CHOP-R, Cheson - Medscape:
Lymphoma: More a Question of Toxicity Than Efficacy
|
|
|
|
|
|
News Medical: Updated results from two clinical trials of Bruton's ibrutinib for CLL/SLL http://bit.ly/KXCMQp
|
|
MDA blog: What it means to take care of yourself, from one caregiver to another http://bit.ly/KH9RGC
|
|
Brentuximab Vedotin and Panobinostat: New Drugs for Hodgkin's Lymphoma—Can They Make One of Medical Oncology's Chemotherapy Success Stories More Successful? http://jco.ascopubs.org/content/30/18/2171.full
|
|
Sacremetno Bee: Reduction of Chemotherapy and PET-Guided Radiotherapy in Advanced-Stage Hodgkin Lymphoma: the GHSG HD15 Trial
Read more here: http://www.sacbee.com/2012/06/14/4564029/reduction-of-chemotherapy-and.html#storylink=cpy and http://bit.ly/MG5NAF
|
|
Leuk Lymph: Intermediate Hodgkin's lymphoma in partial remission after three or four ABVD courses: no benefit of one course of intensive chemotherapy before irradiation. http://1.usa.gov/LW3DBN
|
|
Blood: Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. http://1.usa.gov/KaSBn0
|
|
MSNBC: Drug costs now a bigger issue in cancer treatment Soaring costs of new medicines, reduced reimbursements and use of generics play a role http://on.msnbc.com/Ks6ulz
|
|
Oncology Times: ONLINE FIRST: White Paper Prediction: With Sustained Efforts, Cancer Can Become Chronic, Manageable Disease in 10 Years http://bit.ly/MbmUMc
|
|
WebMD: AmI cured Yet? http://bit.ly/K7xpOG Thanks to Dave P
|
|
Am J Hem: Final results of a randomized trial comparing 1, 3 or 6 infusions of rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost-effective and safer treatment of advanced follicular lymphoma http://bit.ly/LPOFgH
|
|
Weill Cornell: New Clinical Trial: GS-1101 (CAL-101) + Rituximab for Previously Treated CLL http://bit.ly/MuzfwS
|
|
NYTimes: Life, Interrupted: Feeling Guilty About Cancer http://nyti.ms/LYoosR
|
|
MSNBC: Woman challenges bone marrow donation law in effort to save daughters' lives http://bit.ly/MBUCZL What do you think- should the law be changed?
|
|
Power: Considering the Benefits of Randomized Clinical Trials http://bit.ly/MObWPt
|
|
Patient Power: Staying Prepared on Your CLL Journey http://bit.ly/MBTy8k
|
|
Weill Cornell: New Clinical Trial: Ofatumumab and Bortezomib in Untreated Waldenstrom Macroglobulinemia http://bit.ly/MBZLSf
|
|
MSNBC: In one type of cancer, heavier men may live longer (diffuse NHL) http://on.msnbc.com/L3RPMM
|
|
Discover: A world within a tumour – new study shows just how complex cancer can be http://bit.ly/OmHzPc (Thanks to Helen U)
|
|
Aarhus Univ:
Mindfulness reduces anxiety and depression in cancer patients http://bit.ly/KnQt1g
|
|
Exercise report
It was all over the news last week that "exercise doesn't help depression." Here's an analysis of the study which showing that it pays to question what you read in the news! Scientific American: Exercise doesn’t help depression? Let’s take a real look at that study. http://bit.ly/N3A5DV
|
|
Monteray County Herald:
ALL-OUT WAR ON CANCER http://bit.ly/MwZr6x General cancer, not lymphoma specific
|
|
Psych Central:
6 Things Cancer Patients Have Taught Me http://bit.ly/MwZ38e
|
|
ADV HEM:
Novel Therapies for Aggressive B-Cell Lymphoma http://1.usa.gov/LfxG6k
|
|
University of Cambridge:
Everything we think we know – and know we don’t know – about cancer http://bit.ly/JTOOdA
|
|
Cancer Research UK: Ginseng for cancer fatigue? The jury’s still Out http://bit.ly/Mpjms2
|
|
Onc Live: The Treatment Should Not Be Worse Than the Disease http://bit.ly/KEnQNc
|
|
New Weill Cornell Study: Thalidomide and Lenalidomide + Rituximab (ThRiL) for Previously Treated Waldenstrom Macroglobulinemia http://bit.ly/LuqDHZ
|
|
Medical News Today: Tumors Start To Develop As A Result Of Specific Combinations Of Errors In The Processes That Safeguard Cell Integrity http://bit.ly/LzAZVy
|
|
Forbes: Cancer drug targets- the march of the lemmings http://onforb.es/Nmpnr7
|
|
Medicaresupplemental: why we haven't cured cancer, cell by cell http://bit.ly/MhB2oY
|
|
Cancer Fighters Thrive: Covering the Cost of Cancer Care http://bit.ly/KfMJ1M
|
|
NYTimes: Life, Interrupted: Finding My Cancer Style http://nyti.ms/MM01np
|
|
KevinMD: Can you handle being the first to know your own test results? http://bit.ly/JPT2Dg Your thoughts on this?
|
|
USA Today: CaringBridge: 15 years of connecting caregivers http://usat.ly/LbK3x1
|
|
Reuters: Doctors try to make sense of cancer's genetic jumble http://reut.rs/L5FBSb
|
|
|
Cancer Research UK: Ginseng for cancer fatigue? The jury’s still out
|
|
Physicians Practice: When the Doctor Becomes the Patient - A cancer diagnosis taught me about life on the patient’s side of the stethoscope
|
|
The Oncologist: “Less is More”: The Role of Purging in Hematopoietic Stem Cell Transplantation
|
|
CLL Topics: A Happy Ending- journal of mini-allo transplant
|
|
Oncology Times: New Insights into Follicular Lymphoma from Sister-to-Sister Transplantation
|
|
DLBCL - Science: New Drug Shows Promise for Advanced Lymphoma
ibrutinib [eye broo' ti nib] is also known as PCI-32765. The drug blocks a protein called Bruton's tyrosine kinase (BTK) that's part of the B-cell-receptor signaling pathway.
Trials: Ibrutinib
|
|
FL indolent - Cancer Network: Inotuzumab Ozogamicin Achieves ‘Markedly Long’ Antitumor Response in Indolent B-Cell NHL (phase II study)
Trials: Inotuzumab Ozogamicin
|
|
FL Blood: "mini" allogeneic transplantation with or without Zevalin is potentially curative for relapsed follicular lymphoma: 12-year results.
|
|
HL- Interim FDG-PET Scan in Hodgkin's Lymphoma: Hopes and Caveats
|
|
HL Oncology Times: ONLINE FIRST: Hodgkin Lymphoma: Novel Agents Can Act as Bridge to Allogeneic Transplant for Selected Patients
|
|
HL J Clin Onc: Long-Term Results of CCG 5942: Randomized Comparison of Chemotherapy With and Without Radiotherapy for Children With Hodgkin's Lymphoma
|
|
MCL - Lancet: Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
|
|
|
|
Best Pract Res Clin Haematol, 2010: Should double cord blood transplants be the preferred choice when a sibling donor is unavailable?
Mismatch at two antigens actually improves the risk of relapse for umbilical cord blood transplant recipients with relatively low risk of severe acute or chronic graft vs host disease. However, umbilical cord blood transplant is associated with an inferior neutrophil recovery rate when compared to other stem cell sources.
|
|
Communications - KevinMD: How to discuss online health information with your physician
|
|
FL- Cancer: Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the US
|
|
FL Larry W. Kwak: Translational Development of Therapeutic Vaccines for Lymphoma
|
|
KevinMD: How to discuss online health information with your physician
|
|
Travel - NCCN: Traveling with Cancer
|
|
Viral link - Science News: Tracking the viral link to lymphoma: Epstein-Barr has genes that can either suppress or promote blood cancer
|
|
transformed lymphoma - ASH Ed.: The incidence, natural history, biology, and treatment of transformed lymphomas
|
|
Tips - Science-Based Medicine: How to Chose a Doctor
|
|
USA Today: Googling bad for your health? Docs debate online health forums
|
|
Fertility - Live Science - Helping young cancer patients protect their fertility
|
|
FL - Oncology Times: Point-Counterpoint: Should All Patients with Follicular Lymphoma Receive Maintenance Rituximab?
Comment: An excellent debate on the question.
However, my memory of the audience vote was not the same as that reported by Oncology Times, so I wrote one of the speakers and the Chair of the event. Each confirmed that Oncology Times got the voting part wrong. ~ Karl Schwartz.
|
|
Statistics – CancerGuide: The Median ISN'T the Message
|
|
Statistics 101 - CancerGuide: Survival Curves
|
|
ASCO Post: Searching for Quality in an Increasingly Complex Health-care Environment
A Conversation with Sean R. Tunis, MD, MSc
|
|
CLL - OncLive: Dr. Wierda Discusses Watchful Waiting in CLL
|
|
Communications - Cure: Honest Discussions Can Help Ease Kids' Anxiety About Cancer
|
|
Communications - KevinMD: Doctors need to be better trained to deliver bad news
|
|
Complications - HemOnc Today: CLL (and NHL) linked to poorer survival in those with malignant melanoma, MCC
"Trust me, don't forget the sunscreen!"
|
|
Drug Complications - About Lymphoma: What Is Extravasation?
|
|
Financial support - LRF: Patient Transportation Assistance Program to Assist T-Cell Lymphoma Patients
|
|
Hope - ASCO CONNECTION: Beating the Odds
I find interpreting statistics for patients very difficult; not because I don't understand the concept of relative and absolute risks, hazard or odds ratios, or survival rates. It's because in the end, they do not apply at an individual level.
|
|
Stress - Cure: Stressed During Cancer Treatment? Try Meditating-Mindfulness meditation can ease stress during treatment.
|
|
Science Daily: A New Approach to Faster Anticancer Drug Discovery
|
|
Evidence - Cure: Finding Reliable Cancer Information Online--Think before you leap when researching cancer online.
|
|
NEJM - Perspective: Supreme Court Review of the Health Care Reform Law
Gregory D. Curfman, M.D., Brendan S. Abel, B.A., and Renée M. Landers, J.D.
Snips:
"If the Court determines that review is appropriate, it will next consider whether Congress has the authority to require most U.S. citizens to purchase health insurance or pay a penalty."
"Challengers argue, however, that the mandate to purchase a product from a private entity is unprecedented and constitutes an intrusion on individual liberty."
|
|
Aggressive NHL: Leukemia (2011): oral mTOR inhibitor everolimus in relapsed aggressive lymphoma (including transformed)
Comment: It's anticipated that such agents will be most effective as part of combination therapy. We may soon see a pilot study evaluating this oral agent in combination with CHOP or CHOP-R as initial therapy for aggressive lymphoma ... based on its clinical activity as a single agent in the relapse setting. (Temsirolimus is an IV version of this agent that targets the mTOR pathway.)
Studies evaluating Everolimus / RAD001 (oral) -
|
|
|
T-cell - Rev. Bras. Hematol. Hemoter: T-Cell Lymphomas in South America and Europe
|
|
Rituxan - Rheumatology: Non-infectious pulmonary toxicity of rituximab: a systematic review
A very rare side effect-- But, highlights the importance of telling your doc about any respiratory symptoms.
|
|
SCT - Best Practice and Research in Clinical Haematology: Autologous or allogeneic transplantation in B- and T-cell lymphomas
|
|
SCT - OncLive: Nonmalignant Late Effects Pose Heavy Burden After Hematopoietic Cell Transplant
As always, we must weigh benefits against risks. We know many who might no longer be with us had they not had a transplant. Hopefully, with more research, ways will be found to reduce these risks or, at least, ways to improve follow-up care.
|
|
FL - LRF: A Conversation About Follicular Lymphoma With Dr. Sonali M. Smith
|
|
GVHD - News Medical: Researchers identify molecule that helps decrease acute GVHD severity
|
|
Respectful Insolence: Fighting the "acid" of negative (e)motions?
|
|
Supplements - KevinMD: Unregulated supplements is a tragedy in waiting
|
|
Vitamins - MD Anderson: Stop the Multivitamin Madness
|
|
Vitamin C - Cure: Jury Still out on Vitamin C's Effect on Cancer
|
|
Elderly - Best Practice and Research in Clinical Haematology: Therapeutic strategies in elderly and very elderly patients
|
|
WM - YouTube: Dr. Ansell Describes Waldenström Macroglobulinemia
|
|
KevinMD.com: When it comes to cancer, do not just focus on survival
|
|
NYTimes: Answers in Medicine Sometimes Lie in Luck
|
|
NYTimes: Pay Only for Drugs That Help You
|
|
Tumor Biology - Cancer Research UK: On the origin of tumours
|
|
Tumor Biology - USA Today: Scientists are reporting what could be very bad news for efforts to customize cancer treatment based on each person's genes.
|
|
Is it reputable? - a checklist for judging online information PDF
|
|
CLL - Two reports on same study: Chronic Lymphocytic Leukemia - Aggressive Drug Combo Restores Quality Of Life and http://bit.ly/xJitXk
|
|
FL - Blood: Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.
Short of expectations.
|
|
MALT - Gut: Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan
"The excellent long-term outcome of gastric MALT lymphoma after H pylori eradication was confirmed by this large-scale follow-up study."
|
|
Pregnancy - Weill-Cornell: Lymphoma in Pregnancy
|
|
Caregiver - PsychCentral: Caregiving: Taking Care of Your Spouse & Yourself
“Even though Denholm, Ph.D, LMHC, is a medical psychotherapist, she felt incredibly unprepared for her role and found little direction for navigating the many stresses and challenges of being a caregiver.”
|
|
Treatment Tips - Oncolink: Home Safety for Patients Receiving Chemotherapy
Handling Body Waste, Handling Trash or Laundry, Handling Spills, Sexual Contact, Safety for My Family
|
|
CLL - OncLive: New Model Helps Guide Treatment Options in CLL
"While the watch-and-wait method is frequently employed in patients with chronic lymphocytic leukemia (CLL), there are a number of prognostic factors that can help identify those at a high risk for disease progression who may benefit from early intervention."
|
|
CNS lymphoma - MRCC: Primary CNS Lymphoma Treatment (PDQ®)
|
|
Diagnosis - Medscape: Difficulties in Diagnosing Cancer: UK Study /
|
|
DLBCL- OncLive: New Directions in Relapsed / Refractory Diffuse Large B-cell Lymphoma
"the Bruton’s tyrosine kinase inhibitor PCI-32765 was tested in 8 patients with relapsed or refractory ABC DLBCL. The results showed that 2 patients achieved complete response for 11+ and 5 months, respectively; 3 patients achieved stable disease for 4, 2, and 2 months, respectively; and 3 patients had progressive disease. The drug was generally well tolerated across the patient population."
See for more on this kinase inhibitors
|
|
FL - EU J of Nuclear Med and Molecular Imaging: FDG PET/CT predictive role in follicular lymphoma
“Of the different predictive factors, only FDG PET result significantly correlated with patient outcome (p = 0.0002). PET/CT performance at the end of treatment was as follows: 100% sensitivity, 99% specificity, 89% positive predictive value and 100% negative predictive value.”
|
|
Hodgkin - Blood: A phase II study of rituximab-ABVD in classical Hodgkin lymphoma.
"In classical Hodgkin lymphoma (cHL), circulating clonotypic malignant cells express CD20, potentially explaining the observed activity of rituximab. This multicenter phase II study investigated the combination of rituximab-ABVD for stage II-IV untreated cHL."
|
|
Fertility - Weill Cornell: Fertility and Lymphoma
|
|
T-cell, ASH Education Program Book, 2011:
Therapies for Peripheral T-Cell Lymphomas Kerry J. Savage
"...Encouragingly, there have been several new therapies emerging with activity in PTCLs and exciting novel combinations under consideration that will hopefully move the field forward and improve outcome in this challenging group of diseases."
|
|
Evidence - Respectful Insolence: Dr. Stanislaw Burzynski strikes again
|
|
Evidence - Science Based Medicine: Dr. Oz revisited
"All truth passes through three stages. First, it is ridiculed. Second, it is violently opposed. Third, it is accepted as being self-evident."
… When cranks invoke Schopenhauer the implication behind their parroting the above quote is that they have The TRUTH.
|
|
Treatment Tips - Oncolink: Home Safety for Patients Receiving Chemotherapy
Handling Body Waste, Handling Trash or Laundry, Handling Spills, Sexual Contact, Safety for My Family
|
|
SCT - NCI - all about stem cells and stem cell rescue
Each slide has a graphic with narration. Ready for printing.
|
|
CLL Topics Updates: FC + Campath for Chemo-Naive Patients
|
|
Follow up is key -
Oncology Times: Second Thoughts from Sekeres: A Pyrrhic Victory in the War Against Cancer: What We Should Demand from Clinical Trials
"Among the piles of journals that invade our offices weekly, advancing on the sanctity of clean desk space like kudzu, occasionally—very occasionally—an article pops out that upends the conclusions we have always drawn from clinical trials
|
|
FL, early stage - Strahlentherapie Und Onkologie: Radiotherapy in stage I-III follicular non-Hodgkin lymphoma: Retrospective analysis of a series of 50 patients
RT is a curative option in the treatment of limited stage FL. If RT of microscopically uninvolved area is necessary, a reduction in the radiation dose should be carefully weighed against the risk of in-field recurrences.
|
|
Hodgkin - Haematologica: Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin lymphoma
|
|
MCL, relapsed - Haematologica: A multicenter phase II trial (SAKK 36/06) of single-agent Everolimus(RAD001) in patients with relapsed or refractory mantle cell lymphoma.
|
|
NHL, relapsed - Annals of Hematology: Bendamustine with or without rituximab for the treatment of heavily pretreated NHL patients A multicenter retrospective study
|
|
Oncology Times: Lymphoma Highlights from ASH: Important News about Hodgkin Lymphoma, and an Unexpected Negative Transplant Study in DLBCL
|
|
Pixantrone - Medscape: Pixantrone Progresses Toward Approval in the European Union
"We are encouraged by the progression-free survival noted in the PIX301 study and the opportunity this agent provides in treating this difficult-to-treat group of patients," Dr. Coiffier said
|
|
PMLBCL - The Oncologist: R-CHOP with or Without Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma: The Emerging Standard of Care
|
|
SCT - Oncology Times: Haplo Transplant Valid Option for Patients without Conventional Donors
|
|
T-cell - J Clinical Onc: Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
Also see - Clinical trials with Romidepsin
|
|
Transformation - BJH: Incidence, risk factors and outcome of histological transformation in follicular lymphoma
|
|
T-cell therapy - Blood: CD20-specific adoptive immunotherapy for lymphoma (similar to CAR 19)
|
|
WM study - Weill-Cornell Med Ctr: Waldenstrom’s Macroglobulinemia Clinical Database Study
|
|
MCL - Haematolgica: A multicenter phase II trial (SAKK 36/06) of single-agent Everolimus (RAD001) in refractory mantle cell lymphoma.
See Everolimus clinical trials
|
|
CLL - CancerConnect.com: Combination of Campath and Fludarabine Provides Benefit in CLL
NOTE: But the standard treatment against which this protocol was tested is now Fludarabine with Rituxan.
|
|
FL - Nature Bone Marrow Transplantation: Long-term outcome after SCT in patients with recurrent follicular lymphoma
|
|
Nutrition - Medical News Today: How much do nutritional interventions help malnourished cancer patients?
|
|
Pregnancy - Medscape: Hematologic Cancers in Pregnancy Pose Substantial Risks
|
|
SCT - Medical News Today: Blood Cancer Patients To Benefit From Stem Cell Research Breakthrough
"These findings provide a practical, clinical strategy for lowering the risk of death following an unrelated-donor blood stem cell transplant. It builds on the gold-standard which already exists for transplants and could be easily incorporated into the current framework transplant centers use when trying to find the best match."
|
|
WM study - Weill-Cornell Med Ctr: Waldenstrom’s Macroglobulinemia Clinical Database Study
“Participants in this study give their permission for the investigators to collect their clinical information for research purposes. In addition, the researchers will store participants’ blood, urine, check swab, bone marrow and/or tumor tissue samples for research studies to be performed now and in the future. In some cases, participants may be asked by their physician to provide additional samples.”
|
|
FL Video - Dr. Kahl interview: Results of the RESORT Trial for Follicular Lymphoma:
Questions for Patients and Their Physicians
Interview by Patient Power - in association with Patients Against Lymphoma
NOTE: Excellent description of the study by Dr. Kahl ... However, we anticipate that his closing comment on evidence of a lack of resistance to Rituxan will be controversial.
|
|
MCL Video - Dr. Peter Martin interview
Kinase Inhibitors Offer New Hope for Mantle Cell Lymphoma
by Patient Power in Association with Patients Against Lymphoma
|
|
Medscape video: Dietary Supplements and Mortality Rates in Women: A Cautionary Tale
|
|
Bad science - NYTimes:
How Bright Promise in Cancer Testing Fell Apart
|
|
Off-label drugs - WSJ: Dilemma: When One Drug Treats Two Diseases
Balanced perspective provided here ... but the author appears to have confused off-label use of drugs with use of experimental drugs ... only the latter require company permission for use outside of a trial in the US.
|
|
Where's the full report? - Medscape, login required - Dr. Cheson video: Do Unpublished Data Need an Expiration Date?
|
|
CAM - Medpage Today: No Cancer Help from Supplements (omega-3 and B vitamins) for Heart Patients
|
|
Cancer Research Institute: Antibodies to intracellular cancer antigens combined with chemotherapy enhance anti-cancer immunity (pre-clinical)
|
|
Career - NCCS - Working It Out - Your Employment Rights As A Cancer Survivor
Employment Challenges and Cancer Survivors
How to Avoid Job Discrimination
How Employment Discrimination Laws
Protect Cancer Survivors
Know Your Legal Rights
Talk It Out Before You Sue
|
|
Fake drugs - WSJ: Fake Cancer Drug Found in U.S.
|
|
Misdiagnosis - KevinMD.com: 5 ways to avoid a misdiagnosis
|
|
Be The Match - Patients Connect Facebook Page
People can join the Be The Match Registry® – the world’s largest listing of potential marrow donors and donated cord blood units – contribute financially and volunteer.
|
|
NIH: Clinical Trials and You
|
|
aggressive NHL - Am J Hematology: NEAM followed by autologous stem cell transplantation for patients with chemosensitive aggressive NHL
|
|
aggressive NHL - Pubmed: Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study.
|
|
DLBCL - Swiss Medical Weekly: Diagnosis and treatment of diffuse large B-cell lymphoma
|
|
MCL - Haematolgica: A multicenter phase II trial (SAKK 36/06) of single-agent Everolimus (RAD001) in refractory mantle cell lymphoma.
Single agent everolimus is well tolerated and has anti-lymphoma activity in relapsed or refractory mantle cell lymphoma. Further studies of everolimus either in combination with chemotherapy or as single agent for maintenance treatment are warranted.
See Everolimus clinical trials
|
|
SCT - Oncology Times: New Data Emphasize Importance of Alerting Patients Undergoing HCT of Long-Term Risks
|
|
SCT - Oncology Times: Stem Cell Transplants: Overall Survival Same with Unrelated-Donor PBSCs and BMSCs http://bit.ly/wqeSYc
|
|
T-cell - Press Release: Allos Therapeutics reports interim data of Folotyn combination therapy
|
|
T-cell therapy - Blood: CD20-specific adoptive immunotherapy for lymphoma (similar to CAR 19)
“Recent clinical trial data demonstrate that modification of T cells with chimeric antigen receptors (CAR) is a promising strategy … Four patients were enrolled, and 3 received T cell infusions following cyclophosphamide lymphodepletion. Treatment was well tolerated, although one patient developed transient infusional symptoms. Two patients without evaluable disease remained progression-free for 12 and 24 months.”
|
|
The Dirt on Coming Clean: Perverse Effects of Disclosing Conflicts of Interest
"Most important, it assumes that estimators know what to do with the information that is disclosed. There are grounds for skepticism regarding this assumption. "
|
|
Costs - KevinMD.com: A look behind the growing cost of cancer drugs
|
|
Pregnancy - Medical Press: Complications of blood cancers make termination advisable at early stages of pregnancy
“The authors advise that, in the absence of a durable remission of at least 2 years, avoidance of pregnancy is advisable in patients with acute leukaemia or lymphoma because the disease is most likely to recur during that period.”
|
|
Pregnancy - Medscape: Chemotherapy During Pregnancy Appears Safe for Offspring
|
|
Radiotherapy, treating injury - Medscape:
Hyperbaric O2 Helps Most Chronic Radiation Injuries: Study
|
|
SMZL - CancerNetwork: Splenic Marginal Zone Lymphoma: Current Knowledge and Future Directions
|
|
Starting with cpg in situ vaccine:
ASCO Merit Award -, Joshua Brody, MD: Immuno-transplant For Mantle Cell Lymphoma: Phase I/II Study Preliminary Results.
|
|
Btk-inhibitors - Nature Reviews Drug Discovery: Trial watch: BTK inhibitor shows positive results in B cell malignancies
|
|
DLBCL, relapsed - ASH 2011: Bexxar - BEAM Vs. Rituximab - BEAM and Autologous Stem Cell Transplantation for Relapsed DLBCL: No Difference in Progression-Free (PFS) or Overall Survival (OS)
Discussion: http://forums.lymphoma.com/
|
|
FL- Annals of Oncology: A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by Zevalin in untreated intermediate/high-risk follicular lymphoma
|
|
FL- Patient Power: Results of the RESORT trial for follicular lymphoma: questions for patients and their physicians
Discussion: http://forums.lymphoma.com
|
|
FL- BJH: Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times
Contains survival stats that can be challenging to read ... but important and encouraging findings for grade 3b - specifically
"In contrast to grade 1–3A, grade 3B did not relapse beyond 5 years of follow-up in our population-based cohort. This study supports the hypothesis that grade 3B might be an aggressive neoplasm, but if it is treated aggressively, some patients are probably cured."
|
|
Hodgkin - FDA Briefing Document: Oncologic Drugs Advisory Committee Meeting
July 14, 2011 | BLA 125388 for (Adcetris) brentuximab vedotin
Proposed Indication: Treatment of Relapsed or Refractory Hodgkin Lymphoma
|
|
Hodgkin - Haematologica. PET imaging response at time of autologous stem cell transplantation predict outcome of patients with relapsed and/or refractory Hodgkin Lymphoma responding to prior salvage therapy.
|
|
Hodgkin - Medwire News: Chemotherapy alone improves long-term survival in Hodgkin's lymphoma
From Discussion: "We found that the rate of long-term survival is higher with ABVD alone than with treatment that includes subtotal nodal radiation therapy, particularly when subtotal nodal radiation therapy is combined with two cycles of ABVD therapy. As postulated by the study hypothesis, the advantage that is seen with chemotherapy alone is due to the fact that there are fewer deaths from causes other than progressive Hodgkin's lymphoma or acute treatment-related toxic effects. Furthermore, we have addressed the question of whether chemotherapy alone has curative potential for these patients,19 since the rate of 12-year freedom from disease progression that we observed with ABVD alone was 87%.
The major limitation associated with our results is that the subtotal nodal radiation therapy that was used in the radiation-therapy group is outdated, and the extent of radiation therapy is very likely to have contributed to the excess deaths. "
|
|
T-cell - J Clinical Oncology: Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy http://bit.ly/yUzGtL
|
|
MCL - Oncology Times: FDA Approves Supplemental New Drug Application for Velcade (Bortezomib) for Multiple Myeloma and Mantle Cell Lymphoma
"The FDA has approved an update to the label for Velcade (bortezomib) to include the subcutaneous method of administration in its approved indications
…. Although both methods showed similar safety profiles, in the subcutaneous arm of the trial only 6% of patients experienced peripheral neuropathy of grade 3 or higher, compared with 16% in the intravenous group. In the subcutaneous group, 38% of patients experienced neuropathy of all grades, compared with 53% of patients in the intravenous group."
|
|
SMZL - CancerNetwork: Splenic Marginal Zone Lymphoma: Current Knowledge and Future Directions
|
|
T-cell - Cure Today: Romidepsin effective for refractory peripheral T-cell lymphoma
The researchers documented objective responses in 33 patients (25%), including 19 (15%) who had complete responses.
|
|
radiotherapy, treating injury - Medscape: Hyperbaric O2 Helps Most Chronic Radiation Injuries: Study
A positive outcome occurred in 94% of patients with osteoradionecrosis of the jaw (n = 43), 76% of patients with cutaneous radionecrosis that caused open wounds (n = 58), 82% of patients with laryngeal radionecrosis (n = 27), 89% of patients with radiation cystitis (n = 44), 63% of patients with gastrointestinal radionecrosis (n = 73), and 100% of patients who were treated in conjunction with oral surgery in a previously irradiated jaw (n = 166). Source
|
|
New approved drug - Oncolink: Brentuximab Vedotin aka Adcetris
|
|
Expert perspective on Lymphoma research - Oncology Times Key, Dr. Cheson - Lymphoma Takeaways from ASH
|
|
T-cell, cutaneous - review - Oncology Times: Photopheresis in the treatment of cutaneous T-cell lymphoma: current status
CTCL - Extracorporeal photopheresis (ECP), an immunomodulating procedure involving treatment of blood with a photoactive agent, was given regulatory approval by FDA as a medical device for the treatment of cutaneous T-cell lymphoma (CTCL) in 1988 [1]. It is one of many treatment options for CTCL.
|
|
T-cell therapy - Oncology Times: Investigational T-Cell Therapy for CLL Shows the Progress in Immunotherapy
“It worked much better than we thought it would,” senior author Carl H. June, MD, Director of Translational Research and Professor of Pathology and Laboratory Medicine at the Abramson Cancer Center, said. “We saw at least a 1,000-fold increase in the number of modified T cells in each of the patients. Drugs don't do that. In addition to an extensive capacity for self-replication, the infused T cells are serial killers. On average, each infused T cell led to the killing of thousands of tumor cells—and overall, destroyed at least two pounds of tumor in each patient.”
|
|
WM - Acta Hem: Familial (inherited) Aggregation of Waldenström Macroglobulinemia
|
|
Zevalin, media report - Spectrum says its Zevalin drug led to higher survival rates in certain lymphoma patients
|
|
Medical News Today: Blood-Forming Stem Cells' Growth Identified
“The research has implications for bone marrow and umbilical cord blood transplants, Dr. Morrison said. … Doing so will make it possible to expand blood-forming stem cells prior to transplantation into patients, thereby increasing the safety and effectiveness of this widely used clinical procedure."
|
|
Podcast - Cancer.net: How to choose and Oncologist
|
|
Starting with cpg in situ vaccine:
ASCO Merit Award -, Joshua Brody, MD: Immuno-transplant For Mantle Cell Lymphoma: Phase I/II Study Preliminary Results.
A two step process. The first step is to induce tumor-reactive t-cells with cpg vaccine; the second to implant the tumor-reactive t-cells in patients after chemotherapy - a concept first tried in MCL. Encouraging results reported here.
|
|
Fertility resource - Myoncofertility.org
|
|
Financial - Cancer Support Community:
Coping with the cost of cancer care.
|
|
Hope - Harpham, Wendy S. MD - Oncology Times: VIEW FROM THE OTHER SIDE OF THE STETHOSCOPE: Real Good News
“When you order a scan, do you ever wonder what kind of news your patient hopes for? If you assume every patient hopes for “good” news, you'd be right most of the time. But not always. I, for one, don't spend time and energy hoping for good news. To understand why, let's look at hope in the setting of patient evaluations.”
|
|
Living - KevinMD.com: Incorporating 12-step program concepts into cancer survivorship
|
|
Living - KevinMD: A reminder that families suffer together
|
|
Treatment support - Cure Today: Consider Dental Issues Before Beginning Cancer Treatment
|
|
Insurance - KevinMD: The problem of insurance gaps in cancer patients
|
|
Financial - Cure: Resources to Ease the Financial Burden of Cancer
|
|
Living - Psych Central: 9 Ways to Take Care of Yourself When You Have Depression
|
|
Living - MDA: Letting People Know (you have cancer)
|
|
Living - ESMO: Anxiety and Depression in Cancer patients
An excellent presentation on anxiety and depression in cancer patients. Audio would not load, but can go through slides. Talks about cancers that can present with depression (lymphoma is one of them) and medications that can cause symptoms
|
|
Teamwork - CLL topics Update: Controversies in Communication
|
|
Teamwork - Kevin MD: Doctors who give cash to patients for running late
|
|
DLBCL - Cancer: Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and different types of consolidation radiotherapy
|
|
FL - expert perspective - Medscape, Dr. Cheson: Reason to RESORT to Rituximab Maintenance?
|
|
Hodgkin - expert Perspective - Medscape, Dr. Cheson: Radiation Therapy vs Chemo in Hodgkin Lymphoma Patients
|
|
Hodgkin - ASCO: Favorable Early-stage Hodgkin Lymphoma and HD.6: The Take-Home and Don’t–Take-Home Messages
|
|
RIT - expert perspective - Medscape, Dr. Cheson: Radioimmunotherapy: How Strong an Option Is It?
|
|
MZL, nodal, review article - CancerNetwork.com: Nodal Marginal Zone B-Cell Lymphoma: A Diagnostic and Therapeutic Dilemma
|
|
SCT - Annals of Hematology: Allogeneic stem cell transplantation in patients with DLBCL relapsed after autologous stem cell transplantation
|
|
T-cell - Univ Hospitals Case Medical Ctr: UH Case Medical Center publishes study on novel treatment for Cutaneous T-Cell lymphoma
"By adding O6-benzylguanine, we can effectively lower the dosage of the topical treatment, carmustine, and render it less toxic on healthy cells but more effective at killing cancer cells," says Dr. Cooper. "This combination treatment has had excellent initial clinical results and we are following it up with additional ongoing studies."
Related Study of Interest - O6-Benzylguanine and Topical Carmustine in Early-Stage (IA-IIA) Cutaneous T-Cell Lymphoma:
|
|
Transformed lymphoma - BJH (correspondence): Improving survival in patients with transformed B cell non Hodgkin lymphoma: consolidation with Zevalin-BEAM and autologous stem cell transplantation
|
|
Acupuncture - J Altern Complement Med. 2008 - The Status and Future of Acupuncture Clinical Research
|
|
Second Pathology Evaluations: WSJ: Informed Patient: Diagnostic Errors Highlight Need for Second Opinions
|
|
CAM - Is there any merit in the concept that to restore health you have to "Alkalinize your blood to fight cancer?
Respectful Insolence: Acid Base or Woo
Respectful Insolence: Acid Base or Woo, revisited
|
|
CLL Topics Updates: How to Treat Elderly CLL Patients
|
|
Advocacy, expert perspective - Medscape: Clinical Trial Woes: Dr. Bruce Cheson on Where Are the Drugs?
|
|
PBS: Cancer Treatment: Are Personalized Molecular Profiles in Our Future?
|
|
Patient Power: Physician Turned Patient: My Quest for the Best CLL Treatment
|
|
News Medical: Study investigates immune response in cancer
|
|
Cure: Why Banks Need Your Tissue for Research
|
|
Alt Med - Sloane Kettering: Complementary vs. Alternative Cancer Therapies
|
|
BoingBoing: Three common mistakes in medical journalism
|
|
Causes of cancer - Cure Today: Connecting the Dots: Why It's So Hard to Pin Down Environmental Causes of Cancer
|
|
Resveratrol - In the Pipeline: A Resveratrol Research Scandal. Oh, Joy
|
|
allo SCT - Perspective - Current role of allogeneic stem cell transplantation in follicular lymphoma
|
|
Zevalin - Cancer: Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia.
snip: "incidence of sMDS/AML, which nevertheless was comparable to the incidence observed in a matched group of patients who received chemotherapy-based conditioning.”
|
|
Sustainability - NYTimes: It Costs More, but Is It Worth More?
snip: “So a second option is “coverage with evidence development.” In this approach, Medicare would pay for proton beam treatment … only if the patients were enrolled in a randomized trial that would compare the outcomes of their treatment to those from surgery, other kinds of radiation or active surveillance. Medicare has used this approach sparingly, but it should be applied to more cases like this one.”
|
|
Celebrities with lymphoma - Reuters: Black Sabbath guitarist diagnosed with lymphoma
|
|
End of Life - Denialism Blog: How Do you Want to Die?
Speaks frankly about end of life issues, if reading about these issues upsets you please don't open.
Also: How Doctors Die
|
|
Family Practice News: Pregnant Women With Lymphoma Can Have Good Outcomes
|
|
Fertility - Springer: Cancer and fertility -- young women speak up
|
|
Nutrition - ACS: Updated American Cancer Society nutrition guidelines stress need for supportive environment
|
|
Nutrition - Oncology Times: ACS Updates Nutrition and Physical Activity Guidelines
snip: “The guidelines are really about educating people about what they can do on their own to reduce the risk of cancer, but are also designed to spur action for change -- to make it easier for people to get a banana instead of a candy bar,”
|
|
Teamwork - NYTimes: Project Puts Records in the Patients’ Hands
|
|
Teamwork - MDA: Advance Care Planning: A Patient and Provider Partnership
|
|
Hodgkin- Patient Power: Expanding New Treatment Option to Frontline Treatment for Hodgkin Lymphoma
|
|
Hodgkin- The Oncology Report: New Scoring System Devised for Youth With Hodgkin's Lymphoma
|
|
SCT - Patient Power: Keeping Transplant Patients Safe: Behind the Scenes with an Infectious Disease Specialist
|
|
Patient Power: Fighting Cancer in Your 20s: Lessons Learned
Rose Egge never thought she would be facing a cancer diagnosis at 25 years old. ... Now, Rose helps other young adults cope with a cancer diagnosis through her foundation, Thrive Through Cancer.
|
|
MCL - LLS November 2, 2011 - Mantle Cell Lymphoma
archived video and transplant for those who may have missed the presentation
|
|
MCL - Blood: Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database.
Author's comment: "Future trials should focus on novel agents rather than comparing efficacy of current approaches."
|
|
Cancer biology - Johns Hopkins: Cancer Cells feed on Sugar-free diet
|
|
Walter and Eliza Hall Institute: Research shows cells influence their own destiny
|
|
Blood - Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia
Targeting the microenvironment could improve sensitivity to treatment.
|
|
Fertility - Patient Power: Oncofertility: Fertility Preservation for Cancer Patients
|
|
CLL - Patient Power: Dr. Steven Rosen on Breakthroughs in Chronic Lymphocytic Leukemia from ASH 2011
|
|
Hodgkin - Patient Power: Dr. Ajay Gopal on Robust Treatment Options Keep Hope Alive
|
|
Elderly - Cancer Chemo and Pharmacology: Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma
|
|
HCV Infection and Cryoglobulinemia
Antiviral Therapy in HCV-Positive NHL: Pathogenetic Implications
A systematic review of subsequent studies reported that 75% of HCV-infected patients with B-NHL treated with pegylated interferon-α (pIFN-α) plus ribavirin (RBV) achieved a complete hematological response (CHR), whereas no such response was obtained in matched HCV-uninfected B-NHL patients. Our own experience refers to a retrospective analysis ...”
See also MJH, 2010:
Hepatitis C Virus Infection and Lymphoma
|
|
Histone Deacetylase (HDAC) Inhibitors: Potential in Cancer Therapy
|
|
Hodgkin: PubMed: PET/CT surveillance in patients with Hodgkin lymphoma in first remission is associated with low positive predictive value and high costs.
Full text: haematologica.org
|
|
SCT - AM J Hematology: Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidities
|
|
Allo SCT - Biol Blood Marrow Transplant. 2011 - HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation.
HLA-C antigen-mismatched unrelated PBSC donors were associated with worse outcomes compared with 8/8 HLA-matched donors.
|
|
T-cell: Pubmed: Efficacy and safety of the third-generation Fotemustine for the treatment of chemo-refractory T-cell lymphomas.
|
|
Science Based Medicine: Why Do We Really Need Clinical Trials?
"Given the incredible number of complex, interacting factors involved in the development of each particular disease, it shouldn’t surprise us when even a reasonable hypothesis with limited support from observational trials and other lower level evidence turns out to be false."
|
|
Medscape (login required): Dr. Cheson - Great New Drugs Will Be Harder to Come By
"So, it's sort of a conundrum. The more effective regimens we develop, the higher the bar, and the more difficult it is for new drugs to come down the pike."
|
|
ASH review - Cheson and Leonard - Medscape:
Has Rituximab Met Its Match in Lymphoma ... and other topics?
|
|
Preclinical models - NPR: Perhaps Scientists Like Lab Mice TOO Much
|
|
CLL Topics Update: "Doc, how long do I have" Discusses prognostic factors in CLL
|
|
General Health - US Preventative Service Task Force: Vitamin D With or Without Calcium Supplementation for Prevention of Cancer and Fractures An Updated Meta-Analysis
“ Evidence is not sufficiently robust to draw conclusions regarding the benefits or harms of vitamin D supplementation for the prevention of cancer.”
|
|
Living - Cancer Connect: Showing Love in the Face of Loss
the peaks and valleys of my emotions eventually started to level out somewhat. When my child’s birthday or Christmas arrived, I had to brace myself and just concentrate on breathing.
|
|
Living - Crazy Sexy Cancer: 10 Things I Learned from People Who Survive Cancer
|
|
Living - Psych Central: When Cancer Patients also grapple with depression
|
|
Medical Errors - KevinMD.com How patients can avoid medical errors
|
|
Prevention - MDA: Diet and Cancer
... diet is thought to account for about 30% of cancers in Western countries.
|
|
Safety - Science Based Medicine: Reducing the Risk of Adverse Drug Events
“The elderly are seven times as likely as younger people to have adverse drug events. ... Forty percent of people over 65 take 5-9 medications, and 18% take 10 or more. Combinations of medications can cause unexpected problems.”
|
|
Financial - Cure: Medical Debt: An Unspoken Side Effect of Cancer Care
|
|
CLL - Medscape (login required):
New Class of Drug May Vanquish CLL
Also see Navitoclax - Lancet, Wilson et al a Targeted High Affinity Inhibitor of BCL-2 (ABT-263), in Lymphoid Malignancies - full text
|
|
CLL - Patient Power: Dr. Steven Rosen on Breakthroughs in Chronic Lymphocytic Leukemia from ASH 2011
|
|
Hodgkin - Patient Power: Dr. Ajay Gopal on Robust Treatment Options Keep Hope Alive
|
|
MZL - ASH 2011: Patients with Limited Stage Extranodal Marginal Zone Lymphoma Have Excellent Survival regardless of Choice of Therapy Type or Observation
|
|
T-cell, cutaneous - PubMed: Photodynamic Therapy with methyl-aminolaevulinic acid (MAL) for Mycosis Fungoides
|
|
Caregivers - Oncology Times: Gender Differences Can Make a Difference in Caregiving
“Overall, the belief is that women facing a crisis find comfort in discussing their fears, while men take solace in action.”
|
|
Disparities - Cancer: Survival disparities by Medicaid status An analysis of 8 cancers
|
|
General Health - NY Times: The Fat Trap
There have been studies that suggest obesity may raise risk for lymphoma and other cancers. Excellent article on why it's difficult to maintain weight loss
|
|
Skin care - The Examiner: Tips for skin care during cancer treatments
|
|
News Medical: Scientists discover a way to keep normal and cancer cells alive in the lab
|
|
Weill Cornell, Dr. Martin: Obinutuzumab (GA101), a New Generation Rituximab
|
|
CLL: Patient Power: Update on Kinase Inhibitors for CLL: Where Are We Now?
|
|
NPR: The War on Cancer turns 40
|
|
NPR: If it’s not a war on cancer, what is it?
|
|
CLL Topics: A Well Designed PCI-32765 Clinical Trial – just about to open
|
|
Dr. Len's Cancer Blog: We Can Find You A Space In The Mall Parking Lot, Ma'am, But Your CT Scan Will Have To Wait
|
|
Hodgkin - Cure: Brighter Horizons for Hodgkin Lymphoma Patients
|
|
Quackwatch: about Mercola
Respectful Insolence: http://bit.ly/sCKysu
|
|
NEJM: Selling Bone Marrow — Flynn v. Holder
|
|
Medscape: NCI's Varmus Changes the Metaphor: There Is No War on 'Cancer'
|
|
Optimizing Doctor Visits - PDF
Print on both sides of page to create a free
tri-fold brochure
|
|
|
|
Update to Factors Influencing Treatment Decisions - Regarding the Clinical Context
|
|
Aggressive B-Cell Lymphomas: A Review of New and Old Entities in the WHO Classification
|
|
AIDs-related: AIDsMEDs: Rituxan Prolongs HIV-Related Lymphoma Survival abstract
|
|
Allo SCT - Weill Cornell, Dr. Besien: ASH 2011: Major Advances in Allogeneic Stem Cell Transplant Offer New Hope For Patients with Hematologic Malignancies
|
|
Bone marrow biopsy - Medscape: Powered Device Hailed as Advance for Bone Marrow Biopsy
|
|
Childhood, general: Brit J Cancer: Survival from childhood cancer in northern England, 1968-2005.
|
|
CLL - ASH Education Book Dec 2011: Alemtuzumab Use In Relapsed and Refractory CLL/SLL
|
|
CLL- ASH Education Book Dec 2011: Nurture versus Nature: The Microenvironment in Chronic Lymphocytic Leukemia
|
|
CLL- ASH Education Book Dec 2011: Using the Biology of CLL to Choose Treatment
|
|
CLL- ASH Education Book Dec 2011: The Treatment of Relapsed Refractory CLL/SLL
|
|
CLL - Medscape, Dr. Cheson - ASH review: A Dickensian CLL Story
|
|
Diagnosis - Annals of Oncology: Expert second-opinion pathology review of lymphoma in the era of the WHO classification
|
|
DLBCL - Annals of Oncology: R-CHOEP-14 improves overall survival in young high-risk patients with DLBCL compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group
|
|
DLBCL - ASH Education Book 2011: Relapsed/Refractory Diffuse Large B-Cell
|
|
FL - Weill Cornell: ASH: What is the role of rituximab maintenance in patients with low tumor burden follicular lymphoma?
|
|
Georgia Health Sciences University: Scientists may be able to double efficacy of radiation therapy
|
|
Health - Medical News Today: Vitamin D For Cardiovascular Disease, Cancer, And Bone Fracture Protection? Evidence Is Lacking
|
|
HIV-related NHL - Cancer: Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated NHL
|
|
Hodgkin - ASH Education Book Dec 2011: Optimal Therapy of Advanced Hodgkin Lymphoma
|
|
Hodgkin - ASH Education Book Dec 2011: PET in the Management of Hodgkin Lymphoma
|
|
Hodgkin - Hematolgica: Second line salvage chemotherapy for transplant-eligible patients with Hodgkin lymphoma resistant to platinum-containing first-line salvage chemotherapy.
|
|
Hodgkin - Late Effects in the Era of Modern Therapy for Hodgkin Lymphoma
|
|
Hodgkin - PubMed: Management of children with high-risk Hodgkin lymphoma
|
|
Indolent - Medscape: Bendamustine Plus Rituximab Could Replace R-CHOP in Indolent Lymphomas
|
|
Indolent - Monthly Prescribing Reference: Bendamustine Plus Rituximab Provides Superior Progression-Free Survival Benefit to Patients With Relapsed Follicular, Indolent, or Mantle Cell Lymphomas vs. Fludarabine Plus Rituximab
|
|
Indolent - Oncology Times: Bendamustine + rituximab offers new standard first-line treatment option for lymphoma
|
|
JNCI: Autologous stem cell transplantation does not improve os in patients with follicular lymphoma (for newly dx'd pts)
|
|
MCL - Annals of Oncology: Autologous SCT in patients with MCL beyond 65 years of age: a study from the European Group
|
|
MCL - Cancer: Post-treatment (not interim) PET scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD
Also see http://1.usa.gov/trRECZ
|
|
MCL - Pub Med: Indolent mantle cell leukemia: a clinic-pathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis
|
|
MCL - Weill Cornell, Dr. Martin: Update from ASH 2011: New treatments for mantle cell lymphoma are on the horizon
|
|
MCL -Weill Cornell, Dr. Martin: Update from ASH 2011: Rituximab improves survival in patients with mantle cell lymphoma
|
|
PMBCL - PubMed: Randomized Clinical Trial to Assess the Efficacy of Radiotherapy in Primary Mediastinal Large B-Lymphoma.
|
|
Risk factors - CancerConnect: Still No Clear Evidence That Vitamin D Reduces Cancer Risk
|
|
T-Cell - AHS Education Book Dec 2011: Therapies for Peripheral T-Cell Lymphomas
|
|
T-cell - Cancer: Increasing incidence of enteropathy-associated T-cell lymphoma in US, 1973-2008.
|
|
T-Cell - Weill Cornell, Dr. Ruan: ASH 2011: New Treatment for T-Cell Lymphoma
|
|
Trends - Annals of Oncology: Diverging trends in incidence and mortality, and improved survival of NHL, in the Netherlands, 1989–2007
|
|
WM - Medpage Today: ASH: Fludarabine Works Best in Rare Lymphoma Trial (Waldenstrom's)
|
|
Zevalin - Medscape: Renewed Interest in Ibritumomab for NHL
|
|
Communications - Vanity Fair: Miss Manners And the Big C
|
|
Communications - USA Today: Online access to notes on patients gets mixed reaction
|
|
Depression - About Lymphoma: Depression in Blood Cancer Patients
|
|
EOL: Washington Post: When terminally ill patients ask how long they have, doctors find it hard to say
|
|
Health - Medscape: Vitamin D and Calcium Supplementation Reduces Fracture Risk
|
|
QOL - About Lymphoma: Holiday Gift Ideas for the Blood Cancer Patient
|
|
Neuropathy - Medical News Today: What Are The Signs And Symptoms Of Neuropathy?
|
|
Survivorship - Cancer Connect: You’ve Been Diagnosed with Cancer. Now What?
|
|
Survivorship - Cure: The Positive Power of Pets
|
|
Survivorship - Health.com: Study: Cancer Survivors Have Higher Risk of Melanoma
|
|
NYTimes: Computer Scientists Helping to Cure Cancer
|
|
News Medical: GE Healthcare, UCSF collaborate for cord blood project
|
|
CLL - Patient Power: Reflections and Major Developments in CLL from ASH 2011
|
|
NCCN: Asking questions about your cancer video
|
|
NCCN: Video Defining quality in cancer treatment video
|
|
CLL - Medscape: Massive Hunt Finds New Mutations That Drive CLL
|
|
FL - ASH: 2707 Eleven-Year Follow-up of Idiotype Vaccine and DA-EPOCH-Rituximab in Untreated MCL: Correlation with Immune response
|
|
Science Daily: Immune System in Leukemia Patients Repaired Following Chemotherapy
|
|
Preclinical - Prognosis E-news: Targeting tumor resistance mechanism
“All tumors develop resistance to anti-cancer drugs at least partly because their normal tumor suppressor proteins are kicked out of the nucleus.”
|
|
ASCO: Childhood cancer survivors' exposure to chemotherapy, radiation does not increase risk of birth defects in their children
|
|
END OF LIFE ISSUES: KevinMD.com: Saying no to your oncologist is sometimes the right thing to do
|
|
QOL - Medscape: First Study Ever of Long-Term Problems After HCT (free login required for access.)
“Hematopoietic cell transplant (HCT) offers the only potential for a cure for many hematological cancers; however, although the cancer may be cured by the transplant, the recipients remain at risk for psychological and chronic health conditions.”
|
|
Communications - Salon: How to talk to someone with cancer As the holidays approach, here's what your friends with cancer need to hear -- and never want you to say
|
|
CLL Topic Updates: CAL-101: Latest Update at ASH-2011
|
|
CLL Topics Update: PCI-32765: ASH2011 Update
|
|
Science-Real science vs. fake science:
How can you tell them apart?
|
|
Take as Directed: Pseudoscience Sunday
David Kroll Phd, friend and advisor to PAL pointed us to several interesting stories today.
|
|
Respectful Insolence: Dr. Burzynski and the cult of personality of the "brave maverick cancer doctor"
|
|
b-cell lymphoma - Medscape: Genetically Engineered T Cells Show Promise in B Cell Malignancies
|
|
CLL - Patient Power: Reflections and Major Developments in CLL from ASH 2011
Dr. Keatings explains why he is more excited than ever before about prospects for progress against CLL
|
|
CLL, relapsed - News Medical: Celgene announces interim results of REVLIMID study on CLL
|
|
CLL, treated with Fludarabine - News Medical: Treatment with leukemia (CLL) patients' own cells may prevent infections after chemotherapy
Question from the front lines: How long do the infused t-cells persist … is the protection from infection long lasting?
|
|
DLBCL, relapsed- Company Press release: Blinatumomab Produces Durable Responses in Patients with Relapsed DLBCL
|
|
Medscape Education: The Role of Hematopoietic Stem Cell Transplant in Follicular Lymphoma
Julie M. Vose, MD; Edward A. Faber, Jr., DO, MS
|
|
FL, Rituxan maintenance – ASH 2011 -
abstract generating high interest:
Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for (previously untreated) Low Tumor Burden Follicular Lymphoma
Results favors Retreat as Needed
Perspectives on: http://prn.to/vmK5nA | http://bit.ly/tBhxTM | http://bit.ly/vCABbb
|
|
FL - MPR: Fractionated 90Y-Ibritumomab Tiuxetan Effective as First-Line Therapy for Relapsed Follicular Lymphoma
|
|
FL , origins of - AACR: Study of Two Sisters Sheds Light on Lymphoma Evolution Also see
“this case gave scientists the unique opportunity to understand the genetic abnormalities that led to follicular lymphoma in both cases.”
|
|
GVHD, SCT - News Medical: Breakthroughs in hematopoietic cell transplantation to be presented at 53rd ASH meeting | See also
“study reveals that peripheral blood stem cell (PBSC) transplants from unrelated donors are associated with higher rates of chronic graft-versus-host-disease (GVHD) and have no survival advantage when compared to transplants using stem cells taken from the bone marrow.”
|
|
HL, first treated - Business Week: Study finds that Early Hodgkin Lymphoma Patients Can Skip Radiation Therapy
Also in NEJM
|
|
HL- HemOncToday: Six cycles of Besc produced 94% CR in Hodgkin’s lymphoma
|
|
HL, QOL - Psycho-Oncology: Posttraumatic stress disorder (PTSD) in survivors of Hodgkin's
lymphoma: prevalence of PTSD and partial PTSD compared with sibling controls
|
|
HL, refractory - Monthly Prescribing Reference: Patients with Relapsed/Refractory Hodgkin's Lymphoma Benefit from VTEPA Salvage Regimen
|
|
HL, relapsed - MPR: Resminostat Has Potential to Offer Substantial Clinical Benefit to Patients with Relapsed or Refractory Hodgkin's Lymphoma
|
|
HL, relapsed - MRP: Patients with Relapsed/Refractory Hodgkin's Lymphoma Benefit from VTEPA Regimen
|
|
HL, survival - Medscape: Long-Term Data Support Chemo Alone in Hodgkin's Lymphoma
|
|
MCL - MPR: R-BAC Effective In Patients With MCL Not Eligible for Intensive Chemotherapy or Autologous Transplant
|
|
MZL - ASH 2011 - Patients with Limited Stage Extranodal Marginal Zone Lymphoma Have Excellent Overall Survival Regardless of Choice of Therapy Type or Observation
|
|
RIT - Weill Cornell: ASH Conference: Perspective on Radioimmunotherapy as Part of First Line Therapy for Low Grade Lymphoma
|
|
SCT - ASH press release: New methods to improve recovery, survival strategies for patients undergoing transplantation
Also Medpage Today
|
|
T-cell lymphoma - Marketwatch: Phase II Study of ISTODAX(R) in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma: 46% of patients experienced disease control for at least 90 days
|
|
T-cell lymphoma - MPR: Oral Lenalidomide May Have Utility as Maintenance Therapy in Patients with Relapsed/Advanced Cutaneous T-Cell Lymphoma
|
|
Queen's University: New disinfection technique could revolutionize hospital room cleaning
|
|
ACS: annual report on progress against cancer
|
|
Disability Rights Legal Center: prescription drug assistance
|
|
Science Daily: Important Study Facts Often Missing In Media Reports About Medical Research
|
|
Cancer Research UK: The causes of cancer you can control
|
|
RemedyMD to Launch New Registries at 2011 ASH Annual Meeting Next-Generation Hematology Registries Enable Researchers to Harmonize Data From Diverse Sources and Recognize Undiscovered Patterns
|
|
diagnostics -AM J Hematology: The diagnostic value of biopsy of small peripheral lymph nodes in patients with suspected lymphoma
|
|
Dogs - MNdaily.com: New studies help extend the lives of dogs with cancer
|
|
HL - Blood: Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden 1973-2009
|
|
MCL - BJH: Rituximab plus HyperCVAD alternating with high dose cytarabine and Methotrexate for the initial treatment of patients with mantle cell lymphoma
|
|
Pixantrone - Boston.com: FDA plans April decision on Cell Therapeutics drug
|
|
Rituxan - Canada Newswire: Ontario funds life-saving treatment for patients with Follicular Lymphoma
|
|
WM - Cancer: Temporal and geographic variations of Waldenstrom's incidence
|
|
Medscape: ASH Preview: A Look at What’s Hot
|
|
ASH reports by ASH
Such as:
SCT - Studies Investigate New Methodologies to Improve Recovery and Survival Strategies for Patients Undergoing Hematopoietic Cell Transplantation
“Although PBSCs from related donors have demonstrated clinical benefits, our trial demonstrates that when these stem cells originate from unrelated donors they are not superior to bone marrow stem cells in terms of patient survival, and they increase the risk for chronic GVHD,” said lead author Claudio Anasetti, MD, Chair of the Department of Blood & Marrow Transplant at Moffitt Cancer Center in Tampa, Fla. “More effective strategies to prevent GVHD are needed to improve outcomes for all patients receiving unrelated donor transplants.”
|
|
Medscape: What's Hot at ASH
|
|
Scientific American: 2011 Nobel Laureate Ralph Steinman Explains Discovery of Cells Used for Cancer Treatment
|
|
The Scientist: Cancer Immunotherapy Pioneer Dies
|
|
MSKCC: Excellent videos on Stem Cell Transplants
About transplants (stem cell rescue)
Transplant innovations
|
|
Med News Today: Vitamin D benefits: hope or Hype?
|
|
WSJ: It’s Fine to Compensate Bone-Marrow Donors, Court Says
|
|
Free Thought Blogs: A look at the Burzynski clinic’s publications
|
|
Depression - About.com: Depression in Blood Cancer Patients
|
|
Cancernet: Cancer Rehabilitation
Cancer rehabilitation helps a person with cancer obtain the best physical, social, psychological, and work-related functioning during and after cancer treatment.
|
|
KevinMD: Cancer rehab dramatically improves cancer care
|
|
MSNBC - Cautionary tale: If you don’t hear back about a test result.
|
|
NCI Bulletin: Unexpected Complications: Treating Cancer during Pregnancy
|
|
Neurologica Blog: You too can be a Snake Oil Salesman
“Next come up with a marketing angle, some target demographic or condition you want to claim to help. Name your product something that suggests it will help with the identified condition. Then simply claim that your product “may” help, or that it will boost the immune system or support the body’s ability to heal from or deal with the condition.”
|
|
Sign On San Diego: Exercise gives cancer patients healthy boost
|
|
U Of Kentucky: Study shows hospice caregivers need routine care interventions
|
|
Coffee - NYTimes: Really? The Claim: Coffee Can Prevent Some Medications from Working
|
|
City Of Hope: New T cell therapy may rid lymphoma patients of cancer
|
|
Health Canal: Researchers Reveal Deletions and Mutations of the FBXO11 gene in B-Cells Contribute to the Development of the Most Common Type of Lymphoma
|
|
NYU: New potential therapeutic target identified for Diffuse Large B-Cell Lymphoma
|
|
Weil Cornell: Weill Cornell Researcher: A Personalized Approach for Targeting Cancer Tumors
|
|
Velcade - Biotech News: Takeda Pulls FDA Application for Expanded Use of Cancer Drug Velcade
|
|
Gastroenterology and Endoscopy News: Lymphoma in Children With IBD Remains ‘Very Rare’ Some Say Risk for Complications From Not Treating IBD Greater Than Risk for Lymphoma
|
|
Aggressive lymphoma - Medscape: Intense Chemo Best for Aggressive Lymphoma
|
|
AIDS/Lymphoma - About.com: The Link Between HIV/AIDS and Blood Cancers
|
|
DLBCL - Lancet Oncology: Prevention of CNS relapse in DLBCL
|
|
Follicular Grades - BJH: Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times
|
|
GvHD - News Medical: Immune system stimulant used as suppressor to treat chronic graft-versus-host disease
|
|
GvHD - The Oncology Report: Low-Dose IL-2 Safe, Effective in Active Chronic GVHD
|
|
GvHD - Medical News Today: New Approach To Graft-Versus-Host Disease Treatment Results In Sustained Improvement For Some Patients
|
|
MCL and Minimal Residual Disease (MRD) - Hematologica: Detection of MRD following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909
|
|
Stem cells - Advances in Hematology: Long-Term Outcome after Autologous Stem Cell Transplantation with Adequate Peripheral Blood Stem Cell Mobilization Using Plerixafor and G-CSF in Poor Mobilizer Lymphoma and Myeloma Patients
|
|
Rituxan - Annals of Hematology: Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy
|
|
Blood: The “kiss of death” for follicular lymphoma cells
|
|
Blood: MicroRNA profiles of t(14;18)–negative follicular lymphoma support a late germinal center B-cell phenotype
|
|
Blood: Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study
|
|
Cancer Research UK: Hope or false hope? (Article on Burzynski Clinic)
|
|
Classifications - Ash Education: The 2008 WHO classification of lymphomas: implications for clinical practice and translational research
|
|
DLBCL -Medical News Today: Aggressive Lymphoma - Intensive Chemotherapy Significantly Improves Survival And Recurrence In Younger Patients
|
|
Hodgkin’s - Annals of Oncology: Reduced incidence of second solid tumors in survivors of childhood Hodgkin's lymphoma treated without radiation therapy
|
|
MCL - Drugs: Current Status of Targeted Therapies
|
|
MCL - Hematalogica: Salvage treatment with Lenalidomide and Dexamethasone in relapsed/refractory mantle cell lymphoma
|
|
Side effects - Swiss Med Weekly: Prevalence of symptoms, with a focus on fatigue, and changes of symptoms in outpatients receiving cancer chemotherapy
|
|
Zevalin - News Medical: Zevalin Treatment for NHL becomes simpler with removal of bioscan requirement
|
|
BBC - Cancer survival: Macmillan hails major improvement in surviving different cancers
|
|
Cure: Lifting the Fog (article on chemo brain)
|
|
KevinMD: Grief takes no holidays
|
|
KevinMD: Living with chronic illness during the holiday season
|
|
MDA: Tips for getting through the holidays
|
|
Medical News Today: 'Healthy For The Holidays' 10 Tips For Cancer Survivors
|
|
MSNBC: A cancer survivor's thanks
|
|
CLL Topic Updates: “Incurable, Invisible and Inconclusive”
|
|
Medical News Today: Neurological Impairment Associated With Chemotherapy
|
|
Terra Sigillata: FDA Withdraws Avastin Approval in Breast Cancer - important discussion of endpoints that may also apply to lymphoma studies
|
|
Anaplastic large cell lymphoma - Clinical Oncology News: Study Shows Brentuximab Also Effective in Kids
|
|
Burkitt - AM J Hematol: Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia
|
|
CLL - Modern Pathology: Therapy-related myeloid neoplasms following FCR in patients with CLL/SLL
|
|
Cord blood - Medical News Today: Hemacord - First Cord Blood Product Approved By FDA
|
|
Elderly - BJH: Analysis of very elderly (=80 years) with NHL: impact of functional status and co-morbidities on outcome
|
|
Follicular - Czuczman - Oncology Times: Asymptomatic Follicular Lymphoma: Is ‘Watch and Wait’ Now Passé with the Advent of Rituximab? (Perspective)
|
|
Immunization - Blood: Rituximab blocks protective serological response to influenza A(H1N1) 2009 vaccination in lymphoma patients during or within six months after treatment.
|
|
Pain - Annals Onc: Management of cancer pain: ESMO Clinical Practice Guidelines
|
|
MCL- Bone Marrow Transplant: Potential prolongation of PFS in mantle cell lymphoma after R-HyperCVAD: auto-SCT consolidation or rituximab maintenance.
|
|
T-cell - J Dermatology: Radiation therapy in the management of unilesional primary cutaneous T-cell lymphomas.
|
|
T cell/histiocyte-rich large B-cell lymphoma - J Hematology: an update on its biology and classification
|
|
Cancer Research UK: Expert Opinion: Professor Fran Balkwill - Discussion on the tumor microenvironment
|
|
Environmental Health News: Research links pesticides - The results strengthen an argument for an environmental link to increased risk for human NHL that is linked to higher levels of organochlorine pollutants.
|
|
EORTC 2011: Genomic profiling for personalized medicine
|
|
USA Today: More targeted treatments key to progress in war on cancer
|
|
USC: Researchers confirm new cancer-causing virus Common cytomegalovirus has central role in salivary gland cancer and possibly other malignancies (MALT)
|
|
European J Cancer Care: Working while receiving chemotherapy: a survey of patients' experiences
|
|
Healthy Survivorship: Resource on Life after Treatment
|
|
ASCO: Cancer Survivorship - Free Booklet
“Your life may be forever changed by cancer. Some people talk about appreciating life more and gaining a greater acceptance of self after their cancer treatment ends. Others become anxious about their health and unsure of how to cope with life’s demands. In some ways, moving from the period of “active treatment” into survivorship is one of the most complex aspects of the cancer experience because it is different for every person."
|
|
Huffington Post: Things to Never Do When Someone Tells You They Have Cancer
|
|
KevinMD: Useful tips when looking for a new doctor
|
|
KSDK.com: Does a family history of NHL put me at greater risk?
|
|
Medscape: Neurofeedback Improves 'Chemo Brain' in Cancer Patients
|
|
Medscape: Consensus Panel From the 2011 Pan Pacific Lymphoma Conference – requires registration and login
|
|
Medscape: Mindfulness Training Can Improve Symptoms, Mood After HSCT
|
|
NYT: THE ETHICIST-The Topic of Cancer – “My boyfriend of one year has been given a diagnosis of terminal cancer”
|
|
Oncology Times - VIEW FROM THE OTHER SIDE OF THE STETHOSCOPE: Managing Uncertainty (Part 2): Serenity
|
|
Oncology Times: A certain uncertainty
Harpham, Wendy S. MD - Marveling at my remission, Jane asks, Wendy, don't you wish you knew if you were cured? NO! I respond immediately. No? My friend is shocked. Actually my answer makes perfect sense, since there are only two ways to know if my cancer is gone for good. If the lymphoma recurs, I'll know I wasn't cured. If my cancer is in remission when I die of something else, I'll know I was.
|
|
PsychCentral: 8 Tips to Console a Grieving Friend
|
|
Reuters: Cancer doctors score low on pain management: study
|
|
Burkitts: Medical News Today: Burkitt's Lymphoma Generally Rare But Common In Children In Equatorial Africa
|
|
DLBCL - JCO: Study Gives Slight Edge to R-DHAP for B-Cell Lymphoma Subtype- From Journal of Clinical Oncology
|
|
DLBCL - J Cancer Research, Clinical Onc: How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma, addition of maintenance rituximab or observation: multicenter experience
|
|
DLBCL- Leuk Lymphoma: Pilot trial of yttrium-90 ((90)Y)-ibritumomab tiuxetan (Zevalin) consolidation following R-CHOP chemotherapy in patients with limited-stage, bulky DLBCL
|
|
Hodgkin's - Blood: Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome
|
|
Hodgkin's - JCO: More Is Not Necessarily Better When Treating Hodgkin's Lymphoma, Joseph M. Connors
|
|
Hodgkin's- JCO: Long-Term Follow-Up Analysis of ABVD versus Stanford V versus MOPP/EBV/CAD in Newly Diagnosed Advanced-Stage Hodgkin's
|
|
Hodgkins- JCO: Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy
|
|
Follicular - ASH 2011: CHOP + Rituxan versus
CHOP - Bexxar
|
|
MCL - Blood: Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma
|
|
T-Cell - JCO: Use of Zidovudine and Interferon Alfa With Chemotherapy Improves Survival in Both Acute and Lymphoma Subtypes of Adult T-Cell Leukemia/Lymphoma
|
|
USC: USC microbiologists identify two molecules that kill lymphoma cells in mice.
|
|
Live Science: The Truth About Herbal Supplements for Stress
|
|
Medical News Today: Vaccine Could Prevent Mononucleosis And Cancers Linked To Epstein-Barr Virus
|
|
Medical Press: 'If Hamlet give the first or second hit': The development of Burkitt's lymphoma
|
|
MedPage Today: AACR-FCPR: A Decade of Progress in Cancer Prevention
|
|
BBC: Skin transformed for cancer fight
|
|
BBC: Light 'promising' in cancer fight
|
|
Blood: Editorial: Lymphoma spread? Target CD47-SIRPα! http://bit.ly/uFJJyg abstract
|
|
LA TIMES: Promising cancer therapy is based on epigenetics
John's Hopkins report
|
|
Exercise - Medscape: Treatment for Cancer Patients Should Include It
|
|
Hot flashes - Oncology Times: How Do I Treat it in Cancer Survivors?
|
|
Immunity - Nobelprize.org: The Body's Secret Army
|
|
Cure: At Diagnosis: Medical Decisions
|
|
Cancer Legal Resource Ctr: Personal Records file - a good idea for all to have, even when we plan on being here a long time
|
|
Cure: Six Side Effects You May Not Expect During Cancer
|
|
Labtests Online: understanding lab tests
|
|
MSNBC: If you're sitting down, you may be increasing your cancer risk
|
|
Science-Based Medicine: Alpha Brain – What’s Wrong with the Supplement Industry
|
|
MSNBC: Is a doctor reading your X-rays? Maybe not Outsourcing radiology can lead to confusion, missed diagnoses and death
|
|
KevinMD: 5 tips to evaluate medical websites
|
|
Clinical Oncology News: Heightened Risk for Lymphomas Found in Celiac Patients Six-fold increased risk should be taken seriously, expert advises
|
|
Medpage: More Links for Obesity, Lymphoma
|
|
Healthnews: Another day, another slew of misleading media messages on observational study http://bit.ly/u4kG3w
|
|
BoingBoing: Three common mistakes in medical journalism
|
|
Respectful Insolence: Oh, no, antiperspirants cause breast cancer! Well, not really...
|
|
Weill Cornell Medical Center: Lymphoma in the News: Cigarette Smoking Associated with Hodgkin Lymphoma
|
|
Mutations of Mortality: CLL patients refractory to FCR and alemtuzumab (Campath)
|
|
Discover Magazine: From unknown cancer gene to potential cancer drug
|
|
Dana Farber: Research makes it possible to predict how cancers will respond to chemo
|
|
Cell: The Eph-Receptor A7 Is a Soluble Tumor Suppressor for Follicular Lymphoma
|
|
JAMA: Regimen may improve cell transplantation outcomes for older adults with blood, bone marrow cancers http://bit.ly/vDTSGc
|
|
Medical News Today: Genomic Data Leads To New Treatment For Follicular Lymphoma
|
|
Medical Press: Biomarker detects graft-versus-host-disease in cancer patients after bone marrow transplant http://bit.ly/nK6cxO
|
|
CLL Topics Updates: (Almost) Everything You Need to Know About CLL
|
|
CLL - Blood: Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia
|
|
DLBCL - Weill Cornell: PYRAMID: A Personalized Medicine Study in Lymphoma
|
|
Follicular - JCNI: Rituximab Maintenance for the treatment of patients with follicular lymphoma: Systemic Review and Meta-analysis of Randomized Trials
|
|
Hodgkins - Blood: Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group
|
|
Hodgkin's - NEJM correspondence: ABVD versus BEACOPP for Hodgkin's Lymphoma
|
|
Indolent lymphoma - J Clinical Onc: Phase II/III Study of R-CHOP-21 Versus R-CHOP-14 for Untreated Indolent B-Cell NHL: JCOG 0203 Trial
|
|
Infection - Medscape: Protect Outpatient Oncology Patients From Infections
|
|
Lymphoma - AJ Hematology: A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin-s and non-Hodgkin's lymphoma
|
|
Pediatric Blood and Cancer: Gonadal function and parenthood 20 years after treatment for childhood lymphoma: A cross-sectional study
|
|
US News: Finding Hope in Cancer
|
|
Huffington Post: Are You a Cancer Survivor With "Chemo Brain?" You May Qualify for Accommodations at Work
|
|
NCCN: Paying for cancer treatment
|
|
NCCN: Video: Help with depression during cancer treatment
|
|
NEJM publishes 'The 2010 Dietary Guidelines -- The Best Recipe for Health?
|
|
MSNBC: Cancer patients find help, comfort with 'navigator'
|
|
Cancer Research UK: What should you eat while you’re being treated for cancer?
|
|
PRnewswire: Cleaning for Cancer Launches Series of Surveys to Uncover Unmet Needs in Supportive Services for Cancer Patients
|
|
Psych Central: Using Mindfulness To Alter Your Mood
|
|
Science Based Medicine: Constipation Myths and Facts
|
|
Medical News Today: Planning For Life Beyond A Cancer Diagnosis
|
|
WSJ: Informed Patient: A New Push to Prevent Infections in Cancer Patients
|
|
AOL Healthy Living: '50/50' And Cancer: Can Humor Help Us Heal?
|
|
HemOnc Today: Nutrition and cancer: No magic bullet, but an important aspect of treatment, prevention
|
|
Clinical Oncology: Management of Oral Mucositis in Cancer Patients
|
|
Respectful Insolence: Alternative medicine: The illusion of control
|
|
Mutations of Mortality: CLL - A randomized trial of FA v F.
|
|
Cancer Causes and Control: Sunlight exposure, vitamin D, and risk of non-Hodgkin lymphoma in the Nursesʼ Health Study Sunlight exposure, vitamin D, and risk of NHL in the Nursesʼ Health Study
|
|
CLL TOPIC UPDATES: SOS: Save Our Stem Cells
|
|
KevinMD: Physicians should embrace patient engagement
|
|
Modern Medicine: Denser rituximab no extra help in B-cell lymphoma
|
|
BJCP: Model-based design of rituximab dosage optimisation in follicular lymphoma
|
|
CLL: Mutations of Mortality: CD38 as a Marker in CLL
|
|
LLS: Archived event and transcript available for September 14, 2011 - NHL: Understanding Your Treatment Options
|
|
Mediterr J Hematol Infect Dis. 2010: Hepatitis C Virus Infection and Lymphoma (subtypes treated with antiviral therapy)
|
|
PsychCentral:
10 things NOT to say to a depressed person
10 Things You SHOULD Say
|
|
J Clin Onc: Post-Traumatic Stress Symptoms in Long-Term NHL Survivors: Does Time Heal?
|
|
NYTIMES: A Cancer patient finds little solace in cancer statistics
|
|
NYTIMES: Life as a cancer outlier
|
|
Dr. Wendy Harpham Easy to Forgive
|
|
KevinMD.com: What does explanation of benefits mean?
|
|
MSNBC: Many CA survivors dx'd with Post Traumatic Stress Disorder
|
|
Patient Power: An Expert's Perspective: The Changing Landscape of CLL http://bit.ly/poqXwz
|
|
Follicular - Univ. Rochester: Scientists Look to Immune System to Handle Follicular Lymphoma
|
|
Follicular - PubMed: Early steps of follicular lymphoma pathogenesis.
|
|
Medscape: Pitfalls in Lymphoma Pathology
|
|
MZL - Hematology 2008: Marginal Zone Lymphomas: Management of Nodal, Splenic, and MALT NHL http://bit.ly/qp83Hj
|
|
Hodgkin's -JCO: BEACOPP regimens in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis
http://1.usa.gov/rfHy0c
|
|
Hodgkin's - JCO: ABVD Versus Stanford V Versus MOPP/EBV/CAD in Patients With Newly Diagnosed Advanced- Stage Hodgkin's Lymphoma: http://1.usa.gov/oV9X2S
|
|
T-cell lymphoma - Am J Hem: Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management. http://1.usa.gov/nakfo0
|
|
Ann Arbor.com: Cancer researchers drive progress forward, need adequate funding to sustain momentum
|
|
Health News Review Blog: Health care conflict of interest roundup - 3 newsworthy items
|
|
Mutations of Mortality: How to reduce the cost of cancer drugs
|
|
KevinMD: Three major cognitive errors physicians make
|
|
In the Pipeline: Too Many Cancer Drugs? Too Few? About Right?
|
|
CLL - Medical News Today: Chronic Lymphocytic Leukemia Patients' Lives Extended By New Combination Treatment
|
|
Hodgkins: Lymphocyte-Depleted Classical Hodgkin's Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group
|
|
Hodgkins - ASCO: Meta-Analysis of the Association between Smoking and Incidence of Hodgkin's Lymphoma
|
|
Hodgkins: Oncology Stat: PET Scans Key to Less Radiation for Hodgkin's Lymphoma? Also: http://bit.ly/nKlJCT
|
|
MCL – Cancer, 2010: Durable Responses with the Metronomic (low daily dose) RT-PEPC in Elderly Patients with Recurrent Mantle Cell Lymphoma
|
|
Rituxan - JCO, 2010: Hypogammaglobulinemia - the impact of rituximab maintenance on immune competence
|
|
Neuropathic Pain - Med News Today: (company press release) KRN5500 Demonstrated Significant Decrease In The Intensity Of Neuropathic Pain In Patients With Cancer
|
|
Science Based Medicine: Vitamins and Mortality
|
|
Archives of Internal Medicine: LESS IS MORE Dietary Supplements and Mortality Rate in Older Women The Iowa Women's Health Study
|
|
Oncology Times: Institute of Medicine Workshop Stresses Benefits of Patient-Centered Cancer Treatment Planning
|
|
NY Times: When a doctor becomes a patient
|
|
U Maryland Med Ctr: Sleep Hygiene: Helpful Hints to Help You Sleep
|
|
MailOnline (UK) The sisters who were both diagnosed with cancer within 48 hours of each other... but have now beaten the disease
|
|
NEWS: In Sickness and in Health — Does a Cancer Diagnosis Up Divorce Risk?
|
|
NY Times: Caregiving’s Hidden Benefits
|
|
Science Daily: Cochrane Collaboration Urges Free Access to ALL Data from ALL Clinical Trials
|
|
Scientific American: Molecules to Medicine: Clinical trials for Beginners
|
|
Science Based Medicine: The wrong way to open up clinical trials.
|
|
CLL - In the Pipeline: Interview with Derek Lowe with Paul Howard of the Manhattan Institute on the results of that immunotherapy leukemia (CLL) trial (and on some broader topics around the current state of drug discovery).
|
|
NPR transcript and audio: Shortages Lead Doctors To Ration Critical Drugs
|
|
Ted- Ideas worth Spreading: Battling bad science
|
|
Burkitts: Annals of Oncology: Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis
|
|
CLL: PubMed: Single-agent rituximab in treatment-refractory or poor prognosis patients
|
|
Cutaneous T Cell - Brit J Dermatology: Low-Dose Total Skin Electron Beam Therapy as a Debulking Agent: An open-label prospective phase II study
|
|
DLBCL - Weill Cornell: Update on DLBCL
|
|
Hodgkins: Cohort study evaluates risk of secondary malignancy following chemotherapy treatment for Hodgkin's lymphoma - Highlights the need for regular follow-up care.
|
|
Follicular - NCCN: Guidelines Emphasize Patient Preference as Key to Selection of Maintenance Therapy in Follicular Lymphoma
|
|
Follicular - Oncology Times: Is ‘Watch and Wait’ Still a Reasonable Strategy for Patients with Asymptomatic, Low-Tumor-Burden Advanced-Stage Disease?
|
|
Neutropenia - Br J Cancer. 2009 September: Prevention of febrile neutropenia: use of prophylactic antibiotics
|
|
Neutropenia - Support Care Cancer. 2010 May: Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
|
|
Velcade - Biotech News: Takeda Pulls FDA Application for Expanded Use of Cancer Drug Velcade
|
|
Dr. Len's Cancer Blog: Steve Jobs
|
|
DB's Medical Rants: The proper amount of medical care
|
|
NY Times: How to Steer Toward the Path of Least Treatment (general)
|
|
Science Daily: Older Cancer Survivor Population to Increase Substantially
|
|
Respectful Insolence: Steve Jobs, neuroendocrine tumors, and alternative medicine
|
|
Skeptoid- Critical Analysis of Pop Phenomenon: Boost Your Immune System (or Not) -Is "boosting your immune system" for real? Is that possible, and can you really buy it in a bottle?
|
|
Skeptoid- Critical Analysis of Pop Phenomenon: A Lesson in Treating Illness
|
|
Quackwatch: Why You Should Stay Away from Insulin Potentiation Therapy
|
|
Medical News Today: Cancer Patients Can Benefit From Early Detection of Heart Damage Using Echocardiography
|
|
Cure Today: Tell what you're taking (supplements)
|
|
Quackwatch: Questionable Cancer Therapies - A place to look up alternative therapies that may be suggested by well meaning friends/family or stumbled upon on the web
|
|
Rude Introduction to Epidemiology: Every other day, there is report that x, y, or even z causes cancer
|
|
Cure: Managing treatment related diarrhea
|
|
USA.gov - Pre-existing condition insurance plans
|
|
Flu shots? University Of Michigan: What you need to know
|
|
MSNBC: Cancer Kiss-off: Getting dumped after diagnosis
|
"I'm Gonna Love You Through It" - Martina McBride
|
|
|
MD Anderson: Tips for Coping Through a Long Hospital Stay
|
|
KevinMD: A day in the life of a hospice professional
|
|
NY Times: Navigating the Net Wisely in a Health Crisis
|
|
NeedyMeds.org: Pharmaceutical Patient Assistance programs for lymphoma medications
|
|
NeedyMeds.org and the Lymphoma Research Foundation announce a new source of information on Lymphoma medications and the financial help available for those living with the disease
|
|
CNN: Doctors, listen to your patients - Some thoughts from Abraham Verghese MD, author of a wonderful novel- "Cutting for Stone."
|
|
Live Science: Health Value of Omega 3 Fatty Acids questioned
|
|
Science Daily: Pre-Clinical Research may Prove Promising for the Treatment of Blood Cancer
|
|
Walter and Eliza Hall Institute: Discovery helps explain why chemo causes drop in platelet numbers
|
|
BBC: Cancer cost 'crisis' warning from oncologists
|
|
Weill-Cornell-lymphoma: Oral Chemotherapy Bill Signed into Law in New York State
|
|
NCCN - Video: Talking to patients with a new cancer diagnosis
|
|
Patient Power: Personalized Oncology- Where are we now?
|
|
University of Leicester: Public ignorant about key messages concerning diet and cancer
|
|
Neurologic blog: Well it worked for me
|
|
Mail ONline: Don't give out cancer drugs if it's just to extend life?
|
|
KevinMD: Learning the hard way that there is an art to medicine
|
|
Pharmagossip: Use of cancer drugs questioned - Health News - NHS Choices
|
|
Pharmagossip: NICE blames pharma R&D model for spiraling cancer drug costs
|
|
Science Daily: Drug Companies Must Report Clinical Trial Results, Even When They Won't Lead to a Product, Experts Urge
|
|
UCDAVIS: Drug companies must report clinical trial results, even when they won't lead to a product
|
|
Respectful Insolence: Abraham Cherrix still battling Hodgkin's Five Years Later
|
|
Mother risk: Cancer in Pregnancy: Non-Hodgkin's Lymphoma and Pregnancy
|
|
Medscape: Love the Caregiver as Much as the Patient
|
|
ASCO Expert Corner: The Role of a Tumor Board in Cancer Treatment
|
|
Medscape: Chemotherapy Safe to Give During Pregnancy
|
|
NCCN: Financial Assistance for People with cancer
|
|
The Spokesman Review: Diagnosed with lymphoma, photographer turned lens on himself
|
|
Lymphomation: Tools and Tips from Lymphomation
|
|
ASCO: Anti-nausea drugs: Oncology Clinical Practice Guideline Update
|
|
MALT - MedWire: ‘Excellent’ outcomes after H. pylori eradication for gastric MALT
|
|
Pregnancy - ECCO: Chemo during pregnancy does NOT seem to cause developmental problems in children
|
|
NY Presby-Weill Cornell: Two Important Studies Take Us One Step Closer to Personalized Lymphoma Therapy
|
|
Blood: BeEAM (Be = Bendamustine) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients
|
|
Cancer Care: Update on Lymphoma from the 2011 ASCO Annual Meeting
|
|
CLL Topic Updates: Bendamustine and Rituxan- relapsed/refractory CLL Bendamustine
|
|
PubMed: Utility of PET scans in mantle cell lymphoma
|
|
PubMed: Physical activity for patients undergoing an allogeneic hematopoietic stem cell transplantation: benefits of a moderate exercise intervention.
|
|
DLBCL- PubMed: Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory DLBCL
|
|
University of Michigan Health System: 10 ways to make better decisions about cancer care -- how to improve communication about risk
|
|
Cure Magazine: Managing Cancer-Related Diarrhea
|
|
KevinMD: How to ask for help when chronic pain or illness strikes
|
|
The Oncologist: Cancer Disparities in the Context of Medicaid Insurance
|
|
WSJ: Getting Lab Results Directly to Patients
|
|
On Healthy Survivorship: Give Food or Money? Discusses an interesting financial aid site
|
|
Dr. Len's Cancer Blog: We Can Treat The Cancer, But Can We Care For The Survivors?
|
|
Rockefeller University Press: Tumor environment keeps tumor-fighting T cells away
|
|
John's Hopkins: Protein 'switches' could turn cancer cells into tiny chemotherapy factories
|
|
Burkitt - Blood: Adult Burkitt leukemia and lymphoma
|
|
CNSL - The Lancet: Prevention of CNS relapse in diffuse large B-cell lymphoma
|
|
CLL - NCCN: Advances in CLL Therapy Offer Prolonged Survival; Toxicities Continue to Plague Elderly Patients
|
|
DLBCL - The Lancet: CHOP-like therapy with or without rituximab in young patients with good-prognosis DLBCL: 6-year results - (MInT) Group
|
|
DLBCL - BJH: Biweekly R-COMP-14 in elderly patients with poor-risk DLBCL and moderate to high ‘life threat’ impact cardiopathy
|
|
DLBCL - Blood: How I treat patients with
|
|
DLBCL - CA: Improving Outcomes
|
|
HODGKIN'S--J Clin Oncol: Lymphocyte-Depleted Classical Hodgkin's Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group.
|
|
HODGKIN'S-- Blood: Phase II study of PVAG in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma
|
|
HODGKINS & ALCL - FDA Approves Brentuximab Vedotin for Hodgkin and Anaplastic Large-Cell Lymphoma
|
|
Indolent lymphoma - Ntl Elec Library for Med: Phase II/III study of R-CHOP-21 vs. R-CHOP-14
|
|
MALT - MedWire:
‘Excellent’ outcomes after H. pylori eradication for gastric MALT
|
|
MALT - Alimentary Pharmacology and Therapeutics: Common misconceptions in the management of H. pylori-associated gastric MALT
|
|
Marginal Zone - Annals of Hematology: Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy
|
|
NCI: Scientists find approach to enhance and prolong immune attack against tumor cells
|
|
PTCL - Leukemia: Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect
|
|
Science Daily: Costly Blood Clots More Common Than Expected Among Cancer Patients
|
|
MSNBC: Many stem cell 'therapies' offer heartbreak
|
|
Respectful Insolence: Quacks do better than medicine!
|
|
Medical News Today: When To Administer Food And Drugs Together
|
|
Examiner.com: Blood Cancer Research Is The Super Highway To Curing Cancer
|
|
Cure Magazine: Açaí Berry’s Effect on Cancer?
|
|
Cure Magazine: Supplement Research in Cancer Lacking
|
|
Cure Magazine: Supplements During Cancer: Help or Hype?
|
|
Scientific American: Drugs from the Crucible of Nature
|
|
Cornell-lymphoma.com: Understanding the Importance of Clinical Trials - Wickerham, Mitchell, Leonard webcast
|
|
Science Daily: Newest Cancer Therapies Multi-Task to Eliminate Tumors
|
|
Cornell-lymphoma.com: Understanding the Importance of Clinical Trials
|
|
Clinical trial: Phase 2 Safety and Efficacy Study of CAL-101 (GS-1101) in Relapsed or Refractory Hodgkin Lymphoma
|
|
Science Daily: Public May Not Be Aware of Important Uncertainties About Drug Benefits and Harms
|
|
KevinMD: Essential tips for medical journalists
|
|
Science Based Medicine: Boost Your Immune System -- What does that mean?
|
|
Terry Hamblin: Is There a Malignant Stem Cell at the Root of CLL?
|
|
Science Quest: Can scientists win the war against cancer?
|
|
Respectful Insolence: Chemotherapy doesn’t work?
|
|
NCCN: How to Maintain Bone health
|
|
Medpage Today: Zofran - Anti-Nausea Drug - Linked to Arrhythmias (irregular heartbeat)
|
|
The Oncologist: Battling the Hematological Malignancies: The 200 Years' War
|
|
Archives of Pathology: Detecting Minimal Residual Disease in Hematologic Disorders
|
|
Market Watch: NCCN Guidelines Emphasize Patient Preference as Key to Selection of Maintenance Therapy in Follicular Lymphoma
|
|
Nature Leukemia: Allo transplant following a reduced-intensity Conditioning regimen in relapsed/refractory peripheral T-cell lymphomas
|
|
PAL: Learn about different types of lymphoma treatments
|
|
Blood: Ofatumumab is active in patients with Fludarabine-refractory CLL irrespective of prior Rituxan
|
|
NY Times: An Immune System Trained to Kill Cancer (CLL)
|
|
PubMed: Initial treatment with R-CHOP vs R-miniCEOP for elderly pts with diffuse large b-cell lymphoma
|
|
Medical News Today: Chemotherapy-Induced Neuropathic Pain; The Pain Of Surviving Cancer
|
|
PubMed: Pathology review of outside material: when does it help and when can it hurt?
|
|
CBS NEWS: A bit of lymphoma awareness info
|
|
Cancer Legal Resource Center: Legal Issues in the work place for women with cancer
Part 1 and Part 2
|
|
ESMO: A guide for patients with advanced cancer: Getting the most out of your oncologist
|
|
Medical News Today: Cancer Prevention Tips By Age
|
|
ABC News: NHL Kills Nearly 20,000 a Year -- If you have symptoms of depression, talk with your doctor
|
|
Medical News Today: Why Are Patients Reluctant To Reveal Depressive Symptoms To Their Family Doctor?
|
|
Medical news today: Fish Oil Supplements Can Undermine Chemotherapy effectiveness
|
|
LA Times: U.S. requires health insurers to publicly justify big rate hikes
|
|
Chicago Blood Cancer Foundation: First International Lymphoma Awareness Forum (radio broadcast) 9/12/11
|
|
Mutations of mortality: Why experts do better (Commentary on CLL Study posted earlier)
|
|
CLL Topic Updates: Does Your Doctor’s Expertise Matter?
|
|
Science Based Medicine: Commentary on BMJ article on Comparative Drug Research
|
|
Medical News Today: New Drugs Should Be Compared To Current Treatments Before Approval
|
|
Science News: Harmless Soil-Dwelling Bacteria Successfully Kill Cancer
|
|
BBC: Cancer drug resistance clue found-may be possible to extend the usefulness of cancer drugs
|
|
Globes Israeli Business Arena: Curetech lymphoma trial succeeds (phase 2, diffuse)
|
|
Nature: A phase II trial of the oral mTOR inhibitor Everolimus in relapsed aggressive lymphoma
|
|
Current Hematologic Malignancy Reports:
PET in T-Cell Lymphoma
|
|
European J Nuclear Med and Molecular Imaging: Early interim 18F-FDG PET in Hodgkin’s lymphoma: evaluation on 304 patients
|
|
JCO: Is There a Role for Bortezomib Combinations in the Management of Patients With Follicular Lymphoma? (Velcade)
|
|
Cornell-lymphoma.com: Upcoming Cancer Care Workshop: Update on Diffuse Large B-cell Lymphoma
|
|
News Medical: Pulitzer photojournalist with lymphoma films his experiences
|
|
Cancer: Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer
|
|
Pubmed: Sexual well-being among survivors of NHL
|
|
NY Times: Need Sleep? Stay Out of the Hospital
|
|
NCCN: Taking Charge of Follow Up Care
|
|
CaringBridge: If you haven't seen it, Caringbridge is a great way to keep in touch with family and friends during treatment
|
|
NY Times: When Doctors Become Patients
|
|
PAL updates:
|
Lymphoma Studies sponsored by CALGB cooperative group - now called the ALLIANCE
|
|
Cancer-related fatigue - a patient's perspective
|
|
Understanding the lymphatic system
|
|
Treatment support
|
|
Advancing the Informed and Routine Consideration of Clinical Trials
|
|
Treatment-Related Questions for Your Doctor
|
|
|
|
Words of encouragement for lymphoma patients
|
|
Watchful waiting for indolent lymphomas
|
|
Exercise - just "do it!"
|
|
|
|
|
|
|
|
PET scan - clinical use
"very little is certain and agreed upon."
|
|
|
NPR Radio interview: Delivering Viruses To Try And Kill Tumors
|
|
Cure:
New solutions to boost enrollment are breaking barriers that keep cancer patients out of clinical trials
|
|
Cure:
Abysmal' participation in cancer trials
|
|
Press release:
Phase 1b/2 Study of TRU-016 in Combination with Rituxan and Bendamustine in Relapsed - Indolent Lymphoma
|
|
NY Times:
Ingredients of Shady Origins, Posing as Supplements
|
|
Cancer.gov:
Investigating Nature's Mysteries for Drug development
|
|
Terra Sigillata:
The best objective herbal medicine information for less than $100 per year
|
|
Oncology Times:
Old vs. New Drug Combinations for Optimal Frontline Therapy for Untreated, Symptomatic CLL
|
|
KevinMD:
The trouble with Dr. Google
|
|
Oncology Times:
MUSINGS OF A CANCER DOCTOR:
The Cost of Drugs
|
|
NY Times:
Cancer Fighting Words
|
|
John W. Sweetenham:
The Role of Radiolabeled Monoclonal Antibodies as Part of the Conditioning Regimen for Stem Cell Transplants (autografts)
|
|
JNCI:
Should Antioxidants Be Avoided During Chemo and Radiation Therapy?
|
|
Pubmed - Leuk Lymphoma:
The Impact of High- Dose Chemotherapy, Autologous Stem Cell Transplantation and Conventional Chemotherapy on Quality of life of Long Term Survivors with Follicular Lymphoma.
|
|
Systematic Review and Meta-Analysis:
Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma
|
|
Pubmed - Leuk Lymphoma:
Improved outcome for very elderly patients with diffuse large B-cell lymphoma in the immunochemotherapy era
|
|
Pub Med:
Maintenance rituximab following chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network.
|
|
Annals of Hematology:
Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of NHL patients with cardiac risk factors
|
|
Blood:
Adding Rituxan to chemo alone as first-line therapy improves over-all survival in elderly patients with Mantle Cell lymphoma
|
|
Blood:
Treating limited stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome
|
|
Pharmalive:
Study Demonstrates Effectiveness of Extracorporeal Photopheresis in Early-Stage Cutaneous T-Cell Lymphoma
|
|
Thomas Jefferson Hospital:
New half-match bone marrow transplant procedure yields promising outcomes http://bit.ly/pG2zuL
|
|
ASH press release:
First injection of cultured red blood cells in human donor
|
|
Cancer:
Disease-specific expertise and survival: Lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
|
|
NCI:
Cancer Research Now: Natural Products Branch (video)
|
|
Dr Farnsworth:
The Science of Herbs (video)
|
|
PBS NewsHour Video:
Drug Shortages Force Tough Choices for Patients, Doctors
|
|
Medscape:
New Way to Predict the Right Drug for the Right Patient (video)
|
|
MSNBC:
Roundup kills weeds, but does it harm us?
|
|
Cancerandcareers:
Cancer and work
|
|
Cancerandcareers:
Cancer as Inspiration for Career Changes
|
|
ACS:
How to find a support group
|
|
Cancer and Careers:
Resources for Men working with cancer
|
|
MSNBC:
Single and seriously ill - care circles fill in for family
|
|
MSNBC:
Does Gov. Perry's use of an unproven stem cell 'treatment' send wrong message?
|
|
MSNBC:
High price tag for treatment with new cancer drug for anaplastic large cell lymphoma
|
|
The Week:
The 'amazing' cancer treatment that costs $100,000 A slew of new drugs are powerfully effective at fighting cancer.
|
|
NY Times:
An Insurance Maze for U.S. Doctors
|
|
ACS: Earthquakes, hurricanes, floods, oh my--
Coping With Cancer After a Natural Disaster
|
|
KevinMD.Com:
Are doctors to blame for long waiting room times?
|
|
Cancer Research UK:
UK Government releases new cancer patients’ waiting time stats
|
|
KevinMD:
The entire approach to food based on nutrients is wrong
|
|
Oncology Times:
Speak Up: 8 Words & Phrases to Ban in Oncology!
|
|
Oncology Times:
Lymphoma Expert Calls for more Focus in Clinical
|
|
Respectful Insolence:
The complexity of cancer, Part 1
Part 2: Enter the quacks
|
|
Respectful Insolence:
If we can put a man on the moon, why can't we cure cancer?
|
|
CancerNetwork:
Electronic Health Record System Gets Government’s Stamp of Approval
|
|
Medical News Today:
KRN5500 For Chemotherapy-Induced Neuropathic Pain Gets Fast Track Designation By FDA
|
|
Medical News Today:
On Trail Of A Treatment For Cancer Of The Immune System
|
|
EmpowHER:
Adcetris Targets CD30 Cells in Hodgkin's Lymphoma
|
|
NCCN:
Ability to Create Better, Safer Medicines Brings Hope to Many With Cancer
|
|
Medical News Today:
Cancer Viral Therapy Attacks Tumors And Does Not Harm Healthy Tissue
|
|
7th Space Interactive:
Subtype Distribution of Lymphomas in Southwest China: (for our readers in China)
|
|
Lerner Research Institute:
Researchers find new hope for treatment of chronic leukemia
|
|
Youtube:
Learn about the importance of a specific subtype diagnosis in adults with NHL in this video, led by Dr. John Sweetenham.
|
|
ASCO POST:
Combined Therapy Produces Good Outcomes in Primary Testicular Diffuse Large B-cell Lymphoma
|
|
ODAC:
Recommends Accelerated Approval for Brentuximab
|
|
CURE:
New drug for two types of lymphoma
|
|
NCCN:
Updated patient info on NHL
|
|
PubMED:
Interim (mid-treatment) PET Not Justified In DLBCL During First Line Immuno-Chemotherapy
|
|
AM J Hematology:
Follicular lymphoma: 2011 update on diagnosis and management
|
|
Cochrane:
Comparison of chemotherapy including escalated BEACOPP vs chemotherapy including ABVD for patients with early unfavorable or advanced stage Hodgkin lymphoma
|
|
ISRN Hematology:
A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma
Comment: Speaks to the need for routine referral to clinical trials for patients with PTCL NOS.
|
|
Consortium for Improving Survival of Lymphoma:
Multicenter retrospective analysis of 581 patients with primary intestinal non-Hodgkin lymphoma
|
|
Blood: Bazarbachi, Suarez, Fields, Hermine
How I treat adult T-cell leukemia/lymphoma
|
|
NCCN:
Understanding Your Risk of Developing Secondary Cancers
|
|
ASH:
The 2008 WHO classification of lymphomas: implications for clinical practice and translational research
|
|
UCLA:
Results of medication studies in top medical journals may be misleading to readers- study highlights 3 types of confusing outcome measures
|
|
AMer J Roengenology:
Whole-Body MRI at Initial Diagnosis of Lymphoma - a non-ionizing modality, may be useful as an alternative to PET/CT in the malignant lymphoma."
|
|
KevinMD:
Top 10 musts for your hospital visit
|
|
NCCN:
Oral Chemotherapy: Potentials and Misconceptions
|
|
UCSF:
Study Shows Greater Impact of Chemo on Fertility
|
|
Live Science:
Nurses Exposed to Toxic Cancer Drugs, Study Finds
|
|
KevinMD:
Taking care of yourself sometimes means being selfish (For the caregivers out there!)
|
|
KevinMD:
Patients need to contribute to help their doctors
|
|
NEJM:
The Doctor’s Dilemma — What Is “Appropriate” Care?
|
|
Oncology Times:
VIEW FROM THE OTHER SIDE OF THE STETHOSCOPE: “It's Okay”
|
|
Information Week:
Patients say they want more e-mail-based communications with their clinicians. Despite obstacles, momentum is growing.
|
|
Oncology Times:
Stopping Time. Excellent essay by Dr. Wendy Harpham (end of life issues)
|
|
Cancer Research UK:
In the news: re-tooling the body’s police force to beat leukemia
http://bit.ly/qCp7Ge
|
|
Cure today:
Why is randomization in clinical trials important?
http://bit.ly/rlrIcW
|
|
Washington Post
‘Comparative effectiveness research’ tackles medicine’s unanswered questions
http://wapo.st/nw8hCi
|
|
Clinical Oncology News
40 Years of DLBCL Give CHOP, Add Rituxan-Is that all there is?
http://bit.ly/qofYq7
|
|
Clinical Oncology News:
Is Patient Optimism unrealistic In Early-Phase Trials?
http://bit.ly/nSd5h0
|
|
Cancer Network: ASCO 2011:
Steve Joffe Discusses Controversies in Phase I Clinical Trials
http://bit.ly/qjQoSH
|
|
Annals of Oncology:
Response criteria for NHL: Importance of 'normal' lymph node size and correlations with response rates
http://bit.ly/opz6U9
|
|
NCI: Hyperthermia in Cancer Treatment?
http://1.usa.gov/pccdOj
|
|
Medscape:
Do Biologics (used for rheumatologic disease) Cause Cancer
http://bit.ly/qWdAOA
|
|
BBC Cancer
Discovery offers hope of tackling spread of disease
http://bbc.in/rp83Go
|
|
Cancer Network:
Novel PARP Inhibitor for Solid Tumors & Lymphomas
http://bit.ly/n4HY9G
|
|
Medical News Today:
Stem Cells Central To Pathogenesis Of Mature Lymphoid Tumors
http://bit.ly/n4UOYw
|
|
University of Copenhagan:
Researchers on the trail of a treatment for cancer of the immune system (EBV related blood cancers)
http://bit.ly/pVdrVr
|
|
Cancer Research:
In Vivo Programming of Tumor Antigen-Specific T Lymphocytes from Pluripotent Stem Cells to Promote Cancer Immunosurveillance
http://bit.ly/nijbfE
|
|
Data mining' to generate hypotheses for testing new indications for existing drugs.
http://bit.ly/peyN5M
|
|
Cornell-lymphoma Blog:
Cyclophosphamide may be associated with an increased risk of secondary myeloid neoplasia when given with Fludarabine in CLL
http://bit.ly/mTba5D
|
|
Advances in Hematology:
Review Article Recent Advances in the Pathobiology of Hodgkin's Lymphoma: Potential Impact on Diagnostic, Predictive, and Therapeutic Strategies
http://bit.ly/rkgSPH
|
|
NY Times: Cancer’s Secrets Come Into Sharper Focus
http://nyti.ms/nJIfoS
|
|
Disappearance of Genetic Material Allows Tumor Cells to Grow
http://bit.ly/nL0OJq
|
|
National Comprehensive Cancer Network:
Cancer treatment is viewed as a true partnership video
http://bit.ly/mSLcgZ
|
|
Health Smart:
Facing Cancer Together General cancer video
http://bit.ly/pbhLpz
|
|
Fox Chase:
IMRT improves outcomes in patients with extranodal lymphoma of the head and neck
http://bit.ly/pKv5kd
|
|
British J of Haematology:
VcR-CVAD induction chemo followed by maintenance Rituxan in MCL
http://bit.ly/oJwSeH
|
|
Medical News Today:
New Drug In Early Clinical Testing Offers New Hope For Treatment Of Chronic Leukemia
http://bit.ly/r0qVHm
|
|
Univ of PA press release:
Triple therapy regime puts patients with leukemic form of cutaneous lymphoma in remission (Retrospective study)
http://bit.ly/r5zDO3
|
|
NEJM Early Stage Hodgkin's
http://bit.ly/nKNTAx
|
|
Is ecstasy ‘being developed to treat blood cancers’? Not quite…
http://bit.ly/qVaVKu
|
|
NYT: Finding a quality doctor
http://nyti.ms/pDRtAj
|
|
NCI: Facing Forward: Life After Cancer Treatment
http://1.usa.gov/n5MjjS
|
|
WSJ: For Cancer Patients, Help Navigating the Maze
http://on.wsj.com/nrVHU0
|
|
KevinMD: Taking the time to answer patient questions
http://bit.ly/ofUNOm
|
|
Philly.com: Studying the positive side of Trauma and Grief
http://bit.ly/pNredd
|
|
My Cancer Advisor: Should you get a second opinion
http://bit.ly/q6mB4C
|
|
My Cancer Advisor: Preparing for hair loss after Chemo
http://bit.ly/qBzOfY
|
|
My Cancer Advisor: How Do I Get My Medical Records?
http://bit.ly/rqgr4M
|
|
KevinMD.COM: Why developing trust with your doctor is important
http://bit.ly/nUUAxZ
|
|
Medical News Today: Docs Urge Cancer Patients To Discuss Supplements Before Treatment
http://bit.ly/oObsiM
|
|
Retractions of Scientific Research Papers Going Up http://bit.ly/o4xuhz
|
|
Use of Chemo Assays Outside Clinical Trials Still a No No http://bit.ly/p5GbOU
|
|
Annual Review 2010/11 – Revolutionizing the way we diagnose and treat cancer http://bit.ly/nOdnNI
|
|
Depression during Cancer Treatment http://bit.ly/otRJjP
|
|
Video from U Penn on Redirecting T cells trial reported in NEJM http://bit.ly/nV1y74
|
|
Video on natural "cures" http://youtu.be/r3yzXXPeLo0
|
|
Help dealing with stress as a cancer caregiver video http://bit.ly/qM3i7G
|
|
Video from U Penn scientist on http://bit.ly/nV1y74
(Good overview from the scientists, but not much covered on on risks and preliminary nature of this impressive new development)
|
|
Why Some Patients [May] Not Respond To Standard Lymphoma (Rituxan) Therapy
http://bit.ly/oukJBH
|
|
Chemotherapy Primer:
Why? What? and How? http://bit.ly/mTRKqI
|
|
Clinical guidelines for treatment of follicular lymphoma
http://bit.ly/bFv7hZ
|
|
Cancer statistics 2011
http://bit.ly/p9VPBd
|
|
Exercise should be 'standard part of cancer care' http://bbc.in/nNIgTL
|
|
Sorry you're sick, but wow, you're so skinny!
Covetous compliments on illness-related weight loss can rankle
http://on.today.com/rb1ErH
|
|
Before Treatment: Seeking a Second Opinion
http://bit.ly/nn9XT3
|
|
Letting Doctors Make the Tough Decisions?
http://nyti.ms/mQ9OIq
|
|
Free subscription to Cure magazine
http://bit.ly/nssy0Q
|
|
Surveillance CT scans are a source of anxiety and fear of recurrence in long-
term lymphoma survivors
http://bit.ly/d8ODSC
|
|
Alternative Therapies for Curing Cancer: What Do Patients Want? What Do Patients Need?
Excellent article by a physician who has lymphoma
|
|
Difference between hematological malignancy and Solid tumor research articles
published in four major medical journals
http://bit.ly/oDkj5K
|
|
Risk for second malignancies in NHL survivors: a meta-analysis
http://bit.ly/o6L5Mp
|
|
Cancer cartoons
http://bit.ly/nFIjTW
|
|
Answers to questions about sunscreen from MSKCC dermatologist Steven Wang
http://on.fb.me/ov3WbK
|
|
Who was Thomas Hodgkin?
http://bit.ly/qiN9xf
|
|
Advances in cancer treatment are hyped by headlines
http://bit.ly/oufHVD
|
|
Improving radiation Rx safety
http://bit.ly/q1JLof
|
|
Hospice medical care for dying patients
http://nyr.kr/di8Mqi
Very difficult to read, but excellent article on end of life care and hospice--warning- not for the faint hearted-- but does raise issues to think about
|
|
You Look Great’ and Other Lies
http://nyti.ms/lqbCZA
|
|
The Doctor Will See You ... Eventually
http://nyti.ms/mTqnJr
|
|
With cancer, sometimes there is no right answer
http://bit.ly/oWGYGy
|
|
Men, Cancer & Work: Coming to Terms with the "New Normal"
http://bit.ly/nNu6A2
|
|
Patients want and need to take a greater role in their medical care
http://bit.ly/mPMe5C
|
|
End of life issues: The Truth About Hospice Care
http://bit.ly/psZOSy
|
|
Who's a Survivor? An oncologist who's had breast cancer considers the problematic phrase "cancer survivor."
http://bit.ly/ctL1Du
|
|
Preclinical: Scientists Strike Genetic Gold in Lymphoma Study http://bit.ly/qnts5t
|
|
Are Cancers Newly Evolved Species? http://bit.ly/oOiYXn
|
|
The epidemiology of NHL http://bit.ly/o4feIb
|
|
ASCO: Making e-visits work for cancer patients http://bit.ly/nR24tK
|
|
Planning 'Worry Time' May Help Ease Anxiety http://bit.ly/oBI6Bn
|
|
Doctors Differ in How Best to Care for America's 12 Million Cancer Survivors http://bit.ly/mUFl9G
|
|
On Chemo brain: Fog May Be From Cancer, Not the Chemo http://nyti.ms/9vrOJh
|
|
Some supplements claim that they "boost the immune system." Is this a reasonable claim? http://bit.ly/q8VjGw
|
|
Stay safe in the ER with life-saving strategies
As many as 98,000 Americans die every year as a result of medical mistakes
http://on.msnbc.com/ndPaJm
|
|
Seeking Serenity: Serious illness won’t get off my back http://bit.ly/qJIlI8
|
|
Oral fludarabine and rituxan as initial therapy for CLL/SLL: population-based experience matches clinical trials. http://1.usa.gov/pyCmCX
|
|
Lenalidomide associated with durable remissions in elderly patients with symptomatic CLL http://bit.ly/pFwbUE
|
|
2 genetic variations predict second cancers after radiation for children with Hodgkin lymphoma http://bit.ly/qSoxrU
|
|
Rituximab and/or Lenalidomide in Treating Patients With Follicular NHL That is Not Refractory to Rituximab http://1.usa.gov/oh391X
|
|
Lenalidomide and Rituxan in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular NHL http://1.usa.gov/nsI9Et
|
|
Treatment Options for Peripheral T-cell lymphoma http://bit.ly/o4BHH4
|
|
Evolving Therapy of Peripheral T-cell Lymphoma 2010 and Beyond http://bit.ly/mS54RG
|
|
Cutaneous Lymphoma Patient Educational Opportunities http://bit.ly/n1HTKy
|
|
Combo Regimen Advised as 2nd-Line Therapy for Waldenstrom's Macroglobulinemia
http://bit.ly/qnRTIA
|
|
Maintenance Rituxan associated with improved clinical outcome in rituxan naïve Waldenstrom Macroglobulinaemia who respond to a rituxan-containing regimen http://bit.ly/qoo1KA
|
|
Analysis of 581 patients with primary intestinal NHL from the Consortium for Improving Survival of Lymphoma http://bit.ly/pzqV1V
|
|
New Cancer Treatment? Universal Donor Immune Cells http://bit.ly/ocd7iD
|
|
Immunotherapy: Past, Present and Future http://bit.ly/pNgAXl
|
|
Specialized Regulatory T Cell Stifles Antibody Production Centers http://bit.ly/q9yAp
|
|
Histone modifying genes play a role in non-Hodgkin's lymphoma http://bit.ly/p7SsG
|
|
Research on tumor microenvironment - Monocytes and T cells cooperate to favor normal and follicular lymphoma B-cell growth: role of IL-15 and CD40L signaling http://bit.ly/nT2rDa
|
|
Pitfalls in lymphoma pathology: avoiding errors in diagnosis of lymphoid tissues http://bit.ly/peFZlr
|
|
Is routine G-CSF support needed for treatment with ABVD of Hodgkin lymphoma? http://1.usa.gov/rv01AP
|
|
Lenalidomide + Rituxan Shows Promise as First-Line Therapy in Patients with Indolent Lymphoma http://bit.ly/poj0fD
|
|
Caring for Patients With Diabetes and Cancer, Psarakis, RN, APRN http://bit.ly/oG4UjY
|
|
Revised Response Criteria for Malignant Lymphoma http://bit.ly/ruWNfW
|
|
Social Security's Compassionate Allowances Program Means So Much To People In Time Of Need http://bit.ly/oW0YMo
|
|
10 Things To Avoid On Your Resume - Cancer and Careers http://bit.ly/nLJOW4
|
|
ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned http://bit.ly/pwq2Ej
|
|
ABVD versus BEACOPP summary from medscape-- requires registration: Chemo Toxicity May Tip Scales in Advanced Hodgkin's Lymphoma http://bit.ly/mUveA8
|
|
What is the lump on this girl's neck? http://bit.ly/p1NaYe "Of neck lumps in children, over 90% are simply reactive nodes "
|
|
The Prepared Patient, When Pain Doesn't END http://bit.ly/p2S3zK
|
|
Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin's lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG 9809. http://1.usa.gov/qVHcKJ
|
|
An Oncologist's Pulitzer-Winning Cancer Biography http://n.pr/pGxWrG
|
|
Treatment of Hodgkin lymphoma with ABVD without g-csf support http://1.usa.gov/rv01AP
|
|
Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma http://1.usa.gov/p48iQa
|
|
Add Patience to a Leap of Faith to Discover Cancer Signatures http://nyti.ms/mZv4bJ
|
|
Battling the Hematological Malignancies: The 200 Years' War Patients http://bit.ly/p3f8B6
|
|
Researchers Discover Possible Drug Targets For Common Lymphoma http://bit.ly/pJutZc
|
|
WebMagic: Active, helpful lymphoma support forum http://forums.lymphoma.com/index.php
|
|
Expert perspective: "Aiming at a curative strategy for follicular lymphoma" Bendandi http://bit.ly/oaItLl
|
|
Revised Response Criteria for Malignant Lymphoma http://bit.ly/ruWNfW
|
|
Financial Management During a Loved One’s Medical Crisis – CarePages.com http://bit.ly/LnWLy
|
|
Clinical Challenges in Caring for Patients With Diabetes and Cancer http://bit.ly/oG4UjY
|
|
Curr Opin Oncol: Maintenance therapy in follicular lymphoma. http://1.usa.gov/q0OXGF
|
|
ASCO Post Important Briefs:
Lymphoma research - improved approaches http://bit.ly/qlhrUu
|
|
FDA Advisor Panel Backs Accelerated Approval of Brentuximab for Hodgkins Lymphoma and ALCL http://bit.ly/pr3er1
|
|
Stem Cell Treatment May Restore Cognitive Function in Patients [Treated for] Brain Cancer http://fb.me/XD2iFlce
|
|
PET scans: when and how? http://bit.ly/qQPoCk
James Olen Armitage
|
|
Epidemiology of adult NHL http://bit.ly/qdokmY
|
|
OT: Taking zinc for the common cold?
http://bit.ly/q5XFP2
|
|
Tips for Getting Through Cancer Treatments http://bit.ly/qmgt8h
|
|
Teleconferences on Cancer and Careers, http://bit.ly/obqyIZ
|
|
Clinical Questions that Can Only Be Answered by Clinical Trials PDF
|
|
Autologous stem cell transplantation as a first-line treatment strategy for CLL: a multicenter, randomized, controlled trial http://bit.ly/je7iRh
snip: " This is the first published randomized clinical trial of ASCT as part of the first-line treatment for patients with stage B or C CLL. We found that ASCT doubled the EFS (effect free survival) probability in patients who entered CR after up-front chemotherapy. This is consistent with the results of previous phase 2 trials of ASCT for first-line treatment consolidation, in which the median EFS ranged from 5-6.3 years.19-21 In contrast, ASCT was not more beneficial than FC in our non-CR patients rescued with DHAP."
|
|
Lugano Conference: Rituximab + Lenalidomide Prolonged Remission in Mantle Cell Lymphoma http://bit.ly/lVhZmJ
The researchers found that more than half (57.8%) of patients responded to treatment, and most responses lasted for at least 18 months. The combination was very well tolerated, with few bothersome side effects. These results are striking for this group of patients, especially as many had not responded to previous therapy.
|
|
Mantle Cell Lymphoma - Rituxan maintenance: EHA 2011: Remission duration of lymphoma doubled http://bit.ly/jQ7TIY
"Clinical research has shown that recurrence of Mantle Cell Lymphoma, a variant of malignant lymphoma, can be reduced by almost 50% in patients who receive maintenance treatment with the antibody rituximab. These results are presented by Dr Hanneke Kluin-Nelemans at the 16th Congress of the European
Hematology Association in London."
Also see Medcape item: http://www.medscape.com/viewarticle/744453
|
|
Management of Follicular Lymphoma in the Up-Front and Relapsed Settings http://bit.ly/mjsYzy
snip: “This paper reviews recent practice patterns in the broad context of the published findings from major phase III randomized trials; it documents potential gaps between trial results and actual practice, and the implications of these for continuing education of oncologists."
|
|
Treatment options for high-risk CLL http://bit.ly/kTWK01
|
|
A doctor's letter to a patient with newly diagnosed cancer http://bit.ly/mjDC5T
Reader comment: "That was a beautifully written, yet very difficult to read example of a frank, but compassionate communication."
|
|
ASCO11: Antibody Drug Conjugates (ADCs) Are Rapidly Changing The Landscape of Lymphoma Therapy facebook.com/notes/lymphoma-resources/
|
|
Clinical report showing activity of CD19 antibody + cytotoxic - maytansinoid (SAR3419) ASCO 2011
|
|
Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis annonc.oxfordjournals.org
|
|
Hope, hype and hypocrisy http://bit.ly/muHf3M
"At a higher level, scientists are in a fierce competition to maintain and increase public support and funding, and they oblige and numb their critical sensitivities to do so. The net effect is that hype and hope have become common…"
|
|
Splenic marginal zone lymphoma: hydra with many heads? http://bit.ly/lAWHaV
Luca Arcaini1, Marco Paulli2
|
|
Rituximab for Follicular Lymphoma: Maintaining an Open Mind
Commentary by Dr. Bruce D. Cheson http://bit.ly/mxny1J
|
|
Being around kids when you receive treatment? Tips from Patients
|
|
RECOMMENDED: 5 rules for living well with a chronic illness
http://bit.ly/k6uect
|
|
NPR Walt Bogdanich interview:
[Benefits and] Hidden Dangers Of Medical Radiation
Includes many useful tips - questions to ask, who to ask, how to identify credentialed centers ....
|
|
Acetaminophen tied to blood cancers http://reut.rs/jc93zU
This article could be used as a model for how to explain such findings.
|
|
Role of Stem Cell transplant in Follicular lymphoma,
Foster, Gabriel, Shea, 2010 ncbi.nlm.nih.gov
|
|
When Laypersons Give medical advice? PAL
|
|
Prospective Study of Survival Outcomes in Non-Hodgkin’s
Lymphoma Patients With Rheumatoid Arthritis jco.ascopubs.org full.pdf
|
|
NPR Mukherjee interview
Author of 'The Emperor of all Maladies' http://n.pr/dEtPXf
|
|
Novel therapeutic agents for B-cell lymphoma: developing rational combinations - Blood 2011 Full text: http://bit.ly/i7c7qs
Fairly technical but a useful review of the landscape, providing summary discussion of 1) the class of drug, the 2) mechanism of activity, 3) its use so far in lymphoma, and 4) toxicities.
|
|
State by state health insurance options for people with pre-existing conditions http://1.usa.gov/fGvYoQ
|
|
Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Produces High CR Rates and Long-Term Disease Free Survival in Patients with Relapsed Aggressive NHL Who Previously Failed Frontline CHOP Therapy http://bit.ly/gLKS4P
|
|
Treatment-related Questions for Your Doctor PAL
|
|
8 Survival Tips for the Spouse (or significant other) of a Terminally Ill Person http://bit.ly/fcy1wl
|
|
BEACOPP regimen associated with 97% OS in young patients with high-risk Hodgkin’s lymphoma http://bit.ly/hl8w38
|
|
Standard Therapy for Mantle Cell Lymphoma?
http://bit.ly/htWQpf
|
|
Evaluating FLIPI-2, the Follicular Lymphoma Prognostic Index journals.lww.com
|
|
Interim Results From a Phase 1 Study of CAL-101, a Selective Oral Inhibitor of PI3K in Patients with Relapsed or Refractory Hematologic Malignancies Slides ASCO 2010 http://bit.ly/hqMLvL
N =106, (99 evaluable) relapsed/refractory, mixed histologies (CLL, indolent NHL, DLBC, MCL, AML, MM)
|
|
Pre-existing Conditions Health Insurance Plans
http://nyti.ms/hxm6ZO
|
|
R-CHOP v. R-CVP in the treatment of follicular lymphoma: a meta-analysis http://bit.ly/hbYG0W
|
|
Relapsed CLL: Does adding lumiliximab (anti-cd23) improve on FCR?
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810983/
"Thirty-one patients gave consent and were treated at 5 clinical sites.
|
|
Positive Results With Acadra (Acadesine) in CLL prnewswire.com
|
|
Gorski: Why haven’t we cured cancer yet?
How many times have you heard these questions, or variants thereof? How many times have you asked this question yourself?
|
|
How I treat CLL up front http://bit.ly/favAVV
John G. Gribben, Institute of Cancer, Queen Mary University of London, Barts and The London School of Medicine and Dentistry, London, United Kingdom
|
|
Study of interest:
Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell Transplantation
NCI-10-C-0054 http://bit.ly/gUw3gV
|
|
Lymphoma Clinical Trial Lookup Tool
by subtype and treatment status PDF
|
|
Report on Vorinostat (SAHA) for Relapsed Indolent NHL and MCL http://bit.ly/dGBVLp See for studies http://bit.ly/aFsxvB
All 35 eligible patients were evaluable for response. The median number of vorinostat cycles received was nine. ORR was 29% (five complete responses [CR] and five partial responses [PR]). For 17 patients with FL, ORR was 47% (four CR, four PR). There were two of nine responders with MZL (one CR, one PR), and no formal responders among the nine patients with MCL, although one patient maintained stable disease for 26 months. Median PFS was 15.6 months for patients with FL, 5.9 months for MCL, and 18.8 months for MZL. The drug was well-tolerated over long periods of treatment, with the most common grade 3 adverse events being thrombocytopenia, anemia, leucopenia, and fatigue.
|
|
Novel Agents for Follicular Lymphoma Lymphoma:
Translating Basic Science into Therapy Leonard, Martin http://bit.ly/hY59Bl
Agents That Target:
Cell Surface molecules (such as anti-CD20 Antibodies)
Cell Surface molecules with immunoconjugates (such RIT, or a toxin bound to an antibody)
Intracellular Processes (such as CAL101, BTK, MTOR, ...)
Proteasome (such as Velcade)
Microenvironment (such as Lenalidomide)
|
|
Dose Intensive R-ACVBP vs Standard R-CHOP In Younger Patients with DLBCL http://bit.ly/heJlx2
It will be interesting to see if this result is considered practice changing in Europe for younger patients (given the tradeoffs - higher risk for significantly better outcomes) ... and how younger patients in the US feel about this option.
|
|
Treatment Approaches for Follicular Lymphoma Continue to Evolve -- An Interview with Dr. Andre Goy http://bit.ly/fbfIfm Free login registration required
Liz: Interview of Dr. Andre Goy (pronounced Gwah, he's French) with an excellent, well balanced run down on the current and emerging landscape in treating FL in a variety of settings.
|
|
Slides only: Managing patients with relapsed follicular lymphoma: Extending survival through judicious use of available agents, J. Leonard 2011 http://bit.ly/eAHXui
|
|
Ki-67 as a prognostic marker in mantle cell lymphoma—consensus guidelines of the pathology panel of the European MCL Network
ncbi.nlm.nih.gov
|
|
Insuring Your Health:
Looking At The Changes 2011 Brings http://bit.ly/ibyhZL
Michelle Andrews speaks with KFF's Jackie Judd about changes in lifetime insurance limits, keeping children insured, the new high-risk pools.
|
|
11 Tips to Help Manage Anxiety http://bit.ly/dHSGD7
For the last two months I have been under the very clear direction of my doctor to “distract, don’t think.”
|
|
Novel Insights into the Biology of CLL
Lanasa, Asheducation Book 2010 http://bit.ly/eJHpEM
|
|
Novel Agents for Follicular Lymphoma, Dec 2010
John P. Leonard1 and Peter Martin http://bit.ly/dOaSUh
|
|
Value of PET in Follicular Lymphoma: Discussion http://www.medscape.com/viewarticle/583796_4
|
|
Management of Follicular Lymphoma in the Up-Front and Relapsed Settings http://bit.ly/dNGsP5 (might require free registration)
|
|
Vaccines and Autism link:
It's easy to confuse correlation with causation - Tony L. Hines
|
|
Vaccine therapy for EBV-driven lymphomas (Hodgkins and NHL) moving forward - expanding EBV cytotoxic lymphocytes (CTL) and then infusing CTLs to delay relapse http://bit.ly/f8ZKyG
This approach is thought to cause an immune response to cancerous cells which co-express viral antigens (which is not the same as having a lymphoma and testing positive for EBV in the blood)
|
|
Going Home After Your Autologous Stem Cell Transplant NYU
|
|
Story of hope and perspective Linda
|
|
Survival curves - the basics http://cancerguide.org/scurve_basic.html
"You will often find survival curves inhabiting technical papers in the medical literature, and some understanding of these curves is essential to understanding the technical literature."
|
|
Does Progression Free Survival predict better survival in Follicular Lymphoma? PDF
|
|
Zevalin-based abstracts at ASH 2010 PAL
|
|
Locally Extensive and Advanced Stage Hodgkin's Lymphoma:
ABVD Vs. Stanford V +/- Radiation Therapy ash.confex.com
|
|
Relapsed or Refractory Hodgkin Lymphoma -- Brentuximab Vedotin (SGN-35) ash.confex.com
|
|
Relapsed/Refractory Hodgkin Lymphoma Patients Following Autologous Hematopoietic Stem Cell Transplant Final Analysis: Phase II Study of Oral Panobinostat ash.confex.com
|
|
Patient Power: Breakthroughs in Lymphoma
Interview with Dr. Anas Younes
Dr. Anas Younes, a renowned lymphoma expert, discusses two promising medicines for Hodgkin's disease and anaplastic large cell lymphoma and gives his views on whether watch and wait is still a reasonable approach for B-cell lymphoma patients who have no symptoms.
|
|
Things you can do to get your health insurance to cover a clinical trial cancer.gov ... still an issue until 2014, when the Health Care Reform measure kicks in.
|
|
FDA describes evidence of Flu Vaccine efficacy
in health care facilities WinPlayer Video
|
|
Abstracts reporting on t-cell lymphomas at ASH 2010
|
|
How Not to Fight Colds http://nyti.ms/gBPNHq
“Most of us come down with at least a couple of colds a year; children get up to a dozen. But we all know people who seem never to catch one. What’s their secret? Do they have extraordinarily robust immune systems, and the rest of us, pathetically weak ones?”
|
|
Positive attitude is all you need? http://bit.ly/fsKsVf
|
|
Influenza Vaccine — Safe, Effective, and Mistrusted http://bit.ly/hHyHQj
|
|
A Study Of anti-cd22 immunoconjugate (IO) Plus Rituximab For Relapsed/Refractory Aggressive NHL Patients Who Are NOT Candidates For Intensive High-Dose Chemotherapy
http://bit.ly/hBqoFd
IO is a humanized anti-CD22 antibody conjugated to calicheamicin, a cytotoxic agent (antibody with chemo attached). IO targets CD22, which is expressed in the majority of B-cell NHL.
2010 ASH report on IO:
Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab In Relapsed DLBCL Patients Followed by Stem Cell Transplantation: Preliminary Safety and Efficacy
http://ash.confex.com/ash/2010/webprogram/Paper33326.html
|
|
Cancer Pain Management - important NCCN updates
|
|
IOM: Dietary Reference Intakes for Calcium and Vitamin D http://bit.ly/fV2Ghh
Over the last ten years, the public has heard conflicting messages about other benefits of these nutrients—especially vitamin D—and also about how much calcium and vitamin D they need to be healthy.
To help clarify this issue, the U. S. and Canadian governments asked the Institute of Medicine (IOM) to assess the current data on health outcomes associated with calcium and vitamin D. The IOM tasked a committee of experts with reviewing the evidence, as well as updating the nutrient reference values, known as Dietary Reference Intakes (DRIs).
|
|
study of interest: Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell NHL http://bit.ly/farwZY
RATIONALE: Vaccines, such as dendritic cell therapy (DC) made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells. Cryosurgery kills cancer cells by freezing them. Giving vaccine therapy together with cryosurgery may kill more tumor cells. PURPOSE: This clinical trial studies giving vaccine therapy together with or without cryosurgery in treating patients with residual, relapsed, or refractory B-cell Non-Hodgkin's lymphoma
Also see preclinical rationale: Combined Dendritic Cell Cryotherapy of Tumor Induces Systemic Antimetastatic Immunity
|
|
How far would you go to sustain the life of someone you love, or your own?
http://to.pbs.org/eNFp1a
An excellent Frontline piece about end of life issues, and the tradeoffs of modern medicine.
|
|
When to Consider Clinical Trials, based on 7-clinical-circumstances.pdf
|
|
What Not to Say to a Depressed Person
By Therese J. Borchard http://bit.ly/alzxrY
|
|
When do you move from living to dying?
Nov 03 2010 Published by Pal MD under Medical Musings, Medicine http://bit.ly/bPhDS4
Toby writes: Good post!! Recommend to all patients and caregivers!
|
|
Vaccination for Whooping Cough (Pertussis)? PAL
|
|
Follicular Lymphoma: Emerging Therapeutic Strategies:
Therapy for Untreated FL http://bit.ly/a18BZW
Nice overview by Vaishalee P Kenkre1 and Brad S Kahl†1
|
|
Trial Search for relapsed DLBCL - excluding stem cell transplant http://bit.ly/aVbuVF
|
|
Standard Regimen is Still Most Effective in Hodgkin's Lymphoma http://bit.ly/9LFOnv
For patients with early intermediate-stage Hodgkin's lymphoma, standard therapy should remain the same. That was the conclusion of a new study that assessed the feasibility of using a reduced dose of radiation or a more intensive dose of chemotherapy.
The results of the study demonstrated that lower doses of radiation were not as effective as the standard dose, when combined with chemotherapy. Another finding was that a more intensive chemotherapy (bleomycin, etoposide, doxorubicin, cyclophosphamide, Oncovin [vincristine], procarbazine, prednisone; BEACOPP) was not more effective than the current standard regimen (Adriamycin [doxorubicin], bleomycin, vinblastine, and dacarbazine; ABVD) in this population.
Before this study, it was not clear what the optimal chemotherapy regimen was, or what the most effective dose of radiation was, explained lead author Hans Theodor Eich, MD, PhD, radiation oncologist at the University of Cologne, Germany.
|
|
Letting Go: What should medicine do when it can’t save your life?
by Atul Gawande http://nyr.kr/di8Mqi
JoJo writes: Amazing article thanks. Aug 26th my 85 year old mother had a major stroke 10 days after getting a pace-maker. Dayle called me at work and I spoke to the paramedics as they were transporting her. At the hospital my sister and I were questioned about DNR's etc as we contacted my brother who lives 3000 miles away. You think you are ready to deal with these tragedies in our lives but we realized as a family we had not discussed Mum's wishes.
|
|
Theory, Observations, and Endpoints http://bit.ly/973RMz
There was once a time in history when doctors prescribed blood-letting, and were convinced that it was effective – and could cite many success stories. In comparison, homeopathy (water with trace amounts of different compounds) along with good hygiene appeared effective! Each practice (disproven by modern scientific methods) was based on a prevailing theory and substantial clinical observation.
|
|
Carfilzomib - investigational agent that similar to Velcade inhibits proteasome system by by a different mechanism - see background and links to trials PAL
|
|
Novel Treatment Regimens for Waldenström’s Macroglobulinemia: Other Drugs under Investigation in Waldenström's Macroglobulinemia http://bit.ly/cxzcal
|
|
Clinical Questions that Can Only be Answered by Clinical Trials http://bit.ly/cTBymX
|
|
Radiation Therapy After R-CHOP for Diffuse Large B-Cell Lymphoma: The Gain Remains http://jco.ascopubs.org/content/28/27/4105.full
|
|
Determinants of the optimal first-line therapy for follicular lymphoma: A decision analysis http://bit.ly/9xMJBK
"A significant limitation of our study lies in the quality of data available for input into the meta-analysis. Many of the trials examining these chemotherapy regimens in patients with FL have only been published in abstract form. However, practicing clinicians are forced to use these limited data when making daily decisions about patient care.
In summary, using decision analysis methodology, we have shown that the most important factor in maximizing quality-adjusted life years in patients with advanced-stage, low-grade FL is the PFS (duration of progression free survival) associated with the chosen therapy rather than its short-term effect on QOL (quality of life). "
|
|
Tumor Lysis Syndrome in Patients with CLL http://bit.ly/aHpGYF
|
|
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin, GVD, a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804 annonc.oxfordjournals.org
GVD is a well-tolerated, active regimen for relapsed HL with results similar to those reported for more toxic regimens. High RRs in patients in whom prior transplant failed confirms this regimen's activity even in heavily pretreated patients
|
|
Temsirolimus Has Activity Also in Non–Mantle Cell NHL http://bit.ly/dn8Q6R | See also PAL's Pipeline
|
|
Autoimmune Cytopenias in Chronic Lymphocytic Leukemia: Prevalence, Clinical Associations, and Prognostic Significance http://bit.ly/boX70s
|
|
Cure Magazine: The Treatment Option You May Be Missing http://bit.ly/bItRI7
|
|
Translational medicine provides new insight for treating cutaneous lymphomas http://bit.ly/9UQhU9
“Clinical observations from the use of immune modulators and histone deacetylase (HDAC) inhibitors are providing researchers with clues into the mechanism of cutaneous T-cell lymphoma (CTCL), an expert says.”
|
|
How I treat CLL up front, 2010 John G. Gribben
Full text: http://bloodjournal.hematologylibrary.org
|
|
Studies recruiting for DLBCL, not eligible for transplant http://bit.ly/aVbuVF
|
|
Overview: Stem Cell Transplant in Follicular Lymphoma PAL
|
|
Personality Does Not Influence Cancer; Hypothesis Should Be Retired http://bit.ly/9m78qV
|
|
Conflict of Interest in Medical Decision-making PAL
|
|
Zevalin as a Single Agent in Patients With Pretreated B-Cell Lymphoma: Evaluation of the Long-Term Outcome http://bit.ly/doQm0a
Overall response rate was 93% (53 of 57); complete response (CR) rate was 70% (40 of 57). Twenty-six of 40 patients (65%) who obtained a CR are in continuous CR (CCR) with a median follow-up of 20 months (range, 10-42 months); 4 of them still maintain their CCR after 36 months.
|
|
Evolving Questions in Follicular Lymphoma Highlighted at International Hematology Meeting http://bit.ly/90NUp5
|
|
Treatment-decisions - schema PDF
|
|
Deep Venous Thromboses in Patients With Hematological Malignancies After Peripherally Inserted Central (PICCs) Venous Catheters http://bit.ly/97jQtl
For patients with hematologic cancer, changing from peripherally inserted central catheters (PICCs) to centrally inserted tunneled, internal jugular catheters dramatically reduced the incidence of catheter-associated deep venous thrombosis.
|
|
Reassessing the Standard of Care in Indolent Lymphoma: A Clinical Update to Improve Clinical Practice CME/CE medscape.com
|
|
Health Insurers Break Profit Records
as 2.7 Million Americans Lose Coverage http://bit.ly/92JBoC
|
|
study of interest: Lenalidomide In Previously Untreated, Advanced Stage Indolent Lymphoma http://bit.ly/b3xIvp
|
|
Role of Radiation Therapy in Localized Aggressive Lymphoma jco.ascopubs.org
|
|
Dietary Supplements in Cancer Care http://bit.ly/dqs2oY
Webcam presentation by registered dietician, Susan Dixon, Cancer Nuitrition specialist
|
|
MCL: interview with Jonathan Alter
Part 1 http://bit.ly/9NMieP and 2: http://bit.ly/9tAhgR
|
|
Radioimmunotherapy for Other Lymphoma Subtypes and Indications PAL
|
|
High Rates of Durable Responses in Relapsed NHL With Anti-CD22 Fractionated Radioimmunotherapy http://bit.ly/9IbqxW
|
|
Study Finds Consumers Need Education Regarding Evidence-based Care http://bit.ly/99N18b
|
|
NEJM: Buying Health Care, the Individual Mandate, and the Constitution http://bit.ly/9FElMG
|
|
Comments on the PRIMA study and how to measure success of first line maintenance Rituxan PDF
|
|
GS-9219 A Novel agent with Potent Antineoplastic Activity in Dogs with Spontaneous NHL http://clincancerres.aacrjournals.org
About nucleotide analogue GS 9219 (NCI) Formulated to selectively accumulate in lymphocytes, nucleotide analogue GS 9219 is converted to its active metabolite, PMEG diphosphate (PMEGpp), via enzymatic hydrolysis, deamination, and phosphorylation; subsequently, PMEGpp is incorporated into nascent DNA chains by DNA polymerases, which may result in the termination of DNA synthesis, S-phase cell cycle arrest, and the induction of apoptosis in susceptible lymphoma cell populations.
A Trial of GS-9219 in CLL, NHL or MM http://clinicaltrials.gov (has completed enrollment)
|
|
The effects of β-glucan on human immune and cancer cells
Chan, et al. J Hematol Oncol. 2009; 2: 25. http://bit.ly/cIBT0P
|
|
Targeted Therapies for Lymphoma Tutorial, NCI http://bit.ly/cF17bg
A bit advanced, but with excellent illustrations and good background on lymphomas.
|
|
Walking the Tightrope of Health Insurance Reform between 2010 and 2014 http://bit.ly/azJJgH
|
|
Clinical Questions that can only be answered by trials PDF
|
|
Beautifully written. I expect this piece will resonate with patients and experts alike.
Musings of a Distractible Mind:
Thoughts of a moderately strange (yet not harmful) primary care physician.
A Letter to Patients With Chronic Disease http://bit.ly/b68MKj
|
|
Response to Second-line Therapy Defines the Potential for Cure in Patients with Recurrent DLBCL: Implications for the Development of Novel Therapeutic Strategies http://www.medscape.com/viewarticle/723577
"No clear indication exists that palliative approaches are inferior to further intensive approaches in this setting. This fact may make a comfort-directed or investigational strategy more acceptable to some patients, because they do not risk losing the chance for a cure by choosing an alternative to established standard chemotherapy regimens."
|
|
A 19 page comic strip explanation of homeopathy http://bit.ly/bYNidX
|
|
Targeting PD-1 to modulate immune response against lymphoma
Clinical Report: http://bit.ly/a3lHUc
Clinical Trials: http://bit.ly/1Bj7r1
|
|
CHOP-R + bortezomib (Velcade) as initial therapy for DLBCL http://bit.ly/9ifYVY
|
|
Survey Results: Patient Preference of Chemo-based Therapy following
Relapse of indolent follicular lymphoma (Completed) PAL
|
|
Advocacy Alert: Contact your Elected representatives - ask them to support House Resolution 143 to make September Blood Cancer Awareness Month. PAL
|
|
Panobinostat Produces Objective Responses in Advanced Hodgkin's Lymphoma http://bit.ly/bHEBIb
"Of 129 patients, 4 (3%) had a complete response to panobinostat, 29 (22%) had a partial response (defined as a reduction of tumor size by a least 50%), and 111 were deemed to have disease control (defined as a combination of complete and partial responses and stable disease)
A ceiling is likely going to be reached in relapsed/refractory patients, and the major questions are going to be: Is there sufficient independent activity for efficacy, such as in maintenance?" he said. "Is there synergy, and is it feasible to combine this agent with other therapies? And are there predictive biomarkers?"
|
|
Study of interest: Combination Veltuzumab (Anti-CD20) and Fractionated 90Y- Epratuzumab (Anti-CD22) Radioimmunotherapy in Patients With Follicular Lymphoma http://bit.ly/c80PPu
|
|
Cancer Prevention, Naturally http://bit.ly/cfSFJR
|
|
Transparency at the Food and Drug Administration http://bit.ly/cGqhip
"More than 30 years ago, FDA Commissioner Donald Kennedy noted "a basic principle of our political system [is] that people affected by governmental decisions have a right to know the basis on which they are made." With the daily practice of medicine routinely affected by the decisions of the FDA, the medical community has a large stake in transparency at the agency. The full set of draft proposals can be found on the FDA's Web site (www.fda.gov/transparency)."
|
|
What is responsible for the recent improvements in outlook for patients with follicular lymphoma? http://bit.ly/dev1l0
|
|
Hitting the sweet spot for lymphoma http://bit.ly/d7bnsS
Targeted delivery of liposomal doxorubicin to CD22.
“As envisioned by scientists as far back as the 1800s, the ideal chemical therapy would possess exquisite selectivity, thereby restricting, if not eliminating, collateral cellular damage (eg, Ehrlich's "magic bullet").”
|
|
"Natural Cancer Treatments," a Review by Steven Novella, MD. http://bit.ly/c6T5IU
|
|
ASCO 2010 Wrap-up: Converting Cancer to a Chronic Disease medscape.com
|
Marginal zone lymphomas - Factors that affect outcome interscience.wiley
|
|
Questions to ask about drug risks, Harlan M. Krumholz MD, SM, http://bit.ly/bP4BLA
"Doctors cannot tell you what will happen. The best they can do is to be clear about what is known about the options -- and what remains uncertain."
|
|
The Path to Personalized Medicine http://bit.ly/amxlBF
Margaret A. Hamburg, M.D., and Francis S. Collins, M.D., Ph.D.
As the leaders of the National Institutes of Health (NIH) and the Food and Drug Administration (FDA), we have a shared vision of personalized medicine and the scientific and regulatory structure needed to support its growth. Together, we have been focusing on the best ways to develop new therapies and optimize prescribing by steering patients to the right drug at the right dose at the right time.
|
|
The Interface Between Cancer and Psychiatry http://bit.ly/d8JSoj
"As a psychiatrist who has lymphoma, I have developed a deep understanding of the ways in which our training can help us help patients who find themselves forced to deal with the complicated emotional aspects that accompany various forms of cancer. ... Cancer is an alienating and existential experience. I know of no other common disease that immediately causes so much fear, anxiety, depression, confusion, and sense of impending disaster in a patient or his or her significant others as when they hear the word cancer for the first time."
|
|
ACS cites studies on Access to Healthcare for Cancer Survivors http://bit.ly/bYMcXT
|
|
Dr. Cheson: ASCO lymphoma highlights 2010 http://bit.ly/aHIN0Q
Important talk. Do give a listen.
|
|
Many studies great news for mice, not so much for humans us.cnn.com
"In terms of cancer, it is difficult to translate animal models to human applications because a human tumor takes several years to develop, and rodent studies often just inject human tumors into the rat or mouse, said Dr. Gabriel Lopez-Berestein, professor of medicine and cancer biology at the University of Texas M.D. Anderson Cancer Center."
|
|
How to Think about Future Health Care Spending,
NEJM, Fuchs, Ph.D. http://bit.ly/cCkLwe
"Lost in the din are two critical problems related to future spending — one empirical, the other conceptual."
|
|
PRIMA data for maintenance Rituxan:
Draft Discussion and Questions PDF |
|
|
Guidelines Call for Cancer Patients to Get Moving http://bit.ly/bSoetK
"The primary objective of prescribing exercise to cancer patients and survivors is to help them regain and improve physical function, said Dr. Schmitz of the center for clinical epidemiology and biostatistics at the University of Pennsylvania in Philadelphia. Exercise can also help improve body image and quality of life for these patients."
|
|
Emotional Patients Do Not Perceive Medical Consultations and Advices http://bit.ly/axdznz
|
|
Oral green tea in asymptomatic, Rai stage 0-II CLL AbstView_74_47574
Comment: Here are reported what appears to be good signals of activity and relatively modest side effects at the chosen dose (compared to other CLL treatments). Note that there were also toxicities at what appears to be the active dose - including signals of liver toxicities - transaminitis (31% grade 1, 12% grade 2), and nausea in 55%. These are modest side effects compared to standard CLL treatments, but this has to be weighed against no treatment, because treatment is not given for early stage CLL.
When estimating the treatment effects you need to consider also the natural history of the condition in the selected population, in this case early stage CLL ... What is its typical clinical course? Does it wax and wane? How long until treatment is needed? I think it can be ten years or more. So are these clinically meaningful responses - leading to better quality of life or survival? If anything, quality of life was impaired by the side effects (up to 6 months of nausea in 55%), so long term impacts on survival - or time to first treatment (compared to observation in a controlled study) could be the key questions going forward.
|
|
Treatment of HIV-associated Hodgkin's lymphoma (HIV-HL): Results of a prospective multicenter trial http://bit.ly/9h1Tc3
"Conclusions: In pts with HIV-HL risk-adapted CT and concomitant HAART is feasible and effective. However, pts must closely be monitored for neutropenic infections. These data suggest that the prognosis of HIV-HD may approach results achieved in the HIV-negative population with HL." (Which is very good indeed.)
|
|
Hypogammaglobulinemia (hypogam) in patients receiving Rituxan and the impact of Rituxan maintenance http://bit.ly/cYmqll
We identified 215 pts treated with R for lymphoma between 12/1998 and 4/2009 and also had quantitative serum immunoglobulin levels (sIg) evaluated prior to and after treatment with R. Data on the use of IVIG was collected. ...
Rituxan was associated with developing hypogam in 39% of pts with normal baseline sIg. Pts receiving RM (Rituxan maintenance) had a significantly higher risk of developing hypogam and requiring IVIG. The risk of symptomatic hypogam should be considered in the use of R maintenance.
|
|
Meta-analysis of risk for lymphoma with immunomodulators for inflammatory bowel disease http://bit.ly/aFd4kp
|
|
Extranodal lymphomas http://bit.ly/a6AhWt
Emanuele Zucca and Franco Cavalli
|
|
Complete response rates with Lenalidomide (Revlimid) plus rituximab for untreated indolent B-cell NHL http://bit.ly/dBQerx
"28 pts were evaluable for response. The overall response rate was 86%. Complete responses (CR) were attained in 79% (65% CR/14% CRu) of pts, 2 pts (7%) had a partial response, and stable disease was seen in 4 (14%). Response rates were impressive in follicular lymphoma, with nearly all patients 16/17 (94%) attaining a CR. At a median follow up of 14.1 (9.7-18.8) months, one patient experienced progression of disease."
|
|
Lenalidomide (LEN) in patients with transformed lymphoma: Results from a large international phase II study (NHL-003). http://bit.ly/a234dx
"LEN has promising clinical activity and achieves durable responses in patients with TL. Also, it may be necessary to consider the original histology when setting a course of therapy for patients with TL. Further studies are needed in this hard-to-treat population."
|
|
Low Absolute Lymphocyte Count (ALC) associated with relapse in DLBCL http://bit.ly/cPITVc
"Patients with an ALC >/=0.96 x 10(9)/l (N=103) had a cumulative incidence of relapse of 6 versus 79% with an ALC <0.96 x 10(9)/l (N=46) (P<0.0001). This study suggests that lymphopenia measured by ALC can be used as a marker to assess risk of DLBCL relapse during routine follow-up after standard chemotherapy.
Comment: As always, it will be important for another group to replicate the finding.
|
|
Yoga Eases Sleep Problems Among Cancer Survivors http://healthday.com/Article.asp?AID=639340
Study found those who practiced it for four weeks after chemo slept better, used fewer sleep aids
|
|
Radioimmunotherapy of Lymphoma: Ahead of Its Time or Past Its Sell-By Date? http://bit.ly/9x2RgL
Tim Martin Illidge, School of Cancer and Imaging Sciences, Manchester Academic Health Sciences, University of Manchester, Manchester, United Kingdom
As we look to the future, few things are certain, but we can be sure that there will continue to be increasing numbers of patients with follicular lymphoma who are refractory to both chemotherapy and rituximab. For the latter group, there are compelling data that RIT can play an important role in both chemotherapy- and rituximab refractory disease, leading to high response rates with durable remissions.
|
|
Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation therapy (RT) http://bit.ly/cHNXNh
N = 6,568. Overall Survival at 5, 10, 15, and 20 years in the RT group was 81%, 62%, 45%, and 35% versus 71%, 48%, 34%, and 23% in patients not receiving RT. RT for early stage low-grade follicular lymphoma is greatly underused in the US population; increased use of upfront RT could prevent thousands of deaths from lymphoma in these patients.
|
|
Poverty of Riches - analysis of number of lymphoma studies versus available patients PDF
|
|
Radioimmunotherapy Consolidation in Mantle Cell Lymphoma http://bit.ly/9kt6WK PDF http://bit.ly/c7HIxm
Wojciech Jurczak, European Oncological Disease - Published: October 2008
A thorough description of the rationale for consolidation with RIT for MCL – but also informative for other lymphomas.
|
|
Orac: The never-ending saga of DCA - dichloroacetate as a cancer treatment http://bit.ly/cbfTVJ
"I don’t say this because I want DCA to fail; I say it because I would very much like to see DCA succeed."
|
|
Rituximab Maintenance Treatment of Relapsed/Resistant Follicular
NHL: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study http://bit.ly/9mVxh5
|
|
Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy. PRIMA (corrected) study: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstractID=44082
|
|
CVP followed by Bexxar in Untreated Follicular Lymphoma:
Eight-Year Follow-Up of a Multicenter Phase II Study http://bit.ly/chKTgk
After a median follow-up of 8.4 years, the median response duration had not been reached (range, 3 to 111+ months).
COMMENT: Encouraging, but once again, we have a Bexxar study design that suffers from being small (n=30) and having no randomized comparator – such as CVP-R. Further it supports the FIT study which demonstrated that chemo followed by RIT consolidation is very much worth considering – that study used Zevalin.
Regarding the risk factors in this study population, which is a problem when comparing results across studies (historical controls) – that 15 of the participants had bulky disease suggests that at least 50% had high risk FL. ~ KarlS (layperson perspective)
|
|
Lifestyle Factors Significantly Impact Survival Of Lymphoma Patients http://bit.ly/cZZB7S
"Most importantly, we didn't answer the question of whether changing these factors after diagnosis would impact survival," he says. "That is best done with a clinical trial."
|
|
Gene Expression Signature of Host Immune Response Is Predictive of Follicular Lymphoma Patient Survival in Independent Cohorts, and Correlates with Transformation to Diffuse Large B-Cell Lymphoma ASH 2009
|
|
Statin Use by Donors May Protect Stem Cell Transplant Patients From Graft Versus Host Disease http://bit.ly/8ZNK88
In a retrospective study of 567 patients who underwent hematopoietic cell transplantation from matched sibling donors between 2001 and 2007, patients whose donors had been taking statins at the time of stem cell donation experienced no severe acute GVHD.
|
|
REDUCING ENVIRONMENTAL CANCER RISK
What We Can Do Now http://bit.ly/bAe3hu
|
Critical Commentary by David Sampson (ACS): http://bit.ly/co2Esw
|
|
Orac's take http://bit.ly/c0hNZv
|
|
NPR http://bit.ly/9lg5oU
|
|
|
Too many vitamin tablets could be bad for your health http://bit.ly/aeM43O
|
|
Wilm's Tumor 1 Protein Vaccine ... for relapsed NHL after allo SCT
Patients with the blood antigen HLA-A2 and the WT1 cancer protein who have persistent or recurrent blood cancers after [allo] stem cell transplantation.
Background: "Most patients [with blood cancers] including NHL have a protein called Wilm's Tumor 1 (WT1) in their cancer cells. This protein is thought to be able to influence the growth of these cancers.
A vaccine made with the WT1 protein may boost the immune system to help fight these cancers in patients whose cancer cells contain the protein."
http://bit.ly/cGFFDG
|
|
Low Dose Naltrexone – Bogus or Cutting Edge Science? http://bit.ly/aIACkO
A scholarly examination of how “science is abused in the pursuit of health (or making money from those who are pursuing health).”
|
|
Primary Radiation Therapy in Patients With Localized Orbital MALT Lymphoma
http://bit.ly/9YUyKD Forty-three patients (93%) achieved complete remission (CR), and three patients (7%) achieved partial remission (PR). Five-year relapse-free survival, cause-specific survival, and overall survival were 93%, 100%, and 100%, respectively.
|
|
Novel antibodies in the treatment of lymphoma, S.A. Bhat, M.S. Czuczman http://bit.ly/ccYZkg
|
|
Rituximab maintenance therapy: a step forward in follicular lymphoma http://bit.ly/9pncbR
|
|
Talking to Your Doctor about Cancer-Related Symptoms http://bit.ly/dgctDj
"Because symptoms are what you experience, your healthcare providers can only know about your symptoms if you tell them. This puts you in the unique position of being the symptoms expert. Other people may not realize when or how much you hurt, that you’re exhausted and sleeping poorly, that you’ve lost your appetite, or that you’re feeling distressed." by Charles S. Cleeland, PhD, with Diana Lazzell
|
WellPoint Insurance Company routinely targets breast cancer patients http://bit.ly/bfhTad
"That tens of thousands of Americans lost their health insurance shortly after being diagnosed with life-threatening, expensive medical conditions has been well documented by law enforcement agencies, state regulators and a congressional committee. Insurance companies have used the practice, known as "rescission," for years. And a congressional committee last year said WellPoint was one of the worst offenders."
Battling the Hematological Malignancies: The 200 Years' War http://bit.ly/bnfGDv
"As we move to consider these tumors by their genetic abnormality (genotype) rather than their cellular appearance (phenotype), one converts the generalities of leukemia, lymphoma, and myeloma into hundreds of diseases with distinct genetic causes, clinical manifestations, and drug responsiveness."
Voluntary Ethics Code Set for Medical Organizations healthday.com
Role of SCT in treatment of Follicular Lymphoma - and evidence-based review http://bit.ly/d4QBN4
Decreasing Incidence of Gastric MALT Lymphomas in the Era of Anti-Helicobacter pylori Interventions http://bit.ly/c0hEQk
Fever therapy for cancer revisited http://bit.ly/9d71eD
|
|
Allergic to Rituxan? Rapid Drug Desensitization can enable you to take it. http://bit.ly/aROY6G
"413 desensitizations were performed, 94% of which induced limited or no side effects. During desensitizations, no life-threatening HSRs or deaths occurred, and all patients received their full target dose.
|
Who “owns” extra biopsy tissue? http://bit.ly/bqIYkw
Why Cancer Patients Must Advocate Vigorously for caHUB
The diligent get sick, too ... Martina Navratilova's response to her diagnosis risks feeding the idea of illness as personal failing http://bit.ly/9jXtVt
Michael Specter: The danger of science denial http://bit.ly/bAKQEg
Another Cancer Battle: Costs http://bit.ly/96zEqj
Toxicological evaluation of fucoidan from Cladosiphon okamuranus (seedweed). http://bit.ly/9vcKjT
Request for Input on the Biospecimen Procurement Program for the NCI's cancer Human Biobank (caHUB) http://bit.ly/9729P3
|
CD3 immunotoxin therapy of cutaneous T cell lymphoma http://bit.ly/b8Wvma
This novel immunotoxin has dramatic clinical activity even at the lowest dose in CTCL patients and merits applications at higher doses in CTCL and other CD3+ T cell leukemia/lymphoma patients. The lymphodepletion with recovery of T regulatory cells suggests the drug may be beneficial for immunosuppression of T cell autoimmune disorders.
Clinical trials: http://bit.ly/cz7jlZ
|
|
Dr. Brad Kahl of the University of Wisconsin talking about results/findings from Dec. '09 ASH conference
|
|
A User's Manual For The IOM's 'Quality Chasm' Report http://bit.ly/bTZGZe
Patients' experiences should be the fundamental source of the definition of "quality."
|
|
NCCN Survey of Clinicians: at Least Half of Their Patients Have Difficulty Paying for Treatment http://bit.ly/cwema3
|
|
Medication Checklist by PAL PDF
|
|
Radioimmunotherapy review article http://bit.ly/d181ic
"Currently in the United States, RIT is mainly used in the salvage setting; however, emerging data suggest that to enhance patient benefit, RIT should be administered earlier in the treatment of follicular lymphoma. In an analysis of 1,177 patients treated with 131I-tositumomab, the ORR, CR rate, and duration of response decreased as the number of prior therapies increased."
|
|
Allogeneic stem cell transplantation in follicular lymphoma: recent progress and controversy http://bit.ly/9QY8aa
"Allogeneic stem cell transplantation (allo HCT) is a curative treatment for follicular lymphoma, but is hampered by a relatively high treatment-related mortality and by difficulties in identifying high-risk groups for whom transplant is warranted."
|
|
Gene Mutations Reveal Potential New Targets for Treating aggressive form of NHL http://bit.ly/9DUMQ2
When a normal B cell encounters a foreign substance, proteins on the cell surface known as B cell receptors (BCR) activate signaling pathways that tell the cell to survive and proliferate. A signaling pathway is a stepwise series of biochemical events that help regulate important cellular functions, such as proliferation and survival. Each pathway contains points at which normal signaling can become altered, causing cells to function abnormally. Alterations in signaling pathways have been found in many types of cancer cells. Previous research had suggested that BCR signaling might contribute to the development of lymphomas; however, direct genetic and functional evidence was lacking.
In the new study, researchers first used advanced laboratory techniques to identify critical points in the BCR signaling pathway that affect the survival of lymphoma cells. They found that interference with several individual components of this pathway caused lymphoma cells to die. Thus, ongoing BCR signaling -- which the authors refer to as chronic active signaling -- is necessary for ABC subtype DLBCL cell survival.
Clinical trials: Dasatinib and NHL OR CLL http://bit.ly/a5HDEd
|
|
Analysts: about two million people will be eligible for enrollment in the high risk Health Insurance pool http://bit.ly/9hQv0e
|
|
What's in the Health Care Bill? http://bit.ly/bCqr6h
Selected Highlights for patients:
This year, adults who are uninsured because of pre-existing conditions will have access to affordable insurance through a temporary subsidized high-risk pool.
This year, insurance companies will be banned from dropping people from coverage when they get sick, and they will be banned from implementing lifetime caps on coverage.
Once the new health insurance exchanges begin in the coming years, pre-existing condition discrimination will become a thing of the past for everyone.
This year, health care plans will allow young people to remain on their parents' insurance policy up until their 26th birthday.
|
|
PET - Clinical Use Overview PAL
|
|
Anthracycline-Induced Cardiotoxicity http://bit.ly/aZOuVR
“The incidence of congestive heart failure secondary to doxorubicin-induced cardiomyopathy depends on the cumulative dose of the drug.
At total doses of less than 400 mg/m2 body surface area, the incidence of congestive heart failure is 0.14%; … this incidence increases to 7% at a dose of 550 mg/m2 body surface area and to 18% at a dose of 700 mg/m2 body surface area [6] (Figure 1).
The rapid increase in clinical toxicity at doses greater than 550 mg/m2 body surface area has made the 550-mg dose the popular empiric limiting dose for doxorubicin-induced cardiotoxicity. “
|
|
Lymphoma clinical trials including Gene expression analysis http://bit.ly/8Y8lGR
|
|
Advance Care Planning Consultation – text of Health Care Bill http://bit.ly/blPT63
We have opted for neutrality in the Healthcare debate, not for lack of heart-felt opinion on it, but to prevent ideological debates from distracting from our MISSION, which is to provide support and evidence-based information for lymphoma survivors no matter his or her ideological beliefs.
What follow is not OUR opinion on the controversial Advance Care Planning provision in the present Health Care Bill proposal, but the actual text. The purpose is to allow you to read it and to judge it first-hand. (The alternative is to form opinion based on opinion.) Here also is a link to the full text of the proposed bill: http://docs.house.gov/edlabor/AAHCA-BillText-071409.pdf
|
|
PAL Perspective: PERSONALIZED MEDICINE - not just a concept http://bit.ly/dcdqqi
|
|
Study recruiting: Bexxar vs. Zevalin: side effects, best dose, and efficacy http://bit.ly/bPlsIc
|
|
“German New Medicine”... Evidence-based, or Quackery? http://bit.ly/Germannew
|
|
FDA Initiative to Reduce Unnecessary Radiation Exposure from Medical Imaging http://bit.ly/c3wUcZ White paper: http://bit.ly/a16I0s
"FDA does not oversee the practice of medicine; however, there are direct and indirect actions FDA can take to provide healthcare professionals with tools that would inform their decisions with respect to medical imaging."
|
|
Grey Zone Lymphomas: Pitfalls in diagnostic hematopathology http://bit.ly/ba9M1V
|
|
Excellent gift ideas for cancer survivors from NHL survivor: Dr Harpham http://bit.ly/helpfulgifts
|
|
Why We Need Science: “I saw it with my own eyes” Is Not Enough http://bit.ly/aDMeWi
"For many centuries doctors used leeches and lancets to relieve patients of their blood. They KNEW bloodletting worked. Everybody said it did. When you had a fever and the doctor bled you, you got better. Everyone knew of a friend or relative who had been at death’s door until bloodletting cured him. Doctors could recount thousands of successful cases."
|
|
Cancer and Health Insurance http://bit.ly/d0KfR5
Battling the disease and realities of health insurance
|
|
Anaplastic Large-Cell Lymphoma, T-/Null-Cell Type
Eric Jacobsen, The Oncologist, July 2006 http://bit.ly/aKYe7y
|
|
Radioimmunotherapy-based conditioning regimens for stem cell transplantation - http://bit.ly/bhbmmg
|
|
Cesium Chloride (high pH therapy) for cancer?
http://bit.ly/dqmSzd | Related News
|
|
Mini-allo SCT for relapsed DLBC Lymphoma: a multicentre experience http://bit.ly/a8hDdq
|
|
Guideline for Maximum Adult Dose Limits of Chemotherapy http://bit.ly/dfTc2a, Institute for Safe Medication Practices
|
|
Cancer patients' awareness of clinical trials, perceptions on the benefit and willingness to participate: Korean perspectives http://bit.ly/dqO8Qq Br J Cancer. 2008
|
|
fertileHOPE: Cancer & Fertility Referral Guide http://bit.ly/9tfUYb
|
|
Medical and Psychosocial Aspects of Fertility After Cancer http://bit.ly/9S6nDp Cancer J. 2009
|
|
Endpoints in Oncology FDA
|
|
Selection Bias, Phase II Trials, and the FDA Accelerated Approval Process,
JNCI 2003 http://bit.ly/8ZdFGv
Selection bias, the bias induced by the enrollment process on clinical trials,
can seriously damage the external validity of trials.
|
|
Environmental and Occupational Causes of Cancer New Evidence, 2005–2007, Rev Environ Health 2009 http://bit.ly/afBT4S
|
|
Do adult transplant survivors feel need for help from mental health professionals?
Click here to participate in study http://bit.ly/bVDzdI
Click here for Frequently Asked Questions http://bit.ly/bpmWS7
(Approved by the Eastern Michigan University Human Subjects Review Committee.
Primary Investigators: J. Carey & F. Hoodin
|
|
Exhibit A in Debate on Insurance http://nyti.ms/cGHXtS
Comment: Eventually it will dawn on people that we are in a terrible downward spiral. Eventually even our representatives - who have guaranteed government-provided health insurance for life.
Misinformation, fear of change, and political one-up-man-ship has led to a tragic and malignant loop: rising rates forcing citizens to drop insurance, which drives rates ever higher, which forces more to drop insurance.
So we are fast becoming a nation of millionaire HAVES among millions of HAVE NOTS. Eventually even the wealthy will see that this will stop medical progress and erode the quality of care for all.
~ KarlS (independent comment, not necessarily representing the policy of PAL)
|
|
Expert Perspective: Constitutionality of Individual Mandate for Health Insurance http://bit.ly/b3jhyh
|
|
Preclinical: Targeted delivery of interferon alpha via fusion to anti-CD20
results in potent antitumor activity against B-cell lymphoma.
http://bit.ly/cTNX4X
|
|
Hyperthermia in Cancer Treatment: Questions and Answers http://bit.ly/cRBVH7
|
|
Preclinical: Thermal ablation of lymphoma cells with carbon nanotubes http://bit.ly/awgJny
|
|
Pixantrone briefing Doc for FDA Advisory Committee Review http://bit.ly/cEIzzm
|
|
Preventing infectious complications in patients with CLL http://bit.ly/cpSReT
|
|
Avoid Insomnia With the Three R's http://bit.ly/ctmwAM
Relaxation, Restricted sleep, and Reconditioning can be more effective than other treatments when dealing with insomnia. Find out why falling asleep may be easier to do when you follow the three R's.
|
|
What NOT To Say To People With Cancer http://bit.ly/9LObG3
You might be surprised to learn that some of the well-meaning words said to people with cancer are the things they want least to hear.
|
|
Tumor-associated Antigens for the Serological Diagnosis of
Cancer http://bit.ly/9xqoNy
|
|
Gene-based vaccines and immunotherapeutics
http://bit.ly/buNUth
|
|
Do It For The Fat Lady http://bit.ly/dk6P4p
Chaya (CLLTopics) connects the dots and speaks to what's
important and missing in clinical research.
|
|
WISE COMMENTS: Dr Wendy Harpham on radiation error articles http://bit.ly/9BFc35
|
|
SPECIAL REPORT: Progress and Deficiencies in Clinical Trial Reporting http://bit.ly/a9ffVv
"... the practice of publishing only some results, but not others,3,4 undermines our collective ability to make rational decisions about medical care. ... Ethical clinical research should contribute to generalizable knowledge and improve human health. The dedication of patients who take the risks to participate in clinical research is dishonored when their data remain secret. "
|
|
Preliminary info on stem cell toxicity: Bendamustine versus Fludarabine http://bit.ly/aOgmrR
|
|
Antioxidants Can Impair Muscle Functions http://bit.ly/9jnFVJ
|
|
Outcomes in poor countries:
Pediatric B-cell lymphoma - by subtype http://bit.ly/buMFH8
|
|
MALT: Re-infection rate and endoscopic changes after successful eradication of Helicobacter pylori http://bit.ly/52OwYs
|
|
case report: Resolution of massive pleural effusion due to lymphoma with intrapleural interleukin-2. Elkadi D, Wiernik PH, Tong TR. http://www.ncbi.nlm.nih.gov/pubmed/20063279
|
|
Gene mutation discovered: common to BOTH diffuse large B-cell lymphoma and follicular lymphoma http://bit.ly/7HRIwZ
"This morning, scientists at the BC Cancer Agency are announcing a major research discovery regarding two types of non-Hodgkins lymphoma.
BC Cancer Agency researchers have identified a never before seen mutation (or DNA spelling mistake), in the two most common types of non-Hodgkin’s lymphoma. No other types of lymphoma or other cancers have been found to contain this particular mutation.
This groundbreaking discovery, which was published online on January 17 in the prestigious international science journal Nature Genetics, is of particular importance because cancer related mutations (DNA spelling mistakes) are often observed in different sites in genes associated with individual tumours while this mutation is found in exactly the same location in samples from different lymphoma patients."
|
|
R-DHAOx - 95% (21 of 22) relapsed follicular lymphomas patients realize CRs - many with durable remissions http://bit.ly/6VASEB
Twenty-one patients (95%) achieved a complete response and one had a partial response. Responses were obtained in patients with and without resistance to prior treatment, either alone or combined with rituximab. The median follow-up time was 58.3 months (range, 8.7-92.6 months). Progression-free survival reached a plateau at 84% at 38.2 months. Only two of the 21 complete responders have relapsed.
|
|
Health Now: Insomnia: A Guide for People with Chronic Illness -Webcast http://bit.ly/8tvD8e
|
|
Stress causes cancer? http://bit.ly/6UFuB5
|
|
Radiolabeled and Native Antibodies and the Prospect of Cure of Follicular Lymphoma http://bit.ly/7mcys1
In this review, we hypothesize that the combination of an optimized biological treatment together with radiolabeled antibodies and chemotherapy early in the disease course of advanced-stage follicular lymphoma may represent the best approach to achieve prolonged disease-free survival and eventually cure.
|
|
The Mantle Cell Lymphoma Prognostic Index (MIPI) Found Superior to IPI http://bit.ly/5UsntE | Details: http://bit.ly/5gatOH
|
|
Technical: B lymphocytes: how they develop and function http://bit.ly/5PN6kj
|
|
CLL: Scientists find new leukemia gene risk factors http://bit.ly/7zIA4W
The findings mean scientists now know of 10 genetic variants associated with chronic lymphocytic leukemia (CLL), scientists at Europe's Institute of Cancer Research who conducted the study said.
|
|
Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting.
|
|
Comparing Zevalin and Bexxar in clinical practice - full text http://bit.ly/8U6IBD
|
|
How to make stem cell transplantation less toxic
http://bit.ly/8SL7qD
"In the protocol, published in the Lancet journal, TBI and standard chemotherapeutic doses were replaced by monoclonal antibodies"
|
|
Gene expression and angiotropism in primary CNS lymphoma http://bit.ly/5pQTqi
|
|
MRI and PET in monitoring response to lymphoma treatment http://bit.ly/4X6L4D
|
|
New Lymphoma Treatment Target Identified http://bit.ly/5i8pmc
|
|
Jen Cannistra (White House Office of Health Reform): How will you be affected by Health Care Reform http://bit.ly/5yoSyL
|
|
Basic genetic research: giving disease the "finger" http://bit.ly/7UFTDj
|
|
Med Bills: Tips for Dealing with a Debt Collector http://bit.ly/debt-tips
|
|
Study recruiting: Bexxar or Zevalin as First Therapy
http://bit.ly/76DI6F
|
|
A prospective study of MRI (versus CT) in lymphoma staging http://bit.ly/MRI-CT
|
|
When testimonials are used in medical advertising
http://bit.ly/orac-test
|
|
Data on Relapse pattern for MALT lymphoma http://bit.ly/MALT-recur
|
|
EMA Grants Orphan Drug Designation for Pixantrone in DLBC Lymphoma http://bit.ly/4tISak
|
|
Surviving Adult T-cell Leukemia/Lymphoma http://bit.ly/surv-t-cell
|
|
Technical: The microenvironment in mature B-cell malignancies: a target for new treatment strategies http://bit.ly/8TGgVc
|
|
Hodgkin's treatment destroys tumors with antibody linked to radioactive particle - CHT25 http://bit.ly/CHT25
|
|
How to report adverse drug events to FDA http://bit.ly/Medwatch
|
|
Fludarabine Provides OS Advantage vs Chlorambucil in Previously Untreated CLL http://bit.ly/5LgDhj
|
|
Do Male Lymphoma Survivors Have Impaired Sexual Function? http://bit.ly/6E3NTU
|
|
ASH 2009: Treanda-R versus CHOP-R for first line treatment of low grade lymphoma http://bit.ly/B-R_CHOP-R
|
|
ASH 2009: Long-Term Survival Reported with Bexxar after Rituxan Failure http://bit.ly/8Fj0W7
|
|
ASH 2009: Bexxar therapy for follicular lymphoma: Impressive Long-Term Data http://bit.ly/glaxo-bex
"Across ten years, we are seeing a consistent result and effect on survival by treating patients with BEXXAR first. Rarely are there data to show a treatment can produce a durable response over a decade, and what's most exciting is that these results were achieved after a single treatment," said Mark Kaminski, MD
|
|
TRU-016 (Anti-CD37) Early Promising Clinical Activity in Relapsed CLL: http://bit.ly/TRU-016
|
|
Lenalidomide (Revlimid) Oral Monotherapy in Patients with Mantle
Cell Lymphoma Previously Treated with Bortezomib (Velcade) http://bit.ly/VandR
|
|
SGN-35 Active Against Relapsed CD30-Positive Lymphomas
Abstract: http://bit.ly/sgn-35 Trials: http://bit.ly/sgn-35-trials
|
|
Vitamin D Deficiency Associated with Inferior Outcomes in DLBCL
http://bit.ly/vit-D-survival | Comment
|
|
Help Consolidating Medical Bills / Avoiding Bankruptcy? http://bit.ly/nfcc-org
|
|
Therapeutic Potential of Anti-CD137 Antibody in Lymphoma, - targeting T-regs, Levy http://bit.ly/Anti-CD137
|
|
Adoptive Cell Therapy for Lymphoma: Use of CpG-Loaded Tumor Cells to Generate Potent Anti-Tumor CD4 T Cell Immunity, Levy http://bit.ly/cpg-loaded
|
|
Gene Expression Signature of Host Immune Response Predictive of Follicular Lymphoma Patient Survival and Correlates with Transformation http://bit.ly/FL-gene-exp
|
|
Preclinical: Novel Anti-CD19/Idiotype Bispecific Diabody Vaccine for B-Cell Lymphoma http://bit.ly/Diabody
|
|
Preclinical: Antibody Targeting CD47 Synergizes with Rituximab to Completely Eradicate Human B-Cell Lymphoma in Mice http://bit.ly/cd47-rit
|
|
SB1518 Oral JAK-2 Inhibitor SB1518 active in Patients with Relapsed Lymphoma http://bit.ly/SB1518
Clinical trial info http://bit.ly/7E9hds
|
|
Oxygen Therapies for Cancer? ONCOLOGY. Vol. 23 No. 13, Integrative Oncology http://bit.ly/oygen-tx-cancer ... NOT!
|
|
Trial: Lenalidomide With AT-101 (bcl-2 inhibitor) for Relapsed or Refractory CLL http://bit.ly/L-AND-R-CLL
|
|
Diffuse Large B-Cell Lymphoma http://bit.ly/DLBCL-friedberg
Jonathan W. Friedberg, M.D., M.M.Sc.* (2009)
|
|
Very good NY Times article on hospice care http://bit.ly/4Qu0y8
|
|
Increased Cancer incidence and mortality associated with folic acid and vitamin B12 treatment http://bit.ly/folic-acid-cancer
Results mainly driven by increased lung cancer incidence in participants who received folic acid plus vitamin B(12).
|
|
Detailed Statistics for NHL http://bit.ly/SEER-NHL
|
|
Detailed Statistics for Hodgkins http://bit.ly/SEER-Hodkgins
|
|
Register for Dr Friedberg talk: Treatment advances from ASH http://bit.ly/LLS-ash-report
|
|
Natural history of follicular grade 3 non-Hodgkin's lymphoma.
Bierman PJ. Curr Opin Oncol. 2007 Sep;19(5):433-7. Review
|
|
Thumbs up! Start your clinical trial search with TrialCheck.org http://bit.ly/5N9AFh
|
|
Valproic acid leads to CR in a patient with refractory DLBCL ncbi.nlm.nih.gov (no abstract)
|
|
Clinical trial query: Lymphoma or CLL AND Valproic acid: http://bit.ly/4yx3VU
|
|
Case reports: Successful antibiotic treatment of H- pylori negative gastric MALT lymphomas http://bit.ly/6rQCG2
|
|
Reports on "psychological stress" AND risk of lymphoma http://bit.ly/4Tu0Ni
|
|
Risk Factors for Early Transformation of Follicular Lymphoma: Report From the National LymphoCare Study (NLCS) http://bit.ly/5KN44N
|
|
Bexxar for NHL Patients Who Progressed After Rituxan: Long Term Follow-up http://bit.ly/5RRJgD (n = 40)
|
|
Mayo Clinic on chemo mouth sores: what causes, which days are worst, how to help prevent, how to cope. http://bit.ly/78jiYn
|
|
New cancer target - heat shock protein 90, necessary for BLC-6 protein known to drive lymphoma tumor cells http://bit.ly/8U2TJT
|
|
Dr. Mitchell Smith
-
indolent lymphomas
|
|
SEER: Lymphoma incidence rates by subtype (2001-06) http://bit.ly/8MGIXM
|
|
SEER: NHL lymphoma Relative Survival by Subtype (1988-2001) http://bit.ly/4LHubC
|
|
Technical: Transformation of follicular lymphoma to DLBCL proceeds by distinct oncogenic mechanisms http://bit.ly/8Sx0e1
|
|
Bexxar for Previously Untreated, Advanced-Stage, Follicular Lymphoma: Median 10 Year Follow-up Results http://bit.ly/368zpv
|
|
Lenalidomide and Rituximab in Relapsed / Refractory Indolent NHL http://bit.ly/4jrg36
|
|
The anticancer immune response: indispensable for therapeutic success? http://bit.ly/4mm0rn
|
|
Cytarabine (ARA-C) Plus Methotrexate Superior for Patients With Primary CNS Lymphoma http://bit.ly/3am1t8
|
|
Wendy Harpham on The Art of Survivorship
|
|
When to suspect a diagnosis of lymphoma, Dr Philip Murphy
http://bit.ly/48ibqg
|
|
Reusable queries to locate studies that include genetic analysis Follicular | CLL | DLBCL | Lymphoma unspecified
|
|
Lenalidomide: Durable Responses in Indolent NHL http://bit.ly/1SKZQH
|
|
Statins found not to influence prognosis of patients with DLBCL receiving R-CHOP therapy http://bit.ly/4wZkKS
|
|
Relapsed or refractory nongastric marginal zone B-cell lymphoma: Multicenter retrospective analysis of 92 cases.
Am J Hematol. 2009. PubMed - Related Articles
|
|
BEACOPP in refractory and relapsed Hodgkin lymphoma. Leuk Lymphoma. 2009;50:1803-8. (n=23) PubMed - Related Articles
|
|
Interim PET scan in Hodgkin lymphoma: Leuk Lymphoma. 2009;50:1761-4. PubMed - Related Articles
|
|
Concurrent Radiation and Weekly Cisplatin Followed by VIPD in Newly Diagnosed, Stage IE to IIE, Nasal, Extranodal NK/T-Cell Lymphoma, J Clin Oncol. 2009. (n=32, newly diagnosed pt) PubMed - Related Articles
|
|
Mucosa-associated lymphoid tissue lymphoma of the breast: bilateral metachronous presentation. Leuk Lymphoma. 2009. PubMed - Related Articles
|
|
A phase 1/2 trial of arginine butyrate and ganciclovir (anti-viral) in patients with EBV–associated lymphomas http://bit.ly/3g1dn6
|
|
Systematic review: 131I–Tositumomab (bexxar) in lymphoma http://bit.ly/3zGtur
|
|
Azacytidine is a so-called epigenetic agent, which might "activate tumor suppressor genes silenced by hypermethylation, resulting in an antitumor effect." The goal of pre-treating with this agent is to make the tumor cells more sensitive to standard treatments.
... The concept of the following two studies is a bit like pre-soaking your clothes before putting them in the regular wash.
* Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma
http://clinicaltrials.gov/ct2/show/NCT01004991
* Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory
Follicular Lymphoma
http://clinicaltrials.gov/ct2/show/NCT00901069
* All CLL/Lymphoma studies incorporating Azacytidine http://bit.ly/2qDAXc
* One report on clinical safety report for Azacytidine:
http://clincancerres.aacrjournals.org/content/14/19/6296.full
|
|
Getting closer to curing pediatric acute lymphoblastic lymphoma http://bit.ly/35rUl3
|
|
Immunotherapy Demonstrates Long-Term Success in Treating EBV+ Lymphoma http://bit.ly/71qLT
|
|
Oncologists: Challenges to Enrolling Our Patients in Trials
Obstacles: Chart PDF | Most Significant Chart PDF
|
|
When Children get Cancer: Help for Mom and Dad
|
|
Lymphoma Patients Benefit From Exercise http://bit.ly/4A5sXL
|
|
Cheson: The case against maintenance Rituxan for follicular lymphoma http://bit.ly/2XZODb
|
|
Ofatumumab (ant-cd20 mAb) approved for CLL http://bit.ly/1KvFvf
|
|
CAL 101 Shows "Encouraging" Preliminary Results in
Small Lymphoma/CLL Studies http://bit.ly/45ieDF
|
|
Understanding Population and Individual Risk Assessment: The Case of Polychlorinated Biphenyls and Lymphoma http://cebp.aacrjournals.org/content/15/5/830.full
|
|
Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease http://bit.ly/2nx4Ue
|
|
The use of PET scanning in lymphoma: progress and problems
by Morton Coleman, MD http://bit.ly/2YqBvQ
|
|
New strategies to deliver anticancer drugs to brain tumors (technical, Oct 2009) http://bit.ly/37NTog
|
|
Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma.
n = 10 http://www.ncbi.nlm.nih.gov/pubmed/19817748
|
|
Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell NHL
n = 18 http://www.ncbi.nlm.nih.gov/pubmed/19808874
|
|
Study of KRX-0401 (Perifosine) in Relapsed or Refractory CLL/SLL Open for Enrollment at Duke CCC http://bit.ly/ WVFAT
|
|
Regarding FDA transparency policy
|
|
FDA warns against fake online H1N1 remedy claims http://bit.ly/4nTjiY
|
|
Mapping the Emotional Journey (through Cancer)
(Excellent coping skills and tips!)
Dr. Joseph Himle, PhD, Director, Psychosocial Programs,
University of Michigan Depression Center
|
|
Rationale for Consolidation to Improve Progression-Free Survival in Patients with Non-Hodgkin's Lymphoma: A Review of the Evidence http://bit.ly/2ttiY3
"With the higher CR rates and longer Progression Free Survival (PFS) times observed in patients with FL and DLBCL, as well as encouraging early data from MZL and MCL consolidation trials, RIT appears to have an important role in the treatment of patients with NHL."
|
|
Researchers Urge Quicker Approval for Biosimilars http://bit.ly/2lYndn
|
|
Gene Activity Networks That Let Tumors Thrive And Suggests New Modes Of Therapy http://bit.ly/1418dI
|
|
Cancer survivors: Managing late effects of cancer treatment http://bit.ly/2pRN9B
|
|
Reproductive factors, exogenous hormone use and risk of lymphoid neoplasms among women in the National Institutes of Health-AARP Diet and Health Study Cohort. http://bit.ly/1gEc3z
|
|
Green tea consumption and hematologic malignancies in Japan: the Ohsaki study http://bit.ly/LH0B
|
-
Lymphoma 101, Dr. Klein
-
Lenalidomide (Revlimid) Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent NHL http://bit.ly/1SKZQH
-
Transplants in lymphoma: Current Use and Outcomes http://bit.ly/TfFqK
-
Rationale for Consolidation to Improve Progression-Free Survival in Patients with Non-Hodgkin's Lymphoma: A Review of the Evidence Full text: http://bit.ly/2ttiY3
"With the higher CR rates and longer Progression Free Survival (PFS) times observed in patients with FL and DLBCL, as well as encouraging early data from MZL and MCL consolidation trials, RIT appears to have an important role in the treatment of patients with NHL."
-
Radiotherapy showed favorable outcome in treating early stage extranodal nasal-type NK/T-cell lymphoma in children and adolescents. Pubmed/19812381
-
Stem cell mimicry: key to lymphoma transformation? http://bit.ly/2bTkKc
-
Zevalin® Active for Treatment of Extranodal Marginal-zone Lymphoma
http://bit.ly/63o6Y
-
Advance Directives: Five Wishes: http://bit.ly/362YEO
Five Wishes lets your family and doctors know: Link to PDF
-
Few Risks To Newborn Offspring Of Parents Who Are Childhood Cancer Survivors, Studies Find http://bit.ly/2RbjHM
-
Study recruiting: Bendamustine with Rituxan , then Revlimid Maintenance for relapsed CLL and SLL http://bit.ly/ah5Ie
This seems a study worth considering, given the proven activity of Bendamustine and Revlimid in CLL and the need for protocols that may induce more complete remissions in the relapse setting ... that are also longer lasting.
-
High-dose methotrexate plus high-dose cytarabine improved outcome in CNS lymphoma http://bit.ly/151Qss
After chemotherapy, more patients in the combination therapy group achieved complete remission (46%; 95% CI, 31-61) than in the methotrexate alone therapy group (18%; 95% CI, 6-30). The overall response rate was 69% (95% CI, 55-83) in the combination group vs. 40% (95% CI, 25-55) in the monotherapy group.
The three-year failure-free survival rate was 38% in the combination group compared with 21% in the group assigned to methotrexate alone (P=.01).
-
NEW Chronic pain treatments work better together http://bit.ly/M0rip
"When given both an anti-seizure drug (gabapentin) and an antidepressant (nortriptyline), patients suffering from neuropathic pain caused by nerve damage or disease experienced less pain than when they took one or the other individually, reports Ian Gilron"
-
Tumor suppressor gene methylation in follicular lymphoma: a comprehensive review http://bit.ly/4Eih9o
Hyper-methylation: similar to car with an ignition that is filled with a glue (methyl). The ignition (the gene) cannot be turned off so the car runs continuously . See PAL
-
Boosting your immune system to fight cancer? http://bit.ly/1euzrK
-
What is Lymphoma? PDF
Free to print and distribute
-
Update: The PROBLEMS with Testimonials PDF
-
FDA grants accelerated approval for FOLOTYN (pralatrexate) to treat relapsed peripheral t-cell lymphoma http://bit.ly/29Rb4l
-
Expert perspectives on follicular lymphoma vaccine http://bit.ly/kJKQL
-
Folate, B vitamins, methionine and risk of NHL http://bit.ly/j2Ugq
-
Randomized Controlled Trial of the Effects of Aerobic Exercise on Physical Functioning and Quality of Life in Lymphoma Patients http://bit.ly/3q2BEf
-
Extranodal natural killer/T-cell lymphoma:
current concepts in biology and treatment. Kohrt H, Advani R Leuk Lymphoma. 2009 Sep 10:1-12. PMID: 19757316
-
study: Health Insurance and Mortality in US Adults http://bit.ly/2E9sv3
-
Comment: on advocacy that demonizes FDA PAL
-
Progenitor and lymphoma cells in blood stem cell harvests: impact on survival following transplantation http://bit.ly/tk7sJ
"Lymphoma contamination of transplanted apheresis products had no apparent impact on event-free and overall survival." Bone Marrow Transplantation (2001) 28, 207-212.
-
Regarding ABT-263 - inhibitor of inhibitors of lymphoma cell death - a Dose Finding Study http://bit.ly/10qBna
-
Skin cancers occur more frequently in lymphoma survivors - could be secondary to treatment or a risk factor of the disease
Action: Be sure to self-check for suspicious moles (see chart below), and have your doctor examine you regularly - once a year. See for additional information
-
GVHD (Graft-Versus-Host Disease):
A Guide for Patients and Families After Stem Cell Transplant http://bit.ly/DrGiY
-
Bid on Drawing donated to support Patients Against Lymphoma http://bit.ly/sIeiS
-
Controversies in the Treatment of Lymphoma with Autologous Transplantation http://bit.ly/EG68R
-
The Biology of Human Lymphoid Malignancies Revealed by Gene Expression Profiling Louis M. Staudt and Sandeep Dave http://www.pubmedcentral.nih.gov (full text)
-
What's Really in Supplements?
-
Regulators and Physicians Raise Alarms About Dangerous Ingredients in Many Herbal Remedies
-
GVHD: Prochymal no better than a placebo in two final trials http://bit.ly/BkDo9
Osiris said Tuesday preliminary results for two Phase III trials evaluating Prochymal for the treatment of acute graft versus host disease showed no statistical difference between the drug and a placebo in either trial. Osiris said Prochymal did show significant improvements in response rates in difficult-to-treat liver and gastrointestinal graft versus host disease even as it failed to meet its primary endpoint in both trials.
-
The late adverse events of rituximab therapy--rare but there! http://bit.ly/m9Zjw
"... late adverse events of rituximab are indeed uncommon but at the same time probably under-reported. In this review, we detail late adverse events reported since its use in hemato-oncological neoplasias and other disorders. These adverse events include the development of late-onset neutropenia, defects of immune reconstitution with associated immune compromise, infections, progressive multifocal leukoencephalopathy, reactivation of hepatitis, intestinal perforation and interstitial pneumonitis."
-
John Hopkins Radioimmunotherapy Survey of Lymphoma for Medical Oncologists http://bit.ly/W0RuE
-
Encouraging report: Arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed adult T-cell leukemia/lymphoma (ATL). http://bit.ly/3t5gvg
n = 10 newly diagnosed ATL
"An impressive 100 percent response rate was observed including 7 complete remissions, 2 complete remissions but with more than 5% circulating atypical lymphocytes, and 1 partial response. Responses were rapid and no relapse was noted. Side effects were moderate and mostly hematologic. In conclusion, treatment of chronic ATL with arsenic, interferon-alpha, and zidovudine is feasible and exhibits an impressive response rate with moderate toxicity."
-
Support for immunologic therapy research lacking
http://bit.ly/MyIWo
comment: NCI should dedicate more resources to the study of immunotherapy against lymphomas and other cancers, including how tumors hide, escape, or promote tolerance. The rationale is that such research is not only promising (as described nicely in the article), but discoveries would likely have broad application, well beyond lymphomas/cancers, such as improving our understanding and treatment of autoimmune diseases.
-
Zevalin wins approval for first line use in follicular lymphoma as consolidation therapy http://bit.ly/k0bm9
"the FIT trial demonstrated that when used as part of first-line chemotherapy for patients with follicular NHL, ZEVALIN significantly improved the median progression-free survival time from 18 months (control arm) to 38 months (ZEVALIN arm) (p<0.0001)."
-
A Tale of Two FDA ODAC Deliberations see comments
-
H-pylori infection and dermatologic diseases (including lymphoma) http://bit.ly/2JXMPF
-
Anxiety screening test http://bit.ly/13xVBV
helps "determine whether you might have an anxiety disorder that needs professional attention. This screening measure is not designed to make a diagnosis of an anxiety disorder or take the place of a professional diagnosis or consultation."
-
Second SCT for lymphoma patients who relapse after autotransplantation? Freytes CO, Lazarus HM. Bone Marrow Transplant. 2009 Aug 24.
-
Primary central nervous system mucosa-associated lymphoid tissue lymphoma: case report and literature review. Razaq W, Goel A, Amin A, Grossbard ML. Clin Lymphoma Myeloma. 2009 Jun;9(3):E5-9. PMID: 19525185
-
Phase I of AR-12, a PDK-1 Inhibitor Targeting the PI3K/Akt Pathway http://bit.ly/13CT7p
-
‘‘America’s Affordable Health Choices Act of 2009’’ H. R. 3200 http://bit.ly/EAPTw
-
Financial Management During a Medical Crisis http://bit.ly/LnWLy
By Linda Foster, MA Medically reviewed by Cynthia Haines, MD ... When your loved one has a medical crisis, the last thing you want to — or can — think about is money. Sound financial planning will give everyone peace of mind.
-
Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. http://bit.ly/yYvN9
-
Technical: How lymphoma cells may become resistant to Rituxan http://bit.ly/ClWzy
-
Transformation of medicine from a 'one size fits all' to one much more narrowly focused. http://bit.ly/3H8TH
-
Responses to the panobinostat (pan HDAC inhibitor) in refractory Hodgkin Lymphoma http://bit.ly/11whFy | Open studies http://bit.ly/1hGznY
-
Dr. J. Leonard, 2007 audio: Clinical use of radioimmunotherapy
-
Access to Investigational Lymphoma or Cancer Drugs Outside of a Clinical Trial (Expanded Access) http://bit.ly/K6Cor
HOWEVER: "Manufacturers may not always be willing or able to provide access to a drug outside of their clinical trials. Physicians may not always be able to seek expanded access for patients, depending on a patient’s medical history and the risks associated with taking an investigational drug. The physician must determine that the probable risk from the drug is not greater than the probable risk from the disease."
Also See Our Resource on Compassionate Use
-
When to Consider Clinical Trials for lymphoma? (and other cancers):
based on clinical circumstances? PAL
Comment: New clinical practice policy is needed ... indeed it might be unethical to
not discuss clinical trials in some clinical circumstances? ~ KarlS
-
Zelenitz, 2007 Treatment strategies for patients with mantle-cell lymphoma
-
Elements of evidence: C-P-R: Credibility, Plausibility, Reproducibility. http://bit.ly/evidenceCPR
Comment: Very nice and easy-to-remember principles, with a familiar example of causality based on reproducibility: "Touching a hot stove burner always results in a burned hand. No matter how frequently you test this causal relationship, the result will be similar."
-
Experts on Health Care Reform 2009 at http://healthcarereform.nejm.org/
"A growing series that currently includes almost 100 Journal articles and online features, a diverse group of authors representing all parts of the health care system and all points of view have wrestled with the issues the country faces. The articles provide thoughtful commentary on universal coverage, comparative-effectiveness research, outcomes research, health information technology, economic challenges and cost containment, and new delivery systems." nejm.org
-
Why We Need Science: “I saw it with my own eyes” Is Not Enough
"For many centuries doctors used leeches and lancets to relieve patients of their blood. They KNEW bloodletting worked. Everybody said it did. When you had a fever and the doctor bled you, you got better. Everyone knew of a friend or relative who had been at death’s door until bloodletting cured him. Doctors could recount thousands of successful cases."
-
Results from a Study of Arzerra (Ofatumumab) in Rituximab Refractory Follicular NHL ad-hoc-news
Comment: Not impressive but certainly not surprising - since the participants were refractory to the same class of drug (rituxan). Mindful that in a 10% response rate, 90% did not respond and got only the toxicity ... could have been better off treated differently. (If we had a biomarker predicting response to ofatumumab in this population .... that would be a horse of a different color!) What remains to be seen is if ofatumumab is equivalent or better than rituxan in previously untreated or once-treated FL patients. My expectation is that it will be at least equivalent (and this study seems to support that belief), so I do hope it finds a path to approval. I'm not confident this is it ... but perhaps it will succeed for relapsed CLL ~ KarlS
-
Favorable clinical outcome in patients with small intestinal NHL
Leuk Lymphoma. 2009 Aug 10:1-7. PMID: 19672778
"... all patients who underwent complete resection of the small intestinal lesion had extremely favorable results. Further studies are warranted to establish optimal therapeutic strategies."
-
High rate of survival in transformed lymphoma after autologous stem cell transplant: pathologic analysis and comparison with de novo diffuse large B-cell lymphoma. http://www.ncbi.nlm.nih.gov/pubmed/19672775
n = 56 "select" patients with transformed lymphoma (25) or de novo DLBCL (25)
Comment: encouraging news given the prognosis of transformed lymphoma, but the study is small (n = 25 transformed) and the participants were selected by investigators using unspecified criteria ... key factors such as age and having chemo-sensitive disease, untreated/previously treated, etc. were not described in the abstract.
-
Expert and Fact-based Perspective on Health Care Reform PAL
Added content: Health Insurance Reform - FACT CHECK whitehouse.gov
-
Sponsor reports Positive Phase II Results Using PROCHYMAL™ for the Treatment of Acute Graft vs. Host Disease osiristx.com pdf
Phase II study using PROCHYMAL for the treatment of acute Graft vs. Host Disease or GVHD. In the study, 29 of 31, or 94% of evaluable patients responded after receiving two infusions of PROCHYMAL. More significantly, 23 patients, or 74% achieved a complete response, meaning the patients had experienced total clinical resolution of the disease. Currently, PROCHYMAL is being evaluated in a Phase III trial for the treatment of steroid refractory GVHD.
Clinical Trials for Graft versus Host Disease
-
Allogeneic Transplantation with Reduced Intensity Conditioning (mini): Importance of Histology for Outcome pubmedcentral.nih.gov
Biol Blood Marrow Transplant. 2009 (Full text) Philippe Armand, MD, PhD,1 Haesook T. Kim, PhD,2 Vincent T. Ho, MD,1 Corey S. Cutler, MD,1 John Koreth, MD,1 Joseph H. Antin, MD,1 Ann S. LaCasce, MD,1 Eric D. Jacobsen, MD,1 David C. Fisher, MD,1 Jennifer R. Brown, MD, PhD,1 George P. Canellos, MD,1 Arnold S. Freedman, MD,1 Robert J. Soiffer, MD,1 and Edwin P. Alyea, MD1
"These results emphasize the importance of lymphoma histology for patients undergoing RIC SCT, as well as the lack of relevance of donor chimerism for outcome in this patient population"
-
FDA Final rule for Expanded Access to Investigational Drugs for Treatment Use (PDF - 603KB)
AND Charging for Investigational Drugs (PDF - 394KB)
-
Research to Practice - Interviews with Lymphoma Experts (2005-7) researchtopractice.com
-
Gemcitabine and Bortezomib in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma clinicaltrials.gov/
This phase I/II trial is studying the side effects and best dose of bortezomib when given together with gemcitabine and to see how well they work in treating patients with relapsed or refractory B-cell or T-cell non-Hodgkin's lymphoma.
-
Follicular Lymphoma: Experimental Vaccine Extends Disease-Free Survival oncology-times.com
Dr. Levy noted that in the time since patients were recruited, rituximab has added a powerful advantage in improving the treatment of follicular lymphoma.
There still could be a role for vaccination, but there need to be trials in which the vaccine Is given before and/or after treatment with chemotherapy plus rituximab, he said.
Also needed are methods to produce the vaccine more quickly. Dr. Levy's conclusion: a qualified yes that the trial is a positive result. But, he said, much more work needs to be done.
See also PAL comment
-
Patients with certain blood cancers [Mantle Cell] eligible for Quick Disability Determination examiner.com
-
Cancer cells protected by immune system sciencedaily.com
Comment: This item appears to address why immune-boosting has not worked, and would not work as cancer treatment. A key to using this information will be figuring out how to suppress regulatory t-cell function in a way that's specific to the tumor and does not lead to autoimmune disease. ~ KarlS
-
UK study: Rituxan vs. observation in asymptomatic follicular lymphoma ClinicalTrials.gov
-
Role of Stem Cell Transplant in the Management of Follicular Lymphoma theoncologist.alphamedpress.org
-
Orac on Cancer research and clinical trials
"... we absolutely can't make any progress against cancer without well-designed clinical trials that accrue enough patients to have the statistical power to tell if a new treatment is working better than the standard of care."
-
The World Health Organization's ranking of the world's health systems. photius.com |
Original report by WHO: PDF
# 1 = France .... see also Health Care Lessons From France npr.org
-
New PAL topic: Types of Protocols:
Standard | On Label | Off-label | Off-Protocol | Investigational - Expanded Access | Alternative?
Part of coming to terms with the diagnosis of a lymphoma (or any cancer) is the challenge of understanding the language of our doctors as it relates to our medical choices and even what is covered by insurance and why.
-
Lack of Study Volunteers Hobbles Cancer Fight nytimes.com/
Comment: We wholeheartedly agree... that patient participation in trials is the most significant obstacle to progress ....
Hey Arnie, as per usual I think you're on to something ... fixing the system rather than blaming any of the parties. It could be important to such a system that the compensation not be tied to any recommended investigational protocol,, instead basing it on the appropriateness of the study to the patients diagnosis and clinical circumstance ... we do not want a conflict
of interest to influence the referral to a study. Do you agree? ~ KarlS
Arnie: It strikes me that a partial solution to the problem of inadequate number of patient volunteers to make clinical trials viable is to realign the financial contingencies oncologists face when attempting to recruit patients for trials. Instead of being financially punished for their efforts to recruit volunteers, why not financially reward oncologists IF a patient
is accepted into a clinical trial. Doctors are the logical focus and source for patient volunteers, who must meet the study's public criteria for acceptance into the study. I have to also believe they recognize the need and value of cancer research. They likely know which of their patients are best qualified for a study and therefore would be highly probable to be
accepted. An accepted patient should be remunerative enough to make an oncologist likely to continue making referrals in the future. The knowledge gained from the completed trials will hopefully justify the expense involved. Can it be any more expensive than what pharma [is trying now].
Betsy: Discouraging...depressing....sad. | First post: Kind of discouraging, isn't it?
See our ongoing project: http://lymphomation.org/clinical-trials-participation.htm ~ KarlS
-
BiTE Receives European Orphan Drug Designation for Treatment of Acute
Lymphoblastic Leukemia (ALL) prnewswire.com | About BiTE
Comment: Good news for ALL patients ... and for ALL of us ... approvals for one indication generally paving the way for broader use for other cancer types that are targeted by the drug. In this case, cd19 is commonly expressed on b-cell lymphomas. ~ KarlS
-
Testimony of Wendell Potter, Before the U.S. Senate Committee on
Commerce, Science and Transportation pbs.org
-
Most cancer patients try nontraditional treatments ctv.ca
"Yet they are extremely popular with cancer patients, who crave control over their disease and want to do everything they can to be healthy -- emotional needs that make them vulnerable to clever marketing and deceptive claims."
-
Antibodies Kill Leukemia, Lymphoma Cells via Lysosomal Toxins oncologystat.com
-
Therapeutic effect of CD137 immunomodulation in lymphoma bloodjournal.hematologylibrary.org
Comment: If ever there was an approach to root for it would be how to prevent immune tolerance of tumor cells following treatment ... T-regs being a suspect in explaining the disappointing results with vaccines to activate immunity against tumors. ~ KarlS
Anti cd137 is already being studied in patients with advanced melanoma, so we should learn from this about any safety issues, which would likely be applicable across cancer types. ~ KarlS
-
Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients
ingentaconnect.com
"On the basis of our results, single-agent treatment with i.v. rituximab appears to be feasible and safe and results in a high rate of durable remissions. Judging from our data, it appears to be an attractive treatment option and should be directly compared with local radiotherapy."
-
More on FIT study to compare the efficacy and safety of Zevalin consolidation versus no
further treatment (control) in patients with advanced-stage follicular NHL responsive to first-line chemotherapy cancerconferences.org .pdf
See page 11 and 12 for details on protocols given prior to Zevalin
-
Gene linked to increasingly common follicular lymphoma eurekalert.org/
"Dr. Brown said individuals who had the A variant were nearly twice as likely to develop follicular lymphoma. ... To reduce the potential for complicating factors, the more than 3,000 samples in the UC Berkeley-TGen study were from individuals who were HIV negative."
-
Finding & Evaluating Online Medical & Support Information PDF
a presentation by Karl Schwartz, President, Patients Against Lymphoma
-
ASCO 2009: Prolonged Rituximab [monotherapy] Extends Remission in Follicular Lymphoma
medscape.com (free login req.)
"Of the 202 patients enrolled in the study, 151 were randomized. The median age of the patients was 57 years, 85% of the cohort had stage III or IV disease, 50% had bone marrow involvement, and two thirds had been previously treated with chemotherapy. All participants received rituximab at the standard dose of 375 mg/m2 weekly for 4 weeks, and were re-evaluated at week 12. Patients who responded to the therapy or who had stable disease were then randomized to either no further treatment, which was standard at that time (observation group; n = 78), or to 4 additional doses of rituximab given at 2-month intervals (extended-rituximab group; n = 73). At a median follow-up of 8.9 years, among surviving patients who had been followed for at least 5 years, the median event-free survival (time to progression, relapse, second tumor, or death) was 13 months in the observation group and 24 months in the extended-rituximab group (P = .0012)."
-
Secondary malignancies after therapy of indolent NHL
Haematologica 2008 93: 336-338., Jonathan W. Friedberg - full text haematologica.org
-
Is it Reputable? a checklist for judging the credibility of online information PDF
-
Bring List - to foster timely, efficient, coordinated care PDF
-
Radioimmunotherapy: FIT to be applied? Randomized study shows improved PFS by 2 yrs in follicular lymphoma when given as consolidation for chemotherapy Medscape.com ( login req.)
n = The trial compared a single Zevalin treatment with observation in 414 patients with advanced (stage 3 or 4) follicular lymphoma who had achieved partial or complete remission after first-line chemotherapy. The choice of which chemotherapy regimen to use for induction was left to the physicians' discretion, and various combinations were used, including CVP, CHP, fludarabine, chlorambucil, and rituximab.
-
Comparison of CT, PET, and PET/CT for Staging of Patients with Indolent NHL
full text: pubmedcentral.nih.gov
-
R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature pubmedcentral.nih.gov
-
ASCO 2009: Expert Video Perspective on Lymphoma James O. Armitage, MD medscape.com/
-
Study Suggests New First-line Treatment Option for Follicular Lymphoma cancer.gov
-
Updated Phase II Results With Radiolabeled Epratuzumab in Non-Hodgkin's Lymphoma drugs.com
n = 62
The overall objective response rate (partial and complete responses) in 62 evaluable patients was 64%, with 49% of patients having a complete response. Both the objective and complete response rates appear to correlate with cumulative doses. In 16 patients unresponsive to last therapy, 75% responded to Y-90 epratuzumab tetraxetan with 56% complete responses. More importantly, responses were seen across all different types of NHL.
-
Understanding Clinical Trial Design: PDF A Tutorial for Research Advocates
Authored by Jane Perlmutter, PhD
for Research Advocacy Network’s Advocate Institute
-
Allogeneic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin's lymphoma Claviez A, Canals C, Dierickx D, Stein J, Badell I, Pession A, Mackinnon S, Slavin S, Dalle JH, Jurado Chacon M, Sarhan M, Wynn RF, Suttorp M, Dini G, Sureda A, Schmitz N.
Blood. 2009 Jun PMID: 19498021
-
Background for professionals: Optimal Use of Prognostic Factors in NHL
asheducation book.hematologyl ibrary.org
-
Reports and background on novel gene-based immunotherapy, ISF35
Intra-nodal injection of adenovirus encoding recombinant CD40-ligand (Ad-ISF35) in patients with CLL (ASCO 2009). http://www.abstract.asco.org/AbstView_65_33602.html
Abstract on chemo-sensitizing properties (ASCO 2009):
http://www.abstract.asco.org/AbstView_65_35718.html
Technical details on ISF35 technology - Patent information:
http://www.faqs.org/patents/app/20080318886
-
ABT-263 activity and safety in patients with relapsed or refractory lymphoid malignancies in particular chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
http://www.abstract .asco.org/ AbstView_ 65_30712. html
ABT-263 showed favorable PK and safety profiles with anti-tumor activity in relapsed/refractory CLL/SLL and follicular lymphoma. Identification of optimal dose and schedule for phase II trials continues.
ABT-263 studies recruiting: ClinicalTrials.gov
-
Comparing R-CHOP 14 and R-CHOP 21 for the treatment of patients with newly diagnosed DLBCL.
n = 1,080 randomized to CHOP-R x14 (dose dense schedule) vs. CHOP-R 21 day schedule
Comment: Very encouraging overall results: 2-year failure-free survival rate for the entire cohort of 74% . Important study because of the size (n >1,000) and that it was randomized. Curious that the protocols compared were not given with an equal number of rounds? x6 vs. x8. Small increased trend in cardiac toxicity with dose dense CHOP-R x 6 - 2% vs 0.4%
-
The "autophagy pathway" could be a very important nut to crack, so it bears watching. http://www.ncbi.nlm.nih.gov/pubmed/19216910
This pathway appears to shut down treatment-stressed cells so that they survive in a dormant-like state, or in hypoxic (low oxygen) conditions. This cell survival pathway might explain resistance to Rituxan http://www.abstract.asco.org/AbstView_65_33619.html
For technical background on autophagy, Autophagy in Cancer: Good, Bad, or Both?: http://cancerres.aacrjournals.org/cgi/content/full/66/19/9349
-
Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete
remission: Phase III clinical trial results. abstract .asco.org
n = 234 pts enrolled; 177 (76%) achieved CR/CRu and were randomized.
Of 177 randomized pts, 117 maintained CR/CRu ≥ 6 mo per protocol requirement and then received at least one dose of vaccine, 55 relapsed before vaccination, 4 were vaccine manufacturing failures, and 1 violated protocol.
Comment: This report from a controlled study appears to support that idiotype vaccines are active and have the potential to provide meaningful clinical benefit. However, this analysis is for a "modified intent-to-treat population" ... representing roughly half of the patients who started in the study, and these outcomes with PACE and vaccine may not compare well with Rituxan-based chemotherapy, the new standard of care. So the key going forward will be if the improvement in outcomes can be reproduced following Rituxan-based chemo.
-
Progressive multifocal leukoencephalopathy [PML] after Rituxan therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project bloodjournal.hematologylibrary.org
In conclusion, rituximab administration may increase risks of developing PML, although the absolute risk of developing PML is probably low. As use of rituximab expands to diverse clinical settings, clinicians and patients should be aware of the potential for PML after rituximab therapy. Awareness and reporting of rituximab-associated PML cases to the FDA are essential to improve our understanding of risk factors, natural course, and alternative therapeutic approaches. Despite widespread public health advisories describing 2 patients with SLE and 1 patient with rheumatoid arthritis who were diagnosed with rituximab-associated PML, we identified 22 previously unreported cases associated with lymphoid malignancies and immunologically mediated cytopenias. Early diagnosis of PML will prompt efforts at immune reconstitution, which may be beneficial in improving survival rates. Finally, early diagnosis before irreversible neurologic damage has occurred will be crucial for evaluation of the efficacy of new antiviral treatments.
-
Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma. Whittaker SJ, Foss FM. Cancer Treat Rev. 2007 Apr;33(2):146-60. Epub 2007 Feb 1. Review. PMID: 17275192
-
Efficacy of lenalidomide (Revlimid) oral monotherapy in relapsed or refractory indolent NHL:
Final results of NHL-001. abstract.asco.org
Oral lenalidomide monotherapy can produce durable responses with manageable side effects in relapsed or refractory indolent NHL
-
Complete remissions with weekly dosing of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in a phase I dose-escalation study in patients with relapsed or refractory Hodgkin lymphoma (HL) or systemic anaplastic large cell lymphoma (sALCL). abstract.asco.org
SGN-35 was generally well tolerated and induced CRs in 7 of 8 evaluable pts at the two highest doses in heavily pretreated patients. Pivotal trials of this antibody-drug conjugate will initiate in early 2009.
-
YM155 shows activity in relapsed and refractory DLBCL. abstract.asco.org
Targets Survivin - inhibitor of apoptosis proteins (IAPs)
-
Additional Evidence That Antibiotics Are Effective Against Gastric MALT Lymphomas http://patient.cancerconsultants.com
-
Rituximab Maintenance for the Treatment of Patients With Follicular Lymphoma: Systematic Review and Meta-analysis of Randomized Trials medscape.com (free login req.)
-
Phase I Trial of Daily Oral Polyphenon E in Patients With Asymptomatic Rai Stage 0 to II Chronic Lymphocytic Leukemia
http://jco.ascopubs.org/cgi/content/short/JCO.2008.21.1284v1?rss=1
Epigallocatechin-3-gallate (EGCG) was administered using the standard phase I design with three to six patients per dose level (range, 400 to 2,000 mg by mouth twice a day).
-
The Sponsor and FDA are negotiating an indication statement for ARZERRA (ofatumumab) in the treatment of chronic lymphocytic leukemia (CLL) under the provisions of accelerated approval based on studies that have investigated response rate, a surrogate endpoint for clinical benefit.
Briefing documents:
Advisory board:
http://www.fda. gov/ohrms/ dockets/ac/ 09/briefing/ 2009-4444b1- 01-FDA.pdf
GSK:
http://www.fda. gov/ohrms/ dockets/ac/ 09/briefing/ 2009-4444b1- 02-GSK.pdf
-
Wrong Way in the War on Cancer alternet.org
"The result is that many of the nation’s 30,000 oncologists are engaged in what could be described as an unobserved and uncontrolled science experiment, especially when it comes to treating the 560,000 Americans who die each year from the more than 100 forms of the disease. As these patients’ cancers advance, their physicians try regimens they read about in journals or hear about from colleagues. The outcomes are never gathered. The data is never analyzed. And the findings are never disseminated."
-
Beyond Monoclonal Antibodies:
New Therapeutic Agents in Non-Hodgkin's Lymphomas
http://theoncologist.alphamedpress.org/cgi/content/full/14/5/511
-
[Rituxan] Linked To Often Fatal Brain Virus [PML] sciencedaily.com
"But concerns about the drug's association with PML first surfaced in 2006 when two patients with lupus developed the illness after taking rituximab and other immunosuppressive treatments."
-
Study Shows Disruption Of Immune-System Pathway Key Step In Cancer Progression medicalnewstoday.com
"Silencing an inter-cell signaling mechanism called the interferon pathway may be one way newly developing cancers gain the upper hand. It may also explain the immune dysfunctions seen in many cancer patients and why cancer immunotherapies are often ineffective."
-
Two Targeted Therapies (Rituxan and Epratuzumab) Yields Very Good Results in Patients with Aggressive Lymphoma bio-medicine.org/
researchers say that adding the targeted therapy epratuzumab to a regimen known as R-CHOP resulted in an overall 12-month survival of 88 percent in 78 patients. While they call that a very good outcome, the researchers were especially encouraged because the survival rate was 85 percent in patients with high-risk disease.
-
Technical and preclinical: Ribavirin (anti-viral drug) suppresses eIF4E-mediated oncogenic transformation
2004 Dec 15. PMID: 15601771
Ribavirin and its derivatives offer a pharmacologic means to interrupt networks of tumor suppressors and oncogenes that maintain and enhance neoplasia and malignancy.
-
Vaccine Concept: Recognition of live labeled tumor cells by dendritic cells: a novel approach to immunotherapy of skin cancer. Shurin MR, Potapovich AI, Tyurina YY, Tourkova IL, Shurin GV, Kagan VE. Cancer Res. 2009 Mar 15;69(6):2487-96. Epub 2009 Mar 10. PMID: 19276376
Dendritic cells (DC) loaded with tumor antigens from apoptotic/necrotic tumor cells are commonly used as vaccines for cancer therapy. However, the use of dead tumor cells may cause both tolerance and immunity, making the effect of vaccination unpredictable. To deliver live tumor "cargoes" into DC, we developed a new approach based on the "labeling" of tumors with a phospholipid "eat-me" signal, phosphatidylserine.
-
Highly increased familial risks for specific lymphoma subtypes.
Goldin LR, Björkholm M, Kristinsson SY, Turesson I, Landgren O. Br J Haematol. 2009 May 4. PMID: 19438470
Relatives were at the highest risk for developing the same lymphoma subtype as the case. DLBCL was increased 10-fold among relatives of DLBCL patients, FL was increased fourfold among relatives of FL patients and HL was increased fourfold among relatives of HL patients. These results imply that germline susceptibility genes are specific to lymphoma subtype.
-
Home Diet and Exercise May Benefit Long-Term Cancer Survivors oncologystat.com
A home-based diet and exercise program reduced the rate of functional decline in a study of more than 600 overweight and older cancer survivors, according to a report in the May 13 issue of JAMA.
-
Ginger Eases Nausea From Chemo healthday.com
Participants were randomized to receive either a placebo or one of three doses of ginger supplement: 0.5 grams, 1 gram or 1.5 grams for three days before the start of chemo and three days after for the next two cycles. All also received traditional antiemetic drugs on the first day of treatment.
-
Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy With Mitumprotimut-T (Fav-Id) and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients With Follicular Lymphoma.
J Clin Oncol. 2009 May 4 PMID: 19414675
TTP was shorter with mitumprotimut-T/GM-CSF compared with placebo/GM-CSF. This difference was possibly due to the imbalance in FLIPI scores.
-
Genetic variation in caspase genes and risk of NHL: a pooled analysis of three population-based case-control studies. Blood. 2009 May 4. PMID: 19414860
"It is noteworthy that genetic variants in CASP8 were associated with risk of all major NHL subtypes. Our findings suggest that genetic variation in caspases may play an important role in lymphomagenesis."
-
Late-onset neutropenia (LON) following RCHOP chemotherapy in diffuse large B-cell lymphoma
Am J Hematol. 2009 Mar 31. PMID: 19415727
"it is reassuring that LON is self-limiting and unassociated with life-threatening infection. A watchful waiting approach is appropriate in majority of patients who develop LON following RCHOP.
-
Extranodal marginal zone lymphoma of the ocular adnexa bloodjournal.hematologylibrary.org
"Besides radiotherapy and chemotherapy, a variety of new treatment options have emerged in the management of patients with ocular adnexal MALT lymphoma, especially monoclonal antibody therapy and antibiotic therapy against Chlamydia psittaci, which has been associated with the pathogenesis of ocular adnexal lymphomas in some parts of the world. In this review, we are presenting a state of the art summary on ocular adnexal MALT lymphomas."
-
Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival bloodjournal.hematologylibrary.org
"In conclusion, we have demonstrated that discordant CD20 expression by FCM (flow cytometry) using diagnostic DLBCL biopsies may be a novel biomarker that could identify a subgroup of high-risk patients treated with R-CHOP. Moreover, this biomarker could be identified using flow cytometry, a technique that is already used in most clinical laboratories.
-
A Phase I Study of a Bispecific Chain Immunotoxin for the Treatment of CD19(+), CD22 (+) B-Lineage Leukemia or Lymphoma ClinicalTrials.gov
"Immunotoxins, such as DT2219ARL, can find certain cancer cells and kill them without harming normal cells.
PURPOSE: This phase I trial is studying the side effects and best dose of DT2219ARL immunotoxin in treating patients with B-cell leukemia or lymphoma that has relapsed or not responded to treatment."
-
PERSPECTIVE: A re-examination of radioimmunotherapy in the treatment of NHL: prospects for dual-targeted antibody/radioantibody therapy Robert M. Sharkey1, Oliver W. Press2, and David M. Goldenberg1 bloodjournal.hematologylibrary.org
Discusses potential of clearing normal b-cells with non-competing antibody to optimize the effect of the radiolabeled antibody - so that all the cd20 receptors are available to the "hot" antibody. Also discusses fractionated dosing to improve safety without compromising efficacy.
-
Early: Molecular 'Key' To Successful Blood Stem Cell Transplants Discovered sciencedaily.com
... identified a molecule called S1P that can tell the thymus to "open the gates" and accept more stem cells. "This discovery gives us a handle on determining whether the thymus will be receptive to migrating stem cells," says Ziltener, a professor in the Dept. of Pathology and Laboratory Medicine.
-
How Should Doctors Break Bad News? parade.com
"A recent study in the journal Radiology suggests that the waiting period itself can be bad for your health. Researchers measured the level of the stress hormone cortisol in 130 women who were awaiting their breast biopsy results. They found that the levels of cortisol in patients who had not yet received their results after five days were “essentially indistinguishable” from those found in women with an actual diagnosis of breast cancer."
-
Swine Flu? Immune-compromised persons should take special precautions to reduce risk of
exposure and contact their doctors should symptoms present.
Here are links to CDC information:
* Things you can do: http://www.cdc.gov/flu/protect/habit...k_internal_003
* Treatment: http://www.cdc.gov/swineflu/recommendations.htm
* Travel: http://wwwn.cdc.gov/travel/contentSwineFluMexico.aspx
* Updates (investigation): http://www.cdc.gov/swineflu/investigation.htm
-
Spontaneous regression of chronic lymphocytic leukemia: clinical and biologic
features of 9 cases bloodjournal.hematologylibrary.org
We describe 9 CLL patients who underwent a spontaneous clinical regression over an 11-year follow-up, in spite of a residual neoplastic clone detected by flow cytometry.
-
Study: SAR3419 in Patients With Relapsed or Refractory B-Cell NHL http://clinicaltrials.gov/ct2/show/NCT00539682
Background on agent:
"SAR3419 is an immunoconjugate consisting of an anti-CD19 monoclonal antibody conjugated to the maytansinoid DM4, a derivative of the cytotoxic agent maytansine (DM1), with potential antineoplastic activity. Anti-CD19-DM4 conjugate SAR3419 targets the cell surface antigen CD19, found on a number of B-cell-derived cancers. Upon antibody/antigen binding and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, resulting in inhibition of cell division and cell growth of CD19-expressing tumor cells." Cancer.gov
-
AACR 2009: Oncologists Should Recommend Exercise, But Not Supplements medscape.com
there is accumulating evidence to show that it can improve both prognosis and quality of life
-
Revlimid® Active for Treating Mantle Cell Lymphoma cancerconsultants.com
n = 15 patients with mantle cell lymphoma who had failed prior therapy, including stem cell transplantation in five.
The overall response rate was 53% with 20% (n=3) having a complete response. The median duration of response was 14 months, and the median progression-free survival was 5.6 months. Four of the five patients who had failed stem cell transplantation responded.
-
CLL Aggressiveness May Be Predicted By New Biomarker medicalnewstoday.com
They found that high levels of a particular enzyme PDE7B) in the blood are an indicator that chronic lymphocytic leukemia (CLL) - the most common form of adult leukemia - will be aggressive and in need of immediate treatment.
-
Population-based study of autoimmune conditions and the risk of specific
lymphoid malignancies interscience.wiley.com
n = 44,350 lymphoid malignancy cases .. vs. 122,531 population control.
These results support a mechanism whereby chronic antigenic stimulation leads to lymphoid malignancy.
-
Strong preclinical validation of Btk as a target in lymphoma was generated using PCI-32765 in a mouse model of B-cell receptor-driven lymphoma and in spontaneous B-cell lymphoma in companion canines. Source: prnewswire.com
-
See also ClinicalTrials recruiting for testing this investigational agent.
-
Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome haematologica.org pdf
-
Baby broccoli appears to control H-pylori (gut bug)' news.bbc.co.uk/
n = 50
In those who ate broccoli sprouts, levels of a marker of H. pylori in human stools called HpSA was cut by over 40%.
-
NCCN Adds Cutaneous B-Cell Lymphoma Guidelines oncologystat.com
-
allo SCT: CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009 Feb 12;113(7):1581-8. Epub 2008 Oct 30. PMID: 18974373
n = Twenty-nine patients with malignancies that were recurrent or progressive after allo-HCT
Three patients with lymphoid malignancy developed objective disease responses following ipilimumab: complete remission (CR) in 2 patients with Hodgkin disease and partial remission (PR) in a patient with refractory mantle cell lymphoma.
-
aggressive NHL: Pixantrone Combination Regimen Produces High Rates of Complete Remission
for Patients With Aggressive NHL Who Fail CHOP Therapy Docguide.com
n = 64 pts with relapsed aggressive NHL
"These data suggest that in the relapsed setting, substituting pixantrone for doxorubicin can offer patients a high probability of achieving a complete remission not available with standard chemotherapy regimens and underscores the rationale for studying the CPOP regimen versus the CHOP regimen in first-line treatment of aggressive NHL,"
-
Quiz: Know your nodes: http://www.lymphoma.ca/kyn/en/default.htm
-
Technical background: T Lymphocyte Therapy of Cancer PDF
"The aim of this article is to review the possibilities, limitations and recent clinical experience with this novel anticancer treatment, namely with adoptive immunotherapy using antigen-specific T cells. "
-
Patient's guide to getting a second opinion Web
Dr. Rosenbaum, why are second opinions so important?
"There are actually two types of second opinions. The first is when you want a second opinion. You’ve already been given a diagnosis, and treatment is about to start. It’s important to know that rarely does treatment have to start tomorrow. You’d like it to start tomorrow, but at the same time you have time to think it out and get some additional advice because there are many choices in treatment. Should you have surgery first then radiation then chemotherapy? Or should you have chemotherapy first and radiation and then get surgery?
The second type of second opinion is going to a tumor board. Now, most oncologists participate in tumor boards, either locally at their community hospital or at a university hospital where there are radiotherapists, chemotherapists, pathologists, maybe 10 or 20 people all discussing a case, not all agreeing but coming out with a consensus. So those are the two types of second opinions which are possible. And the tumor boards usually do not cost money because they’re a service, although sometimes they do. The second opinions could vary between $300 and $600.
-
Hepatitis B Testing Urged for Non-Hodgkin's Lymphoma Treatment: Presented at NCCN DocGuide
-
NCCN: Cutaneous B-Cell Lymphoma Guidelines Debut MedpageToday.com
Primary cutaneous B-cell lymphoma is unlikely to reduce a person's life expectancy, but even with definitive therapy, the disease is likely to recur, doctors said in unveiling new guidelines for treatment of the disease.
About 1,000 to 1,500 cases of cutaneous B-cell lymphoma occur each year in the U.S., said Steven M. Horwitz, M.D., of Memorial-Sloan Kettering Cancer Center in New York and a member of the guideline panel. But because the disease is rarely fatal, there are tens of thousands of people living with it.
-
Resource: What You Should Know about Pain Management jointcommission.org pdf
-
Resource: Immunization in persons with compromised immunity cdc.gov
-
Resource: Decide for Yourself: A guide to Healthcare Directives: haponline.org pdf
-
How Follicular Lymphoma is treated in US: First Report of the National LymphoCare Study.
Friedberg JW, Taylor MD, Cerhan JR, Flowers CR, Dillon H, Farber CM, Rogers ES, Hainsworth JD, Wong EK, Vose JM, Zelenetz AD, Link BK. J Clin Oncol. 2009 Feb 9. PMID: 19204203
Initial therapeutic strategy was: observation, 17.7%; rituximab monotherapy, 13.9%; clinical trial 6.1%; radiation therapy, 5.6%; chemotherapy only, 3.2%; chemotherapy plus rituximab, 51.9%. Chemotherapy plus rituximab regimens were: rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone, 55.0%; rituximab plus cyclophosphamide, vincristine, and prednisone, 23.1%; rituximab plus fludarabine based, 15.5%; other, 6.4%.
-
CNS lymphoma: Is Single-Agent Temozolomide the Treatment of Choice for Recurrent Primary Central Nervous System Lymphoma? medscape.com (free one-time subscription req.)
The authors conclude that in a heavily pretreated population, temozolomide shows potential in the treatment of PCNSL, with modest toxicity. The authors suggest that temozolomide should be further developed as induction, consolidation and maintenance therapy for primary lymphomas.
-
Drug Dispensary of Hope: Locate by location dispensaryofhope.org
Physicians' offices, distributors, and manufacturers send their donated medications to the program's distribution center, which receives prescription requests from the dispensing partners and forwards the medications as needed.
-
Meta-analysis: Rituximab Should Be Used for Maintenance in Follicular Lymphoma
http://www.medscape.com/viewarticle/588413 (free subscription req.)
Requires confirmation ... peer review.
-
Please read! One in Five Cancer Clinical Trials Is Published:
A Terrible Symptom—What's the Diagnosis? theoncologist.alphamedpress.org
So, while perhaps only one in five cancer clinical trials is ever published,
of those unpublished, a significant percentage probably died for lack of accrual ... See also our related project
-
A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: Prospects for dual-targeted antibody/radioantibody therapy. PMID: 19182204
Combining an unconjugated anti-CD20 antibody therapy with a radioimmunoconjugate binding to a non-competing antigen might improve responses by allowing optimal uptake of each agent.
-
Mechanisms of activity: Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. PMID:19196657
We analyzed the response against the immunoglobulin expressed by the FL before and after rituximab monotherapy in five FL patients and found an increase in FL idiotype specific T-cells post-rituximab in 4/5 patients.
-
Attitude! Are You Going to Finish Strong? Inspiring Video
-
Experts: Selection from: Assessing the Standard of Care for Indolent Lymphomas / CLL James O. Armitage, MD Bruce D. Cheson, MD Owen A. O'Connor, MD, PhD
medscape.com/ (one-time, free subscription req.)
-
Auto SCT vs. CHVP + interferon in untreated follicular lymphoma: Blood 2009 113: 995-1001
n = 172 previously untreated pts with follicular lymphoma, transformed excluded
randomized for either immunochemotherapy or high-dose therapy (HDT) followed by purged ASCT.
-
Alert: Green Tea May Negate the Effects of a Common Cancer Therapy prnewswire.com/
"the team was surprised to find that the EGCG compound seemed to prevent bortezomib (Velcade) from fighting the disease by blocking its proteasome inhibitory function -- the two compounds effectively contradicted one another in the cell, leaving nearly 100 percent of the tumor cells intact. "
-
Hodgkins outcomes: Increased Progression Free Survival did not lead to improved Overall Survial in
HD2000 trial hemonctoday.com
n = patients with advanced Hodgkin’s lymphoma. All patients underwent radiation treatment after chemotherapy.
-
Transformation data: Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. PMID: 18838711
n = 600 patients with newly diagnosed FL met the inclusion criteria.
See for detail: News: About Transformation
-
PET SUV and transformation? The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). PMID: 19139176
n = 40
"CONCLUSIONS: Like de novo aggressive lymphomas, the majority of transformations have a high SUV(study-max) for a given pretreatment staging study, although many do not have very high values. Transformation should be suspected in indolent lymphoma with high SUVs on FDG-PET. Biopsies should be directed to the site of greatest FDG avidity."
-
orbital MALT: Treatment with the Zevalin(R) Therapeutic Regimen as Sole Therapy Produces 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma http://news.prnewswire.com
n = 9 patients with MALT lymphoma of conjunctiva or orbit and 3 patients with low grade follicular lymphoma
-
Review: Radio-Immunotherapy with Zevalin®: Updates from the 2006 American Society of Hematology Meeting http://professional.cancerconsultants.com
-
Review: CLL diagnosis and prognosis: implications of the IWCLL guidelines
Roger Owen, Haematological Malignancy Diagnostic Service (HMDS) 2009
lymphomaforum.org.uk
"It is important to recognize that the value of the cellular prognostic markers detailed above is very much determined by the clinical context in which they are demonstrated. "
-
Commentary on Homeopathy: The side effects of inert "remedies" PDF
-
Biospecimen-based study: Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols
http://www.haematologica.org:80/cgi/content/full/94/1/70
n = Pre-treatment biopsy samples of 61 pts with follicular lymphoma treated in an EORTC/BNLI study
-
Editorial: Clinicobiological, prognostic and therapeutic implications of the tumor microenvironment in follicular lymphoma
http://www.haematologica.org/cgi/content/full/94/1/16
-
On science-based medicine: Natural versus “natural” in CAMworld
Published by David Gorski under Cancer, Clinical Trials, Science and Medicine
This is what Swayze said: If anybody had that cure out there, like so many people swear they do,
you’d be two things. You’d be very rich, and you’d be very famous. Otherwise, shut up.
-
Recruiting: Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer This study is currently recruiting participants.
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving a monoclonal antibody, such as alemtuzumab, before transplant and tacrolimus and methotrexate after transplant may stop this from happening.
http://clinicaltrials.gov/ct2/show/NCT00818961
-
Preclinical: Grape Seed Extract Kills Laboratory Leukemia Cells, Proving? Value of Natural Compounds
The real news in this story is how the lead researcher responsibly tempers the interpretation of his 15 October report in Clinical Cancer Research. Grape seed extract
-
CLL Flavopiridol Confirmed Active for Treatment of Relapsed CLL with Adverse Cytogenetics
http://professional.cancerconsultants.com
n = 62 patients with relapsed CLL treated with flavopiridol... pretreated with dexamethasone to block the effects of IL-6 release during therapy.
-
Potential Breakthrough For T-Cell Lymphoma Patients With Drug That Mimics Folic Acid
http://www.sciencedaily.com/releases/2008/12/081209155010.htm
n = 109 patients with peripheral t-cell lymphoma
"These results indicate that pralatrexate produces a major durable response in patients for whom numerous prior treatments have been unsuccessful," says Dr. Owen A. O'Connor
-
Statin Use and Prognosis in Patients with Follicular and Diffuse Large B Cell Lymphoma
http://ash.confex.com/ash/2008/webprogram/Paper8512.html
n = 293 newly diagnosed FL patients and 228 newly diagnosed DLBCL patients
Conclusions: Statin therapy does not appear to be associated with inferior clinical outcome in DLBCL treated with rituximab and CHOP or CHOP-like therapy. Therefore direct inhibition of rituximab binding to CD20 may have limited clinical significance or/and may be overcome by inhibitory impact of statins on cell signaling. The latter possibility is supported by our observation that statin use is associated with improved event-free survival in follicular lymphoma.
-
CLL outcomes: FCR Versus FC Improves Response Rates and Progression-Free Survival of Previously Untreated [and fit] Patients with Advanced CLL
n = 817 pts with good physical fitness - median CIRS score was 1 (range 0-8), median age was 61 years (range 30 to 81), The overall incidences of trisomy 12 and abnormalities of 13q, 11q23, and 17p13 detected by FISH were 12%, 57%, 25%, and 8%, respectively, with no statistically significant differences between treatment arms.
http://ash.confex.com/ash/2008/webprogram/Paper9237.html
-
CLL outcomes: Allogeneic Hematopoietic Stem-Cell Transplantation for Chronic Lymphocytic Leukemia With 17p Deletion: A Retrospective European Group for Blood and Marrow Transplantation Analysis
oncologystat.com
n = 44, majority of 17p deletions were detected via fluorescence in situ hybridization analysis; the median percentage of deleted cells was 63%. 98% had previously received fludarabine, more than half (60%) had fludarabine- resistant disease. [AGE not specified in abstract] .. participants had median of 3 previous lines of chemotherapy. One third of the patients underwent an auto HSCT; half were not in remission at the time of transplantation.
-
NHL outcomes: Sustained Response Duration Seen after Treatment with Single Agent Blinatumomab (BiTE) in the Ongoing Phase I Study in Patients with Relapsed NHL
http://ash.confex. com/ash/2008/ webprogram/ Paper9115. html
n = 39 Relapsed NHL patients requiring treatment were included. Most patients were pre-treated, with a median of 3 previous chemo/immunotherapy regimens.
-
Travel: Tips for Traveling when you have a cancer cancer.net
-
CLL/SLL: Flavopiridol Induces Durable Responses in Relapsed CLL Patients with High-Risk Cytogenetic Abnormalities
http://ash.confex.com/ash/2008/webprogram/Paper11242.html
n = 117 pts with relapsed CLL (n=107) or small lymphocytic lymphoma (n=10) , median age 60 years, 116 pts had received prior purine analog therapy, and 85 pts (73%) were refractory to (n=82) or intolerant of purine analog (n=3). Ninety-three pts were Rai stage III/IV (79%), and 85 pts had bulky lymph nodes ³ 5 cm (73%).
-
Alert: Some patients taking Rituxan may experience bowel obstruction
aol.mediresource.com
"Patients taking Rituxan who experience abdominal pain, especially early in treatment, should contact their physician immediately," Health Canada advised. The average time for patients on the medication to develop bowel perforation was six days from the beginning of therapy."
-
An Oral Inhibitor of Syk (Fostamatinib Disodium (FosD), Is Well-Tolerated and Has Significant Clinical Activity in DLBCL and SLL/CLL
http://ash.confex.com/ash/2008/webprogram/Paper5094.html
n = 68 pts with relapsed/ refractory NHL in 3 separate disease cohorts: DLBCL (23); FL (21) and other B-cell NHL (24) including SLL/CLL (11), MCL (9) marginal zone/MALT (3) and lymphoplasmacytic NHL (1). Median age was 61 (range 41-87); with median of 5 prior therapies, including ASCT (16; 12 with DLBCL) and radioimmunotherapy (8).
-
DLBCL prognosis: Variations in Gene Activity Can Predict the Survival of Patients With DLBC Lymphoma docguide.com
"Our findings reveal new biological variations in DLBCL that influence whether a patient is likely to be cured by chemotherapy," said Dr. Staudt. "These biological variations are significant in patients treated with the current standard of care, R-CHOP. Our results provide many fresh ideas about how existing drugs might be utilised to overcome the remaining resistance of some DLBCL tumours to our current therapy."
-
MCL outcomes: Confirmation of the Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory Mantle-Cell Lymphoma: Results of An International Study (NHL-003)
n = 39 relapsed or refractory MCL and measurable disease ≥2 cm after at least 1 prior treatment regimen were eligible.
http://ash.confex.com/ash/2008/webprogram/Paper13353.html
The ORR with lenalidomide was
41% (16/39), including
13% (5/39) complete response (CR)/unconfirmed CR, and
28% (11/39) partial responses.
Ten (26%) patients had stable disease.
Revlimid mechanisms? Direct Inhibitory Effects of Lenalidomide on the Proliferation and VEGF Production of NHL Cells Are Associated with Increased SPARC Expression
http://ash.confex.com/ash/2008/webprogram/Paper10294.html
n = preclinical
Mechanistic studies indicated that lenalidomide strongly increased the gene expression of the tumor suppressor genes p21cip1 and SPARC to varying degrees.
-
CLL perspectives Opinions & Reports from Dr. Michael Keating The CLL Treatment Surge
http://www.cllglobal.org:80/prescorner.htm
For example: Theme 5 – Stroma CLL Interaction
This concept may prove difficult to fully explain. All CLL cells exist in a matrix of different tissues. There are supporting cells, blood vessel cells, fat cells, and very specific cells which maintain the integrity and survival of the CLL cells. This complex interaction is the reason why CLL cells will last for 100 days in the body but will die in 3 – 6 days when taken out of the body. A number of separate approaches will be used to evaluate how we can modify this matrix to improve CLL therapy.
-
CNSL outcomes : Addition of Systemic High-Dose Methotrexate to Intrathecal Chemotherapy for Central Nervous System Prophylaxis Substantially Reduces CNS Recurrence Rates in Patients with at-Risk Aggressive Lymphoma: A Historically Controlled Prospective Study
http://ash.confex.com/ash/2008/webprogram/Paper4036.html
Monday, December 8, 2008
n = 85 pts with newly diagnosed aggressive NHL with CNS risk factors such as multiple extranodal sites and elevated LDH
-
CLL: Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial
Monday, December 8, 2008: 11:45 AM
http://ash.confex.com/ash/2008/webprogram/Paper5918.htm l
n = 138 previously treated CLL patients (Double refractory, n=59; Bulky fludarabine refractory, n=79
The bottom line here, as I see it anyway, is a next generation rituxan-like antibody with low toxicity was active and achieved responses in this very difficult context: The overall response rate (ORR) to salvage therapy (of any type) for such patients is approximately 20%
For Ofatumumab: the overall response rate was 51% in this study.
Also rituxan monotherapy is not often very effective in CLL even in more favorable circumstances. So this bodes well for Ofatumumab approval I hope, and it could lead to much better outcomes in CLL when Ofatumumab is combined with chemo and used earlier.
-
Stress: Good tips on managing it cancer.net
-
follicular NHL Bexxar outcomes for first-line treatment, an update webmd.com
n = 76 previously untreated with follicular NHL.
Results showed that 95% of the patients responded to the treatment; 75% had a complete disappearance of the signs of their cancer. At follow-up, the estimated eight-year overall survival rate was 86%. Fifty percent of patients continued to show no signs of cancer. Of the 57 patients who had a complete remission, two-thirds remained in remission.
-
follicular lymphoma: Strategies Have Neither Clinical or Survival Benefit Following High-Dose Chemotherapy and Progenitor Cell Rescue in Follicular Lymphoma
http://ash.confex.com/ash/2008/webprogram/Paper10156.html
n = Ninety-nine consecutive pts. who received HDT (cyclophosphamide and total body irradiation) with autologous stem cell rescue for recurrent FL
... annual surveillance investigations do not help to identify pts. that require treatment and do not improve the outcome of this population. They should therefore be abandoned. Time to relapse based on data from pts. on annual surveillance should be interpreted with caution because of the poor correlation with time to next treatment and OS.
-
Statins Use and Prognosis in Patients with Follicular Lymphoma (FL) and
Diffuse Large B Cell Lymphoma (DLBCL)
n = 393 newly dx FL, and 228 newly dx DLBCL
http://ash.confex.com/ash/2008/webprogram/Paper8512.html
-
DLBCL: The Role of Radiotherapy to Bulky Disease in the Rituximab Era: Results from Two Prospective Trials of the German High-Grade NHL Study Group for Elderly Patients with DLBCL
http://ash.confex.com/ash/2008/webprogram/Paper11600.html
n = 166 elderly patients with DLBCL
In the rituximab era additional radiotherapy to bulky disease has no role for elderly patients in CR/CRu after completion of 6xR-CHOP-14 immunochemotherapy, but (unlike 2 additional chemotherapy cycles in the 8xR-CHOP-14 arm of R-CHOP-Rx) appears to be beneficial for patients with bulky disease achieving a PR.
-
follicular: Durable Responses in Patients Treated with Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory Follicular Lymphoma: Long-Term Follow-up of a Phase II Clinical Trial Saturday, December 6, 2008
http://ash.confex.com/ash/2008/webprogram/Paper6805.html
n = 64 pt with fNHL, mean age was 59 yrs., least 1 prior lymphoma therapy; 42% were rituximab naïve, rituxan refractory were excluded. FLIPI low (27%), intermediate (39%), and high (34%).
-
Patient guidance: Cancer Patients Often Forget Details of Doctor Visit cancerpage.com
Communicating prognosis requires careful tailoring to individual patient's preferences for more or less information and balancing the needs for clear information while maintaining hope," the researchers write.
-
RIT consolidation: Effect of Adding Zevalin Consolidation to Three Cycles of CHOP Plus Involved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG 0313) Dec 8, 2008
http://ash.confex.com/ash/2008/webprogram/Paper4856.html
n = 40 pts with limited stage DLBCL with least one adverse risk factor (age > 60 years, elevated LDH and a performance status of 2) OR non-bulky stage II disease.
Estimated 2-year progression-free survival is 91% (95% CI: 81%-100%) and
2-year OS is 95% (95% CI: 87%-100%).
Toxicity has been reversible with no treatment related deaths.
There were 9 grade 3 and 10 grade 4 hematologic events, but only 3 episodes of febrile neutropenia and only one patient requiring platelet support. Other grade 3 toxicities were mostly gastrointestinal symptoms including mucositis and nausea/vomiting or flu-like symptoms.
We conclude that patients with aggressive histologies of NHL and high-risk LD treated with CHOP(3) plus IFRT followed by Z result in outcome that compares favorably to our historical experience in the short term.
Longer follow-up will determine whether these patients exhibit a pattern of late recurrences as seen in our prior experiences.
-
Auto SCT with RIT: Radioimmunotherapy (Zevalin®) Combined with BEAM Conditioning Regimen and Autologous Stem Cell Transplantation for the Treatment of NHL ash.confex.com
n=53, relapsed and refractor (16 follicular, 37 aggressive) , age 65 or less.
In pts with different histology nHL, who failed to achieve CR after previous immuno-chemotherapy, RIT integrated with high-dose chemotherapy (Z-BEAM) is capable to induce 86% of ORR, 74% of CR and 3 ys EFS of 64%, with sustained engraftment and an acceptable extra-haematological toxicity, mainly restricted to pts older then 65 yrs.
-
Perspective: Evidence Mounts for the Efficacy of Radioimmunotherapy for B-Cell Lymphomas jco.ascopubs.org Oliver W. Press
"Together, these two studies confirm and extend prior data demonstrating the tremendous potential of RIT for the treatment of B-cell NHL at diagnosis and after relapse at both conventional and myeloablative doses. Despite the overwhelming body of evidence that has accumulated, however, RIT remains underused in the United States and other countries. The reasons for this underuse have been widely debated but seem to be related, at least partially, to logistic issues involved in transfer of care from the hematologist/oncologist to the nuclear medicine physician, concerns about inadequate reimbursement by Medicare for RIT, and exaggerated emphasis on delayed effects such as marrow damage and secondary malignancies. It is hoped that studies such as those in this issue will encourage wider appreciation and use of RIT."
-
Drug combination (dexamethasone, cytarabine and carboplatin) for NHL produces fewer side effects
virtualmedicalcentre.com
n = 25 children who had newly diagnosed non-Hodgkin lymphoma
The researchers’ aim in using the regimen they dubbed “DAC” was to achieve both an improved effectiveness over conventional therapy and to reduce that therapy’s dosage of two anti-cancer drugs—doxorubicin and cyclophosphamide—that are more likely to produce cardiac problems and infertility.
-
Outcomes fNHL: Phase II Trial of Short-Course CHOP-R Followed by Zevalin and Extended Rituxan in Previously Untreated Follicular Lymphoma. Clin Cancer Res. 2008 Nov 1;14(21):7088-7094. PMID: 18981007
n = 60 patients with stage II to IV symptomatic or bulky FL from a single institution;
median follow up was 19.7 months (range, 0.26-35.9 months).
For intent-to-treat analysis, the complete response (CR) rate after CHOP-R, as assessed by CT and PET imaging, was 40% and 46%, respectively. After RIT, the CR rate improved, as assessed by CT and PET imaging, to 82% and 89%, respectively.
Ten [of 55?] patients have progressed, including eight from best response of CR.
Seven of 18 patients who were PET positive after CHOP-R progressed compared with 3 of 37 patients who were PET negative (P = 0.010).
-
Is it DLBCL or Burkitt's? C-MYC Rearrangements are Frequent in Aggressive Mature B-Cell Lymphoma with Atypical Morphology ijcep.com pdf
"To avoid under- or over-treatment of the patients, it is critical to distinguish Burkitt's lymphoma (BL) from DLBCL when encountering these aggressive mature B-cell lymphomas with atypical morphology. Since diagnosis of BL requires strict criteria (CD10+, BCL6+, close to a 100% proliferation index and IG-MYC), many cases that do not meet all these criteria were diagnosed as DLBCL, and therefore would not receive the benefit of intensified chemotherapy. More recent studies suggest that some of those DLBCL cases indeed had the molecular signatures of BL and over 10% of those molecular BL did not harbor any detectable C-MYC translocations".
-
Background: Helping Your Patients Deal with Questionable Cancer Treatments, William Jarvis, Ph.D.
caonline.amcancersoc.org pdf
-
Outcomes: High dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: A randomized multicenter study by the GOELAMS. Final results with a median follow-up of nine years. Blood. 2008 Oct 27. PMID: 18955565
n = 172 patients with untreated FL for either immunochemotherapy or high-dose therapy (HDT) followed by purged ASCT
In conclusion, the occurrence of a PFS plateau suggests that a subgroup of patients might be cured by ASCT. However, the increased rate of secondary malignancies may discourage the use of purged ASCT in combination with TBI as first-line treatment for FL.
-
Second pathology Evaluations: Comparison of Referring and Final Pathology for Patients With Non-Hodgkin's Lymphoma in the National Comprehensive Cancer Network. J Clin Oncol. 2008 Nov 1;26(31):5107-12. Epub 2008 Sep 2. PMID: 18768434
CONCLUSION I..., the majority of common B-cell NHLs diagnosed in the community were unchanged by second opinion review by an expert hematopathologist. However, for one patient in 20, there was a discordance (non-agreement) in diagnosis that could have altered therapy.
See Also Getting A Second Pathology Evaluation
-
Perspective: "Anecdotal evidence. An oxymoron? Or a valid approach to understanding data? scienceb asedmedicine. org
-
Bendamustine: FDA Approval for TREANDA to Treat Patients with Relapsed Indolent NHL marketwatch.com
n= 100 The FDA approval is supported by a pivotal trial of 100 patients with indolent B-cell NHL who had progressed during or within six months of treatment with a regimen that included rituximab.
-
Pilot: Feasibility of allogeneic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. Leuk Lymphoma. 2008 Oct;49(10):1893-8. PMID: 18949613
n = 8 patients with histologically confirmed transformation to diffuse large B-cell lymphoma underwent HSCT at our institution. The median age was 56 years (range 44-63 years).
Allogeneic HSCT appears feasible in patients with transformed FL and is associated with acceptable treatment-related mortality and low relapse rates.
-
Preclinical: T cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood. 2008 Oct 21. PMID: 18941113
n = 0 (preclinical)
Our results show that the combination of intratumoral CpG and immunomodulatory T cell antibodies has promise for therapeutic vaccination against lymphoma. These reagents are becoming available for human clinical trials.
-
Review: Hematopoietic SCT for peripheral T-cell lymphoma?
Bone Marrow Transplant. 2008 Oct 20. PMID: 18936735
-
Study: Lymphoma Patients' Survival Affected By Socioeconomic And Treatment Factors medicalnewstoday.com
n = >13,000 patients diagnosed at age 65 or older between 1992 and 1999. The metropolitan areas of San Francisco/Oakland, Detroit, Atlanta, Seattle, Los Angeles County, San Jose/Monterey, and the states of Connecticut, Iowa, New Mexico, Utah, and Hawaii were included in this study.
The investigators found that receiving chemotherapy was associated with prolonged survival in patients with NHL and that elderly Caucasian patients with NHL were more likely to receive chemotherapy (52.4 percent) compared with African-Americans (43.2 percent). Also, poor socioeconomic status was significantly associated with increased risk of mortality
-
Review: Evolving Paradigms in Follicular Lymphoma: Re-Evaluating Prognostic Factors and Challenging Treatment Dogmas molecularonc.com | Cara A. Rosenbaum, MD
Current clinical indices and molecular markers in follicular lymphoma must be re-evaluated and incorporated actively into prospective trials to allow development of risk-adapted treatment guidelines and novel targeted therapies. The results of such studies will help to further recommendations regarding the effective timing of therapeutic intervention (ie, watchful waiting versus active treatment) and the efficacy of various chemotherapeutic regimens in different patient populations.
-
Initial treatment and risk of transformation: The impact of initial treatment of advanced stage indolent lymphoma on the risk of transformation ascopubs.org
n = 698 patients with indolent NHL, no prior treatment, age16–60 y and advanced stage disease (III/ IV or I/ II with B symptoms or bulky disease 10cm).
"Conclusion: The use of an anthracycline-based regimen as initial treatment for advanced stage indolent NHL is associated with a marked reduction in the risk of future transformation."
-
T-cell outcome: FDA Grants Full Approval to ONTAK(R) (denileukin diftitox) for Use in Patients with Cutaneous T-Cell Lymphoma (CTCL) Press release
n = 144 with with refractory CTCL (stages Ia-III), expressing CD25 component of the IL-2 receptor.
Also: FDA approval of ONTAK for this indication NetMedia
-
Zevalin report: Cell Therapeutics, Still Fighting, Gets Zevalin Data Published In Cancer Journal
n = 414 patients getting first-line treatment for their slow-growing lymphoma.
Patients on the drug were able to keep their cancer from spreading for a median time of 36.5 months, compared with 13.3 months in a control group. About 77 percent of patients who had partial tumor shrinkage on prior treatments entering the study had their tumors completely wiped out after getting a single shot of Zevalin,
Also see our brochure on when to consider RIT: PDF
-
Outcomes indolent: Durable complete responses from therapy with combined epratuzumab (anti-CD22) and Rituxan (anti-cd20) Abstract
n = 41 patients with relapsed/refractory, indolent (NHL
Twenty-two of 41 patients with FL (54%) had an objective response (OR), including 10 (24%) complete responses (CR) (CR/unconfirmed CR [CRu]), whereas 4 of 7 patients with SLL (57%) had ORs, including 3 (43%) with CR/CRu. Rituximab-naive patients (N = 34) had an OR rate of 50% (26% CR/CRu rate), whereas patients who previously responded to rituximab (N = 14) had an OR rate of 64% (29% CR/CRu rate).
Main caveats: Small study, no control, mix of lymphoma types.
-
Side effects: Full Recovery After Cell Transplantation for Treating Leukemia or Lymphoma Can Take 3-5 Years fhcrc.org
n = 319 adults who had myeloablative (bone-marrow suppression) HCT for treatment of leukemia or lymphoma, 5-year follow-up.
-
MCL/indolent outcomes: Phase II multicenter study of bendamustine plus Rituxan in patients with relapsed indolent B-cell and mantle cell NHL. J Clin Oncol. 2008 Sep 20;26(27):4473-9. Epub 2008 Jul 14. PMID: 18626004
(n = 66 patients with relapsed, indolent B-cell or mantle cell lymphoma (without documented resistance to prior rituximab)
Overall response rate was 92% (41% complete response, 14% unconfirmed complete response, and 38% partial response). Median duration of response was 21 months (95% CI, 18 to 24 months). Median progression-free survival time was 23 months (95% CI, 20 to 26 months). Outcomes were similar for patients with indolent or mantle cell histologies.
-
Transformation: Population-Based Analysis of Incidence and Outcome of Transformed NHL. J Clin Oncol. 2008 Oct 6. PMID: 18838711
(n = 600 patients with newly diagnosed FL)
CONCLUSION: The annual risk of transformation of FL is 3% continuing without plateau beyond 15 years. Advanced stage at diagnosis is predictive of future transformation. Clinically diagnosed transformation has an equal impact on outcome as biopsy proven transformation.
-
fNHL Outcomes: Biovest Announces BiovaxID® Anti-Cancer Vaccine Prolongs Cancer-Free
Survival by 44% Press release
(n = 117; 2:1 ratio of BiovaxID versus control)
... that the median duration of complete remission in the BiovaxID arm of the study was 44.2 months which is clinically and statistically significant compared to the control arm, median duration of cancer-free survival of 30.6 months. BiovaxID prolonged the cancer-free survival by 13.6 months or 44% (p-value = 0.045; HR = 1.6) with a median follow up of 56.6 months (range 12.6 to 89.3 months).
-
Drug approvals: FDA Approvals from July, 2005 to December, 2007 PDF
Includes indications, endpoints, basis for approvals.
-
MCL Outcomes: Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group bloodjournal.hematologylibrary.org
(n = 160 consecutive, untreated patients)
-
Lenalidomide (Revlimid): what is the right dose in CLL?
http://bloodjournal.hematologylibrary.org/cgi/content/full/111/11/5268
(n = 45 patients with relapsed CLL)
-
Astonishing progress in treatment of Childhood Hematologic Cancers http://patient.cancerconsultants.com
Approximately 40% of childhood cancers are classified as hematalogic cancers. Hematologic cancers are cancers of the blood and bone marrow, and include leukemia and lymphoma.
-
For patients to print and bring to next consult:
Confidential CLINICAL TRIAL SURVEY For Oncologists Treating Lymphoma/CLL Patients PDF
Purpose: to identify obstacles to enrolling patients in clinical trials.
-
-
Outcomes LPL / Waldenstrom's: The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG).
Leukemia. 2008 Sep 25. PMID: 18818699
n = 69 patients with previously untreated LPL
-
Pilot vaccine report: Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunological responses in indolent B cell lymphoma patients with relapsed and measurable disease: a pilot study. Blood. 2008 Sep 22. PMID: 18809757
Collectively these results [single arm study, N= 18] demonstrate that vaccination with tumor-loaded DCs may induce both T and B cell responses and produces clinical benefits in indolent NHL patients with measurable disease.
-
Basic research: Follicular lymphoma B cells induce the conversion of conventional CD4(+) T cells to T-regulatory cells. Int J Cancer. 2008 Sep 23. PMID: 18814264
Our study provides evidence for a tumor-specific mechanism by which FL tumor cells promote immune escape through the induction of Treg.
-
Support: Caregiver burnout: 10 ways to recharge and refocus http://cms.carepages.com/CarePages/en/ArticlesTips/HelpfulTips/better_you.html
-
Prognostic marker: Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. Leuk Lymphoma. 2008 Sep;49(9):1745-51. PMID: 18798109
(n = 101 patients with DLBCL who recently completed therapy)
-
Tests: Positron emission tomography (PET) in mantle cell lymphoma.
Leuk Lymphoma. 2008 Sep;49(9):1693-701. PMID: 18798104
-
Outcomes: Intravenous Rituxan® Effective in Primary Central Nervous System Lymphomas professional.cancerconsultants.com
(n = 9 patients with PCNSL who had failed other therapies)
... Rituxan used alone for patients with PCNSL that does not respond to standard therapies may provide effective treatment for some patients, as regression of cancer was achieved in one-third of patients. The authors state that treatment with Rituxan warrants further study in combination with other chemotherapy agents; they add, “Maintenance [Rituxan] is well tolerated and may improve disease control in this patient population.” Further enrollment and follow-up for this trial are ongoing.
Related studies: ClinicalTrials.gov
-
Outcomes: I-131-based Rituxan Safe and Effective for Repeat Treatment professional.cancerconsultants.com
Fourteen of 16 patients responded with nine complete responses (CRs), with a median duration of 10.5 months in responders. Six of 13 reresponders had the same or a longer response and six more remain in complete response. The median event-free survival was not significantly different for the two treatments. There was no significant difference in the severity of myelosuppression. Four patients developed hypothyroidism with three requiring thyroxine. One patient developed AML, with no other cases of MDS. The actuarial progression-free survival rate at 12 months was 36%.
Comment: encouraging; small study, however; might require longer follow up to assess risks.
-
Rituxan risk? Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment? Am J Hematol. 2008 Aug;83(8):673-5. PMID: 18528824
-
Drug targets: Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. Cancer Res. 2008 Aug 1;68(15):6300-5. PMID: 18676854
Our results show that the rapid internalization of large amounts of BL22 bound to CD22 makes CD22 a better therapeutic target than CD19 for immunotoxins and probably for other immunoconjugates that act inside cells. Comment: internalization is when the antibody (and anything bound to it) is taken up into the cell, rather than remaining outside of it.
-
NHL/MCL Outcome: Adoptive immunotherapy for indolent NHL and MCL using genetically modified
autologous [from self] CD20-specific T cells
Of the 7 treated patients, 2 maintained a previous complete response,
1 achieved a partial response, and 4 had stable disease.
These results show the safety, feasibility, and potential antitumor activity of adoptive T-cell therapy using this approach. This trial was registered at Clinicaltrials.gov NCT00012207
-
Story: Gene Wilder Talks about his lymphoma Utube
-
Lenalidomide (Revlimid) down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells.
Blood. 2008 Sep 4. http://www.ncbi.nlm.nih.gov/pubmed/18772452
This is preclinical data, which suggests that Revlimid might work against the activity of Rituxan when treating CLL.
-
Review: Aiming at a Curative Strategy for Follicular Lymphoma caonline.amcancersoc.org
Maurizio Bendandi,MD, PhD
One clear fact is that no patients will ever be cured by adopting a palliative treatment approach. The assumption that patients with follicular lymphoma are incurable is certain to be a self-fulfilling prophecy. Here the author summarizes the large and growing body of knowledge that suggests an expectant approach to management is not appropriate for all patients. (CA Cancer J Clin 2008;58:305–317.) © American Cancer Society, Inc., 2008.
http://caonline.amcancersoc.org:80/cgi/reprint/58/5/305?eaf
-
Outcome: Revlimid (R) Demonstrates Activity against Relapsed/Refractory Aggressive NHL marketwatch.com
According to the publication, of 49 patients eligible for response evaluation in the study, an objective response was observed in 35 percent, with 12 percent exhibiting a complete or unconfirmed complete response. Activity was also seen in other lymphoma subtypes, including diffuse large b-cell, follicular grade 3 and transformed.
-
Outcome: Zevalin® Following an Autologous Transplant? cancerconsultants.com
"Standard-dose [radioimmunotherapy] seems feasible and potentially effective after [autologous stem cell transplantation] in correctly selected patients with follicular lymphoma."
-
Report: Adding fresh frozen plasma to Rituxan for the treatment of patients with refractory advanced CLL oxfordjournals.org
Five patients with severe treatment-resistant CLL. All had been previously treated with fludarabine and three also failed treatment with Rituxan. ... A rapid and dramatic clinical and laboratory response was achieved in all patients. Lymphocyte counts dropped markedly followed by shrinkage of lymph nodes and spleen and improvement of the anaemia and thrombocytopenia. This could be maintained over 8 months (median) with additional cycles if necessary. Treatment was well tolerated in all cases.
Could CLL be a disease of complement abnormality?
One group reports on this question: ncbi.nlm.nih.gov/pubmed/8751471
-
Blood test for fNHL? Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma. Br J Haematol. 2008 Aug 15. PMID: 18710386
-
Report: Zevalin® Effective for Treatment of Cutaneous B-Cell Lymphoma cancerconsultants.com
100% CR rate in small study (10 patients);
40% (4 of 10 pts) remain in complete remission at 19 months.
-
Study: Genmab plans to start ofatumumab studies in CLL & NHL pharmabiz.com
"Ofatumumab is an investigational new generation human monoclonal antibody that targets a distinct, membrane proximal, small loop epitope (specific antibody binding site) of the CD20 molecule on B cells. Ofatumumab is being developed to treat chronic lymphocytic leukaemia, follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, rheumatoid arthritis and relapsing remitting Multiple Sclerosis"
-
Study:
MDX-1411 is a fully human monoclonal antibody that targets the CD70 receptor, which is a member of the tumor necrosis factor (TNF) family. CD70 is expressed in a number of cancers, including ccRCC primary tumors and metastatic lesions. lifescience-online.com
Cellular expression: Activated T and B cells, and macrophages
-
MDS/ALL: FDA Approves Vidaza medicalnewstoday.com/
... "AZA-001 trial, which found that Vidaza is the only agent that extends survival in MDS (myelodysplastic syndromes) patients. Vidaza was also shown to delay progression to acute myelogenous leukemia (AML) in patients with MDS. Roughly 30 percent of patients diagnosed with MDS will progress to AML."
"MDS occur when the bone marrow stem cells malfunction [sometimes as a consequence of treatments for lymphomas]. This results in the production of too many defective blood cells and not enough normal cells. Diagnosis is made through blood tests and a bone marrow biopsy. Once diagnosed, treatment and evaluation should occur under the care of a hematologist or hematologist/oncologist. There are many subtypes of MDS classified according to how the disease manifests itself in the blood and marrow of the patient. Treatments include blood transfusions, growth factors, chemotherapy and bone marrow transplant."
-
BiTE: Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
Science abstract | Financial analysis: seekingalpha.com
-
Study of interest: Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemo in Treating Patients With Relapsed NHL or CLL
Background: http://clltopics.org/SponsoredProjects/NKCellTherapy.htm
Also: Natural killer cell recognition of missing self and haploidentical hematopoietic transplantation.
Semin Cancer Biol. 2006 Oct;16(5):404-11. Epub 2006 Jul 8. Review. PMID: 16916611
"In clinical trials, donor versus recipient NK alloreactions are highly beneficial as they reduce the risk of leukemia relapse, do not cause GvHD and markedly improve event-free survival"
-
|